

US00RE45003E

(19) **United States**  
 (12) **Reissued Patent**  
**Boakes et al.**

(10) **Patent Number: US RE45,003 E**  
 (45) **Date of Reissued Patent: Jul. 8, 2014**

(54) **LANTIBIOTIC BIOSYNTHETIC GENE CLUSTERS FROM *A. GARBADINENSIS* AND *A. LIGURIAE***

(71) Applicant: **Novacta Biosystems Limited**, Hertfordshire (GB)

(72) Inventors: **Steven Boakes**, Hertfordshire (GB); **Jesus Cortes Bargallo**, Hertfordshire (GB); **Michael John Dawson**, Hertfordshire (GB)

(73) Assignee: **Novacta Biosystems Limited**, Hertfordshire (GB)

(21) Appl. No.: **13/705,010**

(22) Filed: **Dec. 4, 2012**

**Related U.S. Patent Documents**

Reissue of:

(64) Patent No.: **7,989,416**  
 Issued: **Aug. 2, 2011**  
 Appl. No.: **12/161,221**  
 PCT Filed: **Jan. 17, 2007**  
 PCT No.: **PCT/GB2007/000138**  
 § 371 (c)(1),  
 (2), (4) Date: **Sep. 11, 2008**  
 PCT Pub. No.: **WO2007/083112**  
 PCT Pub. Date: **Jul. 26, 2007**

(30) **Foreign Application Priority Data**

Jan. 17, 2006 (GB) ..... 0600928.6

(51) **Int. Cl.**  
**A61K 38/12** (2006.01)  
**C07K 7/64** (2006.01)

(52) **U.S. Cl.**  
 USPC ..... **514/2.3**; 514/1.1; 514/2.4; 514/2.6;  
 514/2.7; 530/317

(58) **Field of Classification Search**  
 CPC ..... **A61K 38/12**; **C07K 7/64**  
 USPC ..... **514/2.3**, 1.1, 2.4, 2.6, 2.7; 530/317  
 See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

3,710,795 A 1/1973 Higuchi et al.  
 5,112,806 A 5/1992 Chatterjee et al.  
 5,304,540 A 4/1994 Blackburn et al.  
 5,667,991 A 9/1997 Koller et al.  
 5,683,675 A 11/1997 Vedia et al.  
 5,763,395 A 6/1998 Blackburn et al.  
 5,958,873 A 9/1999 Sakr et al.  
 5,985,823 A 11/1999 Goldstein  
 6,022,851 A 2/2000 Vertesy et al.  
 6,569,830 B1 5/2003 Climo et al.  
 7,122,514 B2 10/2006 Climo et al.  
 2010/0168410 A1 7/2010 Cade et al.

**FOREIGN PATENT DOCUMENTS**

DE 197 45 583 4/1999  
 EP 0195359 9/1986

EP 0572942 12/1993  
 EP 0700998 3/1996  
 EP 1646646 3/2007  
 WO WO 91/07949 6/1991  
 WO WO 91/11172 8/1991  
 WO WO 91/07949 6/1992  
 WO WO 94/02518 2/1994  
 WO WO 97/00694 1/1997  
 WO WO 98/55148 12/1998  
 WO WO 02/00196 1/2002  
 WO WO 02/088367 11/2002  
 WO WO 02/103010 12/2002  
 WO WO 03/099862 12/2003  
 WO WO 2004/033706 4/2004  
 WO WO 2005/093069 10/2005  
 WO WO 2006/080920 8/2006  
 WO WO 2007/036706 4/2007  
 WO WO 2007/083112 7/2007  
 WO WO 2008/151434 12/2008  
 WO WO 2009/010763 1/2009  
 WO WO 2009/010765 1/2009  
 WO WO 2010/058238 5/2010  
 WO WO 2010/082018 7/2010  
 WO WO 2010/082019 7/2010  
 WO WO 2010/092019 7/2010  
 WO WO 2010/089544 8/2010

**OTHER PUBLICATIONS**

Definition of moiety, from <http://dictionary.reference.com/browse/moiety>, pp. 1-3, Accessed Aug. 26, 2010.  
 Rudinger J., "Characteristics of the amino acids as components of a peptide hormone sequence", Peptide Hormones, JA Parsons Edition, University Park Press, pp. 1-7 (Jun. 1976).  
 "Designing Custom Peptides", from SIGMA Genosys., p. 1-2, Accessed Dec. 16, 2004.  
 Schnizel et al., "The phosphate recognition site of *Escherichia coli* maltodextrin phosphorylase", FEBS, 286(1,2):125-128 (Jul. 1991).  
 Berendsen HJC, "A Glimpse of the Holy Grail?", Science, 282:642-643 (1998).  
 Voet et al., Biochemistry, 2nd Ed., John Wiley & Sons, Inc., pp. 235-241 (1995).  
 Ngo et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox", The Protein Folding Problem and Tertiary Structure Prediction, K. Merc Jr. And S. Le Grand Edition, pp. 491-495 (1994).  
 European Search Report issued in European Patent Application No. EP 10 00 0424 (Apr. 1, 2010).  
 European Examination issued in European Patent Application No. 07 704 921.1 (Apr. 4, 2010).  
 International Search Report and Written Opinion in PCT/GB2010/000043 (Mar. 29, 2010).  
 Widdick et al., "Cloning and engineering of the cinnamycin biosynthetic gene cluster from *Streptomyces cinnamoneus cinnamoneus* DSM 40005", PNAS, 100(7):4316-4321 (Apr. 1, 2003).  
 Arioli et al., "Gardimycin, a new antibiotic from Actinoplanes: III. Biological properties" The Journal of Antibiotics 29(5):511-515 (1976).

(Continued)

*Primary Examiner* — Julie Ha

(74) *Attorney, Agent, or Firm* — Morgan, Lewis & Bockius LLP

(57) **ABSTRACT**

Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.

**15 Claims, 4 Drawing Sheets**

(56)

## References Cited

## OTHER PUBLICATIONS

- Bradley et al., "Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat", *J. Mol. Biol.*, 324:373-386 (2002).
- Appleyard et al., "NVB302 : Gastrointestinal Stability and in vivo Activity in the Hamster Cecitis Model for *Clostridium difficile* Infection," Poster F1-1520, 49th ICAAC, Sep. 12-15, 2009, San Francisco, USA.
- Appleyard et al., "NVB302: A Narrow Spectrum Antibiotic under Development for the Treatment of *Clostridium difficile* Infection," Poster F1-1517, 49th ICAAC, Sep. 12-15, 2009, San Francisco, USA.
- Boakes et al., "Organization of the genes encoding the biosynthesis of actagardine and engineering of a variant generation system," *Molecular Microbiology*, 2009, 72(5), pp. 1126-1136.
- European Examination for European Patent Application No. 07704921.1 dated Aug. 30, 2010.
- International Search Report and Written Opinion for PCT/GB2010/000042 dated May 20, 2010.
- International Search Report and Written Opinion for PCT/GB2010/000188 dated May 20, 2010.
- New Zealand Examination Report for New Zealand Patent Application 569486 dated Apr. 27, 2010.
- Translation of Israeli Examination Report for Israeli Patent Application No. 192446 dated Apr. 22, 2010.
- Wadman et al., "NVB302: In vitro Activity Against *Clostridium difficile* and Intestinal Strains of Anaerobic Bacteria," Poster F1-1518, 49th ICAAC, Sep. 12-15, 2009, San Francisco, USA.
- Berge et al., "Pharmaceutical salts" *Journal of Pharmaceutical Sciences* 66(1):1-19 (1977).
- Bierbaum et al., "Cloning, sequencing and production of the lantibiotic mersacidin" *FEMS Microbiology Letters* 127:121-126 (1995).
- Bierman et al., "Plasmid cloning vectors for the conjugal transfer of DNA from *Escherichia coli* to *Streptomyces* spp." *Gene* 116(1): 43-49 (1992).
- Britton et al., "Genome-Wide Analysis of the Stationary-Phase Sigma Factor (Sigma-H) Regulon of *Bacillus subtilis*" *Journal of Bacteriology* 184(17):4881-4890 (2002).
- Castiglione et al., "A novel lantibiotic acting on bacterial cell wall synthesis produced by uncommon actinomycete *Planomonospora* sp." *Biochemistry* 46:5884-5895 (2007).
- Chatterjee et al., "Biosynthesis and Mode of Action of Lantibiotics" *Chem. Rev.* 105:633-683 (2005).
- Coronelli et al., "Gardimycin, A New Antibiotic From Actinoplanes: II. Isolation and preliminary characterization" *Journal of Antibiotics* 29(5):507-510 (1976).
- Cotter et al., "Bacterial lantibiotics: strategies to improve therapeutic potential" *Current Protein Peptide Science* 6(1):61-75 (2005).
- Dabard et al., "Ruminococcin A, a new lantibiotic produced by a *Ruminococcus gnavus* strain isolated from human feces" *Appl. Environ. Microbiol.* 67:4111-4118 (2001).
- Dawson "Lantibiotics as antimicrobial agents" *Expert Opinion on Therapeutic Patents, Informa Healthcare, GB*, 17(4):365-369 (2007).
- Dower et al., "High efficiency transformation of *E. coli* by high voltage electroporation" *Nucleic Acids Research* 16(13):6127-6145 (1988).
- Fleisher et al., "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs" *Advanced Drug Delivery Reviews* 19(2):115-130 (1996).
- Flett et al., "High efficiency intergeneric conjugal transfer of plasmid DNA from *Escherichia coli* to methyl DNA-restricting *Streptomyces*" *FEMS Microbiology Letters* 155(2): 223-229 (1997).
- Fukase et al., "Synthetic study of peptide antibiotic nisin. V. Total synthesis of nisin" *Bull. Chem. Soc. Jpn.* 65:2227-2240 (1992).
- Fumi et al., "Rifaximin treatment for symptoms of irritable bowel syndrome" *The Annals of Pharmacotherapy* 42:408-412 (2008).
- Gardiner et al., "Fate of the Two-Component Lantibiotic Lacticin 3147 in the Gastrointestinal Tract" *Applied and Environmental Microbiology* 73(21):7103-7109 (2007).
- Gravesen et al., "pbp2229-Mediated nisin resistance mechanism in *Listeria monocytogenes* confers cross-protection to class IIa bacteriocins and affects virulence gene expression" *Applied and Environmental Microbiology* 70(3): 1669-1679 (2004).
- Guder et al., "Role of the single regulator MrsR1 and the two-component system MrsR2/K2 in the regulation of mersacidin production and immunity" *Applied and Environmental Microbiology* 68(1):106-113 (2002).
- Guiotto et al., "PEGylation of the antimicrobial peptide nisin A: problems and perspectives" *Il Farmaco* 58(1):45-50 (2003).
- Gust et al., "PCR-targeted *Streptomyces* gene replacement identifies a protein domain needed for biosynthesis of the sesquiterpene soil odor geosmin" *PNAS* 100(4): 1541-1546 (2003).
- Gust et al., "λ Red-mediated genetic manipulation of antibiotic-producing *Streptomyces*" *Advances in Applied Microbiology* 54:107-128 (2004).
- Heinzelmann et al., "A glutamate mutase is involved in the biosynthesis of the lipopeptide antibiotic friulimicin in *Actinoplanes friuliensis*" *Antimicrobial Agents and Chemotherapy* 47(2): 447-457 (2003).
- Hilger et al., "Differential binding of IgG and IgA antibodies to antigenic determinants of bovine serum albumin" *Clin. Exp. Immunol.* 123:387-394 (2001).
- Holtmark, et al., "Purification, Characterization, and Gene Sequence of Michiganin A, an Actagardine-Like Lantibiotic Produced by the Tomato Pathogen *Clavibacter michiganensis* subsp. *michiganensis*" *Applied and Environmental Microbiology* 72(9):5814-5821 (2006).
- Kettenring et al., "Sequence determination of actagardine, a novel lantibiotic, by homonuclear 2D NMR spectroscopy" *J. Antibiot.* 43(9):1082-1088 (1990).
- Lonetto et al., "The sigma 70 family: sequence conservation and evolutionary relationships" *Journal of Bacteriology* 174(12): 3843-3849 (1992).
- Louie et al., "A phase 2 study of the toxin binding polymer tolevamer in patients with *C. difficile* associated diarrhoea" *Proceedings of 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague Congress Centre, Prague, Czech Republic, P548* (May 1-4, 2004).
- Louie et al., "Tolevamer (GT160-246) binds *Clostridium cytotoxins* A/B and is associated with restoration of components of the anaerobic intestinal microflora during treatment of *C. difficile* associated diarrhoea" *Proceedings of 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague Congress Centre, Prague, Czech Republic, P855* (May 1-4, 2004).
- Malabarba et al., "Physico-chemical and biological properties of actagardine and some acid hydrolysis products" *The Journal of Antibiotics* 38(11):1506-1511 (1985).
- Malabarba et al., "Synthesis and biological activity of some amide derivatives of the lantibiotic actagardine" *The Journal of Antibiotics* 43(9):1089-1097 (1990).
- Marahiel et al., "Regulation of peptide antibiotic production in *Bacillus*" *Molecular Microbiology* 7(5):631-636 (1993).
- McClerren et al., "Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic" *PNAS* 103(46):17243-17248 (2006).
- Miner et al., "Steroid-refractory ulcerative colitis treated with corticosteroids, metronidazole and vancomycin: a case report" *BMC Gastroenterology* 5:3 (2005).
- O'Sullivan et al., "High- and low-copy-number *Lactococcus* shuttle cloning vectors with features for clone screening" *Gene* 137:227-231 (1993).
- Parenti et al., "Gardimycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies" *The Journal of Antibiotics* 29(5):501-506 (1976).
- Rea et al., "Antimicrobial activity of lacticin 3147 against clinical *Clostridium difficile* strains" *Journal of Medical Microbiology* 56:940-946 (2007).

(56)

**References Cited**

## OTHER PUBLICATIONS

- Rey et al., "Complete genome sequence of the industrial bacterium *Bacillus licheniformis* and comparisons with closely related *Bacillus* species" *Genome Biology* 5(10):R77 (2004).
- Sahl et al., "Lantibiotics: Biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria" *Ann. Rev. Microbiology* 52:41-79 (1998).
- Somma et al., "Gardimycin, a new antibiotic inhibiting peptidoglycan synthesis" *Antimicrobial Agents and Chemotherapy* 11(3):396-401 (1977).
- Szekat et al., "Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin" *Applied and Environmental Microbiology* 69(7):3777-3783 (2003).
- "Treatment of *Clostridium difficile*—Associated Disease (CDAD)" *Obstetrics and Gynecology* 109(4):993-995 (2007).
- Turner et al., "Solution structure of plantaricin C, a novel lantibiotic" *Eur. J. Biochem.* 264:833-839 (1999).
- Turtell et al., "The use of nisin in cheesemaking. Chapter 5: International acceptance of nisin as a food preservative" *Bulletin of the Int. Dairy Fed.* 329:20-23 (1988).
- Ugurlu et al., "Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture" *Eur. J. Pharm. Biopharm.* 67:202-210 (2007).
- van Kraaij et al., "Lantibiotics: biosynthesis, mode of action and applications" *Nat. Prod. Rep.* 16:575-587 (1999).
- Zimmermann et al., "The three-dimensional solution structure of the lantibiotic murein-biosynthesis-inhibitor actagardine determined by NMR" *Eur. J. Biochem.* 246:809-819 (1997).
- Altena, Karsten, et al., "Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster," *Applied and Environmental Microbiology*, Jun. 2000, pp. 2565-2571, vol. 66, No. 6.
- Zimmerman, Norbert, et al., "The tetracyclic lantibiotic actagardine H-NMR and C-NMR assignments and revised primary structure," *European Journal of Biochemistry*, Mar. 15, 1995, pages 786-797, vol. 228, No. 3.
- Vertesy, Laszlo, et al., "Ala(0)-actagardine, a new lantibiotic from cultures of *Actinoplanes liguriae* ATCC 31048," *Journal of Antibiotics*, Japan Antibiotics Research Association, Aug. 1999, pp. 730-741, vol. 52, No. 8.
- de Vos, Willem M., et al., "Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by gram-positive bacteria," *Molecular Biology*, 1995, pp. 427-437, vol. 17, No. 3.
- Jack, Ralph, et al., "The genetics of lantibiotic biosynthesis," *Bioessays*, 1995, pp. 793-802, vol. 17, No. 9.
- Written Opinion of the International Preliminary Examining Authority in PCT/GB2010/000043, dated Feb. 1, 2011.
- Wikipedia, the free encyclopedia, "Lanthionine", <http://en.wikipedia.org/wiki/Lanthionine>, Nov. 2, 2011.
- Examination Report in New Zealand Patent Application No. 569486 dated Mar. 10, 2011.
- International Preliminary Report on Patentability in PCT/GB2010/000043 dated Apr. 14, 2011.
- International Preliminary Report on Patentability in PCT/GB2010/000042 dated Apr. 19, 2011.
- International Preliminary Report on Patentability in PCT/GB2010/000188 dated Apr. 19, 2011.
- Boakes et al., "Organization of the biosynthetic genes encoding deoxyactagardine B (DAB), a new lantibiotic produced by *Actinoplanes liguriae* NCIMB41362", *The Journal of Antibiotics*, 63:351-358 (2010).




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4

**LANTIBIOTIC BIOSYNTHETIC GENE  
CLUSTERS FROM *A. GARBADINENSIS* AND  
*A. LIGURIAE***

**Matter enclosed in heavy brackets [ ] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue.**

RELATED APPLICATIONS

The present application is a U.S. National Phase Application of International Application No. PCT/GB2007/000138 (filed Jan. 17, 2007) which claims the benefit of Great Britain Patent Application No. 0600928.6 (filed Jan. 17, 2006), each of which is hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

This invention relates to characterisation of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant produced in a strain of *A. liguriae*, and variants of both of these produced according to this invention, utilizing genes from the characterised biosynthetic gene clusters.

BACKGROUND OF THE INVENTION

Lantibiotics are peptides having antibiotic and other activities, produced by Gram-positive bacteria. They contain, among other modified residues, the thioether amino acids lanthionine and methyllanthionine, which cross-link the peptide chain into a polycyclic structure. They have been classified into two classes, type-A and type-B, though such classification is not unproblematic. Type-A lantibiotics are generally elongate amphiphiles that are capable of forming pores in bacterial and other plasma membranes. Examples are nisin and subtilin. Type-B lantibiotics, by contrast, are globular, conformationally defined peptides that inhibit enzyme functions. Examples are cinnamycin and duramycin.

Activities ascribed to type-B lantibiotics such as cinnamycin include antimicrobial activity (providing potential application as antibiotics), inhibition of angiotensin-converting enzyme (providing a potential application in blood pressure regulation), immunomodulation via inhibition of phospholipase A2 (providing a potential application as anti-inflammatories), and interference with prostaglandin and leucotriene biosynthesis.

Type-B lantibiotics appear to exert their activity by interfering with enzyme activities by blocking the respective substrates. For example, type B lantibiotics such as mersacidin and actagardine have been found to inhibit biosynthesis of peptidoglycan; transglycosylation was identified as the target reaction. The substrate for this reaction is the lipid-bound cell wall precursor lipid II. While this is a target for the lantibiotic vancomycin, the site of action is different and is a new target binding site not used by any current antibacterial drug.

For the cinnamycin class of type B lantibiotics antibacterial activity has been observed, in particular with *Bacillus* strains, with effects described on membrane functions, ATP-dependent proton translocation and  $Ca^{2+}$ -uptake, and on ATPases. Also, the formation of defined pores in phosphatidylethanolamine-containing planar membranes has been

reported. These effects can be attributed to the specific binding of these type-B lantibiotics to phosphatidylethanolamine.

Lantibiotics have been shown to have efficacy and utility as food additives and antibacterial agents against *Propionibacterium acnes* and problematic pathogens, e.g. methicillin-resistant *Staphylococcus aureus* (MRSA), which has or is developing resistance to many commonly used antibiotics, and *Streptococcus pneumoniae*. For reviews, see Sahl and Bierbaum (1998) *Annual Rev. Microbiol.* 52:41-79; Jack and Sahl (1995) *TIBTECH* 13:269-278; Gasson (1995) Chapter 10, *Lantibiotics*, in Vining and Stuttard (eds) *Biotechnology Series: Genetics and Biochemistry of Antibiotic Production*, *Biotechnological I 30 Series* 28, pages 283-306.

Within the field of antibiotics, there is a continuing need for the provision of new antibiotic compounds, to overcome issues such as resistance, bio-compatibility, toxicity and the like. Accordingly, methods of producing lantibiotics, and the production of variant forms of lantibiotics (which may have a different activity profile compared to native forms), are desirable.

Actagardine is a known type B tetracyclic lantibiotic, 19 amino acids in length (1890 Da). It has potent activity against important Gram positive pathogens such as *Staphylococcus aureus* and *Streptococcus pyogenes* both in vitro and in vivo animal models. The structure of actagardine is shown in FIG. 4. The compound is produced from a pre-pro-peptide, the C-terminal portion of which has the polypeptide sequence of SSGWVCTLTIECGTVICAC (SEQ ID NO:4). The polypeptide of SEQ ID NO:4 is modified by the following crosslinks, creating secondary and tertiary structure: CROSSLINK 1-6, Lanthionine (Ser-Cys); CROSSLINK 7-12, Beta-methyllanthionine (Thr-Cys); CROSSLINK 9-17, Beta-methyllanthionine (Thr-Cys); CROSSLINK 14-19, Beta-methyllanthionine sulfoxide (Thr-Cys).

Actagardine has been reported to be produced by two species of *Actinoplanes*; *A. garbadinensis* and *A. liguriae*. Also co-produced is an analogue in which the CROSSLINK 14-19 is not oxidized i.e. it is a beta-methyllanthionine not betamethyllanthionine sulfoxide which is named herein deoxy-actagardine.

U.S. Pat. No. 6,022,851 describes the isolation of actagardine from isolated strains of *A. garbadinensis* and *A. liguriae*.

DISCLOSURE OF THE INVENTION

The present invention relates to the cloned, sequenced and elucidated structural and regulatory information relevant to the biosynthetic gene cluster for the type-B lantibiotic, actagardine, from *Actinoplanes garbadinensis* and *A. liguriae*.

We have also surprisingly found that in an isolate of *A. liguriae*, designated herein as *A. liguriae* NCIMB 41362, a novel form of actagardine is produced which we have termed actagardine B or, in the non-oxidised form, deoxy-actagardine B. These forms have similar anti-microbial activity to actagardine and are generated from the primary polypeptide sequence of SEQ ID NO:1, which undergoes similar crosslinking to actagardine. The variants provide new and useful alternatives to actagardine. In addition, the identification of residues in actagardine B which are different from actagardine leads to the provision of further lantibiotics based on these differences.

We have also isolated gene clusters from both actagardine-producing *A. garbadinensis* and *A. liguriae* NCIMB 41362 which comprise the genes for the production of actagardine and actagardine B.

In one aspect, the present invention provides the novel actagardine B and variants thereof, including variants based



3

on the primary polypeptide sequences of SEQ ID NO:2 and SEQ ID NO:3, as well as variants thereof.

In a further aspect, the invention provides nucleic acids encoding actagardine B and its variants, sets of nucleic acids and variants thereof derived from the above-mentioned gene clusters, methods of making actagardine B and its variants, and methods of generating novel variants of actagardine B.

#### DESCRIPTION OF THE DRAWINGS

FIG. 1 provides a map of the actagardine encoding and regulatory gene cluster isolated from *A. garbadinensis*.

FIG. 2 provides a map of the encoding and regulatory gene cluster isolated from *A. liguriae* which encodes a novel variant of actagardine, herein referred to as actagardine B.

FIG. 3 provides a schematic showing a method disclosed herein for generation of actagardine variants utilizing nucleic acid sequences isolated from *A. garbadinensis* or from *A. liguriae*.

FIG. 4 is a representation of the primary structure of mature actagardine where X1-X2 represent Val-Ile, Y is —S(O)— and Z is NH<sub>2</sub>. “Deoxy-actagardine B” is the Val15Leu Ile16Val variant with a non-oxidised methylanthionine bridge between AbuS14 and AlaS19.

#### DESCRIPTION OF THE SEQUENCES

For the convenience of the reader, the sequences of the present application have been numbered non-contiguously as follows:

SEQ ID NO:1 is the primary polypeptide sequence of Actagardine B:

SSGWVCTLTIECGTLVCAC.

SEQ ID NO:2 is the primary polypeptide sequence of Actagardine B variant VV:

SSGWVCTLTIECGTVVCAC.

SEQ ID NO:3 is the primary polypeptide sequence of Actagardine B variant LI

SSGWVCTLTIECGTLICAC.

SEQ ID NO:4 is the primary polypeptide sequence of Actagardine:

SSGWVCTLTIECGTVICAC;

SEQ ID NO:11 is the primary polypeptide sequence of Ala-Actagardine B:

ASSGWVCTLTIECGTLVCAC.

SEQ ID NO:12 is the primary polypeptide sequence of Ala-Actagardine B variant VV:

ASSGWVCTLTIECGTVVCAC.

SEQ ID NO:13 is the primary polypeptide sequence of Ala-Actagardine B variant LI

ASSGWVCTLTIECGTLICAC.

SEQ ID NO:14 is the primary polypeptide sequence of Ala-Actagardine:

ASSGWVCTLTIECGTVICAC.

SEQ ID NO:212 is the primary polypeptide sequence of pre-pro-Actagardine B:

MSAITVETTWKNTDLREDLTAHPAGLGF-  
GELSFEDLREDRTIYAASSGWVCTLTIECG TLV-  
CAC.

SEQ ID NO:22 is the primary polypeptide sequence of pre-pro-Actagardine B variant VV:

MSAITVETTWKNTDLREDLTAHPAGLGF-  
GELSFEDLREDRTIYAASSGWVCTLTIECG  
TVVCAC.

SEQ ID NO:23 is the primary polypeptide sequence of pre-pro-Actagardine B variant LI

4

MSALAIEKSWKDVDLRDGTSHHPAGLGF-  
GELTFEDLREDRTIYAASSGWVCTLTIECG TLI-  
CAC.

SEQ ID NO:119 is the primary polypeptide sequence of pre-pro-Actagardine:

MSALAIEKSWKDVDLRDGTSHHPAGLGF-  
GELTFEDLREDRTIYAASSGWVCTLTIECG  
TVICAC.

SEQ ID NO:100 is the non-vector, *A. garbadinensis*-derived, nucleotide sequence of the cosmid CosAG14.

SEQ ID NOs:101-132 are the polypeptide sequences of the open reading frames orf1-orf32 of SEQ ID NO:100 respectively.

SEQ ID NO:200 is the non-vector, *A. liguriae*-derived, nucleotide sequence of the cosmid CosAL02.

SEQ ID NOs:201-231 are the polypeptide sequences of the open reading frames orf1-orf31 of SEQ ID NO:200 respectively.

SEQ ID NOs:300-312 are primer sequences described herein below.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the gene clusters of SEQ ID NO:100 and SEQ ID NO:200 and the polypeptides encoded by these clusters and variants thereof. The polypeptide of SEQ ID NO:119 is pre-pro-actagardine and the polypeptide of SEQ ID NO:212 is pre-pro-actagardine B. The remaining polypeptides and their variants (as defined herein) are referred to herein generically as “cluster polypeptides”. Cluster polypeptides derived from SEQ ID NO:100 are referred to as “1xx polypeptides” and those derived from SEQ ID NO:200 are referred to as “2xx polypeptides”. Polypeptides which are 100% identical in both sequence and length to a cluster polypeptide are referred to as “wild-type” polypeptides. A cluster polypeptide derived from SEQ ID NO:100 or SEQ ID NO:200 may be wild type or variant.

A polypeptide may be in substantially isolated form. Isolated polypeptides of the invention will be those as defined above in isolated form, free or substantially free of material with which it is naturally associated such as other polypeptides with which it is found in the cell. For example, the polypeptides may of course be formulated with diluents or adjuvants and still for practical purposes be isolated.

A polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the polypeptide in a preparation in which more than 90%, e.g. 95%, 98% or 99% of the polypeptide in the preparation is a polypeptide of the invention.

#### Lantibiotic Polypeptide and LantibioticA Gene

In the present invention, reference to a lantibioticA or LanA polypeptide, the LantibioticA or LanA gene refers generically to a type B lantibiotic polypeptide or the gene encoding such a peptide. Thus reference to these includes reference to cinnamycin, mersacidin, actagardine and actagardine B and the genes encoding these products. Reference to a lantibiotic producing host cell refers to any host cell which in its native form produces a LanA polypeptide, as further defined herein below.

A LanA polypeptide is a polypeptide with anti-microbial activity. Anti-microbial activity may be examined by determining the MIC value against a reference organism, e.g. *Micrococcus luteus*. A LanA polypeptide is considered to exhibit anti-microbial activity if it has a MIC value of less than or equal to 16-fold higher than that of actagardine against the same strain of the reference microorganism. In the present

invention, the *A. garbadinensis* LanA gene is referred to as actA and the *A. liguriae* LanA gene is referred to as LigA.

#### Other Lan Polypeptides

As used herein, reference to a “LanM” polypeptide is a polypeptide derived from a Lantibiotic gene cluster which is a modification factor required for the conversion of a precursor polypeptide to a lantibiotic compound. LanM polypeptides include those of SEQ ID NO:120 (ActM) or a variant thereof, SEQ ID NO:213 (LigM) or a variant thereof, a cinM polypeptide as defined in WO02/088367, a mrsM polypeptide as disclosed in Altena et al, 2000, or a homologous polypeptide from another gene cluster of a bacteria which produces a type B lantibiotic.

Reference to a “LanR” polypeptide is a polypeptide derived from a Lantibiotic gene cluster which is a regulatory factor required for the regulation of production of a precursor polypeptide. LanR polypeptides include those of SEQ ID NO:122 (ActR) or a variant thereof, SEQ ID NO:216 (LigR) or a variant thereof, a cinR1 polypeptide as defined in WO02/088367, a mrsR1 polypeptide as disclosed in Altena et al, 2000, or a homologous polypeptide from another gene cluster of a bacteria which produces a type B lantibiotic.

Reference to a “LanT” polypeptide is a polypeptide derived from a Lantibiotic gene cluster which is a transporter factor required for the production of a precursor polypeptide to a lantibiotic compound. LanT polypeptides include those of SEQ ID NO:123 (ActT) or a variant thereof, SEQ ID NO:214 (LigT) or a variant thereof, a cinT polypeptide as defined in WO02/088367, a mrsT polypeptide as disclosed in Altena et al, 2000, or a homologous polypeptide from another gene cluster of a bacteria which produces a type B lantibiotic.

Reference to a “LanO” polypeptide is a polypeptide derived from a Lantibiotic gene cluster which is a factor believed to be involved in the oxidation of the deoxy-form of actagardine and compounds of the invention to actagardine or to compounds of the invention in which Y is —S(O)—.

LanO polypeptides include those of SEQ ID NO:122 (ActO) or a variant thereof, SEQ ID NO:215 (LigO) or a variant thereof, or a homologous polypeptide from another gene cluster of a bacteria which produces a type B lantibiotic.

#### Cluster Polypeptides

In one aspect, the invention provides an isolated cluster polypeptide selected from any one of SEQ ID NOs: 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230 and 231. In another aspect, the invention provides a cluster polypeptide which is a variant of any of the above-mentioned sequences.

Cluster polypeptides of particular interest include 1xx and 2xx polypeptides which are LanM, LanR, LanT or LanO polypeptides.

A “variant”, in relation to a cluster polypeptide, denotes: any polypeptide having an amino acid sequence which is different from, but which shows significant amino acid sequence identity with, the amino acid sequence of a reference polypeptide (in this case any wild type cluster polypeptide), or a fragment of that polypeptide.

Unless otherwise specified, significant amino acid sequence identity is preferably at least 80%, more preferably 85%, 90% or 95%, still more preferably 98% or 99%. A variant is preferably of a length which is the same as, or at least 70%, preferably at least 80%, more preferably at least 90% and most preferably at least 95% of the length of the wild type cluster polypeptide.

“Percent (%) amino acid sequence identity” is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the sequence with which it is being compared, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. The % identity values used herein are generated by BLAST-2 which was obtained from Altschul et al. (1996). WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span=1, overlap fraction=0.125, word threshold (T)=11. The HSPS and HSPS2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched; however, the values may be adjusted to increase sensitivity. A % amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the “longer” sequence in the aligned region, multiplied by 100. The “longer” sequence is the one having the most actual residues in the aligned region (gaps introduced by WU BLAST-2 to maximize the alignment score are ignored).

Desirably, a variant will retain a biological function of the reference polypeptide. In the present invention, biological function is retained wherein the variant, when present in a host cell with the other members of its cluster, is capable of producing a lantibiotic. This may be determined, for example, by providing a host cell containing SEQ ID NO:100 in the case of a 1xx cluster polypeptide variant, or SEQ ID NO:200 in the case of a 2xx polypeptide variant, wherein the host cells produce actagardine or actagardine B respectively, modifying the sequence to encode the variant, and determining whether a lantibiotic polypeptide is still produced.

#### Precursor Polypeptides

In another aspect, the invention provides polypeptides, preferably in isolated form, which are precursors of the compounds of the present invention or of actagardine. The precursor polypeptides include the polypeptides of any one of SEQ ID NOs:1-4, SEQ ID NOs:11-14, SEQ ID NOs:212, 22, 23 and 119, as well as variants or derivatives thereof which can be converted to a lantibiotic polypeptide.

A variant of a precursor polypeptide of any one of SEQ ID NOs:1-4 is a polypeptide in which one or more, for example from 1 to 5, such as 1, 2, 3 or 4 amino acids are substituted by another amino acid. Preferably the amino acid is at a position selected from positions 2, 3, 4, 5, 8, 10, 11, 13 or 18 of any one of SEQ ID NOs:1-4.

A variant of a precursor polypeptide of any one of SEQ ID NOs:11-14 is a polypeptide in which one or more, for example from 1 to 5, such as 1, 2, 3 or 4 amino acids are substituted by another amino acid. Preferably the amino acid is at a position selected from positions 3, 4, 5, 6, 9, 11, 12, 14 or 19 of any one of SEQ ID NOs:11-14.

A variant of a precursor polypeptide of any one of SEQ ID NOs:212, 22, 23 and 119 is a polypeptide in which one or more, for example from 1 to 5, such as 1, 2, 3 or 4 amino acids of the C-terminal region (residues 46-64) corresponding to SEQ ID NOs:1-4 respectively are substituted by another amino acid. Preferably the amino acid is at a position selected from positions corresponding to positions 2, 3, 4, 5, 8, 10, 11, 13 or 18 of any one of SEQ ID NOs:1-4. Such variants may further include changes to the N-terminal region which retain at least 70%, for example at least 80%, preferably at least 90%, for example at least 95% of the N-terminal regions (residues 1-45). For example, a variant of the N-terminal

7

region of SEQ ID NO:212 or SEQ ID NO:119 may comprise one or more substitutions (e.g. from 1 to 12, such as from 1 to 5, e.g. 1, 2 or 3 substitutions at positions 4, 5, 6, 8, 9, 12, 13, 17, 18, 19, 21 and 32 which our data shows are varied between SEQ ID NO:212 and 119.

Substitutions may be of one amino acid by another naturally occurring amino acid and may be conservative or non-conservative substitutions. Conservative substitutions include those set out in the following table, where amino acids on the same block in the second column and preferably in the same line in the third column may be substituted for each other:


ALIPHATIC	Non-polar	G A I L V
	Polar-uncharged	C S T M N Q
	Polar-charged	D E K R
AROMATIC		H F W Y

For SEQ ID NO:212, the substitutions may be of an amino acid which differs from the amino acid residue located in the corresponding location of SEQ ID NO:119, or vice versa. In either case, the substitution may be to introduce the SEQ ID NO:119 amino acid into SEQ ID NO:212, or vice versa (e.g. Ile at position 4 of SEQ ID NO:212 may be substituted by Leu, and so on).

A precursor polypeptide may be obtained by expression of a nucleic acid encoding the polypeptide in a cell which is a non-producer of a lantibiotic.

#### Compounds

In one aspect, the present invention provides a compound of the formula (I):



wherein:

-X1-X2- represent -Leu-Val-; -Val-Val- or -Leu-Ile-;

Y is —S— or —S(O)—; and

Z is either H<sub>2</sub>N— or Ala-,

or a pharmaceutically acceptable salt thereof. In a further aspect, the invention provides variants and biologically active derivatives of these compounds.

Where -X1-X2- represent -Leu-Val-, Y is —S(O)— and Z is NH<sub>2</sub> the compound of the invention is also referred to as actagardine B.

Where -X1-X2- represent -Leu-Val-, Y is —S(O)— and Z is Ala- the compound of the invention is also referred to as ala-actagardine B.

Where -X1-X2- represent -Leu-Val-, Y is —S— and Z is NH<sub>2</sub> the compound of the invention is also referred to as deoxy-actagardine B.

Where -X1-X2- represent -Leu-Val-, Y is —S— and Z is Ala- the compound of the invention is also referred to as ala-deoxy-actagardine B.

8

It will be understood by reference to Z being a group H<sub>2</sub>N—, that this moiety represents the N-terminus of the alanine residue at position 1 of the above compound. By reference to the group Z being Ala-, it will be understood that this moiety represents an alanine, conventionally referred to in the art as Ala(0), linked to the alanine at position 1 via an amide bond.

#### Variants

A variant of a compound of formula (I) is a compound which one or more, for example from 1 to 5, such as 1, 2, 3 or 4 amino acids are substituted by another amino acid. Preferably the amino acid is at a position selected from positions 2, 3, 4, 5, 8, 10, 11, 13 or 18 of the compound of formula (I).

A variant may also comprise a substitution at position 15 or 16, provided that when both positions 15 and 16 are substituted and none of the other positions are changes, 15 and 16 are not Val and Ile respectively.

Where Z is Ala-, variants of compounds of the invention include those in which Ala- is replaced by another amino acid (particularly a naturally occurring amino acid encoded by the genetic code or its D-isoform), more particularly an amino acid selected from the group Ile-, Lys-, Phe-, Val-, Glu-, Asp-, His-, Leu, Arg-, Ser- and Trp-. In one aspect, the amino acid may be selected from the group Ile-, Lys-, Phe-, Val-, Glu-, Asp-, His-, Leu-, Arg- and Ser-. Such variants may be produced by chemical addition of the residue to compounds where Z=H<sub>2</sub>N, as described in U.S. Pat. No. 6,022,851. It will be appreciated that the chemical addition of an amino acid allows the amino acid to be in the L- or D-configuration. This includes D-Ala, in addition to the D-forms of other amino acids such as those mentioned above.

#### Derivatives

Derivatives of compounds of the invention (including variants) are those in which one or more amino acid side chain of the compound of the invention has been modified, for example by esterification, amidation or oxidation.

Derivatives of compounds of the invention may be monoamide derivatives at one of the carboxy functions of actagardine, particularly at the C-terminal. More particularly, a derivative may be a compound in which the C-terminal of the compound of the invention is of the formula —COR, in which R represents the group —NR<sup>1</sup>R<sup>2</sup>, wherein R<sup>1</sup> and R<sup>2</sup> independently represent:

(i) hydrogen;

(ii) a group of formula —(CH<sub>2</sub>)<sub>n</sub>—NR<sup>3</sup>R<sup>4</sup>, in which n represents an integer from 2 to 8 and R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen or (C<sub>1</sub>-C<sub>4</sub>) alkyl or R<sup>3</sup> and R<sup>4</sup> taken together represent a group —(CH<sub>2</sub>)<sub>3</sub>—, —(CH<sub>2</sub>)<sub>4</sub>—, (CH<sub>2</sub>)<sub>2</sub>—O—(CH<sub>2</sub>)<sub>2</sub>—, —(CH<sub>2</sub>)<sub>2</sub>—S—(CH<sub>2</sub>)<sub>2</sub>— or —(CH<sub>2</sub>)<sub>5</sub>—;

or R<sup>1</sup> and R<sup>2</sup> taken together with the adjacent nitrogen atom represent a piperazine moiety which may be substituted in position 4 with a substituent selected from:

(a) (C<sub>1</sub>-C<sub>4</sub>)alkyl;

(b) (C<sub>5</sub>-C<sub>7</sub>)-cycloalkyl,

(c) pyridyl,

(d) —(CH<sub>2</sub>)<sub>p</sub>—NR<sup>5</sup>R<sup>6</sup> in which p represents an integer from 1 to 8 and R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen or (C<sub>1</sub>-C<sub>4</sub>) alkyl;

(e) piperidinyl;

(f) substituted piperidinyl, wherein the substituted piperidinyl bears a N-substituent which is (C<sub>1-4</sub>)alkyl;

(g) benzyl; and

(h) substituted benzyl, wherein the phenyl moiety bears 1 or 2 substituents selected from chloro, bromo, nitro, (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>)alkoxy.

In one embodiment, in the formula —COR, R represents the group —NR<sup>1</sup>R<sup>2</sup>, wherein R<sup>1</sup> and R<sup>2</sup> independently represent hydrogen, a group of formula —(CH<sub>2</sub>)<sub>n</sub>—NR<sup>3</sup>R<sup>4</sup>, in which n represents an integer from 2 to 8 and R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen or (C<sub>1</sub>-C<sub>4</sub>) alkyl or R<sup>3</sup> and R<sup>4</sup> taken together represent a group —(CH<sub>2</sub>)<sub>3</sub>—, —(CH<sub>2</sub>)<sub>4</sub>—, (CH<sub>2</sub>)<sub>2</sub>—O—(CH<sub>2</sub>)<sub>2</sub>—, —(CH<sub>2</sub>)<sub>2</sub>—S—(CH<sub>2</sub>)<sub>2</sub>— or —(CH<sub>2</sub>)<sub>5</sub>—, or R<sup>1</sup> and R<sup>2</sup> taken together with the adjacent nitrogen atom represent a piperazine moiety which may be substituted in position 4 with a substituent selected from (C<sub>1</sub>-C<sub>4</sub>)alkyl, (C<sub>5</sub>-C<sub>7</sub>)-cycloalkyl, pyridyl, benzyl, and substituted benzyl wherein the phenyl moiety bears 1 or 2 substituents selected from chloro, bromo, nitro, (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>)alkoxy.

Further, a derivative may include a compound in which the carboxy function of a side chain of an internal residue, e.g. that of the residue Glu11, is modified from —COOH to a group —COOR<sup>5</sup> in which R<sup>5</sup> represents hydrogen, (C<sub>1</sub>-C<sub>4</sub>) alkyl or (C<sub>1</sub>-C<sub>4</sub>)alkoxy(C<sub>2</sub>-C<sub>4</sub>)alkyl.

N-terminal derivatives of compounds of the invention may be those in which the N-terminal amino group —NH<sub>2</sub> is instead a group —NHR<sup>6</sup> wherein R<sup>6</sup> represents C<sub>1-4</sub>alkyl.

The term “(C<sub>1</sub>-C<sub>4</sub>)alkyl” represents straight or branched alkyl chains of from 1 to 4 carbon atoms, such as: methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl or 1,1-dimethylethyl while the term “(C<sub>2</sub>-C<sub>4</sub>)alkyl” represents straight or branched alkyl chains of from 2 to 4 carbon atoms such as: ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl or 1,1-dimethylethyl. The term “(C<sub>5</sub>-C<sub>7</sub>)cycloalkyl” represents a cycloalkyl group selected from cyclopentyl, cyclohexyl and cycloheptyl.

The term “(C<sub>1</sub>-C<sub>4</sub>)alkoxy” represents a straight or branched alkoxy chain of 1 to 4 carbon atoms such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy and 1,1-dimethylethoxy.

Derivatives according to the present invention may be made according to the methods described for the manufacture of derivatives of actagardine in EP-0195359, the disclosure of which is incorporated herein by reference.

#### Further Embodiments

Where the derivative is a compound where the C-terminal is of the formula —COR, in which R represents the group —NR<sup>1</sup>R<sup>2</sup>, in some embodiments, R<sup>1</sup> is H and R<sup>2</sup> represents a group of formula —(CH<sub>2</sub>)<sub>n</sub>—NR<sup>3</sup>R<sup>4</sup>, in which n represents an integer from 2 to 8 and R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen or (C<sub>1</sub>-C<sub>4</sub>) alkyl or R<sup>3</sup> and R<sup>4</sup> taken together represent a group —(CH<sub>2</sub>)<sub>3</sub>—, —(CH<sub>2</sub>)<sub>4</sub>—, (CH<sub>2</sub>)<sub>2</sub>—O—(CH<sub>2</sub>)<sub>2</sub>—, —(CH<sub>2</sub>)<sub>2</sub>—S—(CH<sub>2</sub>)<sub>2</sub>— or —(CH<sub>2</sub>)<sub>5</sub>—. In these embodiments, R<sup>3</sup> and R<sup>4</sup> preferably represent hydrogen or (C<sub>1</sub>-C<sub>4</sub>) alkyl. More preferably R<sup>3</sup> and R<sup>4</sup> represent (C<sub>1</sub>-C<sub>2</sub>) alkyl, e.g. methyl. Integer n may be preferably from 2 to 5, and more preferably 2 to 4, e.g. 3.

In other embodiments, R<sup>1</sup> and R<sup>2</sup> taken together with the adjacent nitrogen atom represent a piperazine moiety. The N-substituent in the 4 position may preferably be selected from:

- (a) (C<sub>1</sub>-C<sub>4</sub>)alkyl;
- (b) (C<sub>5</sub>-C<sub>7</sub>)-cycloalkyl,
- (d) —(CH<sub>2</sub>)<sub>p</sub>—NR<sup>5</sup>R<sup>6</sup> in which p represents an integer from 1 to 8 and R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen or (C<sub>1</sub>-C<sub>4</sub>) alkyl;
- (e) piperidinyl; and
- (f) substituted piperidinyl, wherein the substituted piperidinyl bears a N-substituent which is (C<sub>1-4</sub>)alkyl.

The piperidinyl and substituted piperidinyl groups preferably have their nitrogen atom at the 4-position.

The N-substituent may more preferably be selected from:

- (d) —(CH<sub>2</sub>)<sub>p</sub>—NR<sup>5</sup>R<sup>6</sup> in which p represents an integer from 1 to 8 and R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen or (C<sub>1</sub>-C<sub>4</sub>) alkyl; and

- (f) substituted piperidinyl, wherein the substituted piperidinyl bears a N-substituent which is (C<sub>1-4</sub>)alkyl.

If the N substituent is —(CH<sub>2</sub>)<sub>p</sub>—NR<sup>5</sup>R<sup>6</sup>, then R<sup>5</sup> and R<sup>6</sup> may be preferably (C<sub>1</sub>-C<sub>4</sub>)alkyl, more preferably (C<sub>1</sub>-C<sub>2</sub>) alkyl, e.g. methyl. Integer p is preferably 1 to 4, e.g. 3.

If the N substituent is substituted piperidinyl, then the N-substituent is preferably (C<sub>1</sub>-C<sub>2</sub>) alkyl, e.g. methyl. As mentioned above, the N is preferably in the 4-position.

#### Nucleic Acid

A nucleic acid of the invention may be a DNA or RNA, though preferably a DNA. A nucleic acid of the invention may be single- or double-stranded. In one aspect, the invention provides an isolated nucleic acid encoding a cluster polypeptide. In another aspect, the invention provides an isolated nucleic acid encoding a precursor polypeptide or variant or fragment thereof.

In a further aspect, the invention provides an isolated nucleic acid which may comprise all or a fragment of SEQ ID NO:100 or SEQ ID NO:200, including a fragment comprising an intergenic region disclosed herein. Such regions may include a promoter or other regulatory element for the expression of a cluster polypeptide or a precursor polypeptide of the present invention.

Twenty-five nucleotides is recognised by those skilled in the art as a sufficient number of nucleotides to be specific to the particular gene or gene cluster or sub-sequence thereof as disclosed herein. Thus fragments include fragments of SEQ ID NO:100 or SEQ ID NO:200, or variants thereof having significant sequence identity, which are at least 25, e.g. at least 30, e.g. at least 50, e.g. at least 100, e.g. at least 250 nucleotides in length.

Promoters that are variants of those intergenic sequences are also included and the specific intergenic sequences (or parts thereof) are preferred embodiments. In all cases, where a preferred embodiment of an orf, gene, nucleic acid, polypeptide or promoter is defined by reference to a specific sequence, the invention in its broader sense is intended to include embodiments having variants of that specific sequence.

The term “variant” as used herein in relation to a particular nucleic acid (the reference nucleic acid) denotes: any nucleic acid having a sequence which is different from that of the reference nucleic acid, but which is its complement or which shows significant nucleic acid sequence identity with, or hybridization under stringent conditions to, the reference nucleic acid or its complement or a fragment of the reference nucleic acid or its complement; or any nucleic acid which encodes an amino acid sequence having significant amino acid sequence identity with the amino acid sequence encoded by the reference nucleic acid, or a fragment of that nucleic acid. The term “variant” also refers to nucleic acids which differ from each other due only to the degeneracy of the genetic code, and which therefore encode identical deduced amino acid sequences. Variant nucleic acids of the invention are further defined as follows. If a variant nucleic acid of the invention is introduced into the gene clusters identified herein, in place of the sequence of which it is a variant, and the recombinant fragment is introduced into a suitable host cell under suitable conditions for lantibiotic production (e.g. as shown in the Examples), then production of a molecule hav-

ing one or more activities of a lantibiotic (especially antibiotic activity) will result. Preferably production will be regulated to occur at high cell density.

Significant nucleic acid sequence identity is preferably at least 50%, more preferably 60%, 70%, 80% or 90%, still more preferably 95%, 98% or 99%. Significant nucleic acid sequence identity is preferably shown between the variant nucleic acid (or a portion thereof) and a fragment of at least 30 residues of the reference nucleic acid, more preferably a fragment of at least 60, 90 or 120 residues, still more preferably a fragment of 180, 240 or 300 residues, more preferably the entire reference nucleic acid.

“Percent (%) nucleic acid sequence identity” is defined as the percentage of nucleotide residues in a candidate sequence that are identical with the nucleotide residues in the sequence under comparison. The identity values used herein were generated by the BLASTN module of WU BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively.

In relation to variants of the promoters used in the present invention, nucleic acid sequence identity is preferably assessed over a sequence of at least 30 residues, more preferably 40 or 50 residues, still more preferably 60 residues.

“Stringent conditions” or “high stringency conditions”, as defined herein, may be identified by those that: (1) employ low ionic strength and high temperature for washing, for example 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ during hybridization a denaturing agent, such as formamide, for example, 50% (v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50% formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×Denhardt’s solution, sonicated salmon sperm DNA (50 g/ml), 0.1% SDS, and 10% dextran sulfate at 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodium citrate) and 50% formamide at 55° C., followed by a high-stringency wash consisting of 0.1×SSC containing EDTA at 55° C.

When a nucleic acid of interest is said to be in “operative association” with a promoter or regulatory sequence, this means that the promoter/regulatory sequence is able to direct transcription of the nucleic acid of interest in an appropriate expression system, with the nucleic acid of interest in the correct reading frame for translation. Preferably when a nucleic acid of interest is in operative association with a promoter/regulatory sequence, the transcript of the nucleic acid of interest contains an appropriately located ribosome binding site for expression in an appropriate expression system of the polypeptide encoded by the nucleic acid of interest. See for example Sambrook et al. (1989) and Ausubel et al. (1995).

When a nucleic acid is referred to as “isolated”, this may mean substantially or completely isolated from some or all other nucleic acid normally present in *A. garbadinensis* and/or *A. liguriae*, especially nucleic acid from outside the gene cluster segments identified herein.

In light of the foregoing disclosure, it will be appreciated that this invention provides nucleotide sequences or a set of nucleotide sequences encoding the actagardine or actagardine B biosynthetic gene cluster. Accordingly, the entire gene cluster or portions thereof of at least twenty-five contiguous nucleotides may be used for a wide variety of applications, including but not limited to: expression of actagardine or

actagardine B; use as probes to screen other organisms for related molecules and the like; use to induce gene silencing and the like.

Expression Construct

In a further aspect of the invention, there is provided an expression construct comprising a nucleic acid encoding a cluster polypeptide or a lantibiotic polypeptide of the invention operably linked to a promoter.

In a further aspect, there is provided a set of expression constructs. A set of expression constructs comprises two or more polypeptide coding sequences of the present invention and at least one promoter suitable for the expression of said sequences. The promoter(s) may be a promoter with which the polypeptide gene is naturally associated with (or in the case of a variant, the promoter of the gene from which the variant is derived), or may be a constitutive or inducible promoter functional in the host cell. Promoters thus include intergenic regions of SEQ ID NO:100 or SEQ ID NO:200 upstream of any of the open reading frames listed in Tables 1 and 2.

The promoter(s) will be operably linked to the nucleic acids of the set of expression constructs. By “operably linked” it will be understood that the promoter will be able to direct transcription of the nucleic acid of interest in an appropriate expression system, with the nucleic acid of interest in the correct reading frame for translation. Preferably when a nucleic acid of interest is in operative association with a promoter/regulatory sequence, the transcript of the nucleic acid of interest contains an appropriately located ribosome binding site for expression in an appropriate expression system of the polypeptide encoded by the nucleic acid of interest. See for example Sambrook et al. (1989), Ausubel et al. (2002) and Kieser (2000).

Sets of expression constructs according to the invention include numerous permutations of genes encoding precursor and cluster polypeptides of the invention as defined above. In various aspects of the invention, the set will include at least a LanA gene. Examples of such sets are set out as “Set 1” to “Set 7” below, though these sets should be understood to be merely illustrative and not limiting.

Set 1: A LanA gene encoding a precursor polypeptide, preferably a precursor polypeptide capable of being converted to a compound of the invention, plus a LanM gene encoding a LanM polypeptide. The LanM polypeptide is preferably a LanM of SEQ ID NO:120 or a variant thereof, or SEQ ID NO:213 or a variant thereof.

Set 2: A LanA gene encoding a precursor polypeptide, preferably a precursor polypeptide capable of being converted to a compound of the invention, plus a LanR gene encoding a LanR polypeptide. The LanR polypeptide is preferably a LanR of SEQ ID NO:122 or a variant thereof, or SEQ ID NO:216 or a variant thereof.

Set 3: A LanA gene encoding a precursor polypeptide, preferably a precursor polypeptide capable of being converted to a compound of the invention, plus a LanM gene encoding a LanM polypeptide, plus a LanR gene encoding a LanR polypeptide. The LanM polypeptide is preferably a LanM of SEQ ID NO:120 or a variant thereof, or SEQ ID NO:213 or a variant thereof. The LanR polypeptide is preferably a LanR of SEQ ID NO:122 or a variant thereof, or SEQ ID NO:216 or a variant thereof.

Set 4: The genes of Set 3 together with a LanO gene encoding a LanO polypeptide. The LanO polypeptide is preferably SEQ ID NO:122 or a variant thereof, or SEQ ID NO:215 or a variant thereof.

## 13

Set 5: The genes of Set 3 or Set 4 together with a LanT gene encoding a LanT polypeptide. The LanT polypeptide is preferably SEQ ID NO:123 or a variant thereof, or SEQ ID NO:214 or a variant thereof.

Set 6: The genes of SEQ ID NOs:116 to 127 or variants thereof.

Set 7: The genes of SEQ ID NOs:206 to 220 or variants thereof.

In one aspect, a set will comprises sequences which all encode 1xx polypeptides or which all encode 2xx polypeptides. However sets which are made up of both 1xx and 2xx polypeptides are not excluded from the present invention.

#### Recombinant Expression Vector

In another aspect, there is provided a recombinant vector comprising one or more expression constructs of the invention. In an alternative aspect, there is provided a set of recombinant vectors which comprise a set of expression constructs of the invention. Suitable vectors comprising nucleic acid for introduction into bacteria can be chosen or constructed, containing appropriate additional regulatory elements if necessary, including additional promoters, terminator fragments, enhancer elements, marker genes and other elements as appropriate. Vectors may be plasmids, viral e.g. phage, or phagemid, as appropriate. For further details see, for example, Sambrook et al (1989) *Molecular Cloning, A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor. Many known techniques and protocols for manipulation of nucleic acid, for example in preparation of nucleic acid constructs, mutagenesis, sequencing, introduction of DNA into cells and gene expression, and analysis of proteins, are described in detail in Ausubel et al. (1995) *Current Protocols in Molecular Biology*, Wiley Interscience Publishers, (1995). Many aspects of the employment of these techniques in the context of *Streptomyces* spp. are described in detail in Hopwood et al (1985) *Genetic manipulation of Streptomyces a laboratory manual* (Norwich: John Innes Foundation) and *Practical Streptomyces Genetics* (2000) Kieser T. et al., The John Innes Foundation p. 386. The disclosures of Sambrook et al, Ausubel et al, Hopwood et al and Kieser et al are all incorporated herein by reference for these and all other purposes.

#### Expression Cassettes

In another aspect, the inventors have developed a vector system useful for producing and screening lantibiotic derivatives of actagardine B. This is achieved by introducing one or more restriction endonuclease recognition sites into the LanA gene which encodes SEQ ID NO:1, 11 or 212 in order to produce an expression cassette system. Thus in another aspect, the invention provides a recombinant DNA cassette which comprises a nucleotide sequence encoding an actagardine B precursor polypeptide, wherein said sequence comprises

- a first restriction site at or adjacent the N-terminal encoding region of the encoding sequence;
  - optionally a second restriction site downstream of the first restriction site and within the encoding sequence; and
  - a third restriction site at or adjacent the C-terminal encoding region of the encoding sequence,
- wherein at least one of said restriction sites does not occur within the LanA coding sequence shown as SEQ ID NO:200.

In a further aspect, there is provided a recombinant DNA cassette which comprises a nucleotide sequence encoding an actagardine precursor polypeptide, wherein said sequence comprises

- a first restriction site at or adjacent the N-terminal encoding region of the encoding sequence;

## 14

optionally a second restriction site downstream of the first restriction site and within the encoding sequence; and a third restriction site at or adjacent the C-terminal encoding region of the encoding sequence,

wherein at least one of said restriction sites does not occur within the LanA coding sequence shown as SEQ ID NO:100.

Generally, all two or three sites will be different from each other. It is also desirable that when the cassette is carried by a vector, the sites are unique for that vector.

In a preferred aspect, the non-naturally occurring restriction enzyme site is the second restriction site and is located between codons 5 and 16, such as between 6 and 15, of the encoding sequence of SEQ ID NO:1 or SEQ ID NO:4.

The cassette will desirably also include a LanA leader sequence and a LanA promoter, and may include in addition one or more cluster genes, particularly where such a cluster gene is required to complement the loss of the equivalent host cell gene.

The cassette of the invention described above may be engineered in a variety of ways. For example, the fragment obtained by cleaving the cassette between the first and second, first and third, or second and third, restriction sites may be replaced with a variant coding sequence encoding a lantibiotic A variant. Thus the invention provides a variant of the cassette of the invention wherein said variant has from 1 to 15 nucleotide substitutions within the encoding region of the encoding sequence.

As an intermediate to the production of such a variant, the sequence of between the first and second, first and third, or second and third, restriction sites may be replaced by a larger stuffer fragment.

In another aspect, the cassette encoding a lantibiotic derivative may be used to transform a host cell to express the derivative, for example to assess its anti-bacterial properties.

In one aspect, a multiplicity of expression cassettes may be made to provide a library of different derivatives, which may then be screened for activity.

An expression cassette of the invention may be based on any cloning and expression vector used in the art for the expression of genes in host cells. Such vectors will include one or more origins of replication, which may be temperature sensitive. The vectors may include a selectable marker, such as the chloramphenicol acetyl transferase gene, the erythromycin resistance gene, the apramycin resistance gene or the tetracycline resistance gene. The vector may also contain a targeting region, this region being homologous to a genomic sequence present in the host cell outside the LanA gene cluster. Such a vector may be used to integrate the cassette into the genomic sequence homologous to the targeting region.

The expression cassette may also comprise one or more cluster genes in addition to the LanA gene or derivative thereof. Where the host cell is a  $\Delta$ LanA host cell in which the LanA gene has been inactivated in a manner which also inactivates such a cluster gene (e.g. in the strain disclosed in Altena et al, 2000), it is desirable that this gene or an equivalent gene is provided on the expression cassette.

As used herein, by "at or adjacent the N-terminal encoding region" it is meant that the first base of the restriction site is located at a position from six residues upstream of the ATG codon of the LanA leader sequence to no more than six codons downstream of the first codon of the propeptide. Preferably the first base of the restriction site is located at a position from twelve, preferably six, residues upstream to six residues downstream of the first codon of the propeptide encoding sequence.

In one aspect, the first restriction site is a Bg/II site.

Similarly, by “at or adjacent the C-terminal encoding region” it is meant that the first base of the restriction site either includes at least one of the nucleotides of the termination codon of the propeptide or the 5' or 3' nucleotide of the restriction site is no more than twelve, preferably six, residues downstream or upstream respectively of the termination codon.

In one aspect, the third restriction site is a AvrII site.

The second restriction site, when present, will lie between the first and third restriction sites. Preferably the restriction site includes at least one nucleotide present from codon 5 to codon 16, preferably codon 8 to 16 of the propeptide-encoding sequence. In the accompanying examples, a BsrGI site has been introduced by altering codons 6 and 7 of the ActA-encoding sequence. However, other changes are also contemplated by the present invention.

It is also possible to introduce more than one change such that the expression cassette includes two or more sites between the first and third restriction sites.

The cassette may include two or three non-naturally occurring restriction sites. In the accompanying example, all three sites do not normally occur in the ActA sequence encoded by of SEQ ID NO:100.

The expression cassette simplifies the rapid production of lantibiotic derivatives, as discussed further herein below.

In one aspect, the region between the first and second sites, the first and third, or the second and third sites, may be replaced by a stuffer fragment. Where two or more sites between the first and third sites are present, the region between any pair of such sites may also be replaced by a stuffer fragment. A stuffer fragment is a piece of DNA which is larger than the sequence which it replaces. The stuffer fragment may be from 50 to 5000 nucleotides in size, for example from about 500 to 2000 nucleotides in size. The value of introducing these stuffer DNA fragments is that when the region is replaced by a lantibiotic-encoding oligonucleotide there is a significant decrease in plasmid size. The resulting plasmid can thus be readily purified away from any minor population of unrestricted plasmid thus eliminating any background.

A cassette of the invention may be used to introduce specific changes to the ActA sequence in a vector which can then be introduced into a host cell for expression of a lantibiotic. To achieve this, the sequence is desirably operably linked to the LanA (e.g. ActA or LigA) leader sequence, which in turn is operably linked to the LanA promoter (e.g. ActA or LigA)

In addition or as an alternative, the vector comprising the cassette may also include a LanR gene. The LanR gene will be located downstream of, and in tandem with, the lantibiotic A coding sequence.

#### Expression Libraries

Expression cassettes of the invention may be used to provide libraries of lantibiotic-encoding genes. Such libraries may be made by introducing into the cassette, between the first and second restriction sites, the first and third restriction sites, or the second and third restriction sites, a multiplicity of sequences each of which corresponds to the corresponding ActA or LigA sequence apart from having from 1 to 15, for example from 1 to 10, preferably from 1 to 6, for example from 1 to 3 nucleotide changes compared to the propeptide portion of SEQ ID NOs: 100 or 200. Preferably such changes result in a change of the protein encoded by the sequence. However non-coding changes are not excluded.

Libraries form a further aspect of the invention. Such libraries may comprise from 10 to 100,000, such as from 10 to 10,000 for example from 10 to 1,000 different coding sequences which are variants of the lantibiotic A coding sequence of an expression cassette.

An expression cassette encoding a lantibiotic A derivative may be introduced into a host cell for expression of the lantibiotic.

In one embodiment, the library may be transformed into host cells, and colonies isolated and/or screened for antibacterial activity. The sequences of the lantibiotic A expressed by individual colonies showing such activity can be determined. Where the lantibiotic A shows activity, the invention further provides a lantibiotic obtained by the method of the invention.

#### Host Cell

Two main types of host cells are envisaged by the present invention. The first type of host cell is a lantibiotic producing host cell. Alternatively the host cell may be a non-producer cell, i.e. does not contain a LanA gene or its associated cluster genes required for producing a LanA polypeptide.

In one embodiment, the invention provides a host cell transformed with a set of expression constructs of the invention. The set of constructs may be any one of Sets 1 to 7 as defined above, or a set based upon any other combination of precursor and cluster polypeptide-encoding nucleic acids. In another embodiment, the host cell may be transformed with a expression cassette of the invention.

In a further embodiment, there is provided a library of host cells, each one comprising a different expression cassette of the invention.

#### A Lantibiotic-Producing Host Cell.

In one embodiment, the host cell may be a lantibiotic producing host cell. A lantibiotic producing host cell is one in which an expression construct comprising a LanA gene, if introduced into the cell in the absence of any cluster gene, would be expressed and a LanA polypeptide produced. Such cells include any type-B lantibiotic producing cell such as any strain of a bacillus, an actinomycete, or a streptomycete, (e.g. *S. lividans* or *S. coelicolor*) which produces a lantibiotic. Examples of such cells include a cinnamycin-producing host cell (*Streptomyces cinnamoneus cinnamoneus* DSM 40005), or an actagardine-producing *Actinoplanes garbadinensis* or *A. liguriae* NCIMB 41362.

Where the invention relates to the productions of compounds of the formula (I) in which -X1-X2- represent -Leu-Val-, the host cell may be *A. liguriae* NCIMB 41362 without any further modification.

In one aspect, a host cell of this class may comprise a mutation in its endogenous LantibioticA gene such that the gene is not expressed or the gene product is inactive. Such a host cell may be obtained by targeted homologous recombination to delete or mutate the LanA gene of the host cell. Methods to achieve this are known as such in the art and are illustrated in Altena et al, (2000) and WO2005/093069, the disclosures of which are incorporated herein by reference. The resulting host cell is referred to as a  $\Delta$ LanA host cell. In one particular embodiment, the host cell is a  $\Delta$ LigA *A. liguriae* NCIMB 41362 host cell in which the ligA gene has been inactivated, for example by mutation or deletion, e.g. deletion brought about by homologous recombination. In another embodiment, the host cell is a  $\Delta$ ActA *A. garbadinensis* host cell in which the ActA gene has been inactivated, for example by mutation or deletion, e.g. deletion brought about by homologous recombination.

The transformation of a host cell of this type with other cluster genes is also contemplated by the present invention, though where the host cell provides cluster genes necessary for the production of a lanA, the provision of such cluster genes is optional.

#### Non-Producer Cell

A non-producer cell may be any host cell in which expression of a LanA gene encoding a precursor polypeptide capable of being converted to actagardine or a variant thereof, or to a compound of the invention, can produce such a product provided the LanA gene is introduced into the cell as part of

a set of expression constructs which are capable of converting a precursor polypeptide to actagardine or a variant thereof, or to a compound of the invention.

A non-producer host cell may be a bacterial host cell. Bacterial host cells include an actinomycete, or a streptomycete, e.g. *S. lividans*, *S. coelicolor* or *S. cinnamomeus*.

Host cells may be those in which the *lanO* gene is inactivated by mutation or deletion (or in the case of non-producer cells, not present), or those in which the expression of the *lanO* gene is increased, e.g. by provision of two or more copies of the gene or by linking the gene to a promoter which enhances expression in the host cell. Modulation of the *lanO* gene in this manner may be desirable to alter the relative levels of oxidized (Y—S(O)) and reduced (Y—S—) forms of compounds of the invention produced in the host cell.

#### Production of Compounds of the Invention

Compounds of the invention may be produced by expression of a nucleic acid, for example in the form of an expression construct encoding a precursor polypeptide carried in a recombinant expression vector, in a host cell which carries a *LanA* gene together with where necessary, associated cluster genes required for conversion of the precursor polypeptide to the product. As noted above, where the invention relates to the productions of compounds of the formula (I) in which -X1-X2- represent -Leu-Val-, the host cell may be *A. liguriae* NCIMB 41362 without any further modification.

The introduction of the expression cassette, or vector(s) into a host cell may (particularly for in vitro introduction) be generally referred to without limitation as "transformation". This may employ any available technique. For bacterial cells, suitable techniques may include calcium chloride transformation, polyethyleneglycol assisted transformation, electroporation, conjugation and transfection or transduction using bacteriophages.

In one aspect, the present invention provides a method of expressing nucleic acid of the invention, the method comprising providing a host cell (or other expression system) culturing the host cell, so as to express the nucleic acid of interest. The nucleic acid of interest will be in an expression cassette, such that culturing the host cell leads to the production of a product of the invention.

Preferably the nucleic acid of interest is expressed substantially only when the host cell culture reaches high cell density, more preferably at or close to the stationary phase of host cell culture. Cell cultures at or close to stationary phase may have OD<sub>650</sub> values in the range of 1-20. Known methods of culturing cells are well known in the art, for example from Sambrook et al (1989), Ausubel et al (2002), and (in particular for *Streptomyces* spp.) Kieser et al (2000). The expression products of the expression systems may be collected and purified. Isolation methods may comprise capture from the fermentation medium using solvent extraction techniques, adsorption resin such as hydrophobic resins or precipitation methods such as ammonium sulfate precipitation. Purification methods may include chromatography techniques such as ion exchange, hydrophobic interaction, reverse phase, normal phase, solid phase extraction and HPLC, e.g. as described in U.S. Pat. No. 5,112,806 for the isolation of mersacidin

Following culture of the cell, the compounds of the invention may be recovered from the host cell culture. The recovered compounds may be formulated in the form of a pharmaceutical composition, optionally in the form of a pharmaceutically acceptable salt.

Where host cells produce a mixture of compounds of the invention, e.g. those in which Y is —S— or —S(O)— or those in which Z is NH<sub>2</sub> or Ala-, or mixtures of all four types, the products may be isolated using standard separation tech-

niques such as hplc, e.g. as described in U.S. Pat. No. 6,022,851 for the production of Actagardine and Ala-Actagardine.

The recovered compounds may be formulated in the form of a pharmaceutical composition, optionally in the form of a pharmaceutically acceptable salt.

#### Pharmaceutically Acceptable Salt

A "pharmaceutically acceptable salt", may be an acid addition salt in which the base retains the biological effectiveness and properties of the compound and which is physiologically acceptable. Such salts include those formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

Salts also include basic salts, such as an alkali or alkaline earth metal salt, e.g. a sodium, potassium, calcium or magnesium salt.

#### Pharmaceutical Compositions

The antibiotics of the present invention may be formulated together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers, preservatives, antioxidants, lubricants, stabilizers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavouring agents, and sweetening agents. The formulation may further comprise other active agents, for example, other therapeutic or prophylactic agents. Thus, the present invention further provides pharmaceutical compositions, as defined above, and methods of making a pharmaceutical composition comprising admixing at least one active compound, as defined above, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, e.g., carriers, adjuvants, excipients, etc. If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dosage) of the active compound.

The term "pharmaceutically acceptable" as used herein pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, adjuvant, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

Compositions may be formulated for any suitable route and means of administration. Pharmaceutically acceptable carriers or diluents include those used in formulations suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

For solid compositions, conventional non-toxic solid carriers include, for example, pharmaceutical grades of manni-



tol, lactose, cellulose, cellulose derivatives, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, acetylated triglycerides and the like, as the carrier. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc, an active compound as defined above and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see "Remington: The Science and Practice of Pharmacy", 20th Edition, 2000, pub. Lippincott, Williams & Wilkins. The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s) in an amount effective to alleviate the symptoms of the subject being treated.

Dosage forms or compositions containing active ingredient in the range of 0.25 to 95% with the balance made up from non-toxic carrier may be prepared.

For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, cellulose, cellulose derivatives, sodium crosscarmellose, starch, magnesium stearate, sodium saccharin, talcum, glucose, sucrose, magnesium, carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain 1%-95% active ingredient, more preferably 2-50%, most preferably 5-8%.

Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, triethanolamine sodium acetate, etc.

For topical applications, the pharmaceutically acceptable compositions may be formulated in a suitable ointment or gel containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetaryl alcohol, 2-octyldodecanol, benzyl alcohol and water.

The percentage of active compound contained in such parental or topical compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.1% to 10% w/w employable, and will be

higher if the composition is a solid which will be subsequently diluted to the above percentages. Preferably, the composition will comprise 0.2-2% w/w of the active agent in solution.

Further teaching regarding suitable carriers, adjuvants, excipients, etc. can be found in standard pharmaceutical texts, for example, Remington: The Science and Practice of Pharmacy", 20th Edition, 2000, pub. Lippincott, Williams & Wilkins; and Handbook of Pharmaceutical Excipients, 2nd edition, 1994.

#### Administration of Compounds

Lantibiotic compounds and compositions of the invention may be administered to a subject in a method of medical treatment or prophylaxis. The subject may be a human or animal subject. The animal subject may be a mammal, or other vertebrate.

Thus there is provided a compound of the invention for use in a method of treatment or prophylaxis of a subject. There is also provided use of a compound of the invention for the manufacture of a medicament for use in a method of treatment or prophylaxis of a subject.

The method of treatment may be of a bacterial infection, including a skin, mucosal, enteric or systemic infection.

The variants and composition may be used for systemic treatment of bacteraemia (including catheter related bacteraemia), pneumonia, skin and skin structure infections (including surgical site infections), endocarditis and osteomyelitis. These and other such treatments may be directed against causative agents such as staphylococci, streptococci, enterococci. The compounds of the invention or compositions thereof may also be used for topical treatment of skin infections including acne ie. Propionibacterium acnes. The variants and compositions thereof may also be used in the treatment of eye infections, such as conjunctivitis, and for oral treatment for gut super-infection, such as that caused by Clostridium difficile including multiply-resistant C. difficile (pseudomembranous colitis), or gut infections associated with Helicobacter pylori.

The variants may also be used in the treatment or prevention of infection of the skin in wounds or burns. In addition, the variants and compositions thereof may be used in prophylactic methods, such as for the clearance of the nares to prevent transmission of MRSA. This may be practiced on subjects at risk of infection (e.g. patients entering a hospital) or on health professionals or other carers at risk of being carriers of such infections. Prophylactic clearance of gut flora ahead of abdominal surgery is also contemplated.

The compounds according to the invention can be administered enterally (orally), parenterally (intramuscularly or intravenously), rectally or locally (topically). They can be administered in the form of solutions, powders (tablets, capsules including microcapsules), ointments (creams or gel), or suppositories. Possible auxiliaries for formulations of this type are the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, flavor corrigents, colorants and/or buffer substances. As an expedient dose, 0.1-1000, preferably 0.2-100, mg/kg of body weight are administered. They are expediently administered in dose units which contain at least the efficacious daily amount of the compounds according to the invention, e.g. 30-3000, preferably 50-1000, mg.

The experimental basis of the present invention, including its best mode, will now be further described in detail, by way of example only, with reference to the accompanying drawings.

#### EXAMPLE 1

##### Cloning of Gene Clusters

Identifying and cloning the actagardine biosynthetic gene clusters from *A. garbadinensis* and *A. liguriae*.

O/SBDIG-1 is a digoxigenin (DIG)-labelled degenerate oligonucleotide composed of 48 bases. It was designed by translating the known amino acid sequence of actagardine and considering codon usage for Actinoplanes. Southern hybridisation analysis of genomic DNA isolated from *A. garbadinensis* and digested using the restriction enzyme NcoI, identified a ~3 kb fragment which hybridised to O/SB-  
DIG-1. The NcoI digest of the genomic DNA was repeated and DNA fragments of ~3 kb were isolated and cloned into NcoI cut pLITMUS28 (NEB). The resulting plasmids were introduced into *E. coli* DH10B cells and then analysed by Southern hybridisation using the probe O/SBDIG-1. A hybridising clone was identified and submitted for sequence analysis. Sequencing revealed that this plasmid designated pLITAG01 consists of DNA encoding the lanA structural gene for actagardine biosynthesis (actA) together with an upstream region believed to encode a portion of an ABC sugar transporter and a region downstream partially encoding lanM (actM).

The primers O/ACT08F and O/ACT09R were designed based upon sequence from pLITAG01. Using these primers in a PCR reaction together with DIG-labelled dNTPs (Roche) and pLITAG01 as a template, a 2296 by DIG-labelled DNA fragment was generated and designated SBDIG-2.

Two cosmid libraries were generated by cloning Sau3AI digested genomic DNA from *A. garbadinensis* ATCC 31049 and *A. liguriae* NCIMB 41362, into the cosmid SuperCos1 (Stratagene) previously digested using BamHI. Each cosmid library was analysed by Southern hybridisation using SBDIG-1. Twenty-five cosmids from each library believed to hybridise to SBDIG-1 were selected and re-analysed via Southern hybridisation using the probes O/SBDIG-1 and SBDIG-2. Nine cosmids derived from genomic DNA from *A. garbadinensis* and eleven cosmids derived from genomic DNA from *A. liguriae* hybridised to both probes. DNA was isolated from each cosmid and sequenced using the primers T3 and T7. The cosmids CosAL02 and CosAG14 were subsequently fully sequenced (Sequencing facility, Department of Biochemistry, University of Cambridge).

#### Materials and Methods

##### Strains

Bacterial strains used in the present invention are summarised in Table 5.

##### Vectors

The cosmid SuperCos1 was obtained from Stratagene.

The plasmid pLITMUS was obtained from New England Biolabs.

##### Primers

Primer name	SEQ. ID	Sequence 5'-3'
O/SBDIG-1	300	TGGGTSTGCACSCSTSACSATCGARTGCGGNACSGTS ATCTGCGCSTGC
O/ACT08F	301	TCCAGCACGCGCGGGG
O/ACT09R	302	GTTTCGACCAGCCGCC

#### Southern Hybridisation

##### Labelling of DNA Probe

DNA hybridisation probes were prepared using the Digoxigenin (DIG) PCR DNA labeling and detection kit supplied by Roche, according to their instructions.

##### Transfer of DNA to Nylon Membrane

The DNA of interest was initially separated by agarose gel electrophoresis and transferred to a nylon membrane (Hybond-N, Amersham Int., UK) using a vacuum blotter (Q BIO gene). The time taken for depurination of the DNA using 0.5 M HCl was judged by the time taken for the bromophenol

blue marker band to turn completely yellow (typically 15-20 min for a 0.7% agarose gel). The DNA was then systematically denatured with 1.5 M NaCl, 1.5 M NaOH and then neutralised using 0.5 M Tris, 1.5 M NaCl, pH 8.0 for a further 15-20 min each. Complete blotting of the DNA was facilitated by flooding with 20×SSC for a minimum of 60 min. After removing the blotted membrane from the vacuum it was left to air dry at room temperature. The DNA was cross-linked by placing the membrane (DNA face down) on a UV transilluminator (UVP) and exposing it to UV at a wavelength of 365 nm for 5 min.

#### Colony Lifts and Hybridisation

Colonies to be screened by hybridisation were transferred onto a nylon membrane (Roche diagnostics). This was achieved by placing the positively charged nylon membrane over the colonies and pressing firmly for 1 min to ensure effective transfer. Reference points were marked on the membrane to indicate its orientation with respect to the colonies. Following this, the membrane was removed and prepared for hybridisation as directed in the Roche user's manual (DIG Application manual for filter hybridisation).

#### Hybridisation and Development of Membranes

DNA was hybridised with the prepared probe overnight (~16 hr) at 68° C. in a HB-1000 hybridisation oven (UVP). Following hybridisation the membrane was washed for 2 periods of 5 min at room temperature using 2× salt sodium citrate (SSC)+0.1% sodium dodecyl sulphate (SDS). These washes were followed with a second series of 2×15 min washes at 68° C. using 1×SSC+0.1% SDS for the membrane hybridised in the presence of SBDIG-1 and 0.1×SSC+0.1% SDS for the membrane screened using SBDIG-2. Membranes were then developed as recommended in the Roche user's manual (DIG Application manual for filter hybridisation).

#### Software

The consensus sequences were analysed using FramePlot version 2.3.2, BioEdit sequence alignment editor, ClustalW (EMBL-EBI) and the Basic Local Alignment Search Tool (BLAST, NCBI).

#### Results and Discussion

##### CosAG14

The cosmid, CosAG14, contains a 38168 by fragment of genomic DNA isolated from *A. garbadinensis*. Sequence analysis has identified DNA encoding the leader and actagardine prepeptide, this gene has been assigned the name actA. Two alanine residues lie immediately upstream of the actagardine prepeptide. These residues are believed to represent the recognition site for protease cleavage of the leader peptide from actagardine. Partial cleavage at this position resulting in the retention of an alanine is thought to result in the production of ala-actagardine routinely observed in fermentation broths of *A. garbadinensis*. Downstream of the actA gene lies a 3162 by region of DNA with strong sequence similarity to several lanM proteins, for example, mrsM (30% identity) from the mersacidin gene cluster. This putative gene has been designated actM and is thought to be involved in the modification of the actagardine prepeptide, catalysing dehydration and thioether formation. An open reading frame designated actO, that is located 11 bp downstream of actM encodes a 341-amino-acid protein with sequence similarity (~39% identity) to several luciferase-type monooxygenases. The role of the monooxygenase, ActO, is believed to be to catalyse the incorporation of oxygen generating actagardine from deoxy-actagardine. In reverse orientation to actO and located 62 bp downstream is the open reading frame named actR. The protein product of this orf shows sequence similarity (~37% identity) to several two-component response regulators. Posi-



TABLE 1-continued

Annotation of CosAG14 (38168 bp fragment isolated from <i>A. garbadinensis</i> . The SuperCos1 vector backbone sequence is omitted)					
Gene	Description	Position (DNA)	Frame	Size AAs (bp)	Start-end (3AA)
orf24	Hypothetical protein	29462-30196	+2	244 (735)	MIV-RNR
orf25	Response regulator kinase	30235-31338	+1	367 (1104)	VLR-ARA
orf26	Response regulator sensor	31335-31997	+3	220 (663)	MTR-AVG
orf27	Penicillin binding protein	32138-34486	+2	782 (2349)	MLI-PPR
orf28	Methyltransferase	35209-34448	-2	253 (762)	MAP-DRR
orf29	Hydrolase	36030-35245	-3	261 (786)	VPR-PPP
orf30	Response regulator	36086-36820	+2	244 (735)	VSP-TGS
orf31	Fructose biphosphate aldolase	36844-37689	+1	281 (846)	MKD-RAW
orf32	Hydrolase	37590-38168	+3	192 (579)	MGS-DPA

TABLE 2

Annotation of CosAL02 (40402 bp fragment isolated from <i>A. liguriae</i> . The SuperCos1 vector backbone sequence is omitted).					
Gene	Description	Position (DNA)	Frame	Size AAs (bp)	Start-end (3AA)
orf1	Secretion system protein	1008-1	-2	335 (1008)	VRL-VDI
orf2	Response regulator	2198-1122	-3	358 (1077)	MSE-LFP
orf3	Hypothetical protein	3088-2288	-1	266 (801)	MRR-VVR
orf4	Hypothetical protein	4410-3112	-2	432 (1299)	MRR-RTG
orf5	Response regulator ATP- binding	5205-4795	-2	136 (411)	MWK-SAR
orf6	ABC sugar transporter	5516-6607	+2	363 (1092)	MFN-SAY
orf7	ABC sugar transporter ATP- binding	6673-8178	+1	501 (1506)	MLL-DEH
orf8	ABC transport permease	8168-9127	+2	319 (960)	MST-RTR
orf9	ABC transporter permease protein	9130-10092	+1	320 (963)	MSI-RRS
orf10	Metallopeptidase	12046-10586	-1	486 (1461)	MRT-PGS
orf11	Putative StrR-like regulator	12460-13320	+1	286 (861)	MDS-DAA
orf12	ligA	13641-13835	+3	64 (195)	MSA-CAC
orf13	ligM	13907-17047	+2	1046 (3141)	MSS-THV
orf14	ligT, ABC transporter	17040-18767	+3	575 (1728)	MSE-LLT
orf15	ligO, Luciferase type monooxygenase	18785-19828	+2	347 (1044)	MLS-RRW
orf16	ligR, Response regulator	20459-19806	-3	217 (654)	MAD-ELA
orf17	ABC-transporter associated permease	23069-20625	-3	814 (2445)	MIF-LVR
orf18	ABC-transporter. ATP-binding protein	23788-23066	-1	240 (723)	MVS-VTS
orf19	Histidine kinase	23980-25068	+1	362 (1089)	VIA-AVP
orf20	Response regulator	25065-25721	+3	218 (657)	MTE-GPS
orf21	Putative membrane protein	26673-25768	-2	301 (906)	MPI-RFP
orf22	alpha-beta hydrolase	26697-27569	+3	290 (873)	MRN-ASR
orf23	Transcriptional regulator	27574-28011	+1	145 (438)	VRL-RLG
orf24	Pyruvoyl-dependent arginine decarboxylase	28102-28629	+1	175 (528)	MAD-GMN
orf25	Putative diamminopimelate decarboxylase	30946-29626	-2	406 (1221)	MTL-LYA
orf26	Kinase	31860-30931	-2	309 (930)	VRS-PDL
orf27	Transcriptional regulator	33248-32145	-3	367 (1104)	VVF-ANS
orf28	Glycosyl transferase	33600-34553	+3	317 (954)	MPS-NAG
orf29	Glycosyl transferase	34543-35652	+1	369 (1110)	MPA-ARV
orf30	Dihydrolipoamide dehydrogenase	36432-37811	+3	459 (1380)	MGE-INF
orf31	Putative membrane protein	37973-39019	+2	348 (1047)	MTT-TPG

## EXAMPLE 2

## Expression Cassette

## Generation of an Expression Cassette

This example illustrates the production of an expression cassette according to the present invention. This expression cassette, plasmid pAGvarX has been designed for the efficient generation of variant *lanA* genes of the present invention

which can then be introduced into a host cell, such as a strain of *A. garbadinensis* in which the wild-type *actA* has been removed (*A. garbadinensis*  $\Delta$  *actA*). This plasmid, a derivative of the vector pSET152 (Bierman et al., 1992) will integrate into the host's chromosome via the *attP* attachment site. Expression of the mutated *actA* gene by the host organism together with the remaining wild-type genes of the actagardine biosynthetic gene cluster should generate actagardine variants.

## Construction of the Plasmid pAGvarX

Unless stated otherwise all quoted positions relate to SEQ IDNO:100. The scheme for the construction of plasmid pAGvarX is shown in FIG. 3. The base adjacent to the orf lying upstream of the actA at position 21237 to the leucine residue within the actA encoding region at position 21672 was amplified by PCR using the primers O/AGvar01bF and O/AGvar02bR (primer table) and pLITAG01 as a template. The primers were designed to introduce a flanking XbaI site at the 5' end and a Bg/II site via a silent mutation at the 3' leucine region encoding the actA. This fragment was introduced into dephosphorylated pUC19 previously digested using SmaI to yield pAGvar1.

The region of DNA spanning from the C-terminus of the actA to the adjacent downstream orf (21758-21836 inclusive) was amplified by PCR using the primers O/AGvar05F and O/AGvar06R and pLITAG01 as a template. The primers were designed to introduce a flanking AvrII site at the 5' position and an EcoRI site at the 3' end. The resulting PCR product was cloned into dephosphorylated pUC19 previously digested using SmaI to yield pAGvar2. The plasmids pAGvar1 and pAGvar2 were then digested using XbaI and the PCR fragment from pAGvar1 recovered and cloned into dephosphorylated XbaI digested pAGvar2, the correct orientation of the incoming fragment was determined by restriction analysis. The resulting plasmid pAGvar3 was subsequently digested using Bg/II and AvrII and ligated to the annealed oligonucleotides O/AGvar03F and O/AGvar04R generating pAGvar4. The plasmid pAGvar4 was subsequently digested using EcoRI and XbaI and the resulting ~620 bp fragment including the annealed oligonucleotides introduced into pSET152 previously digested using EcoRI and XbaI yielding the vector pAGvarX.

The region of pAGvarX constructed by annealing the respective oligonucleotides, introduce a BsrGI site via a silent mutation at the amino acids 6 and 7 (C and T respectively) with respect to the actagardine peptide. This site can be used in conjunction with either the upstream Bg/II site or downstream AvrII site to introduce DNA encoding targeted mutations to any of the amino acids encoded within the actA peptide.

## EXAMPLE 3

## Host Cell

This example illustrates the production of a lantibiotic-producing host cell in which the lanA gene has been inactivated. In this example, the host cell is *A. garbadinensis* in which the actA gene has been deleted.

Construction of the Strain *A. garbadinensis*  $\Delta$  actA

The strain *A. garbadinensis*  $\Delta$  actA is utilized as a host for expressing variants of the actagardine structural gene actA. This strain was generated from wild-type *A. garbadinensis* using the Redirect technology developed by Gust et al., 2002. Firstly, the region of DNA from the cosmid CosAG14 encoding actA was replaced with the cassette SBdel-1. SBdel-1 consists of the apramycin resistance gene (aac(3)IV) and oriT flanked by FLP recognition target (FRT) sites and was amplified by PCR using the plasmid p1J773 as the template together with the primers O/SB50F and O/SB51R which bind at 21536 and 21802 of SEQ ID NO:100 respectively. Following the Redirect protocol (Gust et al., 2004), actA of CosAG14 was replaced with SBdel-1 generating the cosmid CosAG14 $\Delta$ A. The central part of the SBdel-1 cassette was subsequently removed from CosAG14 $\Delta$ A by FLP-mediated excision following step 7 of the Redirect protocol generating

CosAG14 $\Delta$ B. Removal of this region allows the generation of non-polar, unmarked in-frame deletions as well as repeated use of the same resistance marker (Gust et al., 2003).

The second stage of construction was to engineer the cosmid so that it could be introduced into *A. garbadinensis* via conjugation. This began by first inserting CosAG14 $\Delta$ B into the *E. coli* strain BW25113/p1J790 by transformation. The ampicillin gene of CosAG14 $\Delta$ B was then replaced with SBdel-2 following the Redirect protocol (Gust et al., 2004) generating the cosmid CosAG14 $\Delta$ C. The cassette SBdel-2, like SBdel-1, houses the apramycin resistance gene (aac(3)IV) and oriT flanked by FRT sites but was generated using the primers O/SB52F and O/SB53R together with the template p1J773.

CosAG14 $\Delta$ C was used to transform electrocompetent cells of *E. coli* ET12567/pUZ8002 before being conjugated with *A. garbadinensis* following the Redirect protocol (Gust et al., 2004; see also following paragraph). The resulting strain in which the actA gene has been removed from the chromosome of the wild-type producer is *A. garbadinensis*  $\Delta$  actA.

In more detail, to obtain the *A. garbadinensis*  $\Delta$  actA strain above, CosAG14 $\Delta$ C was used to transform electrocompetent cells of *E. coli* ET12567/pUZ8002 before being conjugated with *A. garbadinensis*. Apramycin resistant exconjugants were obtained and sub-cultured through six successive rounds of growth in TSB without apramycin. Cells from culture 6 were plated onto medium 65 and incubated at 30° C. After 5 days colonies were transferred and patched out over an area of approximately 1 cm<sup>2</sup> onto medium 65. After 3 days incubation at 30° C. the patched cells were transferred to medium 65 containing apramycin at a final concentration of 50  $\mu$ g/ml. Following 72 h incubation at 30° C., cells sensitive to apramycin were selected and the respective patches used to inoculate 50 ml flasks containing 10 ml TSB and grown at 30° C., 250 rpm for 4 days. Genomic DNA was prepared from each culture and analysed by PCR using oligonucleotides O/AGvar01bF and O/AGvar06r. PCR products of a size consistent with the deletion of the actA gene were generated. In parallel, analysis of fermentation broths by hplc demonstrated that these same samples did not produce actagardine.

## EXAMPLE 4

## Heterologous Expression

This example illustrates the expression of actagardine from the SEQ ID NO:100 gene cluster in a host cell which is a non-producer cell, *S. lividans*. Such host cells provide an alternative means of generating active variants of these two peptides.

The cosmids CosAG14 and CosAL02 containing the biosynthetic gene clusters encoding the production of actagardine and deoxy-actagardine B do not possess an origin of transfer (oriT) necessary to facilitate conjugal transfer to a heterologous host. Using Redirect technology (Gust et al., 2002) an oriT together with a phage attachment site attP and integrase (int) can be introduced into the SuperCos1 backbone of CosAG14 and CosAL02 replacing the neomycin resistance gene, neo.

## Construction of Vectors for Heterologous Expression.

The cosmid pMJCOS1 (supplied by the JIC, Norwich) is a derivative of SuperCos1 (Stratagene) in which the gene encoding for neomycin resistance has been replaced by a cassette (HEapra) which includes DNA encoding an oriT, attP, integrase (int) and apramycin resistance gene (aac(3)IV). The cassette HEapra was isolated by digesting pMJCOS1 with SspI and recovering the DNA from an agarose gel.

This cassette together with CosAG14 and CosAL02 were used to generate the cosmids CosAG14HEapra and CosAL02HEapra respectively following the Redirect protocol as described by Gust et al., 2004.

The cosmid CosAG14HEapra was subsequently introduced into *S. lividans* via conjugation. Apramycin resistant exconjugants of *S. lividans*/CosAG14HEapra were isolated. Three exconjugants were used to inoculate TSB seed media. *S. lividans*, *A. garbadinensis* and *A. liguriae* were grown in parallel to provide controls. Following 48 h incubation the seed cultures were used to inoculate a range of four different production media namely, AAS1, GM1, GM3 and TSB. These cultures were incubated for a total of nine days at 30° C. with 1.5 ml aliquots being removed from each flask after 5, 7 and 9 days incubation. The aliquots were centrifuged at 14000 rpm (IEC micromax benchtop centrifuge) for 10 minutes and the supernatants then decanted and used undiluted for bioassays and HPLC-MS analysis.

Zones of inhibition (haloes) indicative of the presence of a biological active compound(s) were observed around all of the wells loaded with supernatants of *S. lividans* containing the cosmid CosAG14HEapra (*S. lividans*/CosAG14HEapra) except for wells loaded with supernatant from fermentations in TSB where no haloes were generated. No biological activity was observed around wells loaded with supernatant from fermentations of *S. lividans* grown in any of the four media. Haloes were evident around all wells loaded with supernatants from cultures of *A. liguriae* and *A. garbadinensis* where growth was supported. All haloes were consistently generated from the first day of sampling on day 5 through to day 9 although a general reduction in the diameter of the haloes was evident.

HPLC-MS analysis of the supernatants from the fermentations of *S. lividans*/CosAG14HEapra confirm the presence of peaks with retention times and masses corresponding to ala(O)actagardine. These same peaks were absent from supernatants of *S. lividans* only. Table 3 summarises the HPLC-MS analyses of supernatants from fermentation of *S. lividans*, *S. lividans*/CosAG14HEapra, *A. garbadinensis* and *A. liguriae* following incubation for 5 days.

TABLE 3

Sample	Fermentation medium	Concentration of product (µg/ml)	Retention Time (min)	Molecular ion (m/z)	Identity
<i>S. lividans</i> /CosAG14HEapra	GM1	83	6.75	981	Ala(O)Actagardine (M + 2H) <sup>+2</sup>
				991	Ala(O)Actagardine (M + H + Na) <sup>+2</sup>
<i>S. lividans</i> /CosAG14HEapra	GM3	33	6.75	981	Ala(O)Actagardine (M + 2H) <sup>+2</sup>
				991	Ala(O)Actagardine (M + H + Na) <sup>+2</sup>
<i>S. lividans</i>	GM1	Not Detected	Not Detected	Not Detected	Not Detected
<i>S. lividans</i>	GM3	Not Detected	Not Detected	Not Detected	Not Detected
<i>A. garbadinensis</i>	GM1	58	6.9	945	Actagardine (M + 2H) <sup>+2</sup>
<i>A. garbadinensis</i>	GM3	24	6.8	981	Ala(O)Actagardine (M + 2H) <sup>+2</sup>
				991	Ala(O)Actagardine (M + H + Na) <sup>+2</sup>
<i>A. liguriae</i>	GM1	Not detected	7.06	937	Deoxy-actagardineB (M + 2H) <sup>+2</sup>
<i>A. liguriae</i>	GM3	Not detected	7.06	937	Deoxy-actagardineB (M + 2H) <sup>+2</sup>

## Antibacterial Activities

## MIC Determination

A selection of the variants produced as disclosed herein above were tested further for activity against a range of bacteria. Minimum inhibitory concentrations (MICs) for all organisms with the exception of *Streptococcus pneumoniae* were determined by two-fold serial antibiotic dilutions in Mueller-Hinton broth (MHB) supplemented with calcium chloride dehydrate to a final calcium concentration of 400 µg/ml. Minimum inhibitory concentrations (MICs) for *S. pneumoniae* were determined by two-fold serial antibiotic dilutions in Brain Heart Infusion (BHI) broth supplemented with 400 µg/ml calcium chloride dihydrate. Antimicrobial agent stock solutions were prepared and stored according to NCCLS standard M7-A6.

Actively growing broth cultures were diluted to contain 105 to 106 CFU/ml by adjusting to an absorbance of 0.2-0.3 at 600 nm, equivalent to the McFarland 0.5 standard. They were then diluted a further 1:100 in broth. The assays were performed in duplicate in sterile 96-well microtitre plates in a total volume of 200 µl (160 µl broth, 20 µl antibiotic, 20 µl inoculum) in a concentration range from 64 µg/ml to 0.06 µg/ml. The 12th well of the microtitre plate contained no antimicrobial agent. Vancomycin was used as a reference antibiotic for quality control. Plates were incubated aerobically, shaking, for 18-20 hours at 37° C. with the MIC defined as the lowest concentration of drug that produced no visible growth.

	E. faecium 19579	E. faecalis 29212	S. aureus R33	S. aureus SH1000	S. epidermidis 11047	S. pneumoniae R6
Actagardine	4, 4	<4, <4	16, 8	8, 8	8, 8	<4, <4
Actagardine	4, 4	<4, <4	16, 16	8, 8	8, 8	<4, <4
Ala(O)Actagardine	8, 8	4, 4	8, 8	8, 8	8, 4	<4, <4
Ala(O)Actagardine	32, 16	8, 8	<4, <4	8, 8	8, 8	<4, <4
Deoxyactardine B	16, 16	4, 4	16, 16	16, 16	16, 16	8, 8
Deoxyactardine B	16, 16	<4, <4	16, 16	16, 16	16, 16	<4, <4

## EXAMPLE 6

## NMR Analysis




## NMR Studies on Actagardine and Deoxy-actagardine

NMR spectroscopy (COSY, TOCSY, HSQC and NOESY) was successfully used to confirm the sequencing results obtained from producers of actagardine (*A. garbadinensis*) and deoxy-actagardine B (*A. liguriae*). Whilst the data obtained did not permit a completely unambiguous assignment of all residues, it was consistent with the structures shown in FIG. 4 and sufficient to confirm that deoxy-actagardine B from *A. liguriae* has at positions 15 and 16 the residues Leu and Val respectively.

## EXAMPLE 7

## Synthesis of Derivatives

The following derivatives of deoxy-actagardine B were made, in which the groups Z and the C-terminal amide were as follows:

Compound Structures		
Compound	Z	C-terminal amide
I	H	
II	H	
III	H	
IV	D-Ala	H
V	L-Ile	H
VI	L-Val	H
VII	L-Phe	H
VIII	L-Lys	H
IX	L-Tryp	H

The synthesis of the compounds I-XI was as follows:

## General Procedure 1. Preparation of Compounds I-III

To a solution of deoxy-actagardine B (20 mg, 11 nmol), the appropriate amine (11 nmol) and diisopropylethylamine (7.2  $\mu$ l, 70 nmol) in dry dimethylformamide (0.8 ml) were added 200  $\mu$ l of a solution of benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBop) (70 mg,

134 nmol) in dry dimethylformamide (1.0 ml). The mixture was analysed by HPLC to follow the progress of the reaction, adding further aliquots of the Pybop solution until all the starting material had been consumed. HPLC analysis at this stage also showed variable amounts (5-20%) of the diamide. After completion of the reaction, the mixture was diluted with 30% acetonitrile in 20 mM Kpi aqueous phosphate buffer, pH 7 (10 ml) and the monoamide was purified by preparative HPLC using the conditions described in Table 4. The appropriate fractions were concentrated to 25% of their original volume and desalted by loading on to a preconditioned C18 Bond Elut column (500 mg) which was subsequently washed by sequential elution with two column volumes of 30, 40, 70 and 90% aqueous methanol. Evaporation of the appropriate fractions gave the desired products as white solids.

## Compound I: Deoxy-Actagardine B

## N-[3-dimethylaminopropyl]monocarboxamide

Was obtained from coupling of deoxyactagardine B and 3-(dimethylamino)propylamine according to General Procedure 1. Yield 18 mg, 85% yield.  $[M+2H\ 2^+]$  calculated 979.0; found 980.2.

## Compound II: Deoxy-Actagardine B N-[1-(1-methyl-4-piperidinyl)piperazine]monocarboxamide

Was obtained from the coupling of deoxyactagardine B and 4-(piperidino)piperazine according to General Procedure 1. Yield 8 mg, 37% yield.  $[M+2H\ 2^+]$  calculated 1019.5; found 1020.0.  $[M+3H\ 3^+]$  calculated 680.0; found 680.0.

## Compound III: Deoxy-Actagardine B [1-(3-dimethylaminopropyl)piperazine]monocarboxamide

Was obtained from the coupling of Deoxy-actagardine B and 1-(3-dimethylaminopropyl)piperazine according to general procedure 1. Yield 10 mg, 46%  $[M+2H\ 2^+]$  calculated 1013.5; found 1014.0.

## General Procedure 2. Preparation of Compounds IV-IX

A solution of the appropriate Fmoc protected amino acid (34 nmol) in dry dimethylformamide (0.4 ml) was treated with a solution of benzotriazole-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate (PyBop) (11.4 mg, 22 nmol) and diisopropylethylamine (11  $\mu$ l, 68 nmol) in dry dimethylformamide (0.4 ml). The mixture was then added to a solution of Deoxy-Actagardine B (2 mg, 11 nmol) in dry dimethylformamide (0.5 ml) The mixture was left at room temperature for 1 h, after which time analytical HPLC (30-65% acetonitrile in 20 mM Kpi aqueous phosphate buffer, pH 7) showed complete conversion of the starting material. The reaction mixture was diluted with 40% aqueous methanol (20 ml) and the mixture was passed through a C18 Bond Elute column (500 mg) that had been preconditioned by washing

with two column volumes of 100% methanol followed by two column volumes of water. The column was eluted sequentially with two column volumes of 40, 50, 60, 70, 80, 90 and 100% aqueous methanol. The fractions were analysed by HPLC and the fractions containing the Fmoc-protected coupling product were evaporated to dryness. The residue was taken up in dimethylformamide (1 ml) and piperidine (50  $\mu$ l) was added to remove the Fmoc protecting group. Progress of the reaction was monitored by HPLC and after complete consumption of the starting material the solution was diluted into 30% aqueous methanol (20 ml). The mixture was then eluted through a C18 Bond Elut cartridge (500 mg) as previously described and the product obtained after evaporation of the appropriate fractions was further purified by preparative HPLC using the conditions described in Table 4. The appropriate fractions were concentrated to 25% of their original volume and desalted by loading on to a preconditioned C18 Bond Elut column (500 mg) which was subsequently washed by sequential elution with two column volumes of 30, 40, 70 and 90% aqueous methanol. Evaporation of the appropriate fractions gave the desired products as white solids.

#### Compound IV: D-Ala(0)deoxy-actagardine B

Was prepared according to general procedure 2 from Deoxy-actagardine B and Fmoc-D-alanine in 74% yield. [M+2H<sup>2+</sup>] calculated 972.5; found 973.0.  
043/188

#### Compound V: L-Ile(0)deoxy-actagardine B

Was prepared according to general procedure 2 from Deoxy-actagardine B and Fmoc-L-isoleucine in 27% yield. [M+2H<sup>2+</sup>] calculated 993.5; found 993.8.

#### Compound VI: L-Val(0)deoxyactagardine B

Was prepared according to general procedure 2 from Deoxy-actagardine B and Fmoc-L-valine in 55% yield. [M+2H<sup>2+</sup>] calculated 986.5; found 985.9.

#### Compound VII: L-Phe(0)deoxyactagardine B

Was prepared according to general procedure 2 from Deoxy-actagardine B and Fmoc-L-phenylalanine in 22% yield. [M+2H<sup>2+</sup>] calculated 1010.5; found 1010.9.

#### Compound VIII: L-Lys(0)deoxyactagardine B

Was prepared according to general procedure 2 from Deoxy-actagardine B and Bis(Fmoc)-L-lysine in 45% yield. [M+2H<sup>2+</sup>] calculated 1001.0; found 1001.6.

#### Compound IX: L-Tryp(0)deoxyactagardine B

Was prepared according to general procedure 2 from Deoxy-actagardine B and Fmoc-L-tryptophan in 55% yield. [M+2H<sup>2+</sup>] calculated 1030.0; found 1029.9.

### EXAMPLE 8

#### Further Antibacterial Data

##### MIC Determination

Staphylococcus, Streptococcus, Enterococcus spp.

Minimum inhibitory concentrations (MICs) were determined and antimicrobial agent stock solutions were prepared

and stored according to the NCCLS reference microdilution broth method for aerobic bacteria (M7-A6, 2003). MICs were determined by two-fold serial antibiotic dilutions in Mueller-Hinton broth (MHB) or Brain Heart Infusion (BHI) broth (*S. pneumoniae*). Actively growing broth cultures were adjusted in sterile broth or by direct colony suspension (*S. pneumoniae*) to a turbidity equivalent to the McFarland 0.5 standard ( $1 \times 10^8$  CFU/ml), then further diluted in sterile broth for a final inoculum in sterile 96-well microtitre plates of approximately  $5 \times 10^5$  CFU/ml. The assays were performed in duplicate with *Enterococcus faecalis* ATCC 29212 included as a reference control strain and Vancomycin as a reference antibiotic for quality control. Plates were incubated aerobically, shaking, for 18-20 hours at 37° C. with the MIC defined as the lowest concentration of drug that produced no visible growth.

##### *Clostridium difficile*

Minimum inhibitory concentrations (MICs) for *C. difficile* were determined and antimicrobial agent stock solutions were prepared and stored according to the NCCLS reference agar dilution method for anaerobic bacteria (M11-A5, 2001). Two-fold serial antibiotic dilutions were prepared in Wilkens-Chalgren agar (WCA). Test organisms were selected from 48 hour growth on Braziers (C.C.E.Y.) agar, subcultured in Schaedler broth to a density equivalent to a McFarland 0.5 standard ( $1 \times 10^8$  CFU/ml), with a final inoculum onto WCA plates of approximately  $10^5$  CFU/spot. *Bacteroides fragilis* ATCC 25285 was included as a reference control strain and Metronidazole was used as a reference antibiotic for quality control. All manipulations were performed in duplicate in ambient atmosphere in pre-reduced media with only brief exposure to oxygen. Plates were incubated anaerobically for 48 hours at 37° C. with the MIC defined as the concentration of drug where a marked reduction occurred in the appearance of growth on the test plate compared to growth on the anaerobic control plate.

##### *Propionibacterium acnes*

Test organisms were selected from 3-7 day growth on Wilkens-Chalgren agar (WCA) supplemented with furazolidone (1-2  $\mu$ g/ml). Fresh Wilkens-Chalgren broth (WCB) was inoculated by direct colony suspension with single colonies of *P. acnes* and adjusted to a density equivalent to the McFarland 0.5 standard ( $1 \times 10^8$  CFU/ml), then further diluted in sterile WCB for a final inoculum in sterile 96-well microtitre plates of approximately  $10^5$  CFU/ml. Two-fold serial antibiotic dilutions were performed in sterile water with stock solutions prepared and stored according to NCCLS standards (M11-A5, 2001). The assays were performed in duplicate with Vancomycin and Clindamycin used as reference antibiotics for quality control. Plates were incubated anaerobically for 48-72 hours at 37° C. with the MIC defined as the concentration of drug where a marked reduction occurred in the appearance of growth on the test plate compared to growth on the anaerobic control plate. All manipulations were performed in duplicate in ambient atmosphere in pre-reduced media with only brief exposure to oxygen.

Culture media were supplemented with calcium ions (as calcium chloride) at 50  $\mu$ g/ml except where higher concentrations are indicated. MIC values in  $\mu$ g/ml are shown in the following Tables:



35

TABLE 6

MIC values against Enterococci, Streptococci and Staphylococci		
Organism	Ala(O)- deoxyactagardine-B	Deoxyactagardine- B
M. luteus 4698 + 200 µg/ml Ca <sup>2+</sup>	4	8
E. faecalis 29212	16	16
E. faecalis 29212 + 200 µg/ml Ca <sup>2+</sup>	4	8
E. faecalis 29212 + 400 µg/ml Ca <sup>2+</sup>		4
E. faecium 7131121 (VRE)	>64	>64
E. faecium 7131121 (VRE) + 200 µg/ml Ca <sup>2+</sup>	>64	>64
E. faecium 7131121 (VRE) + 400 µg/ml Ca <sup>2+</sup>		32
E. faecium 19579	>64	>64
E. faecium 19579 + 200 µg/ml Ca <sup>2+</sup>	>64	>64
E. faecium 19579 + 400 µg/ml Ca <sup>2+</sup>		16
S. aureus R33 (MRSA)	32	32
S. aureus R33 (MRSA) + 200 µg/ml Ca <sup>2+</sup>	16	8
S. aureus R33 (MRSA) + 400 µg/ml Ca <sup>2+</sup>		16
S. aureus SH1000	16	16
S. aureus SH1000 + 200 µg/ml Ca <sup>2+</sup>	8	8
S. aureus SH1000 + 400 µg/ml Ca <sup>2+</sup>		16
S. epidermidis 11047	16	32
S. epidermidis 11047 + 200 µg/ml Ca <sup>2+</sup>	8	16
S. epidermidis 11047 + 400 µg/ml Ca <sup>2+</sup>		16
S. pneumoniae R6	16	16
S. pneumoniae R6 + 200 µg/ml Ca <sup>2+</sup>	32	6
S. pneumoniae R6 + 400 µg/ml Ca <sup>2+</sup>		4
S. aureus 12232 MRSA		16
S. aureus R36 (MRSA)		16
S. aureus R34 (MRSA)		16
S. aureus R39 (MRSA)		>32
S. aureus R40 (MRSA)		>32
S. aureus W71 (MRSA)		>32
S. aureus W74 (MRSA)		>32
S. aureus W96 (MRSA)		>32
S. aureus W97 (MRSA)		>32
S. aureus W98 (MRSA)		>32
S. aureus W99 (MRSA)		>32
S. epidermidis 7755298 (MRSE)		>32
S. epidermidis 7865688 (MRSE)		>32
S. epidermidis 7753921 (MRSE)		>32
S. epidermidis GRL05011 (MRSE)		>32

TABLE 7

MIC values against fusidic acid-resistant <i>Staphylococcus aureus</i>	
Organism	Deoxy- Actagardine B
Fusidic acid-res S. aureus 8325-4	8, 8
Fusidic acid-res S. aureus CS1116	32, 32
Fusidic acid-res S. aureus CS957	32, 32
Fusidic acid-res S. aureus CS767	32, 32
Fusidic acid-res S. aureus CS 858	32, 32
Fusidic acid-res S. aureus CS741	32, 32
Fusidic acid-res S. aureus CS1145	16, 16
Fusidic acid-res S. aureus CS872	16, 16
Fusidic acid-res S. aureus CS866	32, 32
Fusidic acid-res S. aureus CS607	64, 64
Fusidic acid-res S. aureus CS22	16, 16
Fusidic acid-res S. aureus 8325-4 + 200 µg/ml Ca <sup>2+</sup>	4, 4

36

TABLE 7-continued

MIC values against fusidic acid-resistant <i>Staphylococcus aureus</i>	
Organism	Deoxy- Actagardine B
Fusidic acid-res S. aureus CS1116 + 200 µg/ml Ca <sup>2+</sup>	16, 16
Fusidic acid-res S. aureus CS957 + 200 µg/ml Ca <sup>2+</sup>	16, 16
Fusidic acid-res S. aureus CS767 + 200 µg/ml Ca <sup>2+</sup>	16, 16
Fusidic acid-res S. aureus CS858 + 200 µg/ml Ca <sup>2+</sup>	16, 16
Fusidic acid-res S. aureus CS741 + 200 µg/ml Ca <sup>2+</sup>	16, 16
Fusidic acid-res S. aureus CS1145 + 200 µg/ml Ca <sup>2+</sup>	8, 8
Fusidic acid-res S. aureus CS872 + 200 µg/ml Ca <sup>2+</sup>	8, 8
Fusidic acid-res S. aureus CS866 200 µg/ml Ca <sup>2+</sup>	8, 8
Fusidic acid-res S. aureus CS607 + 200 µg/ml Ca <sup>2+</sup>	32, 32
Fusidic acid-res S. aureus CS22 + 200 µg/ml Ca <sup>2+</sup>	4, 4

TABLE 8

MIC values against mupirocin-resistant <i>Staphylococcus aureus</i>		
Organism	Deoxy-actagardine B	
8325-4	8, 8	
GISA-2	8, 8	
LZ6	16, 16	
LZ8	16, 16	
LZ9	16, 16	
LZ10	8, 8	
420	4, 4	
1205	16, 16	
1120	16, 16	
1454	16, 16	
1086	8, 8	

TABLE 9

MIC values against <i>Propionibacterium acnes</i>		
Organism	Deoxy- Actagardine B	
<i>Propionibacterium acnes</i> P37 (lab strain)	4, 4	
P. acnes AT1	4, 4	
P. acnes AT26	2, 2	
P. acnes 101897d	2, 2	
P. acnes PF284 (tet res)	2, 2	
P. acnes PF286 (erythro & clin res)	2, 2	
P. acnes PF289 (clin and co-trimazole res)	4, 8	

TABLE 10

MIC values against <i>C. difficile</i>		
Organism	Ala(O)- deoxyactagardine-B	Deoxyactagardine-B
<i>C. difficile</i> 37779	4	4
<i>C. difficile</i> 19126	2	4
MIC <sub>50</sub> 10		
<i>C. difficile</i> strains		2
MIC <sub>90</sub> 10		
<i>C. difficile</i> strains		4

TABLE 11

MIC values against <i>C. difficile</i>									
Organism	I	II	III	IV	V	VI	VII	VIII	IX
<i>C. difficile</i> 37779			>8	4	4	8	1	4	1
<i>C. difficile</i> 19126			>8	4	4	8	2	4	2

TABLE 11-continued

Organism	MIC values against <i>C. difficile</i>								
	I	II	III	IV	V	VI	VII	VIII	IX
MIC <sub>50</sub> <i>C. difficile</i>	2	2					2		
MIC <sub>90</sub> <i>C. difficile</i>	4	4					2		

### Materials & Methods

The materials and methods used in Examples 2-7 above are as follows:

#### Media

All buffers, solutions and media were made up using reverse osmosis (RO) water and contained per liter the following ingredients:

#### AAS1

Soluble starch	10 g
Glucose	10 g
Peptone	5 g
Dry corn steep liquor	1 g
Yeast extract	2 g
Adjust pH to 6.0	

Lablemco meat extract	4 g
Peptone	4 g
NaCl	2.5 g
Yeast extract	1 g
Soy flour	10 g
Glucose	25 g
CaCO <sub>3</sub>	5 g
Adjust pH to 7.6	

Mueller Hinton broth	21 g
For agar plates add;	10 g
Agar	
ABB13	

Soytone peptone	5 g
Soluble starch	5 g
CaCO <sub>3</sub>	3 g
MOPS	2.1 g
Agar	20 g
Adjust pH to 7.0	

Brain Heart Infusion	37 g
GM3	

Arkasoy soyflour	20 g
Mannitol	20 g
Adjust pH to 7.0	

Luria agar	40 g
LB	

Luria broth	25 g
SFM	

Soya Flour	20 g
D-mannitol	20 g
Agar	16 g
TAE buffer	

Tris	48.44 g
EDTA	3.72 g
Adjust pH to 8.3	

Tryptone	16 g
Yeast extract	10 g
NaCl	5 g
Adjust pH to 6.5-7.0	

-continued

#### SV2

Glucose	15 g
Glycerol	15 g
Peptone	15 g
NaCl	3 g
CaCO <sub>3</sub>	1 g
Adjust pH to 7.0	

TSB	
Tryptic soy broth	30 g
Adjust pH to 7.0	

'65'	
Glucose	4 g
Yeast extract	4 g
Malt extract	10 g
CaCO <sub>3</sub>	2 g
Agar	12 g
Adjust pH to 7.2	

### Bioassays

*Micrococcus luteus* was inoculated from frozen stock into 10 ml Mueller-Hinton broth and grown overnight at 30° C. with shaking at 200 rpm. 1 ml of this culture was used to inoculate 300 ml of Mueller-Hinton agar which was then poured into petri dishes. Wells (6 mm diameter) placed equidistant apart were made using a cork-borer and subsequently loaded with 50 µl of the respective sample. The bioassay plate was placed into a laminar air flow until the loaded samples had diffused, at which point the plates were transferred to a 30° C. incubator and left overnight.

#### Endonuclease Restriction Digestions

Digestions of DNA with restriction enzymes were carried out in the supplied buffers and in accordance with the manufacturer's guidelines. Typically, for preparative digests 5 µg of DNA was digested with 12 units of enzyme for 3 h at the recommended temperature. For analytical digests, 0.5 µg of DNA was digested with 2 units of enzyme for 2-3 h again at the recommended temperature. The digested DNA was analysed by agarose gel electrophoresis.

#### Sub-Culturing Exconjugants

Agar plugs of patched exconjugants were used to inoculate 50 ml flasks containing 8 ml TSB and 2 glass beads. The cultures were incubated at 30° C., 250 rpm for 10 days then 100 µl were removed and added to 10 ml TSB in a 50 ml flask containing 2 glass beads. The flasks were incubated for 2 days then 1 ml was removed and used to inoculate a 50 ml flask containing 10 ml TSB. Using 1 ml inoculum a total of six successive rounds of growth were carried out each incubated for 2 days at 30° C., 250 rpm. Cells from the sixth round of sub-culturing were pelleted by centrifuging at 4000 rpm for 20 minutes (Heraeus Sepatech Megafuge) then sonicated (MSE Sanyo Soniprep 150, amplitude 10-15 microns) for 30 seconds in TSB to disrupt the mycelium. Serial dilutions (10<sup>-1</sup> to 10<sup>-5</sup> in TSB) of the sonicated cells were plated onto medium 65 and incubated at 30° C.

#### Fermentation for Heterologous Expression

50 ml conical flasks each containing 2 glass beads and either 8 ml TSB or AAS1 media supplemented with nalidixic acid and the appropriate selective antibiotic were inoculated using agar plugs or 250 µl of a -80° C. glycerol stock. Following 2-4 days incubation at 30° C., 200 rpm, 1.2 ml (3%) per seed culture was used to inoculate 40 ml of the respective production media in 250 ml conical flasks containing 2 glass beads. These cultures were incubated at 30° C., 200 rpm for 9 days. 1.5 ml whole broth aliquots were removed periodically from each culture for analysis by bioassay and/or HPLC-MS analysis.

Fermentation of *A. liguriae* for the Isolation of deoxyactagardine B

250 ml conical flasks each containing 2 glass beads and 50 ml SV2 media were inoculated with 500  $\mu$ l (1%) of *A. liguriae* cells from a glycerol stock. Following 4 days incubation at 30° C., 250 rpm, 12 ml (3%) per seed culture was used to inoculate 400 ml of GM3 in 2 L conical flasks. These cultures were incubated at 30° C., 225 rpm for nine days. The culture broth was harvested by centrifugation at 4000 rpm (Heraeus Sepatech Megafuge) for 30 minutes after which the supernatant was decanted from the pellet of cells.

Fermentation of *A. garbadinensis* for the Isolation of Actagardine and Ala(O)-actagardine

250 ml conical flasks each containing 2 glass beads and 50 ml AAS media were inoculated with 500  $\mu$ l (1%) of *A. garbadinensis* cells from a glycerol stock. Following 9 days incubation at 30° C., 250 rpm, 12 ml (3%) per seed culture was used to inoculate 400 ml of AAS in 2 L conical flasks. These cultures were incubated at 30° C., 200 rpm for eight days. The culture broth was harvested by centrifugation at 4000 rpm (Heraeus Sepatech Megafuge) for 30 minutes after which the supernatant was decanted from the pellet of cells.

Isolation of Deoxy-actagardine B for MIC Studies

Diaion HP-20 resin (50 g/L) was added and mixed with supernatant isolated from a fermentation of *A. liguriae* and left overnight at 4° C. The suspension was aliquoted into Bond Elut columns (60 ml) and the resin washed sequentially with four bed volumes of water followed by three bed volumes of 25, 50, 75 and 100% methanol. HPLC analysis confirmed the presence of Deoxy-actagardine B in the 50, 75 and 100% methanol fractions. These fractions were combined then concentrated to approximately a quarter of the volume of the starting pool. The concentrate from 1 L of broth was loaded onto two C18 Bond Elut columns (5 g) that had been pre-conditioned by washing with two column volumes of 100% methanol followed by two column volumes of water. The columns were eluted sequentially with two column volumes of 50, 60, 70, 80, 90% methanol followed by two column volumes of 100% methanol. HPLC analysis confirmed the presence of Deoxy-actagardine B in the 80, 90 and 100% methanol fractions, these fractions were pooled and concentrated to a third of the starting volume. An equal volume of 40 mM potassium phosphate pH 2.5 in 50% methanol was added and the concentrate then loaded evenly onto three pre-equilibrated SCX Bond Elut columns (1 g). The SCX columns were initially washed with 40 mM potassium phosphate pH 2.5 in 50% methanol and then eluted using 1.5 column volumes of 250 mM potassium phosphate pH 7.0 in 50% methanol. The eluent was desalted by loading onto a C18 Bond Elut column (5 g) that had been pre-conditioned with two column volumes of methanol followed by two column volumes of water. The column was washed with two column volumes of 50% and then 60% methanol. Deoxy-actagardine B was eluted following the addition of two column volumes each of 70, 80, 90 and 100% methanol. Fractions containing purified Deoxy-actagardine B as confirmed by HPLC and LC-MS analyses were pooled and evaporated to dryness.

Isolation of Ala(O)-Deoxyactagardine B from Fermentation of *A. liguriae*

Diaion HP-20 resin (50 g/L) was mixed with supernatant from a four liter fermentation of *A. liguriae* and left overnight at 4° C. The suspension was collected into a glass sinter funnel and the resin was washed sequentially with four bed volumes of water followed by four bed volumes of 50% Methanol. Deoxy-actagardine B and Ala(O)-deoxyactagardine B were eluted from the resin by washing with five bed volumes of 100% Methanol. The 100% Methanol fraction

was concentrated to a third of the original volume and was then diluted by addition of water to a final concentration of 60% Methanol. The resulting solution was loaded onto four 10 g C18 Bond Elut columns prior to washing with two column volumes of 50% Methanol. Deoxy-actagardine B-related components were eluted from the column using two column volumes of Methanol/0.5% Formic Acid. The resulting eluent was concentrated by evaporation to 40 ml and Ala(O)-deoxy-actagardine B was separated from Deoxy-actagardine B by preparative HPLC using the conditions described in the table below.

Column	Capitol HPLC Ltd C18-BDS-HL5-26052 15 cm x 20 mm
Solvent A	30% ACN in 20 mM Potassium Phosphate pH 5.0
Solvent B	65% ACN in 20 mM Potassium Phosphate pH 5.0
Detection	210 nm
Flow Rate	10 ml/min
Time (T) = 0 min	100% A
T = 1 min	100% A
T = 29 min	35% B
T = 30 min	100% B
T = 33 min	100% B
T = 34 min	100% A
T = 35 min	100% A
Collection	Start 10 min; End 30 min; 0.5 or 0.25 minute fractions

Fractions containing Ala(O)-deoxy-actagardine B (as confirmed by HPLC and LC-MS analyses) were desalted using C18 Bond Elut columns as described above before being evaporated to dryness.

Ala(O)-deoxy-actagardine B was eluted from the column at Retention Time=5.04 minutes. MS analysis confirmed a species of 972.2 m/z (M+2H)<sup>2+</sup>.

Isolation of Actagardine and Ala(O)-actagardine for MIC Studies

Actagardine and Ala(O)-actagardine were purified using the method described for the purification of Deoxy-actagardine B from *A. liguriae* with the exception that preparative HPLC was required to resolve Ala(O)actagardine and Actagardine following the SCX Bond Elut step. Eluent from the SCX Bond Elut column was concentrated by rotary evaporation from 70 to 18 ml and the resulting concentrate was purified by preparative HPLC using the conditions described in Table 4 The respective fractions containing Actagardine and Ala(O)actagardine (as confirmed by HPLC and LC-MS analyses) were desalted using C18 Bond Elut columns as described previously before being evaporated to dryness.

TABLE 4

Preparative HPLC conditions for the separation of Actagardine and Ala(O)actagardine.	
Column	Capitol HPLC Ltd C18-BDS-HL5-26052 15 cm x 20 mm
Solvent A	30% Acetonitrile in 20 mM Potassium Phosphate pH 7.0
Solvent B	65% Acetonitrile in 20 mM Potassium Phosphate pH 7.0
Detection	268 nm
Flow Rate	10 ml/min
Time (T) = 0 min	100% A
T = 1 min	100% A
T = 19 min	25% B
T = 20 min	100% B
T = 25 min	100% B
T = 26 min	100% A
T = 30 min	100% A
Collection	Start 8 min; End 20 min; 1 minute fractions

## Agarose Gel Electrophoresis

Electrophoresis of DNA was carried out as described by Sambrook et al., 1989. Agarose gels (0.7-1%) were prepared in TAE buffer containing a final concentration of 0.1 µg/ml ethidium bromide to allow visualisation of the DNA by UV light. 0.1 volumes of 10× agarose gel loading solution was mixed with the samples. Samples were loaded onto the gel alongside a 100 bp, 1 kb, or lambda DNA-HindIII digest ladders (NEB) and run at 1-5 V/cm. The gel was visualised at λ=300 nm and photographed using a UVP video camera.

## Recovery of DNA from Agarose Gels

DNA was excised from agarose gels and recovered using a Qiaquick gel extraction kit (Qiagen) and eluted in either sterile reverse osmosis purified water, Tris-HCl (10 mM, pH 8.5) or TE buffer.

## End-Filling

Filling the recessed 3' termini created by digestion of DNA with restriction enzymes was done using *E. coli* DNA polymerase Klenow fragment. In a typical reaction 1 unit of enzyme was added per µg DNA along with 250 µM each dNTP. The reaction was incubated at 25° C. for 15-30 min and stopped by adding EDTA to a final concentration of 10 mM.

## Phosphorylation of DNA

PCR products were treated with T4 polynucleotide kinase at 37° C. for 30 min, following the method described by Sambrook et al., 1989. The enzyme was inactivated by incubating at 65° C. for 20 min.

## Dephosphorylation of Linearised Vectors

To avoid self-ligation of linearised vectors, 5'-phosphate groups were removed using shrimp alkaline phosphatase (SAP) following the manufacturer's guidelines. In a typical reaction 1 unit of SAP was added to the restriction mixture for the last hour of the DNA restriction reaction. The enzyme was inactivated by incubating at 65° C. for 20 min.

## Ligations

DNA ligations were performed as described by Sambrook et al., (1989) using 1 unit (U) of T4 DNA ligase in a total volume of 15 µl and incubating for 12-16 h at 16° C.

## Maintenance of Bacterial Cultures

Viable cells were stored as glycerol suspensions by freezing 0.5 ml of the respective culture at -80° C. with glycerol at a final concentration of 10%. Single colonies of *A. garbadinensis* and *A. liguriae* were obtained by streaking 50 µl from a fermentation broth or glycerol stock onto either medium 65 or ABB13 plates.

## Polymerase Chain Reaction

Polymerase chain reactions (PCRs) were performed on a Stratagene Robocycler Gradient96. In a typical reaction 100-200 ng template DNA was mixed with 20 pmol of each oligonucleotide primer and dNTP's at 250 µM each. Thermophilic DNA polymerase buffer as supplied by the manufacturer and DMSO made up 10% (v/v) each of a final volume of 50 or 100 µl reaction mixture. A typical reaction began with an initial cycle of 1 min denaturation (94° C.), 1 min, Y° C. (annealing) and 30 seconds-3 min extension (72° C.), at which point 5 units of thermophilic DNA polymerase was added. This was followed by 30 cycles of 94° C. for 1 min, Y° C. (annealing) for 1 min and 72° C. for X min and a final cycle of 72° C. for 2X min. The extension time X, was 1 min per kb of product when Taq polymerase was used and 2 min per kb of product when Pfu polymerase was used. The annealing temperature Y was 55° C. and 49° C. in the generation of pAGvar1 and pAGvar2 respectively. The conditions used for the generation of SBdel-1 and SBdel-2 were as described in the Redirect protocol (Gust et al., 2004).

## Primers

Primer name	SEQ ID NO:	Sequence 5'-3'
O/AGvar01bF	303	TTCTAGACGTTGTTCTCCATTTTCAC
O/AGvar02bR	304	AAGATCTTCGAAGGTGAGCTCGCCGAA
O/AGvar03F	305	GATCTTCGCGAGGACCGCACCATCTACGCCGCC AGCAGCGGCTGGGTGTGTACACTGACGATCGAG TGCGGCACCGTGATCTGCGCCTGCTGAC
O/AGvar04R	306	CTAGGTGAGCAGGCGCAGATCACGGTGCCGCAC TCGATCGTCAGTGTACACACCCAGCCGCTGCTG GCGGCGTAGATGGTGGGTCTCGCGAA
O/AGvar05F	307	GCCTGCTGACCTAGGTGACGATCGT
O/AGvar06r	308	TGAATTCGGCTGCTCCCCGCGCGAAAT
O/SB50F	309	ATTCGCCCCGGAAGTCCACCGAAAGGAAGACAC ACCATGATTCGGGGATCCGTGACCC
O/SB51R	310	GGGCGATGCCCGCCCGGGCCGAAACGATCGT CGATCATGTAGGCTGGAGCTGCTTC
O/SB52F	311	AAGTATATATGAGTAACTTGGTCTGACAGTTA CCAATGATTCGGGGATCCGTGACCC
O/SB53R	312	GCTTCAATAATATTGAAAAAGGAAGAGTATGAG TATTCATGTAGGCTGGAGCTGCTTC

## Preparation of Plasmid DNA

Plasmid DNA was prepared on a small scale (less than 20 µg preparation) by inoculating 3 ml of sterile 2TY or LB containing the appropriate antibiotic with single colonies picked from 2TY (or LA) agar plates. The cultures were incubated overnight (12-16 h) at 37° C. and 250 rpm. The cells were collected by centrifugation at 12,000×g for 1 min and plasmid DNA obtained using Wizard (Promega) Mini-prep kits according to the manufacturer's guidelines. In the case of larger preparations of up to 100 µg of plasmid DNA, 30 ml of 2TY cultures were grown and plasmid DNA extracted using a Qiagen Midi-prep kit, following the manufacturer's instructions. All plasmid preparations were checked by a combination of restriction analysis and/or sequence analysis.

## Preparation of Cosmid DNA

Cosmid DNA was prepared by inoculating 50 ml of sterile 2TY or LB containing the appropriate antibiotic with single colonies picked from 2TY (or LA) agar plates. The cultures were incubated overnight (12-16 h) at 37° C. and 250 rpm. The cells were collected by centrifugation at 4,000 rpm (Heraeus sepatech Megafuge 2.0R) for 20 min and Cosmid DNA isolated using a Qiagen Midi-prep kit according to the manufacturer's guidelines.

Preparation and Transformation of Electrocompetent *E. coli* Cells.

Electrocompetent *E. coli* DH10B were prepared by the method of Dower et al. (1988). Aliquots (60 µl) of competent cells were thawed on ice and 1.8 µl of ligation mixture or plasmid DNA added. The mixture was placed into an electroporation cuvette (Sigma 0.1 cm) and transferred to the electroporator (Stratagene electroporator-1000). A potential difference of 1.8 kV/mm (25 µF, 200Ω) was applied and 0.5 ml of 2TY or LB medium subsequently added. The cells were then incubated at 37° C. for 45-60 min to allow expression of the antibiotic resistance genes, prior to plating on the appropriate selective medium.

## Preparation of Genomic DNA

Genomic DNA templates were prepared using the procedure described by Kieser et al. (2000).

Conjugation Procedure for *Actinoplanes* sp.

Intergeneric conjugation between *E. coli* and *Actinoplanes* sp. was performed following the procedure described by Heinzmann et al. (2003), except, the strain *E. coli* ET12567/pUB8002 (Kieser et al., 2000) was used in place of the strain *E. coli* ET12567/pUB307 (Flett et al., 1997). Exconjugants were transferred and patched out over an area approximately 1 cm<sup>2</sup> onto medium 65 or ABB13 containing 50 µg/ml nalidixic acid and the relevant selective antibiotic. These plates were incubated at 30° C. for 4-7 days prior to being used as inoculum for broth cultures.

Conjugation Procedure for *Streptomyces* sp.

Intergeneric conjugation between *E. coli* and *Streptomyces* sp. was performed following the procedure described by Kieser et al., 2000. Exconjugants were transferred and patched out over an area approximately 1 cm<sup>2</sup> onto SFM containing 50 µg/ml nalidixic acid and the relevant selective antibiotic. These plates were incubated at 30° C. for 4-7 days prior to being used as inoculum for broth cultures.

TABLE 5

Bacterial Strains	
Name	Description/Use
<i>Actinoplanes garbadinensis</i> ATCC31049	Isolation of the biosynthetic gene cluster for the production of actagardine.
<i>Actinoplanes garbadinensis</i> Δ actA	<i>Actinoplanes garbadinensis</i> ATCC31049 in which the actA gene has been removed. Expression of variant actA genes
<i>Actinoplanes liguriae</i> NCIMB 41362	Isolation of the biosynthetic gene cluster for the production of deoxy-actagardine B. Expression of variant ligA genes.
<i>Escherichia coli</i> XL1-Blue MR	Generation of a cosmid library.
<i>Escherichia coli</i> DH10B	Routine cloning.
<i>Escherichia coli</i> ET12567	Isolation of non-methylated DNA.
<i>Escherichia coli</i> ET12567/pUZ8002	Intergenic transfer of DNA via conjugation.
<i>Escherichia coli</i> BW25115/pIJ790	Strain containing the lambda red recombination plasmid pIJ790. Facilitates the targeted recombination of a cassette flanked by FLP recognition sites.
<i>Escherichia coli</i> DH5α/BT340	Strain containing the plasmid BT340 facilitating FLP-mediated excision of disruption cassettes.
<i>Micrococcus luteus</i> ATCC4698	Bioassay test organism.
<i>Streptomyces lividans</i> 1326	Host organism for the heterologous expression.
<i>Streptomyces coelicolor</i> B757	Host organism for the heterologous expression
<i>Streptomyces cinnamoneus</i> DSM 40005	Host organism for the heterologous expression

## Antibiotics

Antibiotic stock solutions were prepared in water (unless stated otherwise) and filter sterilised by passing through a 0.22 µm Millipore filter. Solutions dissolved in ethanol were not sterilised (Sambrook et al., 1989). All antibiotics were stored at -20° C. In media where apramycin was used, MgCl<sub>2</sub> was added to a final concentration of 10 mM (from a stock of 2.5 M).

	Stock solution	Working concentration
Ampicillin (amp)	100 mg/ml	100 µg/ml
Apramycin (apra)	100 mg/ml	50 µg/ml
Carbenicillin (car)	100 mg/ml	100 µg/ml
Chloramphenicol (cm)	25 mg/ml in ethanol	25 µg/ml
Kanamycin (kan)	50 mg/ml	50 µg/ml
Nalidixic acid (na)	25 mg/ml	25 µg/ml

## Cassettes

Name	Size (bp)	Source	Description/Use
SBdel-1	1462	PCR using the primers O/SB50F and O/SB51R and pIJ773 as a template.	Contains an origin of transfer (oriT) and apramycin resistance gene flanked by FLP recognition target sites. The 5' and 3' regions are homologous to DNA flanking the actA gene from <i>A. garbadinensis</i> .
SBdel-2	1462	PCR using the primers O/SB52F and O/SB53R and pIJ773 as a template.	Contains an origin of transfer (oriT) and apramycin resistance gene flanked by FLP recognition target sites. The 5' and 3' regions are homologous to DNA flanking the ampicillin resistance gene from SuperCos1.
HEapra	5247	pMJCOS1	SspI fragment isolated from pMJCOS1. Cassette consists of an apramycin resistance gene, origin of transfer (oriT), attachment site (attP) and øC31 integrase.

## Vectors

Name	Size (kb)	Resistance marker	Source	Description/Use
pAGvar1	3.1	amp	This study.	449 by PCR fragment generated using the primers O/AGvar01bF and O/AGvar02bR and template pLITAG01 cloned into pUC19 previously digested using SmaI.
pAGvar2	2.8	amp	This study.	91 by PCR fragment generated using the primers O/AGvar05F and O/AGvar06R and template pLITAG01 cloned into pUC19 previously digested using SmaI.
pAGvar3	3.2	amp	This study.	XbaI fragment (~450 bp) cloned into pAGvar2 previously digested using XbaI.
pAGvar4	3.3	amp	This study.	Annealed oligonucleotides O/AGvar03F, O/AGvar04R ligated to pAGvar3 previously digested using Bg/II and AvrII.
pAGvarX	6.3	apra	This study.	XbaI-EcoRI fragment (~650 bp) from pAGvar4 ligated to pSET152 previously digested using EcoRI/XbaI. Variant actagardine genes can be assembled and introduced into the hosts chromosome via the attachment site attP.
CosAL02	47.2	amp and neo.	This study.	40402 by Sau3AI DNA fragment from <i>A. liguriae</i> cloned into

-continued

Name	Size (kb)	Resistance marker	Source	Description/Use
CosAL02HEapra	49.1	amp and apra.	This study.	SuperCos1 previously digested using BamHI. CosAL02 in which the gene encoding neomycin has been replaced with the HEapra cassette.
CosAG14	45	amp and neo.	This study.	38168 by Sau3AI DNA fragment from <i>A. garbadinensis</i> cloned into SuperCos1 previously digested using BamHI.
CosAG14ΔA	46.3	amp, neo and apra.	This study.	CosAG14 in which the actA gene has been replaced by the cassette SBdel-1.
CosAG14ΔB	44.9	amp and neo.	This study.	CosAG14ΔA in which the cassette SBdel-1 has been removed by FLP-recombinase leaving an 81 bp scar.
CosAG14ΔC	45.5	neo and apra.	This study	CosAG14ΔB in which the ampicillin resistance gene has been replaced with the cassette SBdel-2.
CosAG14HEapra	46.9	amp and apra.	This study.	CosAG14 in which the gene encoding neomycin has been replaced with the HEapra cassette.
p1J773	4.3	amp and apra.	John Innes Centre (JIC), Norwich.	Redirect template (Gust et al., 2003) used to generate the cassettes SBdel-1 and SBdel-2.
pLITAG01	6.1	amp.	This study.	3263 by NcoI fragment isolated from <i>A. garbadinensis</i> (19955-23217 CosAG14rc) cloned into pLITMUS28 previously digested using NcoI.
pLITMUS28	2.8	amp.	New England Biolabs (NEB).	Routine cloning
pMJCOS1	9.8	amp and apra.	JIC, Norwich.	SuperCos1 in which the gene encoding neomycin has been replaced by an SspI fragment consisting of an apramycin resistance gene, oriT, attP and $\phi$ C31 integrase. Source of HEapra cassette.
pSET152	5.7	apra.	NRRL B14792	Conjugative plasmid which can facilitate introduction of DNA into the host's chromosome via the attP site.
SuperCos1	7.9	amp and neo.	Stratagene.	T3 and T7 promoter regions flanking a unique cloning site.
pUC19	2.7	amp.	NEB.	Routine cloning

#### High Performance Liquid Chromatography

HPLC analyses were performed using a Hewlett Packard 1050 series HPLC system with the parameters as described below:

Column: Zorbax SB-C18, 4.6 × 150 mm, 5μ  
 Mobile Phase A: 30% Acetonitrile in 20 mM potassium phosphate buffer pH 7.0

-continued

Mobile Phase B: 65% Acetonitrile in 20 mM potassium phosphate buffer pH 7.0  
 Flow rate: 1 ml/min  
 Gradient: Time 0 min 100% A 0% B  
 Time 10 min 0% A 100% B  
 Time 11 min 0% A 100% B  
 Time 11.2 min 100% A 0% B  
 Cycle time 15 min  
 Injection volume: 10 μl  
 Detection: 210 nm

#### High Performance Liquid Chromatography-Mass Spectrometry (HPLC-MS)

HPLC-MS analyses were performed on a Hewlett Packard 1050 series HPLC system linked to a Micromass Platform LC (operated with MassLynx version 3.5 software) with the following parameters:

Column: Agilent Zorbax SB-C18 150×4.6 mm 5μ  
 Flow rate: 1 ml/min  
 Mobile phase: A 10% acetonitrile, 0.1% formic acid 90% water.

B 90% acetonitrile, 0.1% formic acid, 90% water.  
 Linear gradient A to B over 10 minutes, hold 1 min B-A

Wavelength: 200-400 nm

Injection volume: 10 μl

Post column split: 1:10

Mass spectrometer: Micromass Platform LC

Mode: Electrospray positive

Nitrogen flow: 380 l/hr

Capillary voltage: 40V

Skimmer lens offset: 5V

#### Deposit

NCIMB 41362 was deposited under the Budapest Treaty on 7 Dec. 2005 at NCIMB Ltd, Aberdeen, AB21 9YA, Scotland, UK, by Novacta Biosystems Limited.

#### REFERENCES

- Altena, K., Guder, A., Cramer, C. and Bierbaum, G. (2000). Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster. *Applied Environmental Microbiology* 66(6): 2565-71.
- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. and Struhl, K. (2002). *Current Protocols in Molecular Biology* (5<sup>th</sup> edition). Wiley Interscience Publishers.
- Bierman, M., Logan, R., O'Brien, K., Seno, E. T., Nagaraja Rao, R. and Schoner, B. E. (1992). Plasmid cloning vectors for the conjugal transfer of DNA from *Escherichia coli* to *Streptomyces* spp. *Gene* 116(1): 43-49.
- Chatterjee, S., Chatterjee, S., Ganguli, B. N., Chatterjee, D. K., Jani, R. K. H., Rupp, R. H., Fehlhaber, H-W., Kogler, H., Siebert, G. and Teetz, V. (1992) Antibiotic, mersacidin, a process for the preparation thereof and the use thereof as a pharmaceutical. U.S. Pat. No. 5,112,806.
- Dower, W. J., Miller, J. F. and Ragsdale, C. W. (1988). High efficiency transformation of *E. coli* by high voltage electroporation. *Nucleic Acids Research* 16(13): 6127-6145.
- Flett, F., Mersinias, V. and Smith, C. P. (1997). High efficiency intergeneric conjugal transfer of plasmid DNA from *Escherichia coli* to methyl DNA-restricting *Streptomyces*. *FEMS Microbiology Letters* 155(2): 223-229.
- Gravesen, A., Kallipolitis, B., Holmström, K., Høiby, P. E., Ramnath, M. and Knöchel, S. (2004) pbp2229-Mediated nisin resistance mechanism in *Listeria monocytogenes* confers cross-protection to class IIa bacteriocins and

- affects virulence gene expression. *Applied and Environmental Microbiology* 70(3): 1669-1679.
- Gust, B., Challis, G. L., Fowler, K., Kieser, T. and Chater, K. F. (2003). PCR-targeted *Streptomyces* gene replacement identifies a protein domain needed for biosynthesis of the sesquiterpene soil odor geosmin PNAS 100(4): 1541-1546.
- Gust, B., Chandra, G., Jakimowicz, D., Yuqing, T., Bruton, C. J. and Chater, K. F. (2004).  $\lambda$  Red-mediated genetic manipulation of antibiotic-producing *Streptomyces*. *Advances in applied microbiology* 54: 107-128.
- Gust, B., Chater, K. F. and Kieser, T. E. (2002). Methods and materials for targeted gene disruption in actinomycete bacteria. Patent Application WO 02/103010 A1.

- Heinzelmann, E., Berger, S., Puk, O., Reichenstein, B., Wohlleben, W. and Schwartz, D. (2002). A glutamate mutase is involved in the biosynthesis of the lipopeptide antibiotic friulimicin in *Actinoplanes friuliensis*. *Antimicrobial Agents and Chemotherapy* 47(2): 447-457.
- Kieser, T., Bibb, M. J., Buttner, M. J., Chater, K. F. and Hopwood, D. A. (2000). *Practical Streptomyces Genetics*. Norwich, John Innes Foundation.
- Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989). *Molecular Cloning: A laboratory manual*. New York, Cold Spring Harbor Laboratory Press.
- Vertesy, L., Herbert, K., Schiell, M. and Wink, J. (2000). Lantibiotic related to actagardine, and processes for the preparation and use thereof. U.S. Pat. No. 6,022,851.

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 318

<210> SEQ ID NO 1  
 <211> LENGTH: 19  
 <212> TYPE: PRT  
 <213> ORGANISM: *Actinoplanes liguriae*

<400> SEQUENCE: 1

Ser Ser Gly Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Leu Val  
 1 5 10 15

Cys Ala Cys

<210> SEQ ID NO 2  
 <211> LENGTH: 19  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Primary polypeptide sequence of Actagardine B variant V V

<400> SEQUENCE: 2

Ser Ser Gly Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Val Val  
 1 5 10 15

Cys Ala Cys

<210> SEQ ID NO 3  
 <211> LENGTH: 19  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Primary polypeptide sequence of Actagardine B variant L I

<400> SEQUENCE: 3

Ser Ser Gly Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Leu Ile  
 1 5 10 15

Cys Ala Cys

<210> SEQ ID NO 4  
 <211> LENGTH: 19  
 <212> TYPE: PRT  
 <213> ORGANISM: *Actinoplanes garbadinensis*

<400> SEQUENCE: 4

Ser Ser Gly Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Val Ile  
 1 5 10 15

Cys Ala Cys

-continued

---

&lt;210&gt; SEQ ID NO 5

&lt;400&gt; SEQUENCE: 5

000

&lt;210&gt; SEQ ID NO 6

&lt;400&gt; SEQUENCE: 6

000

&lt;210&gt; SEQ ID NO 7

&lt;400&gt; SEQUENCE: 7

000

&lt;210&gt; SEQ ID NO 8

&lt;400&gt; SEQUENCE: 8

000

&lt;210&gt; SEQ ID NO 9

&lt;400&gt; SEQUENCE: 9

000

&lt;210&gt; SEQ ID NO 10

&lt;400&gt; SEQUENCE: 10

000

&lt;210&gt; SEQ ID NO 11

&lt;211&gt; LENGTH: 20

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes liguriae

&lt;400&gt; SEQUENCE: 11

Ala Ser Ser Gly Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Leu  
1 5 10 15Val Cys Ala Cys  
20

&lt;210&gt; SEQ ID NO 12

&lt;211&gt; LENGTH: 20

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial sequence

&lt;220&gt; FEATURE:

<223> OTHER INFORMATION: Synthetic sequence: Primary polypeptide  
sequence of Ala-Actagardine B variant V V

&lt;400&gt; SEQUENCE: 12

Ala Ser Ser Gly Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Val  
1 5 10 15Val Cys Ala Cys  
20

&lt;210&gt; SEQ ID NO 13

&lt;211&gt; LENGTH: 20

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic sequence: Primary polypeptide



-continued

---

sequence of Actagardine B variant L I

<400> SEQUENCE: 13

Ala Ser Ser Gly Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Leu  
1                   5                   10                   15

Ile Cys Ala Cys  
                  20

<210> SEQ ID NO 14

<211> LENGTH: 20

<212> TYPE: PRT

<213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 14

Ala Ser Ser Gly Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Val  
1                   5                   10                   15

Ile Cys Ala Cys  
                  20

<210> SEQ ID NO 15

<400> SEQUENCE: 15

000

<210> SEQ ID NO 16

<400> SEQUENCE: 16

000

<210> SEQ ID NO 17

<400> SEQUENCE: 17

000

<210> SEQ ID NO 18

<400> SEQUENCE: 18

000

<210> SEQ ID NO 19

<400> SEQUENCE: 19

000

<210> SEQ ID NO 20

<400> SEQUENCE: 20

000

<210> SEQ ID NO 21

<400> SEQUENCE: 21

000

<210> SEQ ID NO 22

<211> LENGTH: 64

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

-continued

---

<223> OTHER INFORMATION: Synthetic sequence: Primary polypeptide  
sequence of pre-pro-Actagardine B variant V V

<400> SEQUENCE: 22

Met Ser Ala Ile Thr Val Glu Thr Thr Trp Lys Asn Thr Asp Leu Arg  
1                   5                   10                   15

Glu Asp Leu Thr Ala His Pro Ala Gly Leu Gly Phe Gly Glu Leu Ser  
                 20                   25                   30

Phe Glu Asp Leu Arg Glu Asp Arg Thr Ile Tyr Ala Ala Ser Ser Gly  
          35                   40                   45

Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Val Val Cys Ala Cys  
      50                   55                   60

<210> SEQ ID NO 23

<211> LENGTH: 64

<212> TYPE: PRT

<213> ORGANISM: Artificial sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic sequence: Primary polypeptide  
sequence of pre-pro-Actagardine B variant L I

<400> SEQUENCE: 23

Met Ser Ala Leu Ala Ile Glu Lys Ser Trp Lys Asp Val Asp Leu Arg  
1                   5                   10                   15

Asp Gly Ala Thr Ser His Pro Ala Gly Leu Gly Phe Gly Glu Leu Thr  
                 20                   25                   30

Phe Glu Asp Leu Arg Glu Asp Arg Thr Ile Tyr Ala Ala Ser Ser Gly  
          35                   40                   45

Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Leu Ile Cys Ala Cys  
      50                   55                   60

<210> SEQ ID NO 24

<400> SEQUENCE: 24

000

<210> SEQ ID NO 25

<400> SEQUENCE: 25

000

<210> SEQ ID NO 26

<400> SEQUENCE: 26

000

<210> SEQ ID NO 27

<400> SEQUENCE: 27

000

<210> SEQ ID NO 28

<400> SEQUENCE: 28

000

<210> SEQ ID NO 29

<400> SEQUENCE: 29

000

<210> SEQ ID NO 30

<400> SEQUENCE: 30

000

<210> SEQ ID NO 31

<400> SEQUENCE: 31

000

<210> SEQ ID NO 32

<400> SEQUENCE: 32

000

<210> SEQ ID NO 33

<400> SEQUENCE: 33

000

<210> SEQ ID NO 34

<400> SEQUENCE: 34

000

<210> SEQ ID NO 35

<400> SEQUENCE: 35

000

<210> SEQ ID NO 36

<400> SEQUENCE: 36

000

<210> SEQ ID NO 37

<400> SEQUENCE: 37

000

<210> SEQ ID NO 38

<400> SEQUENCE: 38

000

<210> SEQ ID NO 39

<400> SEQUENCE: 39

000

<210> SEQ ID NO 40

<400> SEQUENCE: 40

000

-continued

---

<210> SEQ ID NO 41

<400> SEQUENCE: 41

000

<210> SEQ ID NO 42

<400> SEQUENCE: 42

000

<210> SEQ ID NO 43

<400> SEQUENCE: 43

000

<210> SEQ ID NO 44

<400> SEQUENCE: 44

000

<210> SEQ ID NO 45

<400> SEQUENCE: 45

000

<210> SEQ ID NO 46

<400> SEQUENCE: 46

000

<210> SEQ ID NO 47

<400> SEQUENCE: 47

000

<210> SEQ ID NO 48

<400> SEQUENCE: 48

000

<210> SEQ ID NO 49

<400> SEQUENCE: 49

000

<210> SEQ ID NO 50

<400> SEQUENCE: 50

000

<210> SEQ ID NO 51

<400> SEQUENCE: 51

000

---

-continued

<210> SEQ ID NO 52

<400> SEQUENCE: 52

000

<210> SEQ ID NO 53

<400> SEQUENCE: 53

000

<210> SEQ ID NO 54

<400> SEQUENCE: 54

000

<210> SEQ ID NO 55

<400> SEQUENCE: 55

000

<210> SEQ ID NO 56

<400> SEQUENCE: 56

000

<210> SEQ ID NO 57

<400> SEQUENCE: 57

000

<210> SEQ ID NO 58

<400> SEQUENCE: 58

000

<210> SEQ ID NO 59

<400> SEQUENCE: 59

000

<210> SEQ ID NO 60

<400> SEQUENCE: 60

000

<210> SEQ ID NO 61

<400> SEQUENCE: 61

000

<210> SEQ ID NO 62

<400> SEQUENCE: 62

000

<210> SEQ ID NO 63

---

-continued

<400> SEQUENCE: 63

000

<210> SEQ ID NO 64

<400> SEQUENCE: 64

000

<210> SEQ ID NO 65

<400> SEQUENCE: 65

000

<210> SEQ ID NO 66

<400> SEQUENCE: 66

000

<210> SEQ ID NO 67

<400> SEQUENCE: 67

000

<210> SEQ ID NO 68

<400> SEQUENCE: 68

000

<210> SEQ ID NO 69

<400> SEQUENCE: 69

000

<210> SEQ ID NO 70

<400> SEQUENCE: 70

000

<210> SEQ ID NO 71

<400> SEQUENCE: 71

000

<210> SEQ ID NO 72

<400> SEQUENCE: 72

000

<210> SEQ ID NO 73

<400> SEQUENCE: 73

000

<210> SEQ ID NO 74

<400> SEQUENCE: 74

000

<210> SEQ ID NO 75

<400> SEQUENCE: 75

000

<210> SEQ ID NO 76

<400> SEQUENCE: 76

000

<210> SEQ ID NO 77

<400> SEQUENCE: 77

000

<210> SEQ ID NO 78

<400> SEQUENCE: 78

000

<210> SEQ ID NO 79

<400> SEQUENCE: 79

000

<210> SEQ ID NO 80

<400> SEQUENCE: 80

000

<210> SEQ ID NO 81

<400> SEQUENCE: 81

000

<210> SEQ ID NO 82

<400> SEQUENCE: 82

000

<210> SEQ ID NO 83

<400> SEQUENCE: 83

000

<210> SEQ ID NO 84

<400> SEQUENCE: 84

000

<210> SEQ ID NO 85

<400> SEQUENCE: 85

000

-continued

---

<210> SEQ ID NO 86

<400> SEQUENCE: 86

000

<210> SEQ ID NO 87

<400> SEQUENCE: 87

000

<210> SEQ ID NO 88

<400> SEQUENCE: 88

000

<210> SEQ ID NO 89

<400> SEQUENCE: 89

000

<210> SEQ ID NO 90

<400> SEQUENCE: 90

000

<210> SEQ ID NO 91

<400> SEQUENCE: 91

000

<210> SEQ ID NO 92

<400> SEQUENCE: 92

000

<210> SEQ ID NO 93

<400> SEQUENCE: 93

000

<210> SEQ ID NO 94

<400> SEQUENCE: 94

000

<210> SEQ ID NO 95

<400> SEQUENCE: 95

000

<210> SEQ ID NO 96

<400> SEQUENCE: 96

000

<210> SEQ ID NO 97



-continued

&lt;400&gt; SEQUENCE: 97

000

&lt;210&gt; SEQ ID NO 98

&lt;400&gt; SEQUENCE: 98

000

&lt;210&gt; SEQ ID NO 99

&lt;400&gt; SEQUENCE: 99

000

&lt;210&gt; SEQ ID NO 100

&lt;211&gt; LENGTH: 38168

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 100

```

gatcggccgc cgtcagctgg agaagcgtg gctggcgcgg ctcacccgca acggccaccc 60
gcatccgacc cgggcgctgg cgctgcgat gggcgcggtg gagttcgcg ggcagctggc 120
gctgcagctc gccgacatgc gcaagcccgg cacgccgta gcgacctgac ccgctgctcg 180
acgcagctcg ctgcgccgtc ccgcgccgcg ccgatcaact ccggcagcac ggcgcgagct 240
tcaatcagcc ggcccggcgc accccctacg ccggtgcgac gaggcattgcc cgagaccagc 300
gcggccgcag agggccggtc ggcgccggac cggtcagcgc gcccgcaatc aggccggcag 360
gcccgccggg agccggaccg gtccggcgcg ccgcaatcag gccgacaggc ccgcccgggg 420
tcaggctggt cggctgcgcc gggccggcag gccggcgagc agcgcgtcga gcgtctcggc 480
atccgcccag ccggtgactg aactgcgcc tgccgcctg accgtgacct caaggcggtc 540
cggtgtcacc gccacgtcga tcggcgcgtc ctgatgcgg tcgctcaagc ggatgaactg 600
ctggttcgtc gagccgacc agggccgctc gtggtccagc aggtcctgcc ggaaggggcc 660
ggccaccagc aggtccgtgg cgtcgagcag tggcgcagc tcggcccggc cgtccgcggc 720
gagagcgcgc agacggggt actcgtagc ggtgaacgtc atgaccgagc gacccgcctg 780
ccgcaccccg gcggccaccg cggcgagacc ggccgcctgc tcgaacggct cgcgcgccgag 840
cagggtgaca cccgtggtgc ccgtggcgag cactcggctc accaactcgg cgggtgcggc 900
cggcacccca ccgctacgc cgaacaaatg cggattgaag catccggcgc accggatggt 960
gcaaccctgc acccagatcg cggtcgcctc gcccggtcct tcggcggtgg tccggtcgag 1020
gaaccgggcc acccgcacga gcggcggctc agacatcgac tatccgaccg aaaggcgtct 1080
ggttcgcttg cggcggcggc tcgcacgaca gccggtcccg gaccgcgacg aactcgtgtg 1140
gtgcgagccc ggccacggcc gcgaactcgc cgagactggc gaatccgccc cgcgcctgcc 1200
gcgcgcgccac gacgtccgcc acccgctgcg gggtagagac gggcacggcg gccaaactgtt 1260
gcgcgtccgc ggtggtgaca tcgagccgct cgggcgccgg ctccagcagc gagcccggca 1320
cacccccagc cggcgagccc agcgcgggct ccagcgggccc gggcgcgggc ccagcgggccc 1380
aggccgctgt gggctcagcc tgccggcggc ctgcgggctc agcctgccag cccgctgccc 1440
getcagcctg ccagcccgtt gccggctcag cctgccagcc cgctgcgggc tcagcgggccc 1500
ggcccgcgcg cggctcagcc agcgggcccc tcgcgggctc agggccggga gtcctccgt 1560

```

-continued

---

agaactcttg	cggcgaagga	acgacaccct	gtagttgcgg	cggcagcggg	gtcgccacgg	1620
gagcggggcg	gttcgcccac	ggcgctgct	ggggctgcgc	ataccacggc	acgtgagcgg	1680
cagccagcg	cagccaggag	gcgttgatga	cgaacgcgtg	cgcgacgctg	atcgccaca	1740
ccatgaacat	gatcgagaac	gcgaggttct	gctggagcga	gtcctcggcg	ccctcactgc	1800
cgagaaagaa	gcagaagttg	gccacgacgg	tgtagaggat	cccggcgatc	caccacaccg	1860
gccgccgggc	gcggatgccg	acgtagagga	acccgaccgc	ggagaaacag	ctgaagggca	1920
ccatcgggcg	gatcaccag	gcgctgtgcg	cgagggcgca	cgacagccgc	gccggcccgg	1980
tccgcttgcc	cggctcgtga	cctggatgcg	gcggatagga	cggatacggc	tgctggtgag	2040
caggcgggaa	cggcggcagc	ggctgctgac	cggaagcagg	cgggaacggc	ggcagcggct	2100
gcttgccgaa	cgacggcggg	tacgccggct	gcgagggcgg	atacgggtcc	tggcccgggt	2160
taggcgggtg	ccacgtcacg	gttcacgatc	cgttcccgcg	cgggtgtgcg	ctgacgcgtg	2220
taatccggcg	tgtacgact	gtgccgcacc	tgcccgcga	cgagatcctc	cagaacggcc	2280
acgtagtcca	ggcagcgtc	gccgagaatg	tccacggctc	cggcactgac	ctggccgtcg	2340
ggaccgaccg	tgacgacgat	ccgaggattc	tccgtcatgc	ccgtccctc	tccacctcga	2400
agaccaggcg	cacactggcg	tccctggccga	ccgactccga	ctccagccgc	agcccggcct	2460
cgggcgcctg	cgcgcgcagc	cgctccagga	cggcctgctg	gaccgcgcgc	ccgtacgagg	2520
tgtcgacggg	cgtcatcaac	tgcacagccc	ctggctgatc	gacgccgggtg	acgtgcgcgg	2580
cccagatgcc	gtccgcgcgc	cgggtgaacg	tgcgcgcgct	ctgcgtccag	gtcgccgaga	2640
tcggtgcgcc	ggcggccgtc	acgggtggctc	cgggtgcgcg	cagcgcgcga	tgcagcaggg	2700
tgacatcgcg	catgcgggtc	tgcacctggc	agatcagccg	gccgtcgtcc	atccggcccc	2760
cggcggcctg	aaccgcggcc	gcgccggcca	tcgccaacgg	caccagcagc	agtgaaacgc	2820
tcaccatgcc	ccccgttctc	gctgtggcca	caccctatcg	gcaggggtgcg	acaaatcatc	2880
ggttggtgag	gtcccagtcg	tcggtgccgg	tggccgacac	ggcgcgattg	cgggcccagc	2940
cgcgcagggc	gtcgaccgcg	tcggcctgcg	tcacgctgag	cggcacgatg	ctcatcaccg	3000
cgcgtacgag	atcgtcgcgc	cgcagtgggc	ggcgttcgga	gaacgcgtcg	aacagtcccc	3060
caatgaccgc	ctgctctatc	tccgcgccgg	agtagccctc	ggtcagcccc	gccagctcgg	3120
tgagcagctc	ggcatcgacc	cgcagctcgc	cggcggcagc	cgggtgccgc	agcggcccgc	3180
cgaggtgcac	ccgccacacc	gcgacccgct	cggaccggct	cggcagatcc	acgaagaacg	3240
tctcgtcgaa	gcgtcccttg	cgcaacagct	ccggcggcag	cccgtcgaag	tcgttgggccg	3300
tcgcgatcac	gaagaccgga	gtccgcttct	cctgcacca	ggtgaggaag	gtgccgaaga	3360
cccgggcacc	ggtgccggaa	tcacccccgg	tgccgcggc	gaagcccttc	tcgatctcgt	3420
cgacccacag	gacgcacggg	gcgaccgct	ccgccgtacg	caatgcgggtg	cgcatgttgt	3480
gctcgtgga	accgaccagg	ccggagaaga	cacggccgat	gtcgaagcgc	agcagaggca	3540
ggttccaggc	ggtcgcgacc	gccttggcgg	tcagcgactt	gccgcagccc	ggcagccggg	3600
tgatcagtac	gccgcgcggc	gcgggcaggg	cgtaccggc	cgctcgtcc	agccaggatc	3660
cgttgcgttt	gaccagccag	gccttgaggt	tctccaggcc	gccgacgtcg	tcgagcacgg	3720
ttccggcggc	catgaactcc	agcacgcccc	atttgcgtac	ggtctggcgc	ttctcctcgt	3780
gcacgatctc	caggtcggcc	agatcgagca	cggcgtcggt	caccatggcc	cgggcgtacg	3840
cgttctccgc	ctcctgcatg	gtcaggccgg	ccgcggccgt	gacgaaccgc	tcccggctct	3900
gctcgtcgag	ctccaccgcg	agccgccccg	acgcgggtgt	cccgcgcacc	atggcgtcga	3960

-continued

---

gcagagcgcg	caactccagc	tggccgggca	gcgggaagtc	gacgatcgtg	acgtccttgc	4020
tcagctcgac	cggcaggtcc	agtaccggcg	agagcagcac	gagtgtccgc	gggtgcggc	4080
cggcccgaa	cgctgggcg	atgtcgcgca	ccagccggac	gacctccggg	ctctgcgca	4140
acagcgggtg	caggtcgcgg	aagacgaaga	cagccggttc	gtcgatgcgc	tgcaccgccc	4200
tgagcgcgtc	ggtggcccgc	tgcgcgcccg	agcgggctc	gccgttcggc	tggaccagac	4260
cggcggtcag	cgaccaggtc	cagacggcac	gtggcacgcg	gacgaggtcg	gcgtcgcgg	4320
cgatgcgggc	gaggtggtgc	agcggcccgt	gtcctcgta	cgtctcgagg	tggagcaccg	4380
ggaaccgggc	cttcaacagc	tgcgcgaacg	tctccgcaa	cgacctctcc	accggcgcat	4440
cctacggccg	cgccggcccg	cgtgtcagag	cccggacggg	gtgccggtgg	cgtcgcgtgc	4500
cgccgggtcc	ttcccgcgct	cgacgggttc	gttgggttga	tcggtcattg	catcctcctg	4560
ctcagtcggg	gcggtagacg	gcggtgtccc	cggacacggc	gccggggtcg	taccccgagc	4620
ggccggtttc	ctccgtggtg	tccgtctcgt	cagcgcgggc	gcctgtcgac	tcgcccgggt	4680
tgcgcagtga	cgccgcgtat	gccggggttc	cgccggctc	gtccgtggga	tgcgcgtgga	4740
gttgttctcg	gtcatcggtc	atgaacggcg	gacttccctg	caagagcgcg	gacaaacgtg	4800
gtcgtttata	ccgcagccgg	gcgggcagtc	gtccaccatg	gaaccatcg	gtgaccctga	4860
cgagcagacc	ggcgacttcg	ccgaagagca	cgaactgacc	gaggtgacag	ccgaggagga	4920
cgacgacggc	gagccggaga	gcccggatcg	ctggaccggc	ggcatggact	ccgacgggtc	4980
cccgtgacct	gcggtacga	tccctcacag	gtgccgccc	cgccgacgac	ccgaggttcg	5040
tagccgttgt	cctccatcac	cgagctgacc	gagtccgtgc	gtgccttcgc	gcgcgagcgc	5100
aactgggagc	agttccacac	gccgaagaac	ctcgcgatgg	ccctggcccg	cgaggtcggt	5160
gagcttctgg	ccgagttcca	gtggctgacg	ccggaacaat	cagccgcggt	catgcgcgat	5220
cccgatctcg	gcccgcgggt	ccgggcccag	atcggagacg	tcacgatcta	tctcgtacgc	5280
ctggcggacg	tgctcggcat	cgacctggtc	gaggcggcca	ccgacaagtt	ggcggagacc	5340
ggccgcccgt	acaccgtcga	agccgcccgc	gactcggccg	ccaagatcga	tcagctgtag	5400
ttcagcgaga	agttgttgac	cgtgaagttg	gactgaccgg	cggtgccgct	gatctcgaag	5460
ccgaactgcg	cctcgcggac	cgtcacgtca	ccccaccagc	cgttggtgcg	cagccagttc	5520
aggatcgcca	ggatgtcgac	ggtgccggag	ttcgtgttgg	tacggatgaa	cgagaagacc	5580
gcgttggegc	cgttcgacct	gcggtagacg	ttccaggtgt	gcccgcggac	ggacaggttg	5640
cggacgttcg	gcaccgcgcc	gttggcgtcg	tactgttcgg	cgatcggccc	gaccgcgccc	5700
tgctggttgg	tccagatcat	gacctcgtag	gcgtggttgt	tcgcccagat	gtcgtaggtc	5760
gtcgagtagt	cgccgctgga	cggcaccgac	acgttgaagg	agctcgtcag	agaattgagc	5820
gagctcagcg	tacggttgag	ggtctttccg	gtgttgggg	aggacttgac	cccgtggtg	5880
cgccgggtgat	tcgcgacgac	gccccagttg	gtgccgctgc	gcgccagat	ggtctgggtg	5940
ccggcgcccg	agccccagat	gttgttgtga	ggatgtatcc	gttgttggtc	cagttcggcc	6000
actgtcccga	gtcgaccag	acggcgtcgc	tcggtacgcc	gttggtgggc	ggctgcgagc	6060
tcgggctggg	ggggccagcc	gatccgggtc	aggcggccc	gttgagcgtg	aacgtgcccg	6120
gtgccggggg	ggcggcgccg	gagccgttga	atccgaacga	cacggtcgcg	ttggtgccga	6180
cggatccggt	gtagccggcg	ttgcggggcg	tgacctgca	tccgctctgg	gtcaggctgg	6240
tgttccaggc	ctgggtgacg	gtctgcccgc	cggagtagga	ccagaccaac	gtccagttcg	6300

-continued

---

tgagcggatc	accaggttg	gtgatggtga	cgttggcgcc	gaagccgccc	ggccactggc	6360
tgctcacggt	gtaggcgacg	cggcagccgg	ccgcggcgga	cgccgggagc	gcggtgacga	6420
cgccggcacc	ggcgatgagg	gcccggagg	cggccaggga	gagcgcgaga	gtacgtctgc	6480
gcatgccggt	ccaatctcgg	agggggaaca	cacgacgctc	gtcgaagcgc	ttcgataatg	6540
aaggctgggg	atctacgagt	gtcgatgctg	gatgaggccg	atgttacgac	ccgccgccc	6600
ggcgaggcaa	ccgctacct	gggcgcatga	cgatcaccca	gaccgatctc	gcccacctgc	6660
gccgatgctg	cgacctggcc	cgcgaggccc	tcgacgacgg	cgacgagccg	ttcggttccg	6720
tcctggtctc	cgccgacggc	aagggtgctg	tcgaggaccg	caaccgggtg	aggcacggcg	6780
acgccaccca	gcaccgggag	ttcgcgatct	cccgtgggc	ggccgagcac	ctgaccccgc	6840
gggagcgcgc	cagcgcgacg	gtctacacct	cggcgagca	ctgcccgatg	tgctcagcga	6900
gccacggctg	ggtccgctg	ggccgcatcg	tgtacgcgcc	gtcgagcgc	cagctgaccg	6960
cctggtacaa	ggagtgggga	atcccggcgg	gcccggctgc	cccgtaccg	atcaccacag	7020
tggtccccgg	cgccgtcgtg	gagggcccgg	tcaccgctt	cgaggccgag	ctgcgggagc	7080
tacatcgcgc	ccgcttcacc	ccagcgcagt	agccgccgga	cgaaaccgca	cccttctcgc	7140
caatgaaccg	gacctgcgag	cgtgtctgga	ttgaccgcg	aggcccgcaa	cgccacaggc	7200
tcgatctccg	tcaccgtcgg	acctcagggg	caggtcgagg	atctgcccct	tgacgaccga	7260
gtgcatgacc	tcccatccca	ggaactgagc	cagcagatcc	tgacagtgat	gcgaaaggct	7320
cagtaccagc	tcaccgagta	cgtctcggcg	cacatccgtg	acaccgtggg	catggattcg	7380
gagaccggtc	gcaatgtgct	cgacgcgctc	gcacagcgc	tcggctgccc	ggagatgacc	7440
gatgagcgtt	gagcaggtac	agctgccgat	cgacgtaatc	aaccggcaca	ccactaccat	7500
cgccgcaacc	gccgatgccc	tacggcaggc	ccgcgcccgc	gcaggtcagg	cagccatgga	7560
ctcgcaagcg	tacggccagt	tgtgtcagtt	cctgccgacc	gcgttcagcg	tcgtgttcga	7620
gagtgcgac	gtcgccatga	cgggcagcgc	cgaagcgttg	caggaaacca	ccttcaacct	7680
gcaggatgcc	gtcacgacgt	tcagatacac	cgacgagtcg	gcccgtcgca	ccatcgctc	7740
cgcaggttcg	ccgccgtgac	cacaccactt	gtcgcccagg	ccggggactc	caccacggga	7800
ttgaccggtc	tggggctcgt	ggaggacgcc	caccagatcg	cagaagccat	ccgcgggaac	7860
agttgggtcg	acggcgtcct	cggcggagtc	ggggccagcc	tcgacggtct	ggcgctggcg	7920
atcgaccgcg	tcggcaccct	tgccgcctgg	ggcgtgcct	ggctcatcga	gcacgtccaa	7980
ccgctacaag	acgccctgga	ctggctggcc	ggcgacgtcg	acgagatagc	cgcccaagcc	8040
gccacctggc	gcaacgtcgc	cgcttcacc	gacagcggc	agcaggatta	cgccgatcgg	8100
ctccgcaccg	aggtegccgg	ctggttcggc	gctccggcg	acgcataccg	ggcccatgcc	8160
agcgaacact	tggccgcact	gaaaggcatc	agcaccgcag	ccggcggcat	ttcgtccgcc	8220
gtcgaaggcg	ccggcctgct	cgtcagcctg	gtgcgcgga	ttgtccgca	cctgatcgcc	8280
cagttcgtcg	ccactctggc	cgttcggctg	ccacaatggc	tcgcccgcga	aggactcact	8340
ctgggctcgc	ccacccccgt	tgtcgcgagc	caagttgcgg	ccctcgtcgc	ccgcggggtc	8400
aacaagatcc	agcacttcat	acgggcgctg	ctcaacagcc	ttcgacggct	gatgcccatg	8460
atcgaccggc	tgggtgaagt	cctggagcgg	ctccgcatgc	tcaccgaccg	gctcgcaagg	8520
tccagcccct	ccaccgccc	ggagccgaca	cccggccccg	ctactcagc	cggaaccgag	8580
aacgcacggc	gaaacaagcc	cgagggcgac	ctcgaaccga	acgaaccgcg	cccggccgag	8640
gctgacgcca	gagacagtac	gcctcagggc	ttcgtggacg	aggtcgtcag	caacccccgg	8700

-continued

---

tcagtcgegg	gacactccgc	gcagtcctac	gcggaccagt	tcaacgccgc	eggatactct	8760
gcggtcgctg	agcagagcac	caggagcggc	acctcgggga	acgccatcca	ggtacgcatt	8820
cacggccacc	cggatatcac	caacatccag	gtgcatccgg	gaggaggacg	gcacacgccg	8880
gaggggtccc	cgtattgga	aatttcgacg	aatacggctg	ggaagatctg	gatcatcccc	8940
gaaaatttcc	ggggcgccga	tgaactgcgt	gggaatgtgg	tgcgctatga	caaataagat	9000
catcaaagtg	gatcgggtgg	gatccgcggg	ggaagctgcc	acgctcgtcg	ccctgggcgt	9060
cgacatcgtc	ggggtcgatc	ttcgtcctga	tccgcgattc	ggtgatgatc	gcacgctgga	9120
cgccgaacag	gttcgccaca	tccgcgaagc	gctgccgcac	acgacgctgg	ccgtcaccat	9180
ggacaccggc	accgagccgg	accatgtcgt	cgaactcgca	aggcgaatcg	gcgaggatct	9240
ggtccagtcg	atcaacggtg	tcatcccgcc	gctcccagta	cgcgtcgccc	tgcgcaaggc	9300
cgacatcgcg	attgtctatg	cgggcacaga	gatctcccac	gacgacgatc	ccggctgggt	9360
cttcagcgcg	tacgacgaca	ctccggacct	gaacgccgcc	ctgtttcaag	tggaggtgct	9420
tccggagtac	ctcgattcct	gggagtttct	gcgtgaccgc	tccccggaat	atgccgacga	9480
gttccagatc	gaagatctcg	acgacctcgg	acgcgctcgc	cccttggttg	ccggcctgaa	9540
tctcacggct	cagaacctcg	acgagatcag	ggcacggctt	ccccacgtcc	gcggtctggc	9600
gctcaccttc	gcgcacgagg	cgcgaggag	cgacgcggcg	ttcttcatgt	ttccccacgt	9660
agtggacatc	cttccgggag	actcgtccgg	gtgaccggca	tgcgcgggga	gggggctggt	9720
gtcgcagagt	caggctgacg	gcattccggc	ggcctgacg	ggaggaacct	catgaccggg	9780
ctgttcacca	tgcgcaagca	cgaggagggc	gccggggagg	ttcgatcgt	cgtgagcggc	9840
gagatcgacg	gcgatgtcag	cgcggcgctc	acctgttca	tgcccaacgc	cgcgagcag	9900
gacggtgtcc	gatcgggtgct	ggtggatctg	gagccgggtg	tgctgctggc	cgcagccggg	9960
atccgggtgc	tgctgagcgg	ccgtgaggcg	gctctgctgc	agggctgctc	ctacgagctg	10020
gtcaacgtcc	ggcacgaggt	cgcggattca	ctgcacgccg	ccggcgtggc	agatctgctg	10080
ctcaccttgc	cggtecctcg	agccggctca	gctcgggtcg	tgaagccct	cgtcggcgcg	10140
ttcgcggcgc	aggtgtgcct	cggcccggcg	cgctgggtca	cccttctccg	ctgccagccc	10200
ggcgtacatg	gcctgcacct	tctcgtacgg	ctggccgggc	ggcagcagcg	ggatcgccgg	10260
atcgaccacg	gcctcgatca	gcgtcggggc	gtccgcggac	agcgcgcct	cccacgcgcc	10320
ggtcaggctg	gacgggtcgg	tgatccgcac	tccgcgcagg	ccgagcagct	cggcgtagcg	10380
cgcgtaaggc	acgtcgggca	gttctcgcga	cgtgacgaag	cgcggctcgc	cctcggcttc	10440
gcgctgctcc	cagctgacct	cggccaggtc	ccggtgtgtc	agcacgcaca	ccacgaagcg	10500
cgggtccgcc	cagtcgcgcc	agcggggcgg	caccgtgatc	agttccgcca	tgcccgccat	10560
ctgcatcgcg	ccgtcgcggg	ccagcaccac	gaccgggcgt	tgcggcgccg	ccagcttggc	10620
ggcgagaccg	tacggcaacc	cgcaccccat	cgacgccagc	gtgctggaca	gatgcgccgg	10680
gacaccgcgg	ggcagccgca	ggtgccgggc	gtaccagtag	acgaccgagc	cgacgtcgac	10740
cgcgacctgc	gcgtccgcgg	gcaggtggtc	ggagagggag	cgaatcacgt	gctgcggggt	10800
gaccggttcg	gcgggcgcgg	cggcccgggc	cgcgctgatc	aggcgcagc	gctgcacca	10860
ttctccacg	cgggcgcccc	aggcgcctct	tgcgggctg	ggcagcagtc	cgagcagctc	10920
acgcaagggt	tccacggcgt	cgcggaggag	cgggacctca	accggatacc	gtacgcccag	10980
acggcgcccc	tccacgtcga	tctgtacggc	ccgcgcctgc	cccggccggg	gatagaactc	11040

-continued

---

ggtccacggg	tcgttcgtgc	cgatcagcag	cagcgtgtcg	cagtgccgca	tcagctcggc	11100
gctggccgtg	gtgccaggt	gccccatgac	gccggtgtgg	aacggcaggt	tctcgtcgag	11160
gaccggcttg	ccgagcagcg	aggtggtcac	gccggcaccg	agccgctgcg	ccagctcgac	11220
gatctcgcgc	tccgcgccgt	acgtccctg	ccccaccatg	atcgccacc	gctcgcggga	11280
gcgagacacc	tcggccgcct	cgcgcaggtc	ttccggggcg	ggcaccacc	ggcgggggcg	11340
cagccccgcg	ctcgtcgcca	gcacaccgtg	ctcatgcgcc	tgcgggtcgg	gcgcgggggc	11400
cgtctgtacg	tcgtgcggca	ggaccacgca	ggtcgggtcg	cgggtcgcga	gcgcgggtcg	11460
gaacgcgcgg	tcgaggagca	tcggcacctg	ctcgtcgtg	tgcgcggcct	gcacgaactg	11520
ggcgcacacg	tcgccgaaga	gccgcaccag	gtcgatctcc	tgctggtacg	cgctgccgag	11580
caccgtcgag	acctgctggc	cgacgatcgc	gacgaccggt	ttggagtcga	gtttcgcgtc	11640
gtagaggccg	ttgagcaggt	gcaccgcgcc	gggaccctgg	gtggcgaggc	agactccggc	11700
accaccggtg	tacttggcgt	ggccgacggc	catgaacgcc	gcgccctcct	cgtgccgggc	11760
ctgcacgaag	gtgggccggc	cggcccggcg	cagcgtcccg	atcacgccgt	cgatgccgtc	11820
cccggagtac	ccgaagacc	gttccacgtc	ccacgcggtc	agacgtcca	cgaccacgtc	11880
cgacacggtc	cgctccgtca	ccgtgcctc	ctcacgtcac	accgggggct	accgctcag	11940
ccgcgcggta	ctgccttgc	gcgaaatgcg	actcgcgtgc	acctcacggg	ccggggcgac	12000
gcggcacgga	tctgagctgg	ttcccggccg	gttctgatcc	cctgtgatcg	gggtacacac	12060
gtgcggtgag	cagggacaag	acgtaccggc	cggtcctgcc	cgacgggatc	cggaccacct	12120
tccacgacgg	tgtactcggg	cgcatgcgga	tccggtgcct	gggcgagccg	cgtccggggc	12180
taccggagat	cgtgatgatc	cagggtatga	ccgtgagtga	ctatctgctg	ccgggtctgg	12240
gcgcgctcag	cgcttgacc	cgggtgcacc	tgggtgagct	gccgggaggc	agcggcagcg	12300
gccggccgcc	gcacgatctc	acggtcgagg	agtacgcgcg	ggccgcggcc	gactggctgt	12360
gcgcccagcg	cctgggccgg	atcgtgctgg	ccggccattc	gagcggcacg	caggtggcgg	12420
cggagaccgc	gctgttgtgc	ccggacgagg	tggccggagt	ggtgctggcc	ggcccggcga	12480
tcgaccgggt	ggcccgcggc	ggcctgcggg	tcttcgcgcg	ctggtggatc	gaccggcgcg	12540
gcgaccogaa	gagcctggac	gaggtgcaca	aaccgaacg	cgagcaggtc	gggttccggc	12600
ggctgttcca	ggtgctgcgc	gcccacctgc	gtcacgacct	ggagaagccg	gtggtcgggc	12660
tctgcgtgcc	ggtgctggtc	atccgcggca	gcgaggaccg	gctcggcacc	gcgcgggtggg	12720
cccggcggt	cgccgatctg	gctgccgtgg	gcggccggta	cgtcgagggtg	ccgggcaccc	12780
actcgttctg	ctggcgttac	ccgcaggcct	ggtccgcgcc	gatccgtgaa	ttcgccggat	12840
ggtcggatc	ggtctccggc	acctgaacgg	acgtttcggg	ggcatcgccg	ccaccgcggg	12900
ccggcgcac	cgcatccaca	gtccggggtg	agggtcagcg	ccgttcggag	gcggagtgtc	12960
gatgatcggg	caattgacgt	gcttccatga	gccgccctac	ggtccgacag	agaaatcggt	13020
atccggacca	ccatcgacat	ccgaatcggg	ggccccggag	ccgatcatcg	accgacccc	13080
ggccaccccc	gctcttgcca	gagggggcga	ggcacatgac	ggaagctgat	catcgtccga	13140
ccgttctcag	gagaatccta	cggctgtgcg	ccgtgcttct	catggtgctc	ggagtgggccc	13200
tggtcggcgc	cccgacgtcg	cacgcggcg	gcaagccgac	catctccaag	gaggcggtcg	13260
gcagcgtcgg	cggcaaggcc	gtcgaccggg	acacctcac	caacgggcgc	ctgcagggtgc	13320
ggatcctcac	ctacggaggc	atcctgcaga	ccatcacggt	ccccgaccac	cgcgcccgca	13380
ggccaacgt	gacgctcgga	ttcaggacc	tcgacgagta	cgtgacgacg	aagaaccggg	13440

-continued

---

cgtacttcgg cgccatcatc ggccgctacg gcaaccggat tgccgacggc cggttcacc 13500  
 tggacggcac gacctaccag ctggcgacca acaaccgacc gaaccacctg cacggcgggg 13560  
 tcgtcggctt cgacaagcgg gtgtgggacg ccacgccgat ccgcgacggc gacagcgtcg 13620  
 ggctgcgcct gacctacacc agcccgcacg gcgaggagaa ctaccccgga accctgcgcg 13680  
 tgacgatgac ctacaccgtc acccggcaga tgggtatccg gatggactac cgggcgacga 13740  
 ccgacagacc gacgatcgtc aacctgacca accacgcgta ctggaacctc ggcgcgagg 13800  
 gcaccgggac catcgacgac cacctgctga agctcaacgc caaccgctac acgcccgtcg 13860  
 acgccacgct gatcccgcag gggcgatcgc acgcggtcgc cggcacaccg atggacttcc 13920  
 gccggcccac gccgatcggc gcgcgcaacc gcgaccggtt ccagcaactg gtgtacgggc 13980  
 gcggctacga ccacaactgg gtgctgaacc gcgaggacgg ccagttccgg cgtctcgagt 14040  
 tcgcgccccg ggcggtcgcac ccggacagcg ggcggcagct caccatctac accaccgagc 14100  
 cgggcatcca gttctacggc ggcaacttcc tcgacggcac cctgtacggc accagcggcc 14160  
 gggcctaccg tcagggagac ggtttcgccc tggagacaca gcaacttccc gattctccga 14220  
 accacgcgaa cttcccgtcg accgtccttc gaccgggaca gacctaac tcgacgacca 14280  
 tctaccagtt cggtagcggc gactgatcgc ctacggccgg ccgcccggg acggcgcgcc 14340  
 gcggccggcc gcacggcagt cagcggcggc gactggaggc acacatgcca cgcattccatc 14400  
 cgaaagtcca ggaggccgtc tctacgctcg acctgaaccg gacgacacga cgccggctgt 14460  
 tgtccggaac cgggttggtc agcgcctcgc tcgcccggg cgcgctgctg agcgcattgca 14520  
 gcgaccagaa cgacggccag aaccagaccg agggcgccgg taacttccc gacacccccg 14580  
 agtggcggtt cacattcgtc aaccacgtga ccaccaacc gttcttcacc ccgacgcagt 14640  
 acgggatgga ggacgcccgc acgctgctcg gcatcgccaa gccgcagtgg accggctcgc 14700  
 agaactcgat cgtggccgaa atggtgaacg cgacgaacac cgcggtcagc gcaaagggtg 14760  
 acggaatcgc catcgccgtg gtcgacaagg acgcttccg ggggcccgtc gaccaggctc 14820  
 tcaacgcggg gataccggtg gtgtcgtaca acgcccagcg agcccggggc gcgcccggca 14880  
 cgaaccggct ggcctatatc ggacagggcc tgtacgagtc cgggtacgcg ctgggcccagc 14940  
 gggcgttgca ggtgctggac tccggcgagg tggccgctt catcgccacc ccgggcgcg 15000  
 tgaacatcca gccgcatc gacggcgcgc aacaggcgtt caaggactcc ggcaagccga 15060  
 tcacgttcac cgcggtcgc acgaacgcc acgtgacag cggctctgtc atcatcgacg 15120  
 cgtacgccc ggggacgccc aacctggccg gcatgctggc ggtggacgcc ggatcgacgt 15180  
 cgtcgggtggg tcagaccgtc aagaagtaca acatgcgccc caaggggctc aaggtggccg 15240  
 gcgggttcga cctgatcccg gagacgctga ccgggatcca ggagggcagc ctcgactaca 15300  
 ccatcgacca gcagccttat ctgcagggat tcctgcccgt gctggcgctg tacttctaca 15360  
 aggtgtccgg cgggctgatc gcgcccagtg agacgaacac cgggctgttg ttcgtcacca 15420  
 aggacaacgt cccccgtac cagagcacga agagccgta cgagggctcc acgaccgaca 15480  
 aggttctcgt acctcgcagc gggccgatcg cccatggatg accgatctc gcctgcgccc 15540  
 gcgagggcg cttccctcga ggtcgagcaa cgccgtggcc ggtggcagcc ggtcacggcg 15600  
 gccggccgga aggtcctcga cgccttctc cggcgccgtg aggccagcgt gctgctcgtc 15660  
 gcgatcggcc tgatgateta ctttcggggc tccagcccgg tcttctgag ccgcgacaac 15720  
 ctggtcaaca tcgccaggc gaccgcgccc gtcgcatca tcgcggtcgg catcgtgctg 15780

-continued

---

ctgctggtca	gcgccgagat	cgacctgtcc	gtcggatctg	tggcccgct	ggcgccgttc	15840
ctgttccact	tcgggatcaa	cttctactcg	ctgccgggtg	tgcccgcctt	cgtggtggcg	15900
ctggcgatcg	cggccggaat	cggcctggtg	aacgggctga	tcgtcacgca	gctgcacgtg	15960
ccctcgttcg	tgacgacgct	gggcacgttc	ttcgccgtgc	agggcatcct	gctgatcacg	16020
tcgcaagcct	atccggtgcc	gatccccgac	gcggccaagg	gcacgttcca	aacctggctc	16080
ggcgccgggc	cgtgggcccag	catcacctgg	gcgtgatca	tcgtcgcgat	cttccacacg	16140
gtgctgacc	tgaccgggtg	gggctgcac	accatctcgg	tcggcggcaa	cccggtcggc	16200
gccaccgagg	ccggcatccg	cgctcccgc	atcaagatcg	gcaacttcgt	gatcaccagc	16260
acgctgggtg	ggctggtcgg	catcatggag	gcgttccgga	tcaacacat	cgacccgaac	16320
atcgccggcg	gcacgacgct	gaccttctac	gccatctcgg	cggcggctat	cggcggcacc	16380
gcgctcgccg	gcggtccgg	caccatcgtc	ggcgcttcc	tgggcgcctt	cgtgctggcc	16440
gagctgcaga	acgggttcaa	cctcatcggc	tacagcga	acaccatctt	cctcatcctg	16500
ggcctggcca	tcctcgtctc	gatgatcgcc	aaccagtacc	tctcccact	gcgccgggca	16560
ggccgatcat	gaccgcgga	accgtgtccg	acgcgtcgg	cgtacagaac	atcgccaaga	16620
gattcggcgc	tctcaccgcg	ctgcaggacg	tgaccctcgg	cgtcgcgaa	ggcgaggtgc	16680
tgggcctgat	cggcgacaac	ggcgccggca	agtcgacct	catcaaaatc	atctgcccgt	16740
accaccggcc	ggacgccggg	cgcatcttcg	tcggcggcga	ggaggtcacg	ctgcgcagcg	16800
tcgaccacgc	ccgctcggtc	ggcatcgacg	ccgtctatca	ggacctggcc	ctggtcaacg	16860
agctgtccgt	ctaccacaac	atgttcctca	accgggagct	cgtacggtgg	ccgctgctga	16920
acaaccgggc	gatgcgccgc	cgtgccgagg	agcacctcgg	cgacatggga	gtgaacctgc	16980
cggacgtcgg	cgtcgaggtg	gccaagctct	ccggcggcca	gcgccaggcg	atcgccgtgg	17040
cccgtcggc	ctactccgac	gcccgcaccc	tgctgctgga	cgagccgcta	gcccgatgg	17100
gcgcgaagga	gggcacgatg	atcctcgacc	tgatccgcga	cctgaaggcg	cgccgcaacg	17160
tgctgatcat	catcatcgcg	cacaactacg	cgcaggtgct	cgacgtgtgc	gaccgggtga	17220
acctgctgca	gcacggcccg	atcaccttcg	acaagaggtc	ggcggacacg	tcgctggccg	17280
aactgaccga	gctggtggtc	gcccagctacc	gcaccggccg	cgggcgggtga	cgccctcagcg	17340
cttgcggccg	actccgctgt	actggctcgc	gcccgtcgtc	tcgtcgcgg	ggtcgggatg	17400
ccactgcggg	ctcggcacga	cgcccggcgg	gaccaggctc	agtcctcga	agaagccggc	17460
gatctcgtcg	ggcgtatgca	tcaggtaggg	caccgcaccg	gaggagtgtg	aggcgtcctg	17520
ggcctggttg	agcgcctcct	ccccggcgac	gcgcacaccg	tcgctgatcg	acaggtagct	17580
gcccggcggc	agcccggcca	tcagctgccc	gacgatgtcg	cggacctccg	cggctgctggg	17640
gatgtggccg	agcacgccgt	tgaggatcag	gccaccggc	cggcccatgt	cgagctcgcg	17700
ggcggcgacc	gccaggatgt	ccgccggttt	ctgcaggctca	ccctcgaggt	agacgtcgga	17760
cgaccggcc	agcagctcac	ggcctgtctc	caccgcgtac	gggtccttgt	cgacgtagag	17820
gaccggggcg	tcaggggcca	cccgtcgcgc	gatctggtgg	gtgttgtcga	cgggtgggag	17880
gcccgcgccg	acgtcgagga	actggcgcac	gcccgcctcg	ccggcgaggt	agcgcacggc	17940
acgcgacagg	taccgccggg	actcgcgggc	gatctcgtcg	atgccgggga	acacggcacg	18000
gtactcgtcg	ccggcagcgc	ggtcgaccgg	gaggttgtcg	gtgccgcga	gccagtagtt	18060
ccagatgcgg	gcccactggg	gcaccgaggc	gcccgactcc	atagtcacgg	atcgatagcc	18120
tagcccttgc	gcccctgggt	ggcgacgccc	tcgacgaagt	agcgtggca	caggaagaac	18180



-continued

---

gcgatgatca	tcggcacctg	ggtgatcacc	gcgcccggcca	ggacgatctc	ccagcggggcc	18240
tcgcccgcct	ggccgaactg	gtcgaggatc	gccttcatgc	cgcgcgccat	ggtgaacagc	18300
gccggatccc	gcagatagat	cagcggcttg	agcaggtcgg	accagctggc	ccgcagctcg	18360
aacacgaacg	ccacgatcag	cgccggcccg	cacagcggca	ccgcgatgcg	ccagaacagc	18420
cgccagtacc	cggcgccgtc	gacgcggggc	gcctcgaaca	gctcacgggg	cacgccgagg	18480
aagaactgcc	ggatcaggaa	gatgtagaag	gcgctgccga	acaggttgcc	ggcccagagc	18540
ggcacctgcg	tggcggccag	gccgagctcg	ttccagatca	ggtacgtggg	gatcatggtg	18600
accgcgccgg	gcagcatcat	cgtgccgacg	accagggcga	acaacacgtt	gcgcccgggg	18660
aagcggaaat	aggcgaagcc	gaacgccacg	accgcgctgg	agatcgtgac	cgcgcccgcg	18720
gcggcgagtg	ccaccacgac	gctggtgaac	atccaggtea	gcacggggcg	ggcgtcccag	18780
atggcggtgt	agttccccgg	cgcccactcg	gcggggagca	gccggttgtc	gaagacgtcg	18840
ggcgggggct	tgaggaggc	gctgaccagc	cagacgaacg	ggtacacgaa	gatcaccccg	18900
gcggcggcca	ggcggtcca	gagcaccacg	ggatgcgggc	cgcgcgaggt	gcgcggtggc	18960
atggtcctgt	cctcagccac	agccacggcc	tactcgcctc	tcgtagtaga	cgaatcgccg	19020
gctgagccgg	acctgcacga	ccgtgatgat	cacgatgatc	aggaacagca	gccaggccag	19080
cgccgagggc	taccccatgt	gcaggaactg	gaaggcctgc	tggaacaggt	agaccacata	19140
gaacagggcg	gcgtcgttgc	cgtacgtctg	ctggttgcca	ctgccgtaga	aggcgggtga	19200
gacctcgtcg	aaggtctgca	gcgagggcat	cgtggtgatg	atcagcgtga	agaagagcgc	19260
gccgctgata	atcggcacgg	tgaccgcgcg	gaaccgcgcc	cacgccgacg	cgccgtccat	19320
ctcgcgggcc	tcgtagaggt	cgcgggggcac	gttctgcagc	gccgccaggt	agatgatgac	19380
cgtgctgccg	aggctccagg	cgccgatcag	caccaggccg	ggcttgatcc	acgggcccgc	19440
gacgggtccag	ttcgccccgt	cgatgccgac	cgtgcccagc	gcctcgttca	cgatgccgac	19500
ctggccggtg	aacagcagca	ggaacagcac	gccacggccc	accttggggg	tgatcgtcgg	19560
caggtagaag	atcgtgcgga	agaaccggcc	ggagcggcgc	ccgaccgggg	ccagcagcat	19620
cgccagggcc	agggacacga	tcatggtgac	cggcacgtgc	agcgcctgtg	agatcagcgt	19680
gttgccgatg	ctcgtaacga	cccgcgggtc	ggcgagcadc	tgccggtagt	tctcgccgcc	19740
gacgaagtcg	gtgctggtga	gcacgtcgta	gtcgggtaac	gacaggacga	ggctggccac	19800
catcgccccc	gccatgaaga	ccgtgaagcc	gatgagccac	ggcgacagga	aaccgaaggc	19860
ggccagggtc	tcccgcggcc	gcacggcggc	actcatcgtc	agcgtccgct	gttggccttg	19920
tccagcggcg	cctgagcctg	ctgctggggc	tcggccatgg	cctggggcgg	tttctgcttg	19980
ccttccagga	cccggttgac	cgcgttctgc	caggcggcct	tgaattcctc	accggcggcg	20040
agcgcgggct	ccgagaagcc	ggactcctgg	gtctgcagga	cgatctgcac	gttggcgtcg	20100
ggtttcacga	cgtctctgaa	gatcactteg	tcggccttct	tgttgccggt	gtagacgccc	20160
gcgaagggtt	tgttctcctt	cttgcgcagc	tcggcacggg	ccctcgcggc	ggcgatccag	20220
gtctcgctcg	cggtcatcgt	cttgatccac	ttacaggcct	gccaggggtg	cgcgctgttc	20280
gccgggatgg	cccaggcgtt	gcccgatgac	cagtcgatcg	gctgcccgtc	gacgcccgcg	20340
aacggcgcca	cggtcacctt	gaccttcggc	gagttgtcgg	cgagcacggt	gaggtagaag	20400
tcctccatcg	ggaaggcgcc	gagctgggtg	ctggcgaact	ggttcttggc	gccgaagaag	20460
tcccacgagt	cgcggaacga	cttgaagttc	gaccagccgc	cctgcgcggt	gatcaggccc	20520

-continued

---

acggcgtatt	cgagggcctc	gaccaccttc	gggttgttca	gctgggcggt	gcgaccgtcg	20580
tcgctgacca	gggcggcgcc	gttcgcgcgc	gccagacgg	gcaggaactc	gggcagcttc	20640
gggtcgaacc	cgatccgctg	gagcttgccg	ccgtcatcc	tggtgagccg	ggcctggcc	20700
gtcgacagcg	cctgccagtc	ccccgtgtcg	aaccggcgg	gatccaagt	gacctcggcg	20760
aacggggcgt	cgttgagcat	caggacgcgg	ttgtttaga	agtccggcag	gccgtacagc	20820
tgcccgttca	gggtcgctc	ggtgaccgcg	gcctcgcgga	actggctcat	gtcgatcttc	20880
tcccgttcga	cgcagtcgcc	gagcggagtg	agcgccttct	tggccgcgta	ggtgccgagc	20940
agccgccgtt	ccatgtacac	caggtccggc	gggtcctgg	aggccaccgc	ggacaggaac	21000
gcctgggcgt	cgaagctgcc	ctcggacgcc	ttcggcaggc	tgggcgcgat	cacggcgttg	21060
gccgcgtcga	agcgggtctt	ggcgatctcg	tcgccggtgc	cgaaacccat	catggtcagc	21120
gtcacgcggg	cgttgctgtc	ggagtccgaa	tcggatccgc	ccacgccacc	gcagcccgcc	21180
gccaatgtca	gaaccagggc	accacccacc	acaaaccgga	tcgatcggat	gaacatcggt	21240
gttctcccat	tttcaactgt	tcccgtgggc	gaagcataag	ttcaactcga	tgcccgcgca	21300
ctcggagcgg	ctgctgtcaa	ccgccgaccg	gttggcggat	caccacgatc	gggtgggtgcg	21360
gccgctgccg	ggccgcgctc	ctgctcccgc	cgccacgcgg	gtgggcagat	accgatcggc	21420
gtcgtctaa	tcgatggcag	ggataccgac	ggtgacaccg	tttctcccgc	ccgcttcac	21480
ccgacgtaat	cgcgggcatg	gcgcctggc	cgcgttctgt	cgaaatcgcc	gggtattcgc	21540
cccgggaagt	ccaccgaaag	gaagacacac	catgtctgct	ctcgccatcg	agaagtctcg	21600
gaaggacgtc	gacctccgtg	acggggcgac	cagccaccgc	gccggcctcg	gcttcggcga	21660
gctcaccttc	gaggaccttc	gcgaggaccg	caccatctac	gccgccagca	gcggctgggt	21720
gtgcacctg	acgatcgagt	gcggcaccgt	gatctgcgcc	tgctgatcga	cgatcgtttc	21780
cggcccgggg	cgggcatcgc	ccgccccggg	ccatccattt	cgcgcgggga	gcagccatgt	21840
caccggttcc	ttcaactcaat	tccacctcgg	tacgcgacag	cgcgtatctg	cacgaacgaa	21900
cggtgaccgg	agaagaccag	ccggcaccgg	ccgcgcaggc	gcggatagcg	tcctggcgcg	21960
attcggcggt	cctcgacgac	cgggttctcg	acatccggct	acgtcaatgg	ggaatcgacc	22020
gtgccacctt	cggccggctg	ctcaccgacg	acgacttcac	cgttcccggc	cggtgctcg	22080
cctgggcgga	cgagctggcc	acggtgctgg	ccaccgacac	gacaccggtc	accggactcg	22140
agttgtccac	caaaactgtg	tcacagggat	tcgaccggct	gctcttcgcc	ggcctgcttc	22200
accggttcc	cgcctactac	gaacagcggc	tgacagagcg	cgtgcccccg	ccgatcgccg	22260
gcagcctgcg	ccggccgctg	ctggagtcgc	tggccaaccg	gctgctcgcc	gtcgcggcac	22320
gcacctgct	gctggagctc	aacgtggccc	gtgtgcacgg	gcggctgacc	ggcgacaccc	22380
cgcagcagcg	ctacgacgac	tacgaccggc	ggctgctcac	cgacccccgc	tacctggccg	22440
ccctcttcga	ggaatacccg	gtgctcggcc	gttgctgggt	cgaatgcggc	cggcgttggg	22500
tggaccacgc	cgccgagctg	ttcaaccggc	tccacgacga	cgagcccgaa	ctgcgcgcg	22560
ccggtctgct	gccgccgctg	gcggaagcgc	tgccgacgct	acggctggac	ctcggggacc	22620
cgcacaacgg	cggccggctg	gtggtgcagc	tgacctcga	cgacggcacc	gacctggtct	22680
acaagccgcg	gccggtcgga	tccgaacgcg	cctacgcoga	gacgatggcc	gcgctggccc	22740
gccacgggct	gccggtgccg	gtgaccgccc	cgcgcgtgct	ggaccgtggc	gggcacggct	22800
ggtgcgagtt	cgtccggccc	gcgccctgcg	ccgacgcgcg	cgagctgtcc	cgttctacc	22860
ggcgcgccgg	atcgggtgctg	gcggccatgc	tgctgctcgg	tggcgtcgac	atgcacatgg	22920

-continued

---

agaacgtcat	cgccgcgggg	tcgtcgttca	ccccgatcga	cctggagacc	gtgctgcagt	22980
ccggagagct	cggcgacggc	gccaccgacg	cgtacggggc	ggccctcgac	ctgctcaacc	23040
gcagcgtgct	ggcgatcggc	atcctgcccg	cccgcgcggt	cggtggcccg	cagcgaaga	23100
gtgtcgacgt	cagcgccctc	ggcggcggcg	aaccgcagac	cgcgcccccg	ccggtgccac	23160
gcatcgtcga	cgcgtacacc	gacacggcac	ggctggaagc	ggtcgaggcc	accatggccg	23220
gcgcccagaa	ccggccgagc	ctgcccggcg	ccgaggtccg	cccgtgggag	cacaccgctg	23280
acgtggctgc	cggtttcacc	gacgcctacg	acatcatgct	ggcccaccgc	gcccacttctg	23340
accggctgct	gcgcggcttc	cacgacgtgg	aggtgcgcta	cctgcccccg	cccaccgctc	23400
gttacagcat	cttctgacc	gagagctacc	accccgacta	cctgcgcgac	gccagcgacc	23460
gggaccggct	gctcgacaag	ctgtggaccg	ccgcggacgc	ccgccccgag	ctgattccga	23520
tcacgcagtc	ggagaagcga	caactgctcg	ccgtgacat	cccgtgcttc	cgcagcgtcg	23580
cggaagccg	gcagatccgc	accgcctccg	gcccgtgca	cccggagttc	ttaccgcgc	23640
cgcccgctac	cgtactgacc	cgcgggctcg	gcgagttcgg	accggtgcac	cgcgcccgcc	23700
aggtacgcat	catccgcgac	tcgatggcca	cgatgcccgg	ccccggccc	gccgcccagc	23760
ctccccga	ccgggcggcg	ggccccggc	cccgcgtcac	ggcgccgac	ccggccacgc	23820
tcgccgaccg	catcgcccgc	aggctcgccg	acgaggcgat	cctcggcgac	cgcgacgtgt	23880
cctggatcgg	cgtcagcatc	gaaggcgtcg	cccaggagac	ctacagctac	aagccgatgg	23940
cgaccggcct	gtacgacggc	gtggccggcc	tggcgtcac	cttcgcgtac	gcggcccgca	24000
ccctcggcga	cgaccgctac	ctggacctgg	cacaccgagc	ggcccgccc	gtcgccggct	24060
acctcgctta	cctcgccgag	caccgcatcg	tcgagaccgt	ggcgccctac	agcggcaccg	24120
ccgggctgct	ctacgcctg	gaccacgtgg	cccacgccac	cggcgacgac	tcctacctcg	24180
acgcggtctc	ggaggcggtg	ccgtggctgc	gcgaatgcgc	caccgcgag	gagtgccccg	24240
acctgatcgc	cgggctggcc	ggctgcgccc	tgatcagcct	ggacctgcac	ggcgccacc	24300
ggatcgacgg	gctgcgcgag	gtggcggcca	tctgcgcca	acggctcgcc	gccctcgccg	24360
tcgacgtcga	cggcgcccgc	ggatggcccg	ccactccgga	cggaccgctg	ctcggcgggt	24420
tctcccacgg	cgcggccggc	atcgccctgg	cgctgcaccg	gctcgccacc	gaactcggcg	24480
accctcgct	gcgcgagctc	gcccgcggcg	cggtccagtt	cgaccgcgac	ctgtacgtgc	24540
ccgcgcggg	cgcctggcgt	gacctgcgcc	cggagatggc	cggcaccgac	tcctaccccg	24600
cgctgtggtg	ccacggggcc	gcccgcacgc	gcctgtcccg	gctgctcatc	gcgcagcacg	24660
accaggacac	gcgactggcc	gcggaggcca	ccgcgcctc	cgacctggtc	ggcgcgcacg	24720
gcttcggcca	caaccacagc	atctgccacg	gcgacttcgg	cgccctcgcc	ctgttcgacc	24780
tggcggcacg	aaccggcttc	gacccggggc	gccacgacgc	ggccgcccgc	gccgtgaccg	24840
ccgacatcgc	cgccaacgga	gcccgttggt	gcctggctcg	cgacatccac	atgccgggac	24900
tcatgctcgg	cgcgcgccgc	atctgcctga	gcctgctcgg	catcgcccac	cccgcgcagg	24960
tgcccgggt	ggcctggctg	cagccgcccgc	tgacctgagg	aggagcccat	gccggaagag	25020
atcgtgctca	gcgtgctgga	ccaggtgccc	gtgttccgtg	acggcagccc	ggcggaggcg	25080
gtgcgcgacg	cggtcgcgct	ggcccgcagc	gccgaacagt	acggctacca	ccgcttctgg	25140
atcgccgagc	accacggcag	cgcggccaac	gcgtgcgccc	ccccgaggt	ggtgacggcc	25200
gcggtggccg	ccgccacgag	ccgatccgg	gtgggcagcg	gcggcgtgct	gctgccgcac	25260

-continued

---

tacagcccgc	tgaaggtggc	cgagacgttc	cgggtgctgg	cggcgctgta	tccgggccgc	25320
atcgacctcg	gtttcggccg	ggctcctggg	gggcccgcgg	cgatggccga	gctgctcaac	25380
ccgtacgcgg	tccgcaccga	cgaggcggtc	ctggagcaga	tccggccggct	gctgggggttc	25440
ctcggcgaca	cccgtacggt	cagccgcgtg	tcggtgacgc	cgcaggtgga	agagcccccg	25500
gtgccgtgga	tgctcggcgc	egggaccggc	agcgcgccga	tggccggcat	gctgggggttg	25560
ccgttctggt	tcgcccagtt	catcgcgacc	gaggagtgcc	cggaggcgat	cgaggcgtag	25620
cgggatgcgt	tccggccgtc	gccctggctg	gagcgacccc	agccgatgct	cgcttgcgg	25680
gtgctgtgcy	ccgactcggg	cgcggaggcc	gaggaactgg	ccacgtgttt	ctggatgtcg	25740
tgcaagaccg	gctggcgtgc	gcaggtgcag	ctcaccgacg	actaccgtgg	gggcgcgccc	25800
aatctcgacg	acgcacgccg	gtaccggctg	accgcggagg	acctcgcgct	gcgggagagc	25860
cggccggtcc	tgcaatctc	cgggacgccg	gccgcggctg	gcaaggagat	ccgcaggttg	25920
caggcggtgt	acggggtatc	cgaggtgggtg	ctcaccacga	actgcccccg	cctgcccggcg	25980
cggcgcgct	cctacgaact	gctcgcggc	gagttcgcat	ccccggcggc	ctgacggcct	26040
caggtccgcy	gtagctccgc	gtaggtcccc	cgcaatgccg	cggacctgac	ggccgtcagg	26100
acaggcagac	gtcgtcgtg	gacagaccgc	acgcatacgc	caggacggcg	gcctgcacgc	26160
ggttggccac	gccgagcttg	ctcaggatca	cgtgacgtg	ctccttcacc	gtggcggcgc	26220
tgaggaacag	ctgccggctg	atctccgctg	tcgtgaggcc	ggcgcggagc	aggcgcagaa	26280
tgtctgctc	ccggtcggac	agctgtttga	cccgtcgcga	ggccgggtgac	ccggcccccg	26340
cggcagatcc	ccgtgagccc	gcacgcacga	ccaccgacga	cgctcgggc	gccagcacga	26400
tgtgccctc	ggccagcgc	cgcacggcgg	cgaccagctg	ttcgggctgg	ctgtcgcgca	26460
acaggaagcc	gcaggcccca	ccccgcagcg	agtcgagcac	cagctcgggt	ggggcgagag	26520
tggtcagcat	cgcgatcgcc	ggcgggctgc	tcagagcccc	cagctgatcg	agcacctcca	26580
gcccgtcgt	ctgggactg	tggccgtcga	gcagcaccac	ggcaggcccg	tgtgctcga	26640
cggccgatct	caggttctcc	cggctcgtcg	tggcgaccgc	gaagccgccg	gtgctctcca	26700
ggatcatctt	gatgccgatg	ctgaccagtg	cttcgcccgc	cacgaccagt	acgtccgtca	26760
cgatcgggtc	cccgcgagcc	gccgaacgca	tgcaacttgc	atccgcattc	gtgacattac	26820
ttcaactata	tggtcgaatc	aatcgatctt	tcgctatag	tcattaacaa	cacacagcgc	26880
gtcgtcagcy	ggtcagacc	tccgcccggg	cgaccgcgc	cgcccgcgc	gccggcgcca	26940
gactggccac	caccccggtc	agcaccgcca	ccaccagcac	ggcggccagc	tggcccccacg	27000
gcaggcggat	caccggatcg	gcggtacgcc	ccaccgccc	cgccaccgcg	gccagcccca	27060
ccgggacacc	gaccacgagg	ccggccaccg	tgccgagcag	cgtgatcacg	accgcctcga	27120
ccgcgagcat	cgcccgcagc	cgcgcccggc	gtgtgcccag	cgcccgcaac	agcgcctct	27180
cgcgtaccgc	ctcgcgacc	gacaggccca	gcagattcgc	gatgccgagc	agtgcgatca	27240
ccaccgtgac	cgccagcatc	gccagcgaca	gtcccacacg	gatcgacagc	acgttcgcca	27300
tgtcaccgcc	ctcgggtgacc	ccgccaccga	cctgcaccag	cgcgtcgcgg	gcggccaccg	27360
cgccgacggc	ggccgacagc	gcctcccggg	cgaagccggg	gtcagcgacg	ccccacaccg	27420
ttgtcggcac	cgcctcgatc	cggttcggcg	ccagggtccg	cgcgctcacc	acgcccagca	27480
gctgcccggt	ggtgtccgcc	agccgcgacg	cccggcgat	caggttcacc	cgccgctcgc	27540
cgacctcgac	gacgatcggg	gcgctgtccg	gcaggcccag	ctcggccaga	taggtcgcgg	27600
gcaccagcac	caccggtctc	ccggcgagct	ccggtgccac	ccgggcccgc	agttcgtcgc	27660

-continued

---

cgggcgcggc	cagcagccgc	ggcgtcgct	tgccgccgtc	cgggaaacgg	gccgcgaccg	27720
tgccgaccgt	gccactggcc	gacagctgtg	gcaccgcggc	gaaggccccg	gcggtggcac	27780
cgctgatcgg	ctcgccgtcg	gtgctcaggc	ccgcccacc	cgggtagcgc	gcctccaggt	27840
cggcgttcac	cgtggccccg	ccgctggctg	ccgccaccgc	caggcaggtg	atcagcgccg	27900
cgccgaccac	caccgccatc	gccgccgaag	ccgtccggcg	cgcgttcttg	ctcaggctgg	27960
tcccggccag	gccggcggcc	acgccgaaac	gctccagcag	ccgcgccgcc	ggcgccaggg	28020
acaacgcgat	cagccgcggc	aacgccgcca	gcaaccccg	cgccagcaga	agcccccca	28080
gcagcgccag	gggcagcgac	gcgccgatcg	ccgccaccgc	gagcgcggcg	gcgcccacca	28140
cggtcaccac	ggtgcccacg	acgagccggc	gaccgcccgc	gaccgtgccg	gccggcggct	28200
cgctcgccgc	ctgcaacgcc	cgcaccgggg	cgatcctggt	ggcacgccgg	gccggcgccc	28260
aggcggccac	cagcgtggcc	agcaccggcg	ccagcacaca	gccggccagg	gcgaacggat	28320
tgaccgcgag	cccggccggc	ctgatgtcga	gcaggtcggc	gccgagataa	cccagcccca	28380
caccgcggc	cgcgccgacc	aggccggcgg	ctgttccggc	gatcgccgcc	tcggccagca	28440
cgaccgggct	cacctgggca	cgatgaccgc	cgaccagccg	cagcagggcg	atctgccgga	28500
tccgctggac	gatcaccacg	tggaaggtgt	tcgctgatgac	cagcaccgcc	gcgagcaggg	28560
cgacagccgc	gaacgccagc	atgatcacga	ccagctggcc	ggtgccggcg	gcgaacctcg	28620
cggcggcctg	atccgcagcc	gccgagggct	cggtcgccga	gatgccgggg	cccatgctgc	28680
gccgcaacgc	gtcaacgggtg	ccggtcagcg	aggcgtcgtc	ggcgacagtc	agcagcgcg	28740
ccggcggcac	gtcaccggcg	aagaacgacg	cgtcggcgta	gaaccggaag	tccgagccgg	28800
tcagcggccg	gaaaccaggg	tcggcggcac	cggtcacggt	gaccggctgc	ggcgccgctt	28860
caccgtggcg	taccgtcagc	gtggccccga	cgtcgatgcc	gaggtcgtcg	agggtgctct	28920
ggtcggcgac	gagctgtccg	ggccccgggtg	gccacgcgcc	ccggtccaag	gtgaaccagc	28980
ggacctgccc	ggtggccggc	atgctctgca	cgttggccga	gccgcgccgc	gatccgccga	29040
acacgctgac	cgtgcccggc	tactgcccgt	ccaccgagcg	cacccccggc	accgcggccc	29100
cggcctcgta	ccaggccggg	tcgcccggcc	tgtcgtcggc	gtcagcacg	atgtcggcgg	29160
tggtcaacgg	cgcggcggcg	gtaccgccga	ggcctcacc	cgaggtggcc	gcgaaggtcg	29220
cggtcgccc	caggaaaccg	gtcggccagca	tcaccgccgc	gacgatcggc	aacagccggg	29280
ccgggtaggc	gcgcagctgg	gaccaggcaa	gcgcgaagat	catcgtcaca	ccgccaccga	29340
cgccatcgcc	gcgaggatct	gatcgccggc	gggactgccc	agttcctcac	ggatccggcc	29400
gtcggccatc	accaggacc	ggtcggcgta	cgtcgcggcg	cccggatcgt	gggtgaccat	29460
gatgatcgtc	tggccggagc	ggcgtgccc	gtcgcgcagc	ccgccagca	gcgcgcggcc	29520
ggtggcgatg	tccagcgcgc	cggtcggctc	gtcggcgaag	accaccgacg	gcttggccag	29580
cagcgcggc	gccaccgcca	cccgtgctg	ctggccggcg	gacagctcgg	acggacgatg	29640
ccccagccgg	tcggtgatct	gcagtgaatc	ggtgatcttc	cgcagctcgc	ccggatccac	29700
ccggcggccg	gcgagccgta	gcggcagcac	gatgttctgc	tccgccgta	gcgtcggcag	29760
caggttgaac	gcctggaaga	cgaagccgat	ccggtcgcgg	cgcaggtcgg	tcagggcccc	29820
gtcgtccaga	ccggccaatg	accgccggc	caggctgacc	gtgcccgccg	tcggtgtgtc	29880
caatccggcc	agcaggtgca	tcagcgtcgt	cttcccggaa	ccggacgggc	ccatgatcgc	29940
ggtgaactgg	cccgcggaga	agccccggga	caccccgtcg	acggctgtca	cggcagccgg	30000

-continued

---

ccctgttccg	tacgtcttgc	tgacgtcccg	gcaactgacc	atctcggcgt	gtgtcgtctg	30060
cgttgtcacc	gcacccacgc	tagaaatccg	cgcggaccgg	cacatcccac	cacgggatcc	30120
cggtcggggc	gtggaccgat	accttcgtat	gaccgcggc	tatcgacctc	gggcggcgtg	30180
ttcccgaat	cgatgatgtc	tgetttaggct	gggaccgtgg	tgcgagggaa	ccgggtgctc	30240
aggatcgacg	ccctcgtcgc	cgccgcggtg	gtcatcggtt	gtctgctcct	cgggctcgcc	30300
gggctgtccg	agtggactg	gtcggccgcg	gtggccgtac	cgttgcttct	ccggcgcagc	30360
gtccgcgct	gcttctggc	gctggctgcc	ggcgtctccg	gctgcacct	gctggcctcg	30420
cacagcttca	tgttccccgg	cgatctggtc	gctctggctg	cggtgcacgc	cgccgcggcg	30480
cacgcgccgg	gccgtgcccg	ccacgcggga	ctgctgctcg	gcgcgcggcg	agctctcgtg	30540
gtggccgccc	aggccctgca	ggaccagcgc	ctcggctcgg	cgctgcccgc	ggtgctgatc	30600
gtcgcgagca	cgatggccgc	ctggctgatc	gggtgatgc	agcgcagca	gcgcagcgc	30660
gtgctcgacg	ccgagcaccg	cgccggctg	gccgaacagg	acagcgcct	gcgcgcgag	30720
ctggccgtgc	acgaggagcg	cacccggatc	agccaggaga	tgcacgacat	catcgcccac	30780
tcgctggcct	cgatcatcgc	ccaggccgaa	ggcggccggg	tcgcccggcg	cgccgacgcg	30840
cggatcgccg	ggccggtgtt	cgaccggatc	gcggccctcg	gccgtcaagc	cctcaccgac	30900
gtgaaacggc	tgtcaccgt	cgtggaccac	gacgacgaat	ggcacgacga	cggactggag	30960
cggctgcccg	tgctgctcgc	cggagtcacc	gaggccgggc	tggacgtgac	cgtggacagc	31020
agcggggcgc	cgcagccgct	cgccgcggcg	atggacctcg	ccgtgtaccg	ggtgatccag	31080
gagtcgctga	ccaacgtgct	caagcacgcg	ccggcgcgcc	gggcctgcct	gcggatgcgg	31140
tggacgcccg	cgctgctcac	ggtcacggtg	agcagcccgc	ttcccgggtg	ccgcggcgc	31200
ggcctggctg	aggggcgcgg	cctgtccggg	atccggcagc	gctgctcact	gttcaacggc	31260
gactgcaccg	tcaccgcgac	cacggaactc	accgtcacca	ccacctggcc	cctcaccgcc	31320
gaaggagcgc	gcgcatgacg	cggccaccga	tcgcccgtgt	gatcgccgac	gatcaggagc	31380
tggtagcgc	cggtttcgcg	atggctcgtg	acgcggcggc	ggacatgcgg	gtcgtggcca	31440
tcgcccggag	cggcgcggag	gcgatcgagc	tggccggcga	acaccggccc	gacgtcatcc	31500
tgatggacat	ccgcatgccc	ggcaccgacg	ggatcacgcg	gaccagcgcg	atcctggccc	31560
ccggcggcga	gcggccaccg	aagatcatcg	cgtgacgac	gtacgacagc	agcgactacg	31620
cgacgcggat	cctcaccgcc	ggggccagcg	gctatctgct	gaaggacgcg	accgccgagg	31680
gcctgacggc	ggcgatccgc	agcgcgtacc	acggcgggtc	ggtgatcgcc	ccgacgacga	31740
cccggaacct	ggtcgcggcc	cgcgcggagc	caccgcggcc	ggctcgcgac	ccggcgcgcg	31800
tggacacggt	caccgcccgg	gaacgcgacg	tgttcgacct	gatcgtggcg	ggcgccaaca	31860
acgcggagat	cgcggcccgg	ctgcacctgg	ccgaggtgac	ggtgaagacg	cacgtcggcc	31920
gggtgctggc	caagctcggg	gtacgcgacc	ggctcaacgt	agtcgtctgg	gcgtaccgca	31980
acggcgtgt	cggtgatcc	gcacctcag	gccctgaca	cggtgccacg	gtggcacggt	32040
gtgatagacc	cgggtcgttt	cgctcacac	tgggtggtgt	gcgggtgagtt	cctgggtacg	32100
ccggcgcgat	cacaacgtct	tcgtcaacgc	gttcaacatg	ctcatatgcg	gcctcatcgc	32160
cggcgtcgtc	gtggccgctg	ccgcgttccc	gttcgcggcg	atgtccggcc	tggccgcaa	32220
ggccggccag	cagacgttcg	cgagcctgcc	cagcgagctg	aaggcgttcc	ggtcaccgca	32280
gatcagccgg	atctacggcg	ccgacaacag	gaccaggtc	gcccagttct	acgacgagtt	32340
ccgcagtgac	gtcccgtca	aggagatgtc	gccgttcatg	cgcgacgcca	tggtcgcggc	32400

-continued

---

cgaggaccgg	cagttctacc	agcaccacgg	cgtggacctg	aaaggcgcgg	cgcggtgcgt	32460
ggtcaacaac	cgcaacggcg	ggcagaaaca	gggcgcgtcg	acgatcacca	tgcagtgggt	32520
acggatctcg	ctggcctact	cggcgaccaa	gccgcaggac	gtcatcgacg	ccaccgagga	32580
cgccccgaag	cgcaaggtcg	ccgagatgaa	gtacgcgctc	gaggtggaga	agcagctcag	32640
caaggaccag	atcctggagc	ggtacctgaa	catcgtgccg	ttcggcaagc	agacgtacgg	32700
catctacgcg	gccagccggg	tctacttcaa	caagaagccc	aaggacctca	cgatcggcga	32760
ggccgcgctg	ctggccgcca	tctgaaggc	gccgtccgcg	tacgacccca	ccgaccggga	32820
cggttacgag	ctcatccggc	agcggcgcaa	cgctatgtc	atcccgggca	tgggtggagat	32880
gggcgccatc	accggggcgc	aggccgacgc	ggcgtcaag	gaggccatcc	cgcgcaaggt	32940
acgcccgatg	agcaacggct	gcgtgtcggg	ggccaagaac	aactggggct	tcttctgcga	33000
ctacttttac	cgctggtgga	tggagcgcaa	ggagtccggg	cccacgccgt	acgaccggga	33060
gcgcccggctg	aagagcggcg	gctaccggat	caccacgaca	ctcgacgtca	aggcgcagaa	33120
gcaggcccgg	gateggatcg	gcgacctgat	ctccgagaag	aacaagaacg	cgctgctgct	33180
ggcagccgtc	gagcccggca	ccggcaaggt	acgcatgctc	gccgccaacc	gccggtataa	33240
gctggacgat	ccggatgatc	cgcagaacgc	gatctcctcc	gacccgagaa	aggcgcgcaa	33300
gggcatccgt	ggctcgtacc	cgaacacgac	gaatcccctg	ctgaccggcg	gcggcgacat	33360
caccggctac	caggccggct	cggtgatgaa	gatgttcacc	atcgtcgccg	cgctggagca	33420
gggctaccgg	ctcgcctaca	cgatcaggac	gcagagccgg	taccgctccc	gctacatcat	33480
cgagagcagc	aacgacgcgg	cctgccccgg	aacgcacttc	tgggtgtcca	gcaacgccgg	33540
tggcggcggc	gaggggtgtct	tcaacatgtg	gaccggcctg	ggcaggtcga	tcaacacgta	33600
cttcgtgccg	ctggaggaac	gcgtcggcgc	ggagaagggtg	gtcagcgccg	cgaaacgctt	33660
cggcattccag	ttccgggagc	cggacgacgc	actgctggcc	gaaccgggca	acgcacacca	33720
gtggggcgcc	ttcacctggg	gcgtctcggc	caccaccccg	ctggacatgg	ccaacgccta	33780
cgccaccctg	gccgcccagc	ggatgtactg	cccgccgacc	ccgategagc	ggatcgccac	33840
ccgtgacggc	gaccagctgg	acgtcggccg	gtcccctgct	gtacgggcca	ccgccaagga	33900
cgtcgccccg	gccgcccctg	acgcccggcg	ctgcccgggtg	ggcgactccg	cgcagctcgg	33960
ccggtgcccgg	ggaagcaccg	ccggcatcac	ccggtcgggtg	gtcgggcatc	cggtgttcgg	34020
caagaccggc	accaccgacc	gcgaccggac	cgctcgtctg	atcgccggca	ccaccgcgct	34080
ggtggtcgcc	ggttacctgg	tcaaccccga	ctaccagaac	caccgcgacc	ggctcgacca	34140
cgaccaggtc	aaccggcccg	tctaccgcac	gctcggccgac	tacatggagg	gcaggccacg	34200
ggagtcgttc	aagcggcccgt	cgagcggggc	gatcgcgctc	ggtgaccagc	gctcgatccc	34260
ggacgtcgag	tgcgaccgga	tgccccgcgc	ccgcgaccgt	ctggaggatg	ccggcttcga	34320
cgtctggcga	ggccaggaag	tggagtcgga	ctgtcccgcg	ggcaccgcgg	ccggcaccga	34380
gccgagcggc	cggaccgtca	agaacggcgt	ggtggtgatc	caggtgagca	agggccgccc	34440
gggcgcgtca	ccgccgatct	tcccggcgat	cgggccaccc	cgctgaccgg	ctgacggcgt	34500
agacgtcgcc	ggcgttcgcc	tctgctggca	gcccggccag	gtgcgcgagc	atctcgtcgc	34560
gggcggccca	ccggccgaag	gtgcggggca	tggctctgcc	cagggagacg	togaagccgt	34620
cgaagcccag	ctcgcgggca	cggtcgaggc	agcgcggggc	cacgtcccgg	gcgatcgtcg	34680
tgaactcgaa	cgacaacgcc	cggacaccgc	ggctcagacc	ggcgagcacc	gcgtcctcgt	34740

-continued

---

acccttcgac	gtcgatcttg	atgaaggccg	gcaggccgaa	tcgctggacg	agcgtgtcca	34800
gggtgaccgc	agggacggtg	atctgctggt	cccagacctc	gttctcccag	ccgcgcgagc	34860
cggtcgccgc	ggtcaggaag	cgcaccgagt	tcgtggagac	cgctgggttc	gccgagttga	34920
tgtagagcgg	cacgctcccg	ccggcggggc	cgcacgcggc	ctcgacgagc	gccacccggt	34980
cgctcgtggc	gtagagcgcg	cgcagcgcgc	gcatgcacag	cggtcgcggt	tcgacggcga	35040
ccacgcgggc	gccgagccgc	cggaagcagg	cgacccggtc	accgacgtgc	gcgccgatgt	35100
cgaagacgac	gtcaccgggc	cggacgaaac	gccggtacat	cgcgctccatc	gcggcctccc	35160
ggccggcgctc	accgtagtag	taacgcagcg	accgggtcag	cggcgccatg	gccgggtcga	35220
ctctcagttt	gcgcaggtea	tcggtcacgg	cgggggcatt	ccccgatca	ggcgatccat	35280
gcatcgccgg	cgcgctgcga	ggtaggcggc	gatcgcccgg	gcggaacgca	cgcccagaggt	35340
ggtcatgacg	ttgtgcgcg	cggccgggac	ggtcacccgac	acgccgccgg	tcacgcgccg	35400
cacctcggca	cgccagcgca	gcggcgccac	cgatcaagc	gacccgccga	gcaccagcgg	35460
gggtacgggc	aaccggcgca	gatcctcctc	gatcgcgctg	cgtaccgagt	ggccgaccgt	35520
ggccagaacc	cgccacggct	tggcgtcggc	gatgtcgcgg	accagcaccg	gcgcctgcca	35580
cggcgcctcg	atccacaggt	ccaccgccc	ccggccgatc	agcggccgcc	gggaccgggc	35640
cgccgggtcg	gtggtcgggc	tggccagcac	gacggcggcg	accaggtccg	gcgcgagcac	35700
cgcgagacgg	gccgccacct	cggcgccgaa	cgagtgcgag	gcgatgcagg	cccggggcac	35760
gccgagcacg	tccagccagg	ccgcgaggtg	ttcggcgtgc	cgccccact	cgtacgcgcg	35820
gcgcggcttg	tcgctgaacc	cgaaccggg	aaggtccgga	acgaggaccg	gatggcggcc	35880
cgccagcgcg	tgggcggtgg	gcatcaggta	gcggtgcgag	acggcgagcc	cgtgtaccag	35940
caccaccgga	aggccgccgg	cgtggcacgc	gtgccggctg	tgcgtacgca	ctccaccgac	36000
cgtcaccagg	cggctgtcga	atcggggcac	cgcgagatg	taccccgctc	ttccgcaatc	36060
tttcccgcgc	ggttagtttc	gagttgtgtc	gccgcccttc	cggtcgcagc	aggcggctgc	36120
cgacgtctac	ggcgacctgc	gcctggcgcc	cgtgctgcgg	cggtcgtgct	ggcacagcgg	36180
ccgcctgacc	ggctcgggtg	ccggcagcgt	gtcgtgatc	gacgcggacc	gcggctgcta	36240
cgtaaggcc	gccgagtacg	gcgcgaactg	ccagctcgga	cgctctttcc	cgctcgacga	36300
gggcgccacc	ggcgcgcct	tcggcagccg	ccggcccgtg	gtgatcccgg	actacggtea	36360
gctgcgggcc	ggtcatctcg	cggcggcgca	tccggcacgg	aagggcccg	ccgtcgcgtg	36420
gccgatctgg	tggcgcggcg	acgtgatcgc	ggtgaacgtc	gccttcgcgc	cgcccttctc	36480
cctgggtggt	gtcgacgaac	tggaggcgct	gaccagctcc	gcggccgccc	cgatcgtccg	36540
cagccggggg	gtgcgggtcc	gcgcgcgacc	gccgtacgcg	gctccggccc	caccgttcac	36600
cccgcgcgag	gccgaggtcc	tcgatctgct	ccggcagggg	ctgaccgacc	gcgagatggc	36660
ccgcgggctc	ggcctgtccg	cgaagaccgt	ggagaagcac	gtcggcgcgca	tcaggcgcaa	36720
gaccgggacc	tccaaccgta	cggcggcggt	cgtcacggcc	ctggacaacg	actgggtggg	36780
gaatcttccc	cataccgcgg	agcacaccac	cgggtcttga	ctggcggcat	gcccgtcgtc	36840
tccatgaagg	acatcctcga	ccgtgcgctg	gccgagcggg	acgggtgtgg	cgcttcaac	36900
atcgtcaacg	acctgaccgt	cgaggccgtg	ctcgccgccc	cggcggagga	acgcgccccg	36960
gtcatcctgc	agacctcggg	caagacggtc	cggtatgacg	gccgcccccg	gctgtacgag	37020
atcgtccacg	ccttcgccc	cgacgcgcgc	gtcccgggtg	ccctgcacct	ggaccactgc	37080
cccgagcggg	cggtcatctc	cgactgcctc	gccggcggtg	ggaactccgt	gctcttcgac	37140



-continued

---

```

gcgcacgagc tgcacgtggc cgacaacctg cgccagacca ccgaggtggt ggccgaggcc 37200
cgtcgcgccc ggcgccacgt cgagggcgag atcgagggca tccaggggtgt cgaggacgac 37260
gtcggcaacg actacgcccc gatggtgcag agcctggagg tggcggtcga cttcatcaaa 37320
cgcaccggcg tgcactgttt cgcgcccggc atcggaacg cgcacggcca gtacaagcag 37380
gcgcccgtgc tcaacacctg cggggtcagc gacctcgttg cggccaccgg catcccgatg 37440
gccctgcacg gcggcaccgg cctctccgac gagcagttca ccgacctcat cgcccgtggc 37500
tgcgcaagg tcaacatctc cacggcgctc aaggagtcgt tcatgaaatc cggcctggag 37560
ttcctgcgcg aggccgatga gcgcccgaaa tgggatccgc cgtcgtctgt ccggcatcag 37620
cgggcccggg tcgtagagat ggcccggcag cacatccggc tcttcggcgg atcggggcgc 37680
gcgtggtgaa cgccctggtc ttcgactgcg acggcgtgct ggccgacacc gaacggcacg 37740
gccacctgcc cgcggttcaac gccacgttcg agcagttcgg gctgcccgtg cggtgaggcg 37800
aggaggaata cggcgagaag ctgcgcatcg gcggcggcaa ggagcggatg gcgtcgtctg 37860
tcgcccgatc cgccttcgcc gcggcggccc gcgacaccga ccgtacggaa ctgctgcgaa 37920
cctggcaccg cgccaagacc gcggctttca cgaagctggt cggcagggc cggattccgg 37980
cccgtccggg cacagcccgg atcatcagcg aggcactccg ggcaggatgg acggtcgccc 38040
tcgcttcac gtcggccgag gattcggtag gcgcagtgct cgtcaacgcc gtgggagcga 38100
cgactgccga gcggatcccg gtgttcgccg gagacgtcgt gcccgcaag aaacccgacc 38160
cggcgatc 38168

```

```

<210> SEQ ID NO 101
<211> LENGTH: 146
<212> TYPE: PRT
<213> ORGANISM: Actinoplanes garbadinensis

```

```

<400> SEQUENCE: 101

```

```

Met Pro Arg Arg Ser Thr Arg Cys Ser Pro Ala Cys Arg Pro Gly Ala
1          5          10          15
Ala Asp Gln Pro Asp Pro Gly Arg Ala Cys Arg Pro Asp Cys Gly Arg
20          25          30
Ala Asp Arg Ser Gly Ser Gly Arg Ala Cys Arg Pro Asp Cys Gly Arg
35          40          45
Ala Asp Arg Ser Gly Ala Asp Arg Pro Ser Ala Ala Ala Leu Val Ser
50          55          60
Gly Met Pro Arg Arg Thr Gly Val Gly Gly Ala Pro Gly Arg Leu Ile
65          70          75          80
Glu Ala Arg Ala Val Leu Pro Glu Leu Ile Gly Ala Ala Arg Asp Arg
85          90          95
Arg Ala Ser Cys Val Glu Gln Arg Val Arg Ser Leu Thr Ala Cys Arg
100         105         110
Ala Cys Ala Cys Arg Arg Ala Ala Ala Pro Ala Ala Pro Arg Thr Pro
115         120         125
Pro Arg Pro Ser Ala Ala Pro Ala Pro Gly Ser Asp Ala Gly Gly Arg
130         135         140
Cys Gly
145

```

```

<210> SEQ ID NO 102
<211> LENGTH: 149
<212> TYPE: PRT

```

-continued

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 102

Val Ser Val Ser Leu Leu Leu Val Pro Leu Ala Met Ala Gly Ala Ala  
 1 5 10 15  
 Ala Val Gln Ala Ala Ala Gly Arg Met Asp Asp Gly Arg Leu Ile Cys  
 20 25 30  
 Gln Val Gln Thr Arg Met Arg Asp Val Thr Leu Leu Asp Ala Ala Leu  
 35 40 45  
 Arg Asp Thr Gly Ala Thr Val Thr Ala Ala Gly Asp Thr Ile Ser Ala  
 50 55 60  
 Thr Trp Thr Gln Ser Ala Ala Thr Phe Thr Arg Gly Ala Asp Gly Ile  
 65 70 75 80  
 Trp Ala Ala His Val Thr Gly Val Asp Gln Pro Gly Ala Val Glu Leu  
 85 90 95  
 Met Thr Thr Val Asp Thr Ala Tyr Gly Arg Arg Val Gln Gln Ala Val  
 100 105 110  
 Leu Glu Arg Leu Arg Ala Gln Ala Pro Glu Ala Gly Leu Arg Leu Glu  
 115 120 125  
 Ser Glu Ser Val Gly Gln Asp Ala Ser Val Arg Leu Val Phe Glu Val  
 130 135 140  
 Glu Arg Glu Arg Ala  
 145

&lt;210&gt; SEQ ID NO 103

&lt;211&gt; LENGTH: 518

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 103

Val Glu Arg Ser Phe Ala Glu Thr Phe Ala Gln Leu Leu Lys Ala Arg  
 1 5 10 15  
 Phe Pro Val Leu His Leu Glu Thr Tyr Glu Glu Gln Arg Ala Leu His  
 20 25 30  
 His Leu Ala Gly Ile Ala Gly Asp Ala Asp Leu Val Arg Val Pro Arg  
 35 40 45  
 Ala Val Trp Thr Trp Ser Leu Thr Ala Gly Leu Val Gln Pro Asn Gly  
 50 55 60  
 Glu Ala Arg Ser Gly Ala Gln Arg Ala Thr Asp Ala Leu Arg Ala Val  
 65 70 75 80  
 Gln Arg Ile Asp Glu Pro Ala Val Phe Val Phe Arg Asp Leu His Pro  
 85 90 95  
 Leu Phe Ala Gln Ser Pro Glu Val Val Arg Leu Val Arg Asp Ile Ala  
 100 105 110  
 Gln Ala Phe Arg Ala Gly Arg Ser Pro Arg Thr Leu Val Leu Leu Ser  
 115 120 125  
 Pro Val Leu Asp Leu Pro Val Glu Leu Ser Lys Asp Val Thr Ile Val  
 130 135 140  
 Asp Phe Pro Leu Pro Gly Gln Leu Glu Leu Arg Ala Leu Leu Asp Ala  
 145 150 155 160  
 Met Val Arg Gly Asn Thr Ala Ser Gly Arg Leu Arg Val Glu Leu Asp  
 165 170 175  
 Glu Gln Ser Arg Glu Arg Phe Val Thr Ala Ala Ala Gly Leu Thr Met  
 180 185 190  
 Gln Glu Ala Glu Asn Ala Tyr Ala Arg Ala Met Val Asn Asp Ala Val

-continued

195	200	205
Leu Asp Leu Ala Asp 210	Leu Glu Ile Val 215	Glu Glu Lys Arg Gln Thr 220
Val Arg Lys Ser Gly 225	Val Leu Glu Phe Met 230	Ala Ala Gly Thr Val Leu 235 240
Asp Asp Val Gly 245	Leu Glu Asn Leu 250	Lys Ala Trp Leu Val Lys Arg 255
Asn Gly Ser Trp 260	Leu Asp Glu Ala 265	Gly Tyr Gly Leu Pro Ala Pro 270
Arg Gly Val Leu Ile Thr 275	Gly Val Pro Gly Cys 280	Gly Lys Ser Leu Thr 285
Ala Lys Ala Val Ala Thr 290	Ala Trp Asn Leu Pro 295	Leu Leu Arg Phe Asp 300
Ile Gly Arg Val Phe 305	Ser Gly Leu Val 310	Gly Ser Ser Glu His Asn Met 315 320
Arg Thr Ala Leu Arg Thr 325	Ala Glu Ala Val 330	Ala Pro Cys Val Leu Trp 335
Val Asp Glu Ile Glu Lys 340	Gly Phe Ala Gly Gly Thr 345	Gly Gly Asp Ser 350
Gly Thr Gly Ala Arg Val 355	Phe Gly Thr Phe Leu Thr 360	Trp Met Gln Glu 365
Lys Arg Thr Pro Val Phe 370	Val Ile Ala Thr Ala 375	Asn Asp Phe Asp Gly 380
Leu Pro Pro Glu Leu Leu 385	Arg Lys Gly Arg Phe 390	Asp Glu Thr Phe Phe 395 400
Val Asp Leu Pro Ser Arg 405	Ser Glu Arg Val Ala 410	Val Trp Arg Val His 415
Leu Gly Arg Ala Leu Arg 420	His Arg Arg Ala Ala 425	Gly Glu Leu Arg Val 430
Asp Ala Glu Leu Leu Thr 435	Glu Leu Ala Gly Leu Thr 440	Glu Gly Tyr Ser 445
Gly Ala Glu Ile Glu Gln 450	Ala Val Ile Ala Gly 455	Leu Phe Asp Ala Phe 460
Ser Glu Arg Arg Pro Leu 465	Arg Arg Asp Asp Leu 470	Val Arg Ala Val Met 475 480
Ser Ile Val Pro Leu Ser 485	Val Thr Gln Ala Glu 490	Arg Val Asp Ala Leu 495
Arg Gly Trp Ala Arg Asn 500	Arg Ala Val Ser Ala 505	Thr Gly Thr Asp Asp 510
Trp Asp Leu Thr Asn Arg 515		

&lt;210&gt; SEQ ID NO 104

&lt;211&gt; LENGTH: 203

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 104

Val Gly Glu Leu Asp Gln Gln Arg Ile His Pro His Asn Asn Ile Trp 1 5 10 15
Gly Ser Gly Ala Gly Thr Gln Thr Ile Trp Ala Arg Ser Gly Thr Asn 20 25 30
Trp Gly Val Val Ala Asn His Pro Arg Thr Ser Gly Val Lys Ser Tyr 35 40 45

-continued

---

```

Pro Asn Thr Gly Lys Thr Leu Asn Arg Thr Leu Ser Ser Leu Asn Ser
 50                               55                               60

Leu Thr Ser Ser Phe Asn Val Ser Val Pro Ser Ser Gly Asp Tyr Ser
 65                               70                               75                               80

Thr Thr Tyr Asp Ile Trp Ala Asn Asn His Ala Tyr Glu Val Met Ile
                               85                               90                               95

Trp Thr Asn Gln Gln Gly Ala Val Gly Pro Ile Ala Glu Gln Tyr Asp
                               100                              105                              110

Ala Asn Gly Ala Val Pro Asn Val Arg Asn Leu Ser Val Gly Gly His
                               115                              120                              125

Thr Trp Asn Val Tyr Arg Gly Ser Asn Gly Ala Asn Ala Val Phe Ser
 130                               135                               140

Phe Ile Arg Thr Asn Thr Asn Ser Gly Thr Val Asp Ile Leu Ala Ile
 145                               150                               155                               160

Leu Asn Trp Leu Arg Thr Asn Gly Trp Trp Gly Asp Val Thr Val Gly
                               165                              170                              175

Glu Ala Gln Phe Gly Phe Glu Ile Ser Gly Thr Ala Gly Gln Ser Asn
                               180                              185                              190

Phe Thr Val Asn Asn Phe Ser Leu Asn Tyr Ser
 195                               200

```

```

<210> SEQ ID NO 105
<211> LENGTH: 219
<212> TYPE: PRT
<213> ORGANISM: Actinoplanes garbadinensis

```

```

<400> SEQUENCE: 105

```

```

Met Arg Arg Arg Thr Leu Ala Leu Ser Leu Ala Ala Ser Ala Ala Leu
 1                               5                               10                               15

Ile Ala Gly Ala Gly Val Val Thr Ala Leu Pro Ala Ser Ala Ala Ala
                               20                               25                               30

Gly Cys Arg Val Ala Tyr Thr Val Ser Ser Gln Trp Pro Gly Gly Phe
 35                               40                               45

Gly Ala Asn Val Thr Ile Thr Asn Leu Gly Asp Pro Leu Thr Asn Trp
 50                               55                               60

Thr Leu Val Trp Ser Tyr Ser Gly Gly Gln Thr Val Thr Gln Ala Trp
 65                               70                               75                               80

Asn Thr Ser Leu Thr Gln Ser Gly Ser Gln Val Thr Ala Arg Asn Ala
                               85                               90                               95

Gly Tyr Asn Gly Ser Val Gly Thr Asn Ala Thr Val Ser Phe Gly Phe
                               100                              105                              110

Asn Gly Ser Gly Ala Ala Thr Pro Ala Pro Gly Thr Phe Thr Leu Asn
                               115                              120                              125

Gly Thr Ala Cys Thr Gly Ser Ala Gly Pro Thr Ser Pro Ser Ser Gln
 130                               135                               140

Pro Pro Thr Asn Gly Val Pro Ser Asp Ala Val Trp Val Asp Ser Gly
 145                               150                               155                               160

Gln Trp Ala Asn Trp Thr Asn Asn Gly Tyr Ile Leu Thr Thr Thr Ser
                               165                              170                              175

Gly Ala Arg Ala Pro Ala Pro Arg Pro Ser Gly Arg Ala Ala Ala Pro
                               180                              185                              190

Thr Gly Ala Ser Ser Arg Ile Thr Arg Ala Pro Ala Gly Ser Ser Pro
 195                               200                               205

Thr Pro Thr Pro Glu Arg Pro Ser Thr Val Arg
 210                               215

```

-continued

---

<210> SEQ ID NO 106  
 <211> LENGTH: 161  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis  
  
 <400> SEQUENCE: 106  
  
 Met Thr Ile Thr Glu Thr Asp Leu Ala His Leu Arg Arg Cys Val Asp  
 1 5 10 15  
  
 Leu Ala Arg Glu Ala Leu Asp Asp Gly Asp Glu Pro Phe Gly Ser Val  
 20 25 30  
  
 Leu Val Ser Ala Asp Gly Lys Val Leu Phe Glu Asp Arg Asn Arg Val  
 35 40 45  
  
 Arg His Gly Asp Ala Thr Gln His Pro Glu Phe Ala Ile Ser Arg Trp  
 50 55 60  
  
 Ala Ala Glu His Leu Thr Pro Arg Glu Arg Ala Ser Ala Thr Val Tyr  
 65 70 75 80  
  
 Thr Ser Gly Glu His Cys Pro Met Cys Ser Ala Ser His Gly Trp Val  
 85 90 95  
  
 Arg Leu Gly Arg Ile Val Tyr Ala Ala Ser Ser Ala Gln Leu Thr Ala  
 100 105 110  
  
 Trp Tyr Lys Glu Trp Gly Ile Pro Ala Gly Pro Val Ala Pro Leu Pro  
 115 120 125  
  
 Ile Thr Thr Val Val Pro Gly Ala Val Val Glu Gly Pro Val Pro Ala  
 130 135 140  
  
 Phe Glu Ala Glu Leu Arg Glu Leu His Arg Ala Arg Phe Thr Pro Ala  
 145 150 155 160  
  
 Gln

<210> SEQ ID NO 107  
 <211> LENGTH: 413  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis  
  
 <400> SEQUENCE: 107  
  
 Val Thr Thr Pro Leu Val Ala Gln Ala Gly Asp Ser Thr Thr Gly Leu  
 1 5 10 15  
  
 Thr Gly Leu Gly Leu Val Glu Asp Ala His Gln Ile Ala Glu Ala Ile  
 20 25 30  
  
 Arg Gly Asn Ser Trp Val Asp Gly Val Leu Gly Gly Val Gly Ala Ser  
 35 40 45  
  
 Leu Asp Gly Leu Ala Leu Ala Ile Asp Pro Leu Gly Thr Leu Ala Ala  
 50 55 60  
  
 Trp Gly Val Ala Trp Leu Ile Glu His Val Gln Pro Leu Gln Asp Ala  
 65 70 75 80  
  
 Leu Asp Trp Leu Ala Gly Asp Val Asp Glu Ile Ala Ala Gln Ala Ala  
 85 90 95  
  
 Thr Trp Arg Asn Val Ala Ala Phe Thr Asp Ser Ala Gln Gln Asp Tyr  
 100 105 110  
  
 Ala Asp Arg Leu Arg Thr Glu Val Ala Gly Trp Phe Gly Ala Ser Gly  
 115 120 125  
  
 Asp Ala Tyr Arg Ala His Ala Ser Glu His Leu Ala Ala Leu Lys Gly  
 130 135 140  
  
 Ile Ser Thr Ala Ala Gly Gly Ile Ser Ser Ala Val Glu Gly Ala Gly  
 145 150 155 160

-continued

---

Leu Leu Val Ser Leu Val Arg Gly Ile Val Arg Asp Leu Ile Ala Gln  
 165 170 175  
 Phe Val Ala Thr Leu Ala Val Arg Leu Pro Gln Trp Leu Ala Ala Glu  
 180 185 190  
 Gly Leu Thr Leu Gly Leu Ala Thr Pro Val Val Ala Ser Gln Val Ala  
 195 200 205  
 Ala Leu Val Ala Arg Gly Val Asn Lys Ile Gln His Phe Ile Arg Ala  
 210 215 220  
 Leu Leu Asn Ser Leu Arg Arg Leu Met Pro Met Ile Asp Arg Leu Gly  
 225 230 235 240  
 Glu Val Leu Glu Arg Leu Arg Met Leu Thr Asp Arg Leu Ala Arg Ser  
 245 250 255  
 Ser Pro Ser Thr Arg Pro Glu Pro Thr Pro Gly Pro Ala Thr His Ala  
 260 265 270  
 Gly Thr Glu Asn Ala Ser Gly Asn Lys Pro Glu Gly Asp Leu Glu Pro  
 275 280 285  
 Asn Glu Pro Arg Pro Ala Glu Ala Asp Ala Arg Asp Ser Thr Pro Gln  
 290 295 300  
 Ala Phe Val Asp Glu Val Val Ser Asn Pro Arg Ser Val Ala Gly His  
 305 310 315 320  
 Ser Ala Gln Ser Ile Ala Asp Gln Phe Asn Ala Ala Gly Tyr Ser Ala  
 325 330 335  
 Val Val Glu Gln Ser Thr Arg Ser Gly Thr Ser Gly Asn Ala Ile Gln  
 340 345 350  
 Val Arg Ile His Gly His Pro Asp Ile Thr Asn Ile Gln Val His Pro  
 355 360 365  
 Gly Gly Gly Arg His Thr Pro Glu Gly Ser Pro Tyr Trp Lys Ile Ser  
 370 375 380  
 Thr Asn Thr Val Gly Lys Ile Trp Ile Ile Pro Glu Asn Phe Arg Gly  
 385 390 395 400  
 Ala Asp Glu Leu Arg Gly Asn Val Val Arg Tyr Asp Lys  
 405 410

&lt;210&gt; SEQ ID NO 108

&lt;211&gt; LENGTH: 217

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 108

Val Gly Lys Pro Cys Pro Asp Leu Val Glu Val Leu Ser Arg Glu Ile  
 1 5 10 15  
 Gln Ala Gly Asn Gln Gly Ala Ser Ala Ser Glu Val Val Glu Ile Phe  
 20 25 30  
 Asp Leu Glu Leu Val Gly Ile Phe Arg Gly Ala Val Thr Gln Lys Leu  
 35 40 45  
 Pro Gly Ile Glu Val Leu Arg Lys His Leu His Leu Lys Gln Gly Gly  
 50 55 60  
 Val Gln Val Arg Ser Val Val Val Arg Ala Glu Asp Pro Ala Gly Ile  
 65 70 75 80  
 Val Val Val Gly Asp Leu Cys Ala Arg Ile Asp Asn Arg Asp Val Gly  
 85 90 95  
 Leu Ala Gln Gly Asp Ala Tyr Trp Glu Arg Arg Asp Asp Thr Val Asp  
 100 105 110  
 Arg Leu Asp Gln Ile Arg Ala Asp Ser Pro Cys Glu Phe Asp Asp Met  
 115 120 125

-continued

Val Arg Leu Gly Ala Gly Val His Gly Asp Gly Gln Arg Arg Val Arg  
 130 135 140  
 Gln Arg Phe Ala Asp Val Ala Asn Leu Phe Gly Val Gln Arg Ala Ile  
 145 150 155 160  
 Ile Asn Glu Ser Arg Ile Arg Thr Lys Ile Asp Pro Asp Asp Val Asp  
 165 170 175  
 Ala Gln Gly Asp Glu Arg Gly Ser Phe Pro Arg Gly Ser His Pro Ile  
 180 185 190  
 His Phe Asp Asp Leu Ile Cys His Ser Ala Pro His Ser His Ala Val  
 195 200 205  
 His Arg Arg Pro Gly Asn Phe Arg Gly  
 210 215

<210> SEQ ID NO 109  
 <211> LENGTH: 592  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 109

Val Ser Asp Val Val Val Glu Arg Leu Thr Ala Trp Asp Val Glu Arg  
 1 5 10 15  
 Val Phe Gly Tyr Ser Gly Asp Gly Ile Asp Gly Val Ile Gly Ala Leu  
 20 25 30  
 Arg Arg Ala Gly Arg Pro Thr Phe Val Gln Ala Arg His Glu Glu Gly  
 35 40 45  
 Ala Ala Phe Met Ala Val Gly His Ala Lys Tyr Thr Gly Gly Ala Gly  
 50 55 60  
 Val Cys Leu Ala Thr Gln Gly Pro Gly Ala Val His Leu Leu Asn Gly  
 65 70 75 80  
 Leu Tyr Asp Ala Lys Leu Asp Ser Lys Pro Val Val Ala Ile Val Gly  
 85 90 95  
 Gln Gln Val Ser Thr Val Leu Gly Ser Ala Tyr Gln Gln Glu Ile Asp  
 100 105 110  
 Leu Val Arg Leu Phe Gly Asp Val Cys Ala Gln Phe Val Gln Ala Ala  
 115 120 125  
 His Thr Ser Glu Gln Val Pro Met Leu Leu Asp Arg Ala Phe Arg Thr  
 130 135 140  
 Ala Leu Ala Thr Arg Ser Pro Thr Cys Val Val Leu Pro His Asp Val  
 145 150 155 160  
 Gln Thr Ala Pro Ala Pro Asp Pro Gln Ala His Glu His Gly Val Leu  
 165 170 175  
 Ala Thr Ser Ala Gly Leu Arg Pro Ala Arg Val Val Pro Arg Pro Glu  
 180 185 190  
 Asp Leu Arg Glu Ala Ala Glu Val Leu Arg Ser Gly Glu Arg Val Ala  
 195 200 205  
 Ile Met Val Gly Gln Gly Ala Tyr Gly Ala Glu Arg Glu Ile Val Glu  
 210 215 220  
 Leu Ala Gln Arg Leu Gly Ala Gly Val Thr Thr Ser Leu Leu Gly Lys  
 225 230 235 240  
 Pro Val Leu Asp Glu Asn Leu Pro Phe His Thr Gly Val Met Gly His  
 245 250 255  
 Leu Gly Thr Thr Ala Ser Ala Glu Leu Met Arg His Cys Asp Thr Leu  
 260 265 270  
 Leu Leu Ile Gly Thr Asn Asp Pro Trp Thr Glu Phe Tyr Pro Arg Pro

-continued

275					280					285					
Gly	Gln	Ala	Arg	Ala	Val	Gln	Ile	Asp	Val	Asp	Gly	Arg	Arg	Leu	Gly
290						295					300				
Val	Arg	Tyr	Pro	Val	Glu	Val	Pro	Leu	Leu	Gly	Asp	Ala	Val	Glu	Thr
305					310					315					320
Leu	Arg	Glu	Leu	Leu	Gly	Leu	Leu	Pro	Ser	Arg	Ala	Ser	Gly	Ala	Trp
					325				330					335	
Gly	Ala	Arg	Val	Glu	Glu	Trp	Val	Gln	Arg	Trp	Arg	Leu	Ile	Ser	Ala
			340					345					350		
Ala	Arg	Ala	Ala	Ala	Pro	Ala	Glu	Pro	Val	Asn	Pro	Gln	His	Val	Ile
		355					360					365			
Arg	Ser	Leu	Ser	Asp	His	Leu	Pro	Ala	Asp	Ala	Gln	Val	Ala	Val	Asp
	370					375					380				
Val	Gly	Ser	Val	Val	Tyr	Trp	Tyr	Ala	Arg	His	Leu	Arg	Leu	Pro	Arg
385					390					395					400
Gly	Val	Pro	Ala	His	Leu	Ser	Ser	Thr	Leu	Ala	Ser	Met	Gly	Cys	Gly
				405					410					415	
Leu	Pro	Tyr	Gly	Leu	Ala	Ala	Lys	Leu	Ala	Ala	Pro	Gln	Arg	Pro	Val
			420					425					430		
Val	Val	Leu	Ala	Gly	Asp	Gly	Ala	Met	Gln	Met	Ala	Gly	Met	Ala	Glu
		435					440					445			
Leu	Ile	Thr	Val	Ala	Ala	Arg	Trp	Arg	Asp	Trp	Ala	Asp	Pro	Arg	Phe
	450					455					460				
Val	Val	Cys	Val	Leu	Asn	Asn	Arg	Asp	Leu	Ala	Glu	Val	Ser	Trp	Glu
465					470					475					480
Gln	Arg	Glu	Thr	Glu	Gly	Glu	Pro	Arg	Phe	Val	Thr	Ser	Gln	Glu	Leu
				485					490					495	
Pro	Asp	Val	Pro	Tyr	Ala	Arg	Tyr	Ala	Glu	Leu	Leu	Gly	Leu	Arg	Gly
			500					505					510		
Val	Arg	Ile	Thr	Asp	Pro	Ser	Asp	Leu	Thr	Gly	Ala	Trp	Glu	Ala	Ala
		515					520					525			
Leu	Ser	Ala	Asp	Arg	Pro	Thr	Leu	Ile	Glu	Ala	Val	Val	Asp	Pro	Ala
	530					535					540				
Ile	Pro	Leu	Leu	Pro	Pro	Gly	Gln	Pro	Tyr	Glu	Lys	Val	Gln	Ala	Met
545					550					555					560
Tyr	Ala	Gly	Leu	Ala	Ala	Glu	Lys	Gly	Asp	Gln	Ala	Arg	Arg	Ala	Glu
				565					570					575	
Ala	His	Leu	Arg	Arg	Glu	Arg	Ala	Asp	Glu	Gly	Phe	Asp	Asp	Pro	Ser
			580					585					590		

&lt;210&gt; SEQ ID NO 110

&lt;211&gt; LENGTH: 266

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 110

Val	Ser	Arg	Asp	Lys	Thr	Tyr	Arg	Pro	Val	Arg	Pro	Asp	Gly	Ile	Arg
1				5					10					15	
Thr	Thr	Phe	His	Asp	Gly	Val	Leu	Gly	Arg	Met	Arg	Ile	Arg	Cys	Leu
			20					25					30		
Gly	Glu	Pro	Arg	Pro	Gly	Val	Pro	Glu	Ile	Val	Met	Ile	Gln	Gly	Met
		35					40					45			
Thr	Val	Ser	Asp	Tyr	Leu	Leu	Pro	Gly	Leu	Gly	Ala	Leu	Ser	Ala	Trp
						55					60				



-continued

---

Thr Arg Val His Leu Val Glu Leu Pro Gly Gly Ser Gly Ser Gly Arg  
 65 70 75 80  
 Pro Pro His Asp Leu Thr Val Glu Glu Tyr Ala Arg Ala Ala Ala Asp  
 85 90 95  
 Trp Leu Cys Ala Gln Arg Leu Gly Arg Ile Val Leu Ala Gly His Ser  
 100 105 110  
 Ser Gly Thr Gln Val Ala Ala Glu Thr Ala Leu Leu Cys Pro Asp Glu  
 115 120 125  
 Val Ala Gly Val Val Leu Ala Gly Pro Ala Ile Asp Pro Val Ala Arg  
 130 135 140  
 Gly Gly Leu Arg Val Phe Ala Arg Trp Trp Ile Asp Arg Arg Gly Asp  
 145 150 155 160  
 Pro Lys Ser Leu Asp Glu Val His Lys Pro Glu Arg Glu Gln Val Gly  
 165 170 175  
 Phe Arg Arg Leu Phe Gln Val Leu Arg Ala His Leu Arg His Asp Leu  
 180 185 190  
 Glu Lys Pro Val Val Gly Leu Cys Val Pro Val Leu Val Ile Arg Gly  
 195 200 205  
 Ser Glu Asp Arg Leu Gly Thr Ala Arg Trp Ala Arg Arg Leu Ala Asp  
 210 215 220  
 Leu Ala Ala Val Gly Gly Arg Tyr Val Glu Val Pro Gly Thr His Ser  
 225 230 235 240  
 Phe Cys Trp Arg Tyr Pro Gln Ala Trp Ser Ala Pro Ile Arg Glu Phe  
 245 250 255  
 Ala Gly Trp Ser Val Ser Val Ser Gly Thr  
 260 265

<210> SEQ ID NO 111  
 <211> LENGTH: 396  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 111

Met Thr Glu Ala Asp His Arg Pro Thr Val Leu Arg Arg Ile Leu Arg  
 1 5 10 15  
 Leu Cys Ala Val Leu Leu Met Val Leu Gly Val Gly Leu Val Gly Ala  
 20 25 30  
 Pro Thr Ser His Ala Gly Gly Lys Pro Thr Ile Ser Lys Glu Ala Phe  
 35 40 45  
 Gly Ser Val Gly Gly Lys Ala Val Asp Arg Tyr Thr Leu Thr Asn Gly  
 50 55 60  
 Arg Leu Gln Val Arg Ile Leu Thr Tyr Gly Gly Ile Leu Gln Thr Ile  
 65 70 75 80  
 Thr Phe Pro Asp His Arg Gly Arg Arg Ala Asn Val Thr Leu Gly Phe  
 85 90 95  
 Arg Thr Leu Asp Glu Tyr Val Thr Thr Lys Asn Pro Ala Tyr Phe Gly  
 100 105 110  
 Ala Ile Ile Gly Arg Tyr Gly Asn Arg Ile Ala Asp Gly Arg Phe Thr  
 115 120 125  
 Leu Asp Gly Thr Thr Tyr Gln Leu Ala Thr Asn Asn Asp Pro Asn His  
 130 135 140  
 Leu His Gly Gly Val Val Gly Phe Asp Lys Arg Val Trp Asp Ala Thr  
 145 150 155 160  
 Pro Ile Arg Asp Gly Asp Ser Val Gly Leu Arg Leu Thr Tyr Thr Ser  
 165 170 175

-continued

Pro His Gly Glu Glu Asn Tyr Pro Gly Thr Leu Arg Val Thr Met Thr  
 180 185 190  
 Tyr Thr Val Thr Arg Gln Met Gly Ile Arg Met Asp Tyr Arg Ala Thr  
 195 200 205  
 Thr Asp Arg Pro Thr Ile Val Asn Leu Thr Asn His Ala Tyr Trp Asn  
 210 215 220  
 Leu Gly Gly Glu Gly Thr Gly Thr Ile Asp Asp His Leu Leu Lys Leu  
 225 230 235 240  
 Asn Ala Asn Arg Tyr Thr Pro Val Asp Ala Thr Leu Ile Pro Thr Gly  
 245 250 255  
 Ala Ile Asp Ala Val Ala Gly Thr Pro Met Asp Phe Arg Arg Pro Thr  
 260 265 270  
 Pro Ile Gly Ala Arg Asn Arg Asp Pro Phe Gln Gln Leu Val Tyr Gly  
 275 280 285  
 Arg Gly Tyr Asp His Asn Trp Val Leu Asn Arg Glu Asp Gly Gln Phe  
 290 295 300  
 Arg Arg Leu Glu Phe Ala Ala Arg Ala Val Asp Pro Asp Ser Gly Arg  
 305 310 315 320  
 Gln Leu Thr Ile Tyr Thr Thr Glu Pro Gly Ile Gln Phe Tyr Gly Gly  
 325 330 335  
 Asn Phe Leu Asp Gly Thr Leu Tyr Gly Thr Ser Gly Arg Ala Tyr Arg  
 340 345 350  
 Gln Gly Asp Gly Phe Ala Leu Glu Thr Gln His Phe Pro Asp Ser Pro  
 355 360 365  
 Asn His Ala Asn Phe Pro Ser Thr Val Leu Arg Pro Gly Gln Thr Tyr  
 370 375 380  
 Asn Ser Thr Thr Ile Tyr Gln Phe Gly Thr Ala Asp  
 385 390 395

&lt;210&gt; SEQ ID NO 112

&lt;211&gt; LENGTH: 378

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 112

Met Pro Arg Ile His Pro Lys Val Glu Glu Ala Val Ser Thr Leu Asp  
 1 5 10 15  
 Leu Asn Arg Thr Thr Arg Arg Arg Leu Leu Ser Gly Thr Gly Leu Phe  
 20 25 30  
 Ser Ala Ser Leu Ala Ala Gly Ala Leu Leu Ser Ala Cys Ser Asp Gln  
 35 40 45  
 Asn Asp Gly Gln Asn Gln Thr Glu Gly Ala Gly Asn Phe Pro Asp Thr  
 50 55 60  
 Pro Glu Trp Arg Phe Thr Phe Val Asn His Val Thr Thr Asn Pro Phe  
 65 70 75 80  
 Phe Thr Pro Thr Gln Tyr Gly Met Glu Asp Ala Ala Thr Leu Leu Gly  
 85 90 95  
 Ile Ala Lys Pro Gln Trp Thr Gly Ser Gln Asn Ser Ile Val Ala Glu  
 100 105 110  
 Met Val Asn Ala Thr Asn Thr Ala Val Ser Ala Lys Val Asp Gly Ile  
 115 120 125  
 Ala Ile Ala Val Val Asp Lys Asp Ala Phe Arg Gly Pro Val Asp Gln  
 130 135 140  
 Ala Leu Asn Ala Gly Ile Pro Val Val Ser Tyr Asn Ala Asp Gly Ala

-continued

145	150	155	160
Arg Gly Ala Pro Gly Thr Asn Arg Leu Ala Tyr Ile Gly Gln Gly Leu	165	170	175
Tyr Glu Ser Gly Tyr Ala Leu Gly Gln Arg Ala Leu Gln Val Leu Asp	180	185	190
Ser Gly Glu Val Ala Ala Phe Ile Ala Thr Pro Gly Ala Leu Asn Ile	195	200	205
Gln Pro Arg Ile Asp Gly Ala Gln Gln Ala Phe Lys Asp Ser Gly Lys	210	215	220
Pro Ile Thr Phe Thr Ala Val Ala Thr Asn Ala Asp Val Thr Arg Gly	225	230	235
Leu Ser Ile Ile Asp Ala Tyr Ala Gln Gly His Ala Asn Leu Ala Gly	245	250	255
Met Leu Ala Val Asp Ala Gly Ser Thr Ser Ser Val Gly Gln Thr Val	260	265	270
Lys Lys Tyr Asn Met Arg Gly Lys Gly Leu Lys Val Ala Gly Gly Phe	275	280	285
Asp Leu Ile Pro Glu Thr Leu Thr Gly Ile Gln Glu Gly Ser Leu Asp	290	295	300
Tyr Thr Ile Asp Gln Gln Pro Tyr Leu Gln Gly Phe Leu Pro Val Leu	305	310	315
Ala Leu Tyr Phe Tyr Lys Val Ser Gly Gly Leu Ile Ala Pro Ser Glu	325	330	335
Thr Asn Thr Gly Leu Leu Phe Val Thr Lys Asp Asn Val Ala Pro Tyr	340	345	350
Gln Ser Thr Lys Ser Arg Tyr Glu Gly Ser Thr Thr Asp Lys Val Leu	355	360	365
Val Pro Arg Ser Gly Pro Ile Ala His Gly	370	375	

&lt;210&gt; SEQ ID NO 113

&lt;211&gt; LENGTH: 352

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 113

Met Asp Asp Arg Ile Ser Pro Ala Pro Ala Gln Ala Pro Ser Leu Glu	1	5	10	15
Val Glu Gln Arg Arg Gly Arg Trp Gln Pro Val Thr Ala Ala Gly Arg	20	25	30	
Lys Val Leu Asp Ala Phe Leu Arg Arg Arg Glu Ala Ser Val Leu Leu	35	40	45	
Val Ala Ile Gly Leu Met Ile Tyr Phe Arg Ala Ser Ser Pro Val Phe	50	55	60	
Leu Ser Arg Asp Asn Leu Val Asn Ile Ala Gln Ala Thr Ala Pro Val	65	70	75	80
Ala Ile Ile Ala Val Gly Ile Val Leu Leu Leu Val Ser Gly Glu Ile	85	90	95	
Asp Leu Ser Val Gly Ile Val Ala Ala Leu Ala Pro Phe Leu Phe His	100	105	110	
Phe Gly Ile Asn Phe Tyr Ser Leu Pro Val Val Pro Ala Phe Val Val	115	120	125	
Ala Leu Ala Ile Ala Ala Gly Ile Gly Leu Val Asn Gly Leu Ile Val	130	135	140	

-continued

---

Thr Gln Leu His Val Pro Ser Phe Val Thr Thr Leu Gly Thr Phe Phe  
 145 150 155 160  
 Ala Val Gln Gly Ile Leu Leu Ile Thr Ser His Ala Tyr Pro Val Pro  
 165 170 175  
 Ile Pro Asp Ala Ala Lys Gly Thr Phe Gln Thr Trp Leu Gly Ala Gly  
 180 185 190  
 Pro Trp Ala Ser Ile Thr Trp Ala Leu Ile Ile Val Ala Ile Phe His  
 195 200 205  
 Thr Val Leu Thr Leu Thr Arg Trp Gly Leu His Thr Ile Ser Val Gly  
 210 215 220  
 Gly Asn Pro Val Gly Ala Thr Glu Ala Gly Ile Arg Ala Ser Arg Ile  
 225 230 235 240  
 Lys Ile Gly Asn Phe Val Ile Thr Ser Thr Leu Gly Gly Leu Val Gly  
 245 250 255  
 Ile Met Glu Ala Phe Arg Ile Asn Thr Ile Asp Pro Asn Ile Gly Gly  
 260 265 270  
 Gly Thr Thr Leu Thr Phe Tyr Ala Ile Ser Ala Ala Val Ile Gly Gly  
 275 280 285  
 Thr Ala Leu Ala Gly Gly Ser Gly Thr Ile Val Gly Ala Phe Leu Gly  
 290 295 300  
 Ala Leu Val Leu Ala Glu Leu Gln Asn Gly Phe Asn Leu Ile Gly Tyr  
 305 310 315 320  
 Ser Ala Asn Thr Ile Phe Leu Ile Leu Gly Leu Ala Ile Leu Val Ser  
 325 330 335  
 Met Ile Ala Asn Gln Tyr Leu Ser Arg Leu Arg Arg Ala Gly Arg Ser  
 340 345 350

&lt;210&gt; SEQ ID NO 114

&lt;211&gt; LENGTH: 253

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 114

Met Thr Ala Glu Thr Val Ser Asp Ala Leu Arg Val Gln Asn Ile Ala  
 1 5 10 15  
 Lys Arg Phe Gly Ala Leu Thr Ala Leu Gln Asp Val Thr Leu Arg Val  
 20 25 30  
 Ala Glu Gly Glu Val Leu Gly Leu Ile Gly Asp Asn Gly Ala Gly Lys  
 35 40 45  
 Ser Thr Leu Ile Lys Ile Ile Cys Gly Tyr His Arg Pro Asp Ala Gly  
 50 55 60  
 Arg Ile Phe Val Gly Gly Glu Glu Val Thr Leu Arg Ser Val Asp His  
 65 70 75 80  
 Ala Arg Ser Val Gly Ile Asp Ala Val Tyr Gln Asp Leu Ala Leu Val  
 85 90 95  
 Asn Glu Leu Ser Val Tyr His Asn Met Phe Leu Asn Arg Glu Leu Val  
 100 105 110  
 Arg Trp Pro Leu Leu Asn Asn Arg Ala Met Arg Arg Arg Ala Glu Glu  
 115 120 125  
 His Leu Arg Asp Met Gly Val Asn Leu Pro Asp Val Gly Val Glu Val  
 130 135 140  
 Ala Lys Leu Ser Gly Gly Gln Arg Gln Ala Ile Ala Val Ala Arg Cys  
 145 150 155 160  
 Val Tyr Ser Asp Ala Arg Ile Leu Leu Leu Asp Glu Pro Leu Ala Ala  
 165 170 175

-continued

Met Gly Ala Lys Glu Gly Thr Met Ile Leu Asp Leu Ile Arg Asp Leu  
 180 185 190

Lys Ala Arg Gly Asn Val Ser Ile Ile Ile Ala His Asn Tyr Ala  
 195 200 205

Gln Val Leu Asp Val Cys Asp Arg Val Asn Leu Leu Gln His Gly Arg  
 210 215 220

Ile Thr Phe Asp Lys Arg Ser Ala Asp Thr Ser Leu Ala Glu Leu Thr  
 225 230 235 240

Glu Leu Val Val Ala Glu Tyr Arg Thr Gly Arg Gly Arg  
 245 250

<210> SEQ ID NO 115  
 <211> LENGTH: 255  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 115

Met Glu Ser Gly Ala Ser Val Pro Gln Ser Ala Arg Ile Trp Asn Tyr  
 1 5 10 15

Trp Leu Gly Gly Thr Asp Asn Leu Pro Val Asp Arg Ala Ala Gly Asp  
 20 25 30

Glu Tyr Arg Ala Val Phe Pro Gly Ile Asp Glu Ile Ala Arg Glu Ser  
 35 40 45

Arg Arg Tyr Leu Ser Arg Ala Val Arg Tyr Leu Ala Gly Glu Ala Gly  
 50 55 60

Val Arg Gln Phe Leu Asp Val Gly Ala Gly Leu Pro Thr Val Asp Asn  
 65 70 75 80

Thr His Gln Ile Ala Gln Arg Val Ala Pro Asp Ala Arg Val Leu Tyr  
 85 90 95

Val Asp Lys Asp Pro Tyr Ala Val Glu His Gly Arg Glu Leu Leu Ala  
 100 105 110

Gly Ser Ser Asp Val Tyr Leu Glu Gly Asp Leu Gln Lys Pro Ala Asp  
 115 120 125

Ile Leu Ala Val Ala Ala Arg Glu Leu Asp Met Gly Arg Pro Val Ala  
 130 135 140

Leu Ile Leu Asn Gly Val Leu Gly His Ile Pro Ser Thr Ala Glu Val  
 145 150 155 160

Arg Asp Ile Val Arg Gln Leu Met Ala Gly Leu Pro Pro Gly Ser Tyr  
 165 170 175

Leu Ser Ile Asn Asp Gly Val Arg Val Ala Gly Glu Glu Ala Leu Asn  
 180 185 190

Gln Ala Gln Asp Ala Tyr Asn Ser Ser Gly Ala Val Pro Tyr Leu Met  
 195 200 205

His Thr Pro Asp Glu Ile Ala Gly Phe Phe Glu Gly Leu Asp Leu Val  
 210 215 220

Pro Pro Gly Val Val Pro Ser Pro Gln Trp His Pro Asp Pro Gly Asp  
 225 230 235 240

Glu Thr Thr Gly Ala Ser Gln Tyr Ser Gly Val Gly Arg Lys Arg  
 245 250 255

<210> SEQ ID NO 116  
 <211> LENGTH: 280  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 116

-continued

Met Pro Pro Arg Thr Ser Arg Gly Pro His Pro Trp Val Leu Trp Thr  
 1 5 10 15  
 Ala Leu Ala Ala Ala Ala Val Ile Phe Val Tyr Pro Phe Val Trp Leu  
 20 25 30  
 Val Ser Ala Ser Leu Lys Pro Arg Pro Asp Val Phe Asp Asn Arg Leu  
 35 40 45  
 Leu Pro Ala Glu Trp Ala Pro Gly Asn Tyr Thr Ala Ile Trp Asp Ala  
 50 55 60  
 Ala Pro Val Leu Thr Trp Met Phe Asn Ser Val Val Val Ala Leu Ala  
 65 70 75 80  
 Ala Ala Ala Ala Val Thr Ile Ser Ser Ala Val Val Ala Phe Gly Phe  
 85 90 95  
 Ala Tyr Phe Arg Phe Pro Gly Arg Asn Val Leu Phe Ala Leu Val Val  
 100 105 110  
 Gly Thr Met Met Leu Pro Gly Ala Val Thr Met Ile Pro Thr Tyr Leu  
 115 120 125  
 Ile Trp Asn Glu Leu Gly Leu Ala Ala Thr Gln Val Pro Leu Trp Ala  
 130 135 140  
 Gly Asn Leu Phe Gly Ser Ala Phe Tyr Ile Phe Leu Ile Arg Gln Phe  
 145 150 155 160  
 Phe Leu Gly Val Pro Arg Glu Leu Phe Glu Ala Ala Arg Val Asp Gly  
 165 170 175  
 Ala Gly Tyr Trp Arg Leu Phe Trp Arg Ile Ala Val Pro Leu Cys Arg  
 180 185 190  
 Pro Ala Leu Ile Val Ala Phe Val Phe Glu Leu Arg Ala Ser Trp Ser  
 195 200 205  
 Asp Leu Leu Lys Pro Leu Ile Tyr Leu Arg Asp Pro Ala Leu Phe Thr  
 210 215 220  
 Met Pro Arg Gly Met Lys Ala Ile Leu Asp Gln Phe Gly Gln Ala Gly  
 225 230 235 240  
 Glu Ala Arg Trp Glu Ile Val Leu Ala Gly Ala Val Ile Thr Thr Val  
 245 250 255  
 Pro Met Ile Ile Ala Phe Phe Leu Cys Gln Arg Tyr Phe Val Glu Gly  
 260 265 270  
 Val Ala Thr Gln Ala Arg Lys Gly  
 275 280

&lt;210&gt; SEQ ID NO 117

&lt;211&gt; LENGTH: 301

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 117

Met Ser Ala Ala Val Arg Arg Arg Glu Thr Leu Ala Ala Phe Gly Phe  
 1 5 10 15  
 Leu Ser Pro Trp Leu Ile Gly Phe Thr Val Phe Met Ala Gly Pro Met  
 20 25 30  
 Val Ala Ser Leu Val Leu Ser Phe Thr Asp Tyr Asp Val Leu Thr Ser  
 35 40 45  
 Thr Asp Phe Val Gly Gly Glu Asn Tyr Arg Gln Met Leu Ala Asp Pro  
 50 55 60  
 Arg Val Arg Thr Ser Ile Ala Asn Thr Leu Ile Tyr Thr Ala Leu His  
 65 70 75 80  
 Val Pro Val Thr Met Ile Val Ser Leu Ala Leu Ala Met Leu Leu Ala

-continued

85					90					95					
Arg	Val	Gly	Arg	Arg	Ser	Ala	Gly	Phe	Phe	Arg	Thr	Ile	Phe	Tyr	Leu
		100						105					110		
Pro	Thr	Ile	Thr	Pro	Lys	Val	Ala	Val	Gly	Val	Leu	Phe	Leu	Leu	Leu
		115					120					125			
Phe	Asn	Gly	Gln	Val	Gly	Ile	Val	Asn	Glu	Ala	Leu	Gly	Thr	Val	Gly
	130					135					140				
Ile	Asp	Gly	Pro	Asn	Trp	Thr	Val	Asp	Gly	Pro	Trp	Ile	Lys	Pro	Gly
	145					150					155				160
Leu	Val	Leu	Ile	Gly	Ala	Trp	Ser	Leu	Gly	Ser	Thr	Val	Ile	Ile	Tyr
				165					170					175	
Leu	Ala	Ala	Leu	Gln	Asn	Val	Pro	Arg	Asp	Leu	Tyr	Glu	Ala	Ala	Glu
			180					185					190		
Met	Asp	Gly	Ala	Ser	Ala	Trp	Ala	Arg	Phe	Arg	Ala	Val	Thr	Val	Pro
		195					200					205			
Met	Ile	Ser	Gly	Ala	Leu	Phe	Phe	Thr	Leu	Ile	Ile	Asn	Thr	Ile	Ala
	210					215					220				
Ser	Leu	Gln	Thr	Phe	Asp	Glu	Val	Tyr	Thr	Ala	Phe	Tyr	Gly	Ser	Ala
	225					230					235				240
Asn	Gln	Gln	Thr	Tyr	Gly	Asn	Asp	Ala	Ala	Leu	Phe	Tyr	Val	Val	Tyr
				245					250					255	
Leu	Phe	Gln	Gln	Ala	Phe	Gln	Phe	Leu	His	Met	Gly	Tyr	Ala	Ser	Ala
			260					265					270		
Leu	Ala	Trp	Leu	Leu	Phe	Leu	Ile	Ile	Val	Ile	Ile	Thr	Val	Val	Gln
		275					280					285			
Val	Arg	Leu	Ser	Arg	Arg	Phe	Val	Tyr	Tyr	Glu	Ser	Glu			
	290					295					300				

&lt;210&gt; SEQ ID NO 118

&lt;211&gt; LENGTH: 445

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 118

Met	Phe	Ile	Arg	Ser	Ile	Arg	Phe	Val	Val	Gly	Gly	Ala	Leu	Val	Leu
1				5					10					15	
Thr	Leu	Ala	Ala	Gly	Cys	Gly	Gly	Val	Gly	Gly	Ser	Asp	Ser	Asp	Ser
			20					25					30		
Asp	Ser	Asn	Ala	Ala	Val	Thr	Leu	Thr	Met	Met	Gly	Phe	Gly	Thr	Gly
		35					40					45			
Asp	Glu	Ile	Ala	Lys	Thr	Arg	Phe	Asp	Ala	Ala	Asn	Ala	Val	Ile	Ala
	50					55					60				
Pro	Ser	Leu	Ala	Lys	Ala	Ser	Glu	Gly	Ser	Phe	Asp	Ala	Gln	Ala	Phe
	65					70					75				80
Leu	Ser	Ala	Val	Ala	Ser	Arg	Thr	Pro	Pro	Asp	Leu	Val	Tyr	Met	Glu
				85					90					95	
Arg	Arg	Leu	Leu	Gly	Thr	Tyr	Ala	Ala	Lys	Lys	Ala	Leu	Thr	Pro	Leu
			100						105					110	
Gly	Asp	Cys	Val	Glu	Arg	Glu	Lys	Ile	Asp	Met	Ser	Gln	Phe	Arg	Glu
		115					120					125			
Ala	Ala	Val	Thr	Glu	Ala	Thr	Leu	Asn	Gly	Gln	Leu	Tyr	Gly	Leu	Pro
		130					135					140			
Asp	Phe	Tyr	Asn	Asn	Arg	Val	Leu	Met	Leu	Asn	Asp	Ala	Ala	Phe	Ala
				145							155				160

-continued

---

Glu Val Asn Leu Asp Pro Ala Gly Phe Asp Thr Gly Asp Trp Gln Ala  
 165 170 175  
 Leu Ser Thr Ala Thr Ala Arg Leu Thr Arg Met Ser Gly Gly Lys Leu  
 180 185 190  
 Gln Arg Ile Gly Phe Asp Pro Lys Leu Pro Glu Phe Leu Pro Val Trp  
 195 200 205  
 Ala Arg Ala Asn Gly Ala Ala Leu Val Ser Asp Asp Gly Arg Thr Ala  
 210 215 220  
 Gln Leu Asn Asn Pro Lys Val Val Glu Ala Leu Glu Tyr Ala Val Gly  
 225 230 235 240  
 Leu Ile Asn Ala Gln Gly Gly Trp Ser Asn Phe Lys Ser Phe Arg Asp  
 245 250 255  
 Ser Trp Asp Phe Phe Gly Ala Lys Asn Gln Phe Ala Ser Asn Gln Leu  
 260 265 270  
 Gly Ala Phe Pro Met Glu Asp Phe Tyr Leu Asn Val Leu Ala Asp Asn  
 275 280 285  
 Ser Pro Lys Val Lys Val Thr Val Ala Pro Phe Arg Gly Val Asp Gly  
 290 295 300  
 Gln Pro Ile Asp Trp Ile Thr Gly Asn Ala Trp Ala Ile Pro Ala Asn  
 305 310 315 320  
 Ser Ala His Pro Gly Gln Ala Cys Lys Trp Ile Lys Thr Met Thr Ala  
 325 330 335  
 Ser Glu Thr Trp Ile Ala Ala Ala Arg Ala Arg Ala Glu Leu Arg Lys  
 340 345 350  
 Lys Glu Asn Lys Pro Phe Ala Gly Val Tyr Thr Gly Asn Lys Lys Ala  
 355 360 365  
 Asp Glu Val Ile Phe Arg Asp Val Val Lys Pro Asp Ala Asn Val Gln  
 370 375 380  
 Ile Val Leu Gln Thr Gln Glu Ser Gly Phe Ser Glu Pro Ala Leu Ala  
 385 390 395 400  
 Ala Gly Glu Glu Phe Lys Ala Ala Trp Gln Asn Ala Val Asn Arg Val  
 405 410 415  
 Leu Glu Gly Lys Gln Lys Pro Ala Gln Ala Met Ala Glu Ala Gln Gln  
 420 425 430  
 Gln Ala Gln Ala Ala Leu Asp Lys Ala Asn Ser Gly Arg  
 435 440 445

<210> SEQ ID NO 119  
 <211> LENGTH: 64  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 119

Met Ser Ala Leu Ala Ile Glu Lys Ser Trp Lys Asp Val Asp Leu Arg  
 1 5 10 15  
 Asp Gly Ala Thr Ser His Pro Ala Gly Leu Gly Phe Gly Glu Leu Thr  
 20 25 30  
 Phe Glu Asp Leu Arg Glu Asp Arg Thr Ile Tyr Ala Ala Ser Ser Gly  
 35 40 45  
 Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Val Ile Cys Ala Cys  
 50 55 60

<210> SEQ ID NO 120  
 <211> LENGTH: 1053  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis



-continued

&lt;400&gt; SEQUENCE: 120

Met Ser Pro Val Pro Ser Leu Asn Ser Thr Ser Val Arg Asp Ser Ala  
 1 5 10 15  
 Tyr Leu His Glu Arg Thr Val Thr Gly Glu Asp Gln Pro Ala Pro Ala  
 20 25 30  
 Ala Gln Ala Arg Ile Ala Ser Trp Arg Asp Ser Ala Phe Leu Asp Asp  
 35 40 45  
 Arg Val Leu Asp Ile Arg Leu Arg Gln Trp Gly Ile Asp Arg Ala Thr  
 50 55 60  
 Phe Gly Arg Leu Leu Thr Asp Asp Asp Phe Thr Val Pro Gly Arg Leu  
 65 70 75 80  
 Leu Ala Trp Ala Asp Glu Leu Ala Thr Val Leu Ala Thr Asp Thr Thr  
 85 90 95  
 Pro Val Thr Gly Leu Glu Leu Ser Thr Lys Leu Trp Ser Gln Gly Phe  
 100 105 110  
 Asp Arg Leu Leu Phe Ala Gly Leu Leu His Pro Phe Leu Ala His Tyr  
 115 120 125  
 Glu Gln Arg Leu His Glu Arg Val Pro Arg Pro Ile Ala Gly Ser Leu  
 130 135 140  
 Arg Arg Pro Leu Leu Glu Ser Leu Ala Asn Arg Leu Leu Ala Val Ala  
 145 150 155 160  
 Ala Arg Thr Leu Leu Leu Glu Leu Asn Val Ala Arg Val His Gly Arg  
 165 170 175  
 Leu Thr Gly Asp Thr Pro Gln Gln Arg Tyr Asp Asp Tyr Asp Arg Arg  
 180 185 190  
 Leu Leu Thr Asp Pro Ala Tyr Leu Ala Ala Leu Phe Glu Glu Tyr Pro  
 195 200 205  
 Val Leu Gly Arg Cys Leu Val Glu Cys Gly Arg Arg Trp Val Asp His  
 210 215 220  
 Ala Ala Glu Leu Phe Asn Arg Leu His Asp Asp Glu Pro Glu Leu Arg  
 225 230 235 240  
 Ala Ala Gly Leu Leu Pro Pro Ser Ala Glu Ala Leu Arg Ser Val Arg  
 245 250 255  
 Leu Asp Leu Gly Asp Pro His Asn Gly Gly Arg Ser Val Val Gln Leu  
 260 265 270  
 Thr Phe Asp Asp Gly Thr Asp Leu Val Tyr Lys Pro Arg Pro Val Gly  
 275 280 285  
 Ser Glu Arg Ala Tyr Ala Glu Thr Met Ala Ala Leu Ala Arg His Gly  
 290 295 300  
 Leu Pro Val Pro Val Thr Ala Pro Arg Val Leu Asp Arg Gly Gly His  
 305 310 315 320  
 Gly Trp Cys Glu Phe Val Arg Pro Ala Pro Cys Ala Asp Ala Ala Glu  
 325 330 335  
 Leu Ser Arg Phe Tyr Arg Arg Ala Gly Ser Val Leu Ala Ala Met Leu  
 340 345 350  
 Leu Leu Gly Gly Val Asp Met His Met Glu Asn Val Ile Ala Ala Gly  
 355 360 365  
 Ser Ser Phe Thr Pro Ile Asp Leu Glu Thr Val Leu Gln Ser Gly Glu  
 370 375 380  
 Leu Gly Asp Gly Ala Thr Asp Ala Tyr Gly Arg Ala Leu Asp Leu Leu  
 385 390 395 400  
 Asn Arg Ser Val Leu Ala Ile Gly Ile Leu Pro Ala Arg Ala Phe Gly

-continued

405				410				415							
Gly	Arg	Gln	Arg	Lys	Ser	Val	Asp	Val	Ser	Ala	Leu	Gly	Gly	Gly	Glu
			420					425				430			
Pro	Gln	Thr	Ala	Pro	Arg	Pro	Val	Pro	Arg	Ile	Val	Asp	Ala	Tyr	Thr
			435				440					445			
Asp	Thr	Ala	Arg	Leu	Glu	Ala	Val	Glu	Ala	Thr	Met	Ala	Gly	Ala	Gln
			450				455				460				
Asn	Arg	Pro	Ser	Leu	Pro	Gly	Ala	Glu	Val	Arg	Pro	Trp	Glu	His	Thr
465				470						475					480
Ala	Asp	Val	Val	Ala	Gly	Phe	Thr	Asp	Ala	Tyr	Asp	Ile	Met	Leu	Ala
			485					490						495	
His	Arg	Ala	Asp	Phe	Asp	Arg	Leu	Leu	Arg	Gly	Phe	His	Asp	Val	Glu
			500					505				510			
Val	Arg	Tyr	Leu	Pro	Arg	Pro	Thr	Arg	Arg	Tyr	Ser	Ile	Phe	Leu	Thr
			515				520					525			
Glu	Ser	Tyr	His	Pro	Asp	Tyr	Leu	Arg	Asp	Ala	Ser	Asp	Arg	Asp	Arg
			530				535				540				
Leu	Leu	Asp	Lys	Leu	Trp	Thr	Ala	Ala	Asp	Ala	Arg	Pro	Glu	Leu	Ile
545				550				555							560
Pro	Ile	Ile	Glu	Ser	Glu	Lys	Arg	Gln	Leu	Leu	Ala	Gly	Asp	Ile	Pro
			565					570						575	
Cys	Phe	Arg	Ser	Val	Ala	Gly	Ser	Arg	Gln	Ile	Arg	Thr	Ala	Ser	Gly
			580					585						590	
Pro	Leu	His	Pro	Glu	Phe	Phe	Thr	Ala	Pro	Ala	Val	Thr	Val	Leu	Thr
			595				600					605			
Arg	Arg	Leu	Gly	Glu	Phe	Gly	Pro	Val	His	Arg	Ala	Ala	Gln	Val	Arg
			610				615				620				
Ile	Ile	Arg	Asp	Ser	Met	Ala	Thr	Met	Pro	Gly	Pro	Arg	Pro	Ala	Ala
625				630						635					640
Gln	Pro	Ser	Pro	Asp	Arg	Ala	Ala	Gly	Pro	Arg	Pro	Arg	Val	Thr	Gly
			645					650						655	
Ala	Asp	Pro	Ala	Thr	Leu	Ala	Asp	Arg	Ile	Ala	Arg	Arg	Leu	Ala	Asp
			660					665					670		
Glu	Ala	Ile	Leu	Gly	Asp	Arg	Asp	Val	Ser	Trp	Ile	Gly	Val	Ser	Ile
			675				680					685			
Glu	Gly	Val	Ala	Gln	Glu	Thr	Tyr	Ser	Tyr	Lys	Pro	Met	Ala	Thr	Gly
			690				695				700				
Leu	Tyr	Asp	Gly	Val	Ala	Gly	Leu	Ala	Leu	Thr	Phe	Ala	Tyr	Ala	Ala
705				710						715					720
Arg	Thr	Leu	Gly	Asp	Asp	Arg	Tyr	Leu	Asp	Leu	Ala	His	Arg	Ala	Ala
			725					730						735	
Arg	Pro	Val	Ala	Gly	Tyr	Leu	Arg	Tyr	Leu	Ala	Glu	His	Arg	Ile	Val
			740					745						750	
Glu	Thr	Val	Gly	Ala	Tyr	Ser	Gly	Thr	Ala	Gly	Leu	Leu	Tyr	Ala	Leu
			755				760							765	
Asp	His	Val	Ala	His	Ala	Thr	Gly	Asp	Asp	Ser	Tyr	Leu	Asp	Ala	Val
			770				775				780				
Ser	Glu	Ala	Val	Pro	Trp	Leu	Arg	Glu	Cys	Ala	Thr	Arg	Glu	Glu	Cys
785				790						795					800
Pro	Asp	Leu	Ile	Ala	Gly	Leu	Ala	Gly	Cys	Ala	Leu	Ile	Ser	Leu	Asp
			805					810						815	
Leu	His	Gly	Arg	His	Arg	Ile	Asp	Gly	Leu	Arg	Glu	Val	Ala	Ala	Ile
			820					825						830	



-continued

145	150	155	160
Glu Glu Pro Pro Val Pro Trp Met Leu Gly Ala Gly Thr Gly Ser Ala 165 170 175			
Arg Met Ala Gly Met Leu Gly Leu Pro Phe Cys Phe Ala Gln Phe Ile 180 185 190			
Ala Thr Glu Glu Cys Pro Glu Ala Ile Glu Ala Tyr Arg Asp Ala Phe 195 200 205			
Arg Pro Ser Pro Trp Leu Glu Arg Pro Gln Pro Met Leu Ala Leu Arg 210 215 220			
Val Leu Cys Ala Asp Ser Asp Ala Glu Ala Glu Glu Leu Ala Thr Cys 225 230 235 240			
Phe Trp Met Ser Cys Thr Thr Gly Trp Arg Ala Gln Val Gln Leu Thr 245 250 255			
Asp Asp Tyr Arg Gly Gly Ala Pro Asn Leu Asp Asp Ala Arg Arg Tyr 260 265 270			
Arg Leu Thr Ala Glu Asp Leu Ala Leu Arg Glu Ser Arg Pro Phe Leu 275 280 285			
Gln Ile Ser Gly Thr Pro Ala Ala Val Gly Lys Glu Ile Arg Arg Leu 290 295 300			
Gln Ala Val Tyr Gly Val Ser Glu Val Val Leu Thr Thr Asn Cys Pro 305 310 315 320			
Gly Leu Pro Ala Arg Arg Arg Ser Tyr Glu Leu Leu Ala Gly Glu Phe 325 330 335			
Ala Ser Pro Ala Ala 340			

&lt;210&gt; SEQ ID NO 122

&lt;211&gt; LENGTH: 231

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 122

Met Arg Ser Ala Ala Arg Gly Gly Pro Ile Val Thr Asp Val Leu Val 1 5 10 15
Val Asp Gly Glu Ala Leu Val Ser Ile Gly Ile Lys Met Ile Leu Glu 20 25 30
Ser Thr Gly Gly Phe Ala Val Ala Thr Thr Asp Arg Glu Asn Leu Arg 35 40 45
Ser Ala Val Glu Gln His Arg Pro Ala Val Val Leu Leu Asp Gly His 50 55 60
Ser Ala Gln Ser Asp Gly Leu Glu Val Leu Asp Gln Leu Arg Ala Leu 65 70 75 80
Ser Ser Pro Pro Ala Ile Ala Met Leu Thr Thr Leu Ala Pro Pro Glu 85 90 95
Leu Val Leu Asp Ser Leu Arg Gly Gly Ala Cys Gly Phe Leu Leu Arg 100 105 110
Asp Ser Gln Pro Glu Gln Leu Val Ala Ala Val Arg Ala Leu Ala Glu 115 120 125
Gly Ser Ile Val Leu Ala Pro Glu Ala Ser Ser Val Val Val Arg Ala 130 135 140
Gly Ser Arg Gly Ser Ala Ala Gly Ala Gly Ser Pro Ala Cys Glu Arg 145 150 155 160
Val Lys Gln Leu Ser Asp Arg Glu Gln Ser Ile Leu Arg Leu Leu Gly 165 170 175

-continued

---

Ala Gly Leu Thr Asn Ala Glu Ile Ser Arg Gln Leu Phe Leu Ser Ala  
 180 185 190

Ala Thr Val Lys Glu His Val Ser Val Ile Leu Ser Lys Leu Gly Val  
 195 200 205

Ala Asn Arg Val Gln Ala Ala Val Leu Ala Tyr Ala Ser Gly Leu Ser  
 210 215 220

Ser Asp Asp Val Cys Leu Ser  
 225 230

<210> SEQ ID NO 123  
 <211> LENGTH: 812  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 123

Met Ile Phe Ala Leu Ala Trp Ser Gln Leu Arg Ala Tyr Pro Ala Arg  
 1 5 10 15

Leu Phe Ala Ile Val Ala Ala Val Met Leu Ala Thr Gly Phe Leu Ala  
 20 25 30

Ala Thr Ala Thr Phe Ala Ala Thr Ser Gly Glu Gly Leu Arg Arg Thr  
 35 40 45

Ala Ala Ala Pro Leu Thr Thr Ala Asp Ile Val Leu Asp Ala Asp Asp  
 50 55 60

Thr Val Arg Asp Pro Ala Trp Tyr Glu Ala Ala Ala Ala Val Pro Gly  
 65 70 75 80

Val Arg Ser Val Asp Ala Gln Tyr Ala Arg Thr Val Ser Val Phe Gly  
 85 90 95

Gly Ser Arg Arg Gly Ser Ala Asn Val Gln Ser Ile Ala Ala Thr Pro  
 100 105 110

Gln Val Arg Trp Phe Thr Leu Asp Arg Gly Ala Trp Pro Thr Gly Pro  
 115 120 125

Gly Gln Leu Val Ala Asp Gln Arg Thr Leu Asp Asp Leu Gly Ile Asp  
 130 135 140

Val Gly Ala Thr Leu Thr Val Arg His Gly Glu Ala Ala Pro Gln Pro  
 145 150 155 160

Val Thr Val Thr Gly Ala Ala Asp Leu Gly Phe Arg Pro Leu Thr Gly  
 165 170 175

Ser Asp Phe Arg Phe Tyr Ala Asp Ala Ser Phe Phe Ala Gly Asp Val  
 180 185 190

Pro Pro Ala Ala Leu Leu Thr Val Ala Asp Asp Ala Ser Leu Thr Gly  
 195 200 205

Thr Val Asp Ala Leu Arg Arg Ser Met Gly Pro Gly Ile Ser Ala Thr  
 210 215 220

Asp Ala Ser Ala Ala Ala Asp Gln Ala Ala Arg Phe Ala Gly Gly  
 225 230 235 240

Asn Gly Gln Leu Val Val Ile Met Leu Ala Phe Ala Ala Val Ala Leu  
 245 250 255

Leu Ala Ala Val Leu Val Ile Ala Asn Thr Phe His Val Val Ile Val  
 260 265 270

Gln Arg Ile Arg Gln Ile Ala Leu Leu Arg Leu Val Gly Gly His Arg  
 275 280 285

Ala Gln Val Ser Arg Val Val Leu Ala Glu Ala Ala Ile Ala Gly Thr  
 290 295 300

Ala Gly Gly Leu Val Gly Ala Ala Ala Gly Val Gly Leu Gly Tyr Leu  
 305 310 315 320

-continued

---

Gly Ala Asp Leu Leu Asp Ile Ser Gly Gly Gly Leu Arg Val Asn Pro  
 325 330 335

Phe Ala Leu Ala Gly Cys Val Leu Ala Gly Val Leu Ala Thr Leu Val  
 340 345 350

Ala Ala Trp Ala Pro Ala Arg Arg Ala Thr Arg Ile Ala Pro Val Arg  
 355 360 365

Ala Leu Gln Ala Ala Asp Glu Pro Pro Ala Gly Thr Val Arg Gly Gly  
 370 375 380

Arg Arg Leu Val Val Gly Thr Val Val Thr Val Val Gly Ala Ala Ala  
 385 390 395 400

Leu Ala Val Ala Ala Ile Gly Ala Ser Leu Pro Leu Ala Leu Leu Gly  
 405 410 415

Gly Leu Leu Leu Ala Ala Gly Leu Leu Ala Ala Leu Pro Arg Leu Ile  
 420 425 430

Ala Leu Ser Leu Ala Pro Ala Ala Arg Leu Leu Glu Arg Phe Gly Val  
 435 440 445

Ala Ala Gly Leu Ala Gly Thr Ser Leu Ser Gln Asn Ala Arg Arg Thr  
 450 455 460

Ala Ser Ala Ala Met Ala Val Val Val Gly Ala Ala Leu Ile Thr Cys  
 465 470 475 480

Leu Ala Val Ala Ala Thr Ser Gly Arg Ala Thr Val Asn Ala Asp Leu  
 485 490 495

Glu Ala Arg Tyr Pro Val Ala Ala Gly Leu Arg Thr Asp Gly Glu Pro  
 500 505 510

Ile Ser Gly Ala Thr Ala Gly Ala Phe Ala Ala Val Pro Gln Leu Ser  
 515 520 525

Ala Ser Gly Thr Val Gly Thr Val Ala Ala Arg Phe Pro Asp Gly Gly  
 530 535 540

Lys Ala Thr Pro Arg Leu Leu Ala Ala Pro Gly Asp Glu Leu Ala Ala  
 545 550 555 560

Arg Val Ala Pro Glu Leu Ala Gly Glu Pro Val Val Leu Val Pro Ala  
 565 570 575

Thr Tyr Leu Ala Glu Leu Gly Leu Pro Asp Ser Ala Pro Ile Val Val  
 580 585 590

Glu Val Gly Glu Arg Arg Val Asn Leu Ile Ala Arg Ala Ser Arg Leu  
 595 600 605

Ala Asp Thr Thr Gly Gln Leu Leu Gly Val Val Ser Ala Arg Thr Leu  
 610 615 620

Ala Ala Asn Arg Ile Glu Ala Val Pro Thr Thr Val Trp Gly Val Ala  
 625 630 635 640

Asp Pro Gly Phe Asp Arg Glu Ala Leu Ser Ala Ala Val Gly Ala Val  
 645 650 655

Ala Ala Arg Asp Ala Leu Val Gln Val Gly Gly Gly Val Thr Glu Gly  
 660 665 670

Gly Asp Ile Ala Asn Val Leu Ser Ile Leu Leu Gly Leu Ser Leu Ala  
 675 680 685

Met Leu Ala Val Thr Val Val Ile Ala Leu Leu Gly Ile Ala Asn Leu  
 690 695 700

Leu Gly Leu Ser Val Val Glu Arg Val Arg Glu Met Ala Leu Leu Arg  
 705 710 715 720

Ala Leu Gly Thr Arg Arg Ala Arg Leu Arg Ala Met Leu Ala Val Glu  
 725 730 735

-continued

---

Ala Val Val Ile Thr Leu Leu Gly Thr Val Ala Gly Leu Val Val Gly  
740 745 750

Val Pro Val Gly Leu Ala Ala Val Ala Ala Ala Val Gly Arg Thr Ala  
755 760 765

Asp Pro Val Ile Arg Leu Pro Trp Gly Gln Leu Ala Ala Val Leu Val  
770 775 780

Val Ala Val Leu Thr Gly Val Val Ala Ser Leu Ala Pro Ala Arg Arg  
785 790 795 800

Ala Ala Arg Val Ala Pro Ala Glu Gly Leu Thr Arg  
805 810

<210> SEQ ID NO 124  
<211> LENGTH: 244  
<212> TYPE: PRT  
<213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 124

Met Ile Val Trp Pro Glu Arg Arg Ala Ala Ser Arg Ser Pro Pro Ser  
1 5 10 15

Ser Ala Arg Pro Val Ala Met Ser Ser Ala Pro Val Gly Ser Ser Ala  
20 25 30

Lys Thr Thr Asp Gly Leu Ala Ser Ser Ala Arg Ala Thr Ala Thr Arg  
35 40 45

Cys Cys Trp Pro Pro Asp Ser Ser Asp Gly Arg Cys Pro Ser Arg Ser  
50 55 60

Val Ile Cys Ser Glu Ser Val Ile Phe Arg Ser Ser Pro Gly Ser Thr  
65 70 75 80

Arg Arg Pro Ala Ser Arg Ser Gly Ser Thr Met Phe Cys Ser Ala Val  
85 90 95

Ser Val Gly Ser Arg Leu Asn Ala Trp Lys Thr Lys Pro Ile Arg Ser  
100 105 110

Arg Arg Arg Ser Val Arg Ala Arg Ser Ser Arg Pro Ala Asn Asp Arg  
115 120 125

Pro Ala Arg Leu Thr Val Pro Ala Val Gly Val Ser Asn Pro Ala Ser  
130 135 140

Arg Cys Ile Ser Val Val Phe Pro Glu Pro Asp Gly Pro Met Ile Ala  
145 150 155 160

Val Asn Trp Pro Ala Glu Lys Pro Ala Asp Thr Pro Ser Thr Ala Val  
165 170 175

Thr Ala Ala Gly Pro Val Pro Tyr Val Leu Leu Thr Ser Arg Gln Leu  
180 185 190

Thr Ile Ser Ala Cys Val Val Cys Val Val Thr Ala Pro Thr Leu Glu  
195 200 205

Ile Arg Ala Asp Arg His Ile Pro Pro Arg Asp Pro Gly Arg Ala Val  
210 215 220

Asp Arg Tyr Leu Arg Met Thr Arg Arg Tyr Arg Pro Arg Ala Pro Cys  
225 230 235 240

Ser Arg Asn Arg

<210> SEQ ID NO 125  
<211> LENGTH: 367  
<212> TYPE: PRT  
<213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 125

Val Leu Arg Ile Asp Ala Leu Val Ala Ala Ala Val Val Ile Gly Cys

-continued

1	5	10	15
Leu Leu Leu Gly 20	Leu Ala Gly Leu Ser 25	Glu Trp Tyr Trp Ser 30	Ala Ala
Val Ala Val Pro 35	Leu Leu Leu Arg 40	Arg Ser Ala Pro Arg 45	Cys Phe Leu
Ala Leu Val Ala Gly 50	Val Ser Gly Leu His 55	Leu Leu Ala Ser His 60	Ser
Phe Met Phe Pro Gly 65	Asp Leu Val Ala 70	Leu Val Ala Val His 75	Ala Ala 80
Ala Ala His Ala Pro 85	Gly Arg Ala Arg His 90	Ala Gly Leu Leu Leu 95	Gly
Ala Ala Gly Ala Leu 100	Val Val Ala Ala Gln 105	Ala Leu Gln Asp Gln 110	Arg
Leu Gly Ser Ala Leu 115	Pro Ala Val Leu Ile 120	Val Ala Ser Thr Met 125	Ala
Ala Trp Ser Ile Gly 130	Leu Met Gln Arg Gln 135	Gln Gln Arg Ser Ala 140	Val Leu
Asp Ala Glu His Arg 145	Arg Arg Leu Ala Glu 150	Gln Asp Ser Ala Met 155	Arg 160
Ala Gln Leu Ala Val 165	His Glu Glu Arg Thr 170	Arg Ile Ser Gln Glu 175	Met
His Asp Ile Ile Ala 180	His Ser Leu Ala Ser 185	Ile Ile Ala Gln Ala 190	Glu
Gly Gly Arg Val Ala 195	Ala Arg Ala Asp Ala 200	Arg Ile Ala Gly Pro 205	Val
Phe Asp Arg Ile Ala 210	Gly Leu Gly Arg Gln 215	Ala Leu Thr Asp Val 220	Lys
Arg Leu Leu Thr Val 225	Val Asp His Asp Asp 230	Glu Trp His Asp Asp 235	Gly 240
Leu Glu Arg Leu Pro 245	Val Leu Leu Ala Gly 250	Val Thr Glu Ala Gly 255	Leu
Asp Val Thr Val Asp 260	Ser Ser Gly Ala Pro 265	Gln Pro Leu Ala Ala 270	Gly
Met Asp Leu Ala Val 275	Tyr Arg Val Ile Gln 280	Glu Ser Leu Thr Asn 285	Val
Leu Lys His Ala Pro 290	Ala Arg Arg Ala Cys 295	Leu Arg Met Arg Trp 300	Thr
Pro Ala Leu Leu Thr 305	Val Thr Val Ser Ser 310	Pro Leu Pro Gly Gly 315	Arg 320
Gly Ala Gly Leu Val 325	Glu Gly Arg Gly Leu 330	Ser Gly Ile Arg Gln 335	Arg
Cys Ser Leu Phe Asn 340	Gly Asp Cys Thr Val 345	Thr Ala Thr Thr Glu 350	Leu
Thr Val Thr Thr Thr 355	Trp Pro Leu Thr Pro 360	Glu Gly Ala Arg Ala 365	

&lt;210&gt; SEQ ID NO 126

&lt;211&gt; LENGTH: 220

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 126

Met Thr Arg Pro Pro 1	Ile Ala Val Leu Ile 5	Ala Asp Asp Gln Glu 10	Leu 15
--------------------------	--------------------------	---------------------------	--------



-continued

---

Val Arg Thr Gly Phe Ala Met Val Val Asp Ala Ala Pro Asp Met Arg  
                   20                                  25                                  30  
 Val Val Ala Ile Ala Ala Ser Gly Ala Glu Ala Ile Glu Leu Ala Ala  
                   35                                  40                                  45  
 Glu His Arg Pro Asp Val Ile Leu Met Asp Ile Arg Met Pro Gly Thr  
   50                                  55                                  60  
 Asp Gly Ile Thr Ala Thr Ser Ala Ile Leu Ala Ala Gly Gly Glu Arg  
   65                                  70                                  75                                  80  
 Pro Pro Lys Ile Ile Ala Leu Thr Thr Tyr Asp Ser Ser Asp Tyr Ala  
                                   85                                  90                                  95  
 Thr Arg Ile Leu Thr Ala Gly Ala Ser Gly Tyr Leu Leu Lys Asp Ala  
                   100                                  105                                  110  
 Thr Ala Glu Gly Leu Thr Ala Ala Ile Arg Ser Ala Tyr His Gly Gly  
                   115                                  120                                  125  
 Ser Val Ile Ala Pro Thr Thr Thr Arg Asn Leu Val Ala Ala Arg Ala  
   130                                  135                                  140  
 Glu Pro Pro Pro Pro Ala Arg Asp Pro Ala Pro Leu Asp Thr Phe Thr  
   145                                  150                                  155                                  160  
 Ala Arg Glu Arg Asp Val Phe Asp Leu Ile Val Ala Gly Ala Asn Asn  
                                   165                                  170                                  175  
 Ala Glu Ile Ala Ala Arg Leu His Leu Ala Glu Val Thr Val Lys Thr  
                   180                                  185                                  190  
 His Val Gly Arg Val Leu Ala Lys Leu Gly Val Arg Asp Arg Leu Asn  
                   195                                  200                                  205  
 Val Val Val Trp Ala Tyr Arg Asn Gly Ala Val Gly  
   210                                  215                                  220

&lt;210&gt; SEQ ID NO 127

&lt;211&gt; LENGTH: 782

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 127

Met Leu Ile Cys Gly Leu Ile Ala Gly Val Val Val Ala Ala Ala Ala  
   1                  5                                  10                                  15  
 Phe Pro Phe Ala Ala Met Ser Gly Leu Ala Ala Lys Ala Gly Gln Gln  
                   20                                  25                                  30  
 Thr Phe Ala Ser Leu Pro Ser Glu Leu Lys Ala Phe Arg Ser Pro Gln  
                   35                                  40                                  45  
 Ile Ser Arg Ile Tyr Ala Ala Asp Asn Arg Thr Gln Val Ala Gln Phe  
   50                                  55                                  60  
 Tyr Asp Glu Phe Arg Ser Asp Val Pro Leu Lys Glu Met Ser Pro Phe  
   65                                  70                                  75                                  80  
 Met Arg Asp Ala Met Val Ala Ala Glu Asp Arg Gln Phe Tyr Gln His  
                                   85                                  90                                  95  
 His Gly Val Asp Leu Lys Gly Ala Ala Arg Ala Leu Val Asn Asn Arg  
                   100                                  105                                  110  
 Asn Gly Gly Gln Lys Gln Gly Ala Ser Thr Ile Thr Met Gln Trp Val  
                   115                                  120                                  125  
 Arg Ile Ser Leu Ala Tyr Ser Ala Thr Lys Pro Gln Asp Val Ile Asp  
   130                                  135                                  140  
 Ala Thr Glu Asp Ala Pro Lys Arg Lys Val Ala Glu Met Lys Tyr Ala  
   145                                  150                                  155                                  160  
 Leu Glu Val Glu Lys Gln Leu Ser Lys Asp Gln Ile Leu Glu Arg Tyr  
                   165                                  170                                  175

-continued

---

Leu Asn Ile Val Pro Phe Gly Lys Gln Thr Tyr Gly Ile Tyr Ala Ala  
 180 185 190

Ser Arg Val Tyr Phe Asn Lys Lys Pro Lys Asp Leu Thr Ile Gly Glu  
 195 200 205

Ala Ala Leu Leu Ala Ala Ile Val Lys Ala Pro Ser Ala Tyr Asp Pro  
 210 215 220

Thr Asp Pro Asp Gly Tyr Glu Leu Ile Arg Gln Arg Arg Asn Ala Tyr  
 225 230 235 240

Val Ile Pro Gly Met Val Glu Met Gly Ala Ile Thr Arg Ala Gln Ala  
 245 250 255

Asp Ala Ala Leu Lys Glu Ala Ile Pro Arg Lys Val Arg Pro Met Ser  
 260 265 270

Asn Gly Cys Val Ser Val Ala Lys Asn Asn Trp Gly Phe Phe Cys Asp  
 275 280 285

Tyr Phe Tyr Arg Trp Trp Met Glu Arg Lys Glu Phe Gly Pro Thr Pro  
 290 295 300

Tyr Asp Arg Glu Arg Arg Leu Lys Ser Gly Gly Tyr Arg Ile Thr Thr  
 305 310 315 320

Thr Leu Asp Val Lys Ala Gln Lys Gln Ala Arg Asp Arg Ile Gly Asp  
 325 330 335

Leu Ile Ser Glu Lys Asn Lys Asn Ala Leu Leu Leu Ala Ala Val Glu  
 340 345 350

Pro Gly Thr Gly Lys Val Arg Met Leu Ala Ala Asn Arg Arg Tyr Lys  
 355 360 365

Leu Asp Asp Pro Asp Asp Pro Gln Asn Ala Ile Ser Ser Asp Pro Arg  
 370 375 380

Lys Ala Arg Lys Gly Ile Arg Gly Ser Tyr Pro Asn Thr Thr Asn Pro  
 385 390 395 400

Leu Leu Thr Gly Gly Gly Asp Ile Thr Gly Tyr Gln Ala Gly Ser Val  
 405 410 415

Met Lys Met Phe Thr Ile Val Ala Ala Leu Glu Gln Gly Tyr Pro Leu  
 420 425 430

Ala Tyr Thr Ile Arg Thr Gln Ser Arg Tyr Arg Ser Arg Tyr Ile Ile  
 435 440 445

Glu Ser Ser Asn Asp Ala Ala Cys Pro Gly Thr His Phe Trp Cys Pro  
 450 455 460

Ser Asn Ala Gly Gly Gly Gly Glu Gly Val Phe Asn Met Trp Thr Gly  
 465 470 475 480

Leu Gly Arg Ser Ile Asn Thr Tyr Phe Val Pro Leu Glu Glu Arg Val  
 485 490 495

Gly Ala Glu Lys Val Val Ser Ala Ala Lys Arg Phe Gly Ile Gln Phe  
 500 505 510

Arg Glu Pro Asp Asp Ala Leu Leu Ala Glu Pro Gly Asn Ala His Gln  
 515 520 525

Trp Gly Ala Phe Thr Leu Gly Val Ser Ala Thr Thr Pro Leu Asp Met  
 530 535 540

Ala Asn Ala Tyr Ala Thr Leu Ala Ala Asp Gly Met Tyr Cys Pro Pro  
 545 550 555 560

Thr Pro Ile Glu Arg Ile Ala Thr Arg Asp Gly Asp Gln Leu Asp Val  
 565 570 575

Gly Arg Ser Pro Cys Val Arg Ala Thr Ala Lys Asp Val Ala Arg Ala  
 580 585 590

-continued

---

Ala Leu Asp Ala Ala Arg Cys Pro Val Gly Asp Ser Ala Gln Leu Gly  
595 600 605

Arg Cys Gly Gly Ser Thr Ala Gly Ile Thr Arg Ser Val Val Gly His  
610 615 620

Pro Val Phe Gly Lys Thr Gly Thr Thr Asp Arg Asp Arg Thr Ala Ser  
625 630 635 640

Leu Ile Ala Gly Thr Thr Ala Leu Val Val Ala Gly Tyr Leu Val Asn  
645 650 655

Pro Asp Tyr Gln Asn His Arg Asp Arg Leu Asp His Asp Gln Val Asn  
660 665 670

Pro Ala Val Tyr Arg Thr Leu Ala Asp Tyr Met Glu Gly Arg Pro Arg  
675 680 685

Glu Ser Phe Lys Arg Pro Ser Ser Gly Arg Ile Ala Phe Gly Asp Gln  
690 695 700

Arg Ser Ile Pro Asp Val Glu Cys Asp Pro Met Pro Arg Ala Arg Asp  
705 710 715 720

Arg Leu Glu Asp Ala Gly Phe Asp Val Trp Arg Gly Gln Glu Val Glu  
725 730 735

Ser Asp Cys Pro Ala Gly Thr Ala Ala Gly Thr Glu Pro Ser Gly Arg  
740 745 750

Thr Val Lys Asn Gly Val Val Val Ile Gln Val Ser Lys Gly Arg Arg  
755 760 765

Gly Ala Ser Pro Pro Ile Phe Pro Pro Ile Gly Pro Pro Arg  
770 775 780

&lt;210&gt; SEQ ID NO 128

&lt;211&gt; LENGTH: 253

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes garbadinensis

&lt;400&gt; SEQUENCE: 128

Met Ala Pro Leu Thr Arg Ser Leu Arg Tyr Tyr Tyr Gly Asp Ala Gly  
1 5 10 15

Arg Glu Ala Ala Met Asp Ala Met Tyr Arg Arg Phe Val Arg Pro Gly  
20 25 30

Asp Val Val Phe Asp Ile Gly Ala His Val Gly Asp Arg Val Ala Cys  
35 40 45

Phe Arg Arg Leu Gly Ala Arg Val Val Ala Val Glu Pro Gln Pro Leu  
50 55 60

Cys Met Arg Ala Leu Arg Ala Leu Tyr Ala His Asp Asp Arg Val Ala  
65 70 75 80

Leu Val Glu Ala Ala Cys Gly Pro Ala Gly Gly Ser Val Pro Leu Tyr  
85 90 95

Ile Asn Ser Ala Asn Pro Thr Val Ser Thr Asn Ser Val Arg Phe Leu  
100 105 110

Thr Ala Ala Thr Gly Ser Arg Gly Trp Glu Asn Glu Val Trp Asp Gln  
115 120 125

Gln Ile Thr Val Pro Ala Val Thr Leu Asp Thr Leu Val Gln Arg Phe  
130 135 140

Gly Leu Pro Ala Phe Ile Lys Ile Asp Val Glu Gly Tyr Glu Asp Ala  
145 150 155 160

Val Leu Ala Gly Leu Ser Arg Gly Val Arg Ala Leu Ser Phe Glu Phe  
165 170 175

Thr Thr Ile Ala Arg Asp Val Ala Arg Arg Cys Leu Asp Arg Ala Gly  
180 185 190

-continued

Glu Leu Gly Phe Asp Gly Phe Asp Val Ser Leu Gly Glu Thr Met Ala  
 195 200 205  
 Arg Thr Phe Gly Arg Trp Ala Ala Arg Asp Glu Met Leu Ala His Leu  
 210 215 220  
 Ala Gly Leu Pro His Glu Ala Asn Ala Gly Asp Val Tyr Ala Val Ser  
 225 230 235 240  
 Arg Ser Ala Gly Trp Pro Asp Arg Arg Glu Asp Arg Arg  
 245 250

<210> SEQ ID NO 129  
 <211> LENGTH: 261  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 129

Val Pro Arg Phe Asp Ser Arg Leu Val Thr Val Gly Gly Val Arg Thr  
 1 5 10 15  
 His Asp Arg His Ala Cys His Ala Gly Gly Leu Pro Val Val Leu Val  
 20 25 30  
 His Gly Leu Ala Val Ser His Arg Tyr Leu Met Pro Thr Ala His Ala  
 35 40 45  
 Leu Ala Gly Arg His Pro Val Leu Val Pro Asp Leu Pro Gly Phe Gly  
 50 55 60  
 Phe Ser Asp Lys Pro Arg Arg Ala Tyr Asp Val Gly Arg His Ala Glu  
 65 70 75 80  
 His Leu Ala Ala Trp Leu Asp Val Leu Gly Val Pro Arg Ala Cys Ile  
 85 90 95  
 Ala Gly His Ser Phe Gly Ala Glu Val Ala Ala Arg Leu Ala Val Leu  
 100 105 110  
 Arg Pro Asp Leu Val Ala Ala Val Val Leu Ala Ser Pro Thr Thr Asp  
 115 120 125  
 Pro Ala Ala Arg Ser Arg Arg Ala Leu Ile Gly Arg Trp Ala Val Asp  
 130 135 140  
 Leu Trp Ile Glu Ala Pro Trp Gln Ala Pro Val Leu Val Arg Asp Ile  
 145 150 155 160  
 Ala Asp Ala Lys Pro Trp Arg Val Leu Ala Thr Val Gly His Ser Val  
 165 170 175  
 Arg Asn Ala Ile Glu Glu Asp Leu Arg Arg Leu Pro Val Pro Pro Leu  
 180 185 190  
 Val Leu Gly Gly Ser Leu Asp Pro Val Ala Pro Leu Arg Trp Arg Ala  
 195 200 205  
 Glu Val Ala Ala Met Thr Gly Gly Val Ser Val Thr Val Pro Ala Ala  
 210 215 220  
 Ala His Asn Val Met Thr Thr Ser Gly Val Arg Ser Ala Arg Ala Ile  
 225 230 235 240  
 Ala Ala Tyr Leu Arg Thr Arg Arg Arg Cys Met Asp Arg Leu Ile Gly  
 245 250 255  
 Gly Met Pro Pro Pro  
 260

<210> SEQ ID NO 130  
 <211> LENGTH: 244  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 130

-continued

---

Val Ser Pro Pro Phe Arg Leu Asp Glu Ala Val Ala Asp Val Tyr Gly  
 1 5 10 15  
 Asp Leu Arg Leu Ala Pro Val Leu Arg Arg Leu Leu Arg His Ser Gly  
 20 25 30  
 Arg Leu Thr Gly Ser Val Ala Gly Ser Val Ser Leu Ile Asp Ala Asp  
 35 40 45  
 Arg Gly Cys Tyr Val Lys Ala Ala Glu Tyr Gly Ala Asn Cys Gln Leu  
 50 55 60  
 Gly Arg Ser Phe Pro Leu Asp Glu Gly Ala Thr Gly Arg Ala Phe Gly  
 65 70 75 80  
 Ser Arg Arg Pro Val Val Ile Pro Asp Tyr Gly Gln Leu Arg Ala Gly  
 85 90 95  
 His Leu Ala Ala Ala His Pro Ala Arg Lys Gly Pro Ala Val Ala Val  
 100 105 110  
 Pro Ile Trp Trp Arg Gly Asp Val Ile Ala Val Asn Val Ala Phe Ala  
 115 120 125  
 Pro Ala Phe Ser Leu Gly Gly Val Asp Glu Leu Glu Ala Leu Thr Gln  
 130 135 140  
 Ser Ala Ala Ala Ala Ile Val Arg Ser Arg Gly Val Arg Val Arg Ala  
 145 150 155 160  
 Asp Pro Pro Tyr Ala Ala Pro Ala Ala Pro Phe Thr Pro Arg Glu Ala  
 165 170 175  
 Glu Val Leu Asp Leu Leu Arg Gln Gly Leu Thr Asp Arg Glu Met Ala  
 180 185 190  
 Arg Arg Leu Gly Leu Ser Ala Lys Thr Val Glu Lys His Val Gly Ala  
 195 200 205  
 Ile Arg Arg Lys Thr Gly Thr Ser Asn Arg Thr Ala Ala Val Val Thr  
 210 215 220  
 Ala Leu Asp Asn Asp Trp Val Gly Asn Leu Pro His Thr Ala Glu His  
 225 230 235 240  
 Thr Thr Gly Ser

<210> SEQ ID NO 131  
 <211> LENGTH: 281  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 131

Met Lys Asp Ile Leu Asp Arg Ala Leu Ala Glu Arg Tyr Gly Val Ala  
 1 5 10 15  
 Ala Phe Asn Ile Val Asn Asp Leu Thr Val Glu Ala Val Leu Ala Ala  
 20 25 30  
 Ala Ala Glu Glu Arg Ala Pro Val Ile Leu Gln Thr Ser Val Lys Thr  
 35 40 45  
 Val Arg Met Tyr Gly Arg Pro Arg Leu Tyr Glu Ile Val His Ala Phe  
 50 55 60  
 Ala His Asp Ala Pro Val Pro Val Thr Leu His Leu Asp His Cys Pro  
 65 70 75 80  
 Glu Arg Ser Val Ile Ser Asp Cys Leu Ala Gly Gly Trp Asn Ser Val  
 85 90 95  
 Leu Phe Asp Ala His Glu Leu Asp Val Ala Asp Asn Leu Arg Gln Thr  
 100 105 110  
 Thr Glu Val Val Ala Glu Ala Arg Arg Ala Gly Ala His Val Glu Gly  
 115 120 125

-continued

Glu Ile Glu Gly Ile Gln Gly Val Glu Asp Asp Val Gly Asn Asp Tyr  
 130 135 140  
 Ala Pro Met Val Gln Ser Leu Glu Val Ala Val Asp Phe Ile Lys Arg  
 145 150 155 160  
 Thr Gly Val Asp Cys Phe Ala Pro Ala Ile Gly Asn Ala His Gly Gln  
 165 170 175  
 Tyr Lys Gln Ala Pro Val Leu Asn Thr Arg Arg Val Ser Asp Leu Val  
 180 185 190  
 Ala Ala Thr Gly Ile Pro Met Ala Leu His Gly Gly Thr Gly Leu Ser  
 195 200 205  
 Asp Glu Gln Phe Thr Asp Leu Ile Ala Arg Gly Cys Ala Lys Val Asn  
 210 215 220  
 Ile Ser Thr Ala Leu Lys Glu Ser Phe Met Lys Ser Gly Leu Glu Phe  
 225 230 235 240  
 Leu Arg Glu Ala Asp Glu Arg Gly Lys Trp Asp Pro Pro Ser Leu Phe  
 245 250 255  
 Arg His Gln Arg Ala Ala Val Val Glu Met Ala Arg Gln His Ile Arg  
 260 265 270  
 Leu Phe Gly Gly Ser Gly Arg Ala Trp  
 275 280

<210> SEQ ID NO 132  
 <211> LENGTH: 192  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes garbadinensis

<400> SEQUENCE: 132

Met Gly Ser Ala Val Ala Val Pro Ala Ser Ala Gly Gly Gly Arg Arg  
 1 5 10 15  
 Asp Gly Pro Ala Ala His Pro Ala Leu Arg Arg Ile Gly Ala Arg Val  
 20 25 30  
 Val Asn Ala Leu Val Phe Asp Cys Asp Gly Val Leu Ala Asp Thr Glu  
 35 40 45  
 Arg His Gly His Leu Pro Ala Phe Asn Ala Thr Phe Glu Gln Phe Gly  
 50 55 60  
 Leu Pro Val Arg Trp Ser Glu Glu Glu Tyr Gly Glu Lys Leu Arg Ile  
 65 70 75 80  
 Gly Gly Gly Lys Glu Arg Met Ala Ser Leu Phe Ala Asp Pro Ala Phe  
 85 90 95  
 Ala Ala Ala Ala Gly Asp Thr Asp Arg Thr Glu Leu Leu Arg Thr Trp  
 100 105 110  
 His Arg Ala Lys Thr Ala Ala Phe Thr Lys Leu Val Ala Glu Gly Arg  
 115 120 125  
 Ile Pro Ala Arg Pro Gly Thr Ala Arg Ile Ile Ser Glu Ala Leu Arg  
 130 135 140  
 Ala Gly Trp Thr Val Ala Val Ala Ser Thr Ser Ala Glu Asp Ser Val  
 145 150 155 160  
 Arg Ala Val Leu Val Asn Ala Val Gly Ala Thr Thr Ala Glu Arg Ile  
 165 170 175  
 Pro Val Phe Ala Gly Asp Val Val Pro Ala Lys Lys Pro Asp Pro Ala  
 180 185 190

<210> SEQ ID NO 133

<400> SEQUENCE: 133

-continued

---

000

<210> SEQ ID NO 134

<400> SEQUENCE: 134

000

<210> SEQ ID NO 135

<400> SEQUENCE: 135

000

<210> SEQ ID NO 136

<400> SEQUENCE: 136

000

<210> SEQ ID NO 137

<400> SEQUENCE: 137

000

<210> SEQ ID NO 138

<400> SEQUENCE: 138

000

<210> SEQ ID NO 139

<400> SEQUENCE: 139

000

<210> SEQ ID NO 140

<400> SEQUENCE: 140

000

<210> SEQ ID NO 141

<400> SEQUENCE: 141

000

<210> SEQ ID NO 142

<400> SEQUENCE: 142

000

<210> SEQ ID NO 143

<400> SEQUENCE: 143

000

<210> SEQ ID NO 144

<400> SEQUENCE: 144

000

-continued

---

<210> SEQ ID NO 145

<400> SEQUENCE: 145

000

<210> SEQ ID NO 146

<400> SEQUENCE: 146

000

<210> SEQ ID NO 147

<400> SEQUENCE: 147

000

<210> SEQ ID NO 148

<400> SEQUENCE: 148

000

<210> SEQ ID NO 149

<400> SEQUENCE: 149

000

<210> SEQ ID NO 150

<400> SEQUENCE: 150

000

<210> SEQ ID NO 151

<400> SEQUENCE: 151

000

<210> SEQ ID NO 152

<400> SEQUENCE: 152

000

<210> SEQ ID NO 153

<400> SEQUENCE: 153

000

<210> SEQ ID NO 154

<400> SEQUENCE: 154

000

<210> SEQ ID NO 155

<400> SEQUENCE: 155

000



-continued

---

<210> SEQ ID NO 156

<400> SEQUENCE: 156

000

<210> SEQ ID NO 157

<400> SEQUENCE: 157

000

<210> SEQ ID NO 158

<400> SEQUENCE: 158

000

<210> SEQ ID NO 159

<400> SEQUENCE: 159

000

<210> SEQ ID NO 160

<400> SEQUENCE: 160

000

<210> SEQ ID NO 161

<400> SEQUENCE: 161

000

<210> SEQ ID NO 162

<400> SEQUENCE: 162

000

<210> SEQ ID NO 163

<400> SEQUENCE: 163

000

<210> SEQ ID NO 164

<400> SEQUENCE: 164

000

<210> SEQ ID NO 165

<400> SEQUENCE: 165

000

<210> SEQ ID NO 166

<400> SEQUENCE: 166

000

<210> SEQ ID NO 167

-continued

---

<400> SEQUENCE: 167

000

<210> SEQ ID NO 168

<400> SEQUENCE: 168

000

<210> SEQ ID NO 169

<400> SEQUENCE: 169

000

<210> SEQ ID NO 170

<400> SEQUENCE: 170

000

<210> SEQ ID NO 171

<400> SEQUENCE: 171

000

<210> SEQ ID NO 172

<400> SEQUENCE: 172

000

<210> SEQ ID NO 173

<400> SEQUENCE: 173

000

<210> SEQ ID NO 174

<400> SEQUENCE: 174

000

<210> SEQ ID NO 175

<400> SEQUENCE: 175

000

<210> SEQ ID NO 176

<400> SEQUENCE: 176

000

<210> SEQ ID NO 177

<400> SEQUENCE: 177

000

<210> SEQ ID NO 178

<400> SEQUENCE: 178

-continued

---

000

<210> SEQ ID NO 179

<400> SEQUENCE: 179

000

<210> SEQ ID NO 180

<400> SEQUENCE: 180

000

<210> SEQ ID NO 181

<400> SEQUENCE: 181

000

<210> SEQ ID NO 182

<400> SEQUENCE: 182

000

<210> SEQ ID NO 183

<400> SEQUENCE: 183

000

<210> SEQ ID NO 184

<400> SEQUENCE: 184

000

<210> SEQ ID NO 185

<400> SEQUENCE: 185

000

<210> SEQ ID NO 186

<400> SEQUENCE: 186

000

<210> SEQ ID NO 187

<400> SEQUENCE: 187

000

<210> SEQ ID NO 188

<400> SEQUENCE: 188

000

<210> SEQ ID NO 189

<400> SEQUENCE: 189

000

-continued

---

&lt;210&gt; SEQ ID NO 190

&lt;400&gt; SEQUENCE: 190

000

&lt;210&gt; SEQ ID NO 191

&lt;400&gt; SEQUENCE: 191

000

&lt;210&gt; SEQ ID NO 192

&lt;400&gt; SEQUENCE: 192

000

&lt;210&gt; SEQ ID NO 193

&lt;400&gt; SEQUENCE: 193

000

&lt;210&gt; SEQ ID NO 194

&lt;400&gt; SEQUENCE: 194

000

&lt;210&gt; SEQ ID NO 195

&lt;400&gt; SEQUENCE: 195

000

&lt;210&gt; SEQ ID NO 196

&lt;400&gt; SEQUENCE: 196

000

&lt;210&gt; SEQ ID NO 197

&lt;400&gt; SEQUENCE: 197

000

&lt;210&gt; SEQ ID NO 198

&lt;400&gt; SEQUENCE: 198

000

&lt;210&gt; SEQ ID NO 199

&lt;400&gt; SEQUENCE: 199

000

&lt;210&gt; SEQ ID NO 200

&lt;211&gt; LENGTH: 40402

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Actinoplanes liguriae

&lt;400&gt; SEQUENCE: 200

gatcaggtcg accgcggagc tgatctggtc acggatcgcg cggatcggca ggtccatgcc 60

-continued

---

ggccatcagc	accatcgtct	ccagccggga	cagcgcgtcc	cgccggcgtgt	tcgctgcag	120
ggtggtcagc	gagccgtcgt	ggccgggtgtt	catcgctcgc	agcatgtcga	gcgcccgggc	180
gtcacggacc	tcgccgacga	cgatccggtc	cgggcgcatac	cgcagcgcgt	tgcggaccag	240
gtcgcgggtg	gtgatcgtgc	cccggccctc	ggagtccggc	ggccgggact	ccagggcac	300
cacgtggtcc	tggaccagt	gcagctcggc	ggcgtcctcg	atggtcacga	tgcctcgtc	360
ggccgggacg	aagctggaga	ggacgttcag	gatcgtggtc	ttgccggagc	cggtgccgcc	420
gctgaccagg	atggtgcgcc	ggccgcgcac	gcacgcgtcc	aggaactcgg	ggcctgccg	480
ggtgagcgtg	ccgtactgca	gcaggtcacc	gacggtgagc	gggaccgcgg	cgaacttgcg	540
gatggtcagc	gtcagaccgt	ccagcgcgat	cggcgggacc	acggcgttga	cccggctccc	600
gtccggcagc	cgggcgtcga	cggtcgggct	ggcctcgtcc	acgcggcggc	cgaccgcga	660
gcagatccgg	tcgatgatcc	ggcgcagggtg	ctgctcgtcg	tcgaactcgg	cgccgacctt	720
ctcgaggcgg	ccgaaccgct	cgacgtagac	cgagtacggc	ccgttcacca	tcacctcgg	780
caccgacggg	tcgcccagca	gcgactcgat	cggtccgtgg	ccgagcacct	cgtcggtcac	840
ctcgcgggtg	atccggggcc	ggtccgcgcc	ggagagcggg	gtctcctccc	ggcgcagcag	900
gtcgtggagc	gcgtcccga	cccgggcgtc	caggtcctcg	ctctggccgg	tggtgtagag	960
cgctggcccc	agctcgtcgg	cgagccgccg	ctggatccgc	agccgcacct	cgccgacctg	1020
gtcctgcggc	ggcggcccg	cgcccccgtg	gcggtcgcgg	ccgcgtggct	cggtggccgg	1080
tggtgggggc	gtgccggcgc	cgctcaggcg	gctggagagg	ctcacgggaa	caacctccc	1140
aggaaccgcg	ggcgcgcgtg	gggtgtgggtg	ccgacgcggg	cgatccggtc	accgagctcc	1200
cggatcgcgc	ggctgaccgg	gtgcagcggg	tcggtgacgg	cgatcggctc	gccgtggttg	1260
accgagaccg	tcacgtccc	gctggccggc	acctgcaccg	cgaacggcat	gccggccgcg	1320
acctccacct	cggacgggct	caggccgacc	tgggcgcggg	cccggttgaa	gaccagcagc	1380
cgcttgctct	tgggtagtc	gagcaggctg	aacatctccg	cggtgagccg	gaccgacttg	1440
agcgcgggaa	gatccggggt	gacgatcggg	atgaaccagt	cggacatgtc	cagcgcggcc	1500
agcacctggt	cggtgaccac	ggacgggggtg	tccaccacga	tgaagtctga	gagcggggcg	1560
gccacgtcca	gcagctcgac	gacgaactcc	cggcggacct	gctcgcctc	ggccgggctg	1620
gccggcgcca	ggagggcgtc	gagactttgc	cggtacgtcg	tgacgatcga	ccgcagccc	1680
ggctcgtcca	gccgaccggc	catctgcagg	cccccgcca	tgttgcgttc	cggggacagc	1740
ttcatcatga	tcgccacgtc	gccgaactgc	aggtccaggt	ccatcagcag	cacccggcgt	1800
ccggcaccgg	ccagcgcgac	ggccagggtc	accgccacca	cgctgcgccc	gcagccgccc	1860
ttgccggcga	agaccgtgac	cacactggcg	tacggggcgt	tgtcgcgggt	cccgcgcag	1920
gtggtgctca	gcgccttga	caggctcacc	gaccggaccg	tcgcgctcgc	gatgccctcc	1980
tcgtcctcct	cggcgaccag	gtcccggatg	ccggactgca	ggcagcgcag	caccacgccc	2040
gcctcgatcg	cgtggcggat	cagcaccacc	ccgatcaccg	ggcgtgcaa	ccgctggtac	2100
gccgtgaaca	tcagcgcctc	gtccagggtc	acgaccgcgc	cgatcaccac	gagcagcgtc	2160
tccgggtagc	gggggagata	cgactccagc	tcgctcatgc	tcttgagcat	cgtgccgccc	2220
atcggccgga	agtcggtgac	ccagtgcgtg	cggcgcctcg	cgccgggctc	gacgtacaca	2280
tagaggctca	tcgcacgacc	cagctcgtgt	cgatcgcggg	gccgggtgctc	gcggtggcgt	2340
tcgggcccag	cagcgcagg	tagagcgatc	cgctctgggc	ggcgtgcacg	agtcgcaggg	2400

-continued

---

cgtcggtgtc	gccgacggcc	agggtcacga	cgtaccgctg	gatctccttg	accgcggcgg	2460
tgtgtgcgcc	ggccgaggcg	gacggaccgg	gggtgggcga	gggcgacggc	gtcacggggg	2520
cctgaccggg	ttccgcctcc	ccgatggtga	tcaccctgtc	cttcggcagc	aggagctcgg	2580
tcatcgggat	ggtctcgtgg	tcctccgcca	tcaggacctt	cgcttggtac	gtgtaataga	2640
ccgcgacctg	gtcgccgggc	gtgatggtgc	cggctacctg	cggggcgacg	ttgagcgcca	2700
ccgagaccgc	gagcgacctg	cggggcaccg	ggatccgccc	ggtgtgcgac	ggcgccgggtg	2760
acgcgaggac	gaacagcgtc	cgcatgagga	gctgcggggg	ctgcaggctc	ccgcgagacc	2820
ggagcgggtc	gagcgcgctg	tcccagggtg	tcagcgcccc	ggcgggcacg	gtgacgggtg	2880
ggaccaggag	ccgctcggtc	aggccccggg	cgcggatctc	ggcgccgctg	gtccccgacg	2940
ggatgtgctg	cccggcgacc	aggatccagg	tgcctcccg	gccgctgagc	gcgcgcccgt	3000
cggccgaccg	ggcgtaggac	aggacggccg	ccccctgat	cccggccagc	accagcgccg	3060
ccagcaggat	caggatgctg	cggcgcatga	cttcaccttc	tcaggcaccg	gtcatcccgt	3120
acggccgatc	accatcgctc	cgtaataccg	cgagggtggc	aaccgcgtcg	gtacgtggtc	3180
cgtgaccagc	gctctggtga	agtagccgta	gaggcaggac	tgcgcccgcg	acagcgctct	3240
ctgcgcccc	ggcacgagcg	aggggaccgc	ggatccgggt	gacaccgggc	cgctgaccgg	3300
gctctcgtag	ccggtgagga	cgagcggcgc	gaagccggcg	atccggtagt	acgacggcag	3360
cgtgccgatc	accgccacct	gcctgtcgaa	gatcggcacc	agcaccggct	gccccgaggt	3420
gatcaggacg	ttcagccggt	cgaggcaggc	cgtggcggcg	gaggcgttgc	cggggccgat	3480
ggtgaatccg	ccgaccagc	tgtccgcccg	cccgtcggtc	gccgggatgc	cggtcagctc	3540
gcaggaggcg	tccggtgctc	tgaccggcag	caggccccgc	agcgccggcg	ggccgtccgg	3600
ctgcccagac	cacgtgtaac	cggcgaccgt	ctcgcggcg	tcggccgggc	aggacgtggc	3660
gaggatgccg	tcgctgatcg	ggatgtagcc	ggccgtcggg	tcggagaggc	cgagcagcgg	3720
gtggacgccg	gtctgcccgt	tcgggcccgt	gggcggcggc	ggggcgaaga	acctcgtgta	3780
gtcgccggtc	agccgcagga	agtcgcaccg	ggagaccgag	agcgcgagga	cgctcgggtg	3840
cgccggagct	ccccaggcga	cccggccgca	ggcgcccatc	ttcgccccgt	ggtacgccga	3900
cccggccaga	ccgcgcccga	acagcggcgg	caccaccgag	gtggtgtcgc	tgttgcgggt	3960
ggacgtccgg	acctcgacgt	accggtaccg	cccggaggcg	ctcggcggcg	cggggcacgt	4020
gaccgggggtg	ttccaggagc	tcgggcagcc	ggcgtcggcg	gtggtgacgc	cggcggcggg	4080
gacggtgggtg	atgcagaact	ggacgtccga	gacgaggtcc	ttggcgcttc	ggtcggcgta	4140
ccgctgcgcg	ttgtcccgtc	gcgcggcgac	ggtgcagggtg	gcggacgtca	ggtcccggcc	4200
ggccgtgccc	gcgaggcctc	gcgcgacctt	ccacgacgcc	gcgtcggccc	cgctctgcaa	4260
ctgctcccgc	tcggcgtaga	gcgcgcccgt	gtcgatcacc	agcgccgcca	tcccagagcag	4320
gacgcggggc	ccggccagga	cggcgaccag	cgcggtgatc	acgccgtgct	cgccgcgggg	4380
cgggaacagg	gcggtgatca	gccgacgcat	gacatcacgc	cggtcgcgct	catcgtgatc	4440
gtgcccattg	tctgcccgcc	gaccagcctg	accagcgcca	ccatcggcgt	gatcggctgg	4500
taccggcggg	tcagcacgac	ctcggcgtcg	gcgcccggca	gcgaggtggc	cgaacaggtc	4560
gtgacggctc	gggtcaccga	cggcgccccg	gtggcgccga	cgatgccgtt	gaccttggcg	4620
tgcaccggcg	cggcctgccc	gttcagggcg	ccgagccggg	cgccctcccg	ggccgcctcg	4680
gtgagctgga	tgtactgctg	gagcagcccg	cccatgtcga	tgatcccga	caggatcagc	4740
agcagcaccg	gcatcacgat	ggcggctctc	agcgccggcg	cgccccggtc	ccggttatcg	4800

-continued

---

tgcggagctc	tccgctccct	gggcgagaac	cgtacgcaac	atcccggcca	gccggtcgce	4860
cgtatacggc	ttcgccacga	atggcgaccc	ggcacggatc	agccctttct	tgatggcgat	4920
ctcctccggg	accccgaga	cgtagacgat	cttcatgccc	ggccggacct	cggaggccga	4980
gcgggcccagc	tccccgccg	agactcccgg	caggcccagg	tcggtgagca	gcacgtcgat	5040
cgctccgctg	tgacccggc	acgtcatgat	ggcgctgacc	gggtctttcg	ccacgaggac	5100
gacgaacccg	cgcactctca	gcactctgtc	ggcgagctca	cgcaggctct	cgctcgtctc	5160
caccaggaga	acgaccggc	cctgccgctc	ggttgctttc	cacatcattc	ctctcccgg	5220
gcacgaggaa	tccggcgacg	actcttccc	tcgctgcctc	tgctcacgct	atccaccggc	5280
ctgctggcc	cgggtggcatt	cgcggaaatg	tcgatgcct	caaatcagca	tttgtccggc	5340
ggcactgtcc	gtgttaacgc	tactacggt	gcgctgacgt	cacgtttcgt	cccggttaaca	5400
gttcggggtc	ttgacagatc	acgagcgctc	atgggtgaat	gtgttcaatc	ctgatcggac	5460
gagtgcagga	taaacaacgt	ttgcgtgtga	agccgtttgg	ctttgagggg	gctccatggt	5520
caattacgtc	agtttcgtgc	gccctaaaac	ctttgccgcc	accttcgctg	cagccgcct	5580
gctgctcggc	tccggcgct	gcgcgaagag	caggactcc	ggggacaccg	tggcggcggg	5640
tcccgccccg	tccggcgctc	aggtggctca	gtccgcctcg	gccggctccg	cgacctgtgc	5700
cttgatcag	tacggcgct	ccaagctcga	cctgaagacc	gcctccgctc	gcttctccca	5760
gtcggagaag	gaggcgaacc	cgttccggat	cgcgagacg	aagtccatca	aggacgaggc	5820
cgcgaagctg	ggcatcacca	acctcaagac	ctcgaacgcg	aactcacaat	tcaacaagca	5880
gatcgcgac	gtcagacaga	tgatcgatgc	ggcgctgcag	ctgctggtga	tcgcccgt	5940
caactcggac	ggctgggact	cgggtgtcgc	caaggcgacg	gcgaagcaca	tcccgatcat	6000
cacgatcgac	cgaagatca	acgcgaccgc	ctgcaaggac	tacctgacct	tcatcggctc	6060
cgacttcgcc	gagcagggca	agcgggccc	cgcgcgctg	gcccaagtgc	tgggcaacaa	6120
ggcgaggtg	gcgatcctgc	tggcgctcc	cggcaacaac	gtcaccacgc	tggcgaccag	6180
cggcttcaag	gacgagatcg	ccaaggctgc	gccggacatc	aagatcacgt	tcgagcagac	6240
cggcaacttc	tcccgggagg	acgggcagaa	ggtcgcgag	cagctgctgc	agtccaagcc	6300
gaacatcaac	ggcatctacg	gcgagaacga	cagatggcg	ctcggcgca	tcaccgcgt	6360
caagggcgcc	ggcaagaagg	cggcgacgt	caagatcgtc	tcgatcgacg	gcaccaaggg	6420
cgcggtgcag	ggcatcgtgg	acggctgggt	ctcccggtg	atcgagtcca	accgcgctt	6480
cgggcccgtg	gccttcgaca	ccgcgacgaa	gttcttcggc	ggcgagccgg	tcggccagga	6540
catcgtcatc	caggaccgtg	cctacgacga	gtcgaacgcc	aagaccgaca	tcggcagcgc	6600
gtactagaga	gcgctcccaa	tcgggtgtcc	gggatgaac	cgggcacccg	ccggcacgga	6660
ggagggcggc	tcatgctgct	ggaagtctcc	ggcgtctcca	agaccttccc	cggcgtacgc	6720
gccctggacg	gggtgtcctt	cacctgaac	ccggcgagg	tgacgcgct	ggtgggggag	6780
aacggcgccg	gcaagtcgac	gttgatcaaa	gtgctcaccg	gggtctacca	gccggacagt	6840
ggcgagctgc	gctaccgctg	cgagccggcc	cggttcgcca	ccccgctgga	cgcccagcgg	6900
gccggtatct	cgaccatcta	tcaggaggtc	aacctcgtcc	cgctgatgag	cgtggcgcac	6960
aacctgttcc	tcggccggga	gccgcgcaac	cggttcgggc	tgctggacga	ggcccggatg	7020
gtcgcgagg	ccaccgagat	cctggccgg	tacggcgta	gcaccgatgt	ccgcgcgc	7080
ctcggcacc	tggccctggg	cgcgcagcag	atggtcgcgc	tcgcccgggc	cgctatggtc	7140

-continued

---

gacgccggg	tcgtggtgat	ggacgagccc	acctcgtcgc	tggagccgcg	cgaggtggag	7200
accctgttcg	gggtgatccg	cgagctgcac	accgcgggca	tcggcatcgt	ctacgtctcg	7260
caccggctgg	acgagctcta	ccgggtgtgc	gacgcggtea	cgatcctcgc	cgacggcaag	7320
ctcgtgcaca	ccggccgat	ggccgatctc	gaccggcgca	cgctggtctc	gctgatgctc	7380
ggccgcgagt	tcggggcgga	cttcaccagc	ttctccgagt	caccgcagag	caccccgag	7440
ggcgagccgg	tcctgcgggt	gtccggcctg	accagccgcc	cccggctcga	cgacatcagc	7500
ttcgacgtgc	gccccggcga	ggtggtcggc	ctgggcggcc	tgctcggcgc	cgccgcgagc	7560
gagacgatca	aggcgatcgg	cggggcgtac	ccgatcgact	ccggcgtgat	cgaggtcggc	7620
ggcgtccggc	tcggcaggcc	cagcacggta	cgggcggtec	gcgcgggctg	ggccaccag	7680
ccggaggacc	gcaaggccga	gggatcgtc	cccggcctgt	cgatccggga	caacatcgcg	7740
ctcgcgatcc	tgccgcggat	ggcccgtttc	ggactggtca	gcgacaagcg	gatcgacagc	7800
atcgtcgcca	cgtacatgag	ccggctgcgg	atcaaggcgt	ccggtccgga	ccaggcggtc	7860
ggcgatctct	ccggtggcaa	ccagcagaag	gtgctgctcg	cgcggtctgt	cgccaccggc	7920
ccgaaggtgc	tgctgctcga	cgagccgacc	cgggcatcgc	atgtcggcgc	caaggccgag	7980
gtgcaggcgc	tgatcgacga	gctggcgaag	gaggggctcg	gtgtcgtgct	ggtctcctcg	8040
gacgccgagg	aactggtcga	gggcgcggac	cggtggtgg	tgctgcgcga	cgccgcggtc	8100
gtcggcacc	tcaccggcga	ccgggtgacc	accgagccc	tgatggccac	gatcgcgag	8160
gccgcggatg	agcactgaga	ccctgaccgc	cccgcggatg	acgttcaacc	cgccgtgggc	8220
ggcacgctac	ggcgtctacg	cggcgatcgt	tctgctgac	gtcgtcaaca	tcgccttcac	8280
gccgtacttc	ctgaccctga	gcaatctgcg	gatccagctg	atccaggcgg	cgccgggtgt	8340
gatcgtcgcg	ctcggcatgg	ccctggtcat	cgccaccgag	gggatcgacc	tctcgggtgg	8400
ttcggtcatg	gcgctcgcg	cgcccttcac	accctctat	ctgggttacg	gcgtgacagc	8460
cgcgatcctc	gtctcgtcct	tcgcccgtgt	ggcggtcggg	ctgatcaacg	gtgtcctggt	8520
cgcaaggcc	ggcctgcagc	cgatcgtggc	gacgctggcc	ctgttcgtcg	gcggtcgcgg	8580
gctggccgtg	gtgatctccg	gtggacagct	caaggacgtg	cgcaacgccg	acctgctcta	8640
cctgggctcc	ggtgacctgc	tcggcgtgcc	ggtcctggtc	tggatcgcg	cgctgctggt	8700
gctcgtggtg	gcgttcgtgg	tccggcgtac	cgtcttcggc	cgccgcctgc	tggccgtcgg	8760
cggaaccgg	cccgcgcgg	agctcgcgg	cctcccgtgc	aagcgggtgc	tgatcggcgt	8820
ctacgtcttc	tgccgggtgc	tcgctcgat	cgccggcctg	ctctcggctg	cgccgatcca	8880
gtccagcgac	gcgtccgcgg	tcggcctgct	gatcgagctc	tccgcgatca	ccgcgggtgt	8940
cgccggcggc	acccgctca	ccggcggcgg	ggtccgggtg	ctcggcaccg	tggccggggc	9000
cctgctcatg	caactggtgg	tcgccaccat	gatcaaacac	gatctcccgc	cgccaccac	9060
cgagatggtg	caggccgtga	tcacccgtgt	cgccgtctac	gtggcccggg	agaggaggac	9120
ccggtgacca	tgtegatccc	cgtgcccgtc	ttccggaacg	gcggcttcgt	gcagcggcag	9180
ggcgcgctcg	cggtgctggt	caccgtggtg	gcgatcagcc	tggccgcgtt	cccggcttc	9240
cgagcgcgg	acaacgccgg	cacgatcctg	gtcgcgcgg	cgccaccgat	gctgatcgcg	9300
ctcggcatga	ccttcgtgat	catcacgggc	gggatcgacc	tctcggctcg	ctcgtctac	9360
gtgctcggcg	gggtggtcgc	cgccggggcg	tcgcagtggg	gagtcgtcgc	ggcgtggcc	9420
gcgcggttc	tcctgtgcgg	ggccatcggc	gtactgaacg	ggatcctgat	ctcgagaacc	9480
gggatggcgc	ccttcacgt	caccctcgcc	gcgctgctcg	gcgcccgtgg	cctcatgcgc	9540



-continued

---

agcatcagcg	atgagggctc	gacgacgtac	ctggtcagga	gcgacgtctt	ccacgagctg	9600
ggcacgggat	cctgctcgg	cgteggctcg	ccggtctggc	tggccgcggt	tctggtcggc	9660
gccgggatcc	tggctgctgaa	ccggaccccg	ttcgggcacg	ccgtgcacgc	catcggcggg	9720
agcgaggacg	ccgccgcgct	gatggggctg	cccgtacggc	gaataaaggt	ctgggtctat	9780
ctcctctccg	ggctgctcgc	gggactcgcc	ggtgcgatca	acgcggccaa	gctcggctcc	9840
ggggtcaccg	tgctcggcag	tggcatggag	ctcgacgcca	tcgccgccgt	cgtgatcggg	9900
ggcacgctgc	tcaccggcgg	ctccgggtcg	atcgccggca	cggtcgcggg	ggtgctgctg	9960
ctcggcgtga	tccagaacct	gatcaaccag	gtcggcaacg	tcaacagcaa	ctggcagcag	10020
gtgatcagcg	gtgggttctt	cgccgctgtg	gtcgtggcgc	agacaactct	cgtacgcgca	10080
agaagatctt	gacgtggagg	cccgcccggg	gaccctgccg	cgggcgggca	ggcgtaggtt	10140
gcccgcgatga	cggagcatcg	ggtctccccg	gcccggcggg	cgctcgcgctg	gctgatgctg	10200
gtctccgggt	tcgcccggt	cgtegggtcg	ttcctgccgt	gggcctgggt	cgacttcccc	10260
gagcagggca	gcagccaggt	gtccgggagc	ctcgtgtccg	acctgttcac	cgcgttcttc	10320
ggggtcgtgc	tcgccgggta	cgccgtgccc	gccgtgcgcg	gcgagcgctt	gcccggcctc	10380
gagacgttct	tctcggtcgg	cgccgggctg	gtgctgttca	cgctcggggc	ctgggacagc	10440
cggcacctga	cctcgatgac	cgccgccctg	gtcgcggccg	acaccggcac	gaccatcggg	10500
cccgtctctt	ggctgtgcat	gatcggcggc	ctgctgggcg	cgctcgcggc	ggcggccctc	10560
gccgtccggg	gacgccggcc	ggtcgtcagc	tcccgggtgt	gaccaccag	tccgggtggt	10620
tcggcatcgg	aggggtcgtg	acgccgagga	gccaggaggt	caggaacggc	cgcagatcct	10680
ggcggggcag	ccgcgaggcg	agcgtgatga	agtcaaccgt	cgaggcggag	cgcccgcggt	10740
acgtcgtcag	ccaggcgcgt	tcgacccgct	ggaacgtcgc	cgcccgatc	ttctgccgga	10800
gcgcgtagag	gaccagcgcg	ccgccggcgt	agacgttcgg	ggtgaagacg	tcccacgtgg	10860
tcgcccgctc	gagcggggcg	gcgaccggac	cgtacctggc	gcggaagatg	tcgccggcgg	10920
cgtagacggc	cttgaagaac	gcctcgcggg	cgccaggcc	ggtgtactgc	gggaaccgc	10980
cggtctctct	cgaccagagc	atctcgtacc	agtgggcgtg	gccctcgttg	agccagacgt	11040
cgtccacga	gaacggcag	acgtgtcgc	cgaaccactg	gtgggcccagc	tcgtgggtca	11100
tcgacgggcc	gcggtggtc	tcggggcccg	tgaacagggc	ggcgcctac	agcgaaaggg	11160
tctgggtctc	cagggcgtag	cccaggctcg	cgtcgatcac	cagggagccg	tagtcctcga	11220
acggataggg	cccggcctgc	ttctccatcc	aggcgagctg	ctcgcgttcc	ccggcgatcg	11280
cgggcagcag	cgtgccggcg	aggcgtcgcg	gcaccacgtc	gcggatcggg	gtgccgccgg	11340
ccgccggggc	gcgctcgacc	acgaagtcgc	cgacggcgt	ctgcaccagc	tcggtggcca	11400
tcggggcgga	ctcgcggtag	accgagctga	cgtggccgtc	gtgctcggtc	gtgctacca	11460
gctgcccgtt	ggcgtcccg	gtccagccgg	ccggcacggg	gagcgtgatc	gtgaaggctg	11520
ccttgtcccg	tggatggtcg	ttgccgggga	acagcaggtg	cgccgagccg	ggctgggcag	11580
cgagcaccgt	cccgtccggc	gtcgccacga	gagcggccgg	ggcggcgggtg	aagttcgcga	11640
ccgtgaccgc	gaacagccgc	ccccggggaa	gggggcggcg	cgggatgacg	gtcagctcgt	11700
cgccgtcccg	ggcggcccgc	gcggtctgcc	cgtcgaccga	gacgcgcccg	atcgaggcgc	11760
cgccgaagtc	gaggtcgaag	cgggacaggc	tctgcccggc	gacggcgggtg	atcgtcacat	11820
cgccggatag	gacctgcttc	gggtccttct	ccgggtagcg	cagggcggagg	tcgtagtcga	11880

-continued

---

gcacgtcgta	gccgccgttg	cagagcagcg	ggtagaggcg	gtcgccgagg	ccggcggacc	11940
cgggtgacgg	cgagggcccg	gcctgcgccg	gtgcggcggc	tgcggccagg	gcgaggacga	12000
cggtggcgcc	gacggtgagg	acgcggtgic	ccgcggacgt	tccgatggct	tccgacgcta	12060
ggcgacacca	ccggaagcca	togacccatg	ggcatgtatg	aaatcccaca	atctccgatg	12120
tggacggacg	gatggtgccc	agtatgcaac	ttgcagattt	cgggacattc	cctagcccgg	12180
cggttgccgt	gtgcacccgt	togaccactg	tccggaaccg	cgtggtgagc	agggtgaacg	12240
ttcatgcggc	ccgggccggc	ggaggtcccg	tgaccgttcg	cattgcccgtg	cgccggtgaa	12300
tcactccgct	ttacgacttc	gcgacaagtg	gttaatgtcg	gcgaagcgat	atatcgtcca	12360
gttattcggg	ggactgcggt	gcatgagcaa	aaaatcactc	cggcgattgc	cagcggatca	12420
ccgcaaattg	aattgctgcc	cgtcaattcc	ctgcgagtga	tggattcgcc	gcgactgaac	12480
ggtgaggacc	cgccggcacac	cgaggtgctc	gccggcttcg	gggcccggagct	cccggccgatc	12540
gtcgtgcacc	ggggcaccat	gcgggtcctc	gacggcggc	accggctgag	cgccggcccgg	12600
ctgcgcggcg	acgaccgat	cagggcggtg	ctgttcgacg	gcaccgagca	ggaggccctac	12660
gtgctgagcg	tcaaggccaa	cgtgacgcac	gggtgcccgc	tgtcccggc	cgagcgcacc	12720
cgtgcggcgg	agcgcacat	cacgatgcat	cctgactggt	cggaccgat	gatcgcggcg	12780
tccagcgggc	tggggcggcg	gaccgtcggc	ggcctcccgc	ggcggcggc	ggcctcccgc	12840
gagagcccgg	cgggcctccg	ctcgcggccc	ggccgggaca	gccgcgtccg	gccggcccggc	12900
agcaccggcg	gccggctgaa	agcggctgac	tacctccagg	accggccgga	cgccctcactg	12960
cgggagatcg	cccggcacgc	cggcgtctct	ccgtcgaccg	cccgtgacgt	ccgggaccgg	13020
ctgcaccggc	gcgaggacc	gatccccgcc	acgcaaccgc	cggcggcacg	ccccggaaac	13080
gattccccgc	cgctgcggtc	gctggtccag	ggcttggcga	gcgaccgctc	gttgcgattc	13140
agcagatccg	ggcgcgatct	gctgcgctgg	ttgattgccc	acgccgttca	ggacggcgaa	13200
tggaaagggc	tggctgacac	tattcccggc	cattcccggc	aggcgtggc	gaaaatcgcg	13260
cgccattggt	cgccggaatg	gcgtgagttc	gcggacatcc	tggagaagga	cgccgcgtag	13320
gccaccggca	tttcttcccg	caccgggtcc	gccctcccgc	acgcacaggt	cagagtactg	13380
atggcggctg	tcaaccggcc	gatctgcggg	taggtgcccga	cgtccttccc	ccgaccgtct	13440
gccgaacgca	tccggctcgt	gcccgatgtg	cgggtaggca	ttaccgatc	agggttgctc	13500
caatgtctct	cgctgatacc	gcggctgata	cctcccgggt	actcggcaga	acactccgtg	13560
gctatggcgc	cgtggtcccg	gagcctttcc	tgaagtactt	cggacgtacc	tgtccggagt	13620
ccccacaga	aggagacatc	atgtcggcca	tcaccgtgga	aaccacctgg	aagaacaccg	13680
acctccggga	ggacctcacc	gctcacccgg	ccggcctcgg	cttcggcgag	ctgagcttcg	13740
aggacctgcg	tgaggaccgc	accatctacg	cggccagcag	cggctgggtc	tgcaccctga	13800
ccatcgagtg	cggcacgctc	gtctgcgcct	gctgaccaac	ggtcatcgca	ctgccgggac	13860
cggggctgac	cccggctccc	gcaccctctc	cccggcagga	gcctgcatgt	catcctttgc	13920
gatcgcggct	tgcgccggca	gcgcgtacct	gcacgagcgc	tccgccggcc	ccggcggcga	13980
ccccgtggcg	gagcacgagc	gggtcagatc	gtggcggcag	tccgcgttcc	tggacgaccc	14040
ggtcctggac	atccgcctgc	gcgagctcgg	actcagccgg	gccgagttcg	gccggctgct	14100
gaccgacggc	gcgtacgacg	ccgggagcac	ggcctcagac	tgggcggcgg	agctggccgc	14160
cgtgctggcg	accgggaccg	gcgcggtcac	cggactcggc	cggtcgacca	agctgtgggc	14220
gcagggcttc	gaccggctgc	cgttcggccg	gctgatcgag	aggttcctcg	cgtactacga	14280

-continued

---

gccgcgggtg	ccgcgcaccg	ccgggaccgt	ccgggtgtcc	ctgctggaga	gcctcgcgaa	14340
ccgcctgctc	acggctgcga	cccggaccct	gctgctggaa	ctgaacgtgg	cccgggtgca	14400
cggccgcctg	accggcgcca	ccccgggga	acgtacgac	cactacgacc	gggtcctgct	14460
gaccgacccg	gactacctgc	gctcgtcttt	cggcgagtag	ccgggtgctcg	gccgggcat	14520
ggtcagagtgc	ggccgccgct	gggcgtcggc	gatggccgag	ctgttccagc	gcctggacgc	14580
cgaccgtccc	gccctgcacg	ccgccgggct	gctgccggcc	ggcgcgggcg	aggtcacccg	14640
gctccggccc	gacctcggag	accgcacaaa	cagcggccgc	gcggctcgcga	tcttgacctt	14700
ccggctccgt	gccagctgg	tgtacaagcc	ccggccggtc	gggcccggagc	gcgcgtacgc	14760
cgagaccgcc	gcggccctga	accggcacgg	cctgagcctg	ccgctgaccg	ccgtggacgt	14820
gctcgaccgc	ggcgcctacg	gctggtgcga	gctggtccgg	cacgagccgt	gcgccgaccg	14880
cgccgacctg	gaccgcttct	accggcgtac	cggcgcggtc	ctggccacca	ctctgctgct	14940
cggcgcctgc	gacgtgcaca	tggagaacgt	catcgcggcc	ggctcgtcct	gcatgcccat	15000
cgacctggag	acgtgctgc	agcccggggt	cccgtccggt	gacgcgacgg	acgcctacac	15060
ccgggcgctc	gacctgctca	accagagcgt	gctggcgatc	gggatcctgc	ccgccggggc	15120
gttcggcggc	cgggagcgca	agagcgtcga	cgtcagcgcg	atcggcggcg	gcgaggcaca	15180
gaccgcgccc	cggccggtgc	cgatggtcgt	ggagccgttc	accgacgtgg	cccggatcga	15240
ggcgggtggaa	gcgaccatgc	tgggcgcgca	gaaccggccg	gtgctggtcg	gcgccgaggt	15300
gcggcccagag	gagcacaccg	aggcgggtgg	ggccggcttc	accgaggcgt	acgacctgat	15360
ctcccgccac	cgcgaggact	tgcgccacct	gctggccggc	ttcggtgacg	tgcagggtgcg	15420
ctacctgccc	cgcccgacct	gccggtacag	catgttctct	accgagagct	accaccggga	15480
ctacctgcgc	gacgcgcgtg	accgcgaccg	gctgctcgac	aagctgtgga	ccgccgcggg	15540
cgcccgtccc	gacctgatcc	ccatcatcga	gtcggagaag	cgccagctgc	tggccggcga	15600
catcccgtgc	ttccgcgcgc	tggccggcga	ccgggcgatc	cgcaccgcgt	ccgcccgggt	15660
ggcgcgggac	ttcttcgacg	ccccggcat	cgaggtgctg	gccggccgcc	tgcggcagtt	15720
cgggcccgtg	caccgggctg	cccagctgcg	gatcatccgc	gagtcgatgg	gaacctgcc	15780
cgccccggc	ccgatcgccg	ggacacccgc	gccatcctcc	gagcggcgtg	gcggcctcga	15840
ccccgtgag	gccgccacgc	tggggaccg	gctcgtgcgg	gagctcgcgg	acgaggcgat	15900
cctcggggcc	gacgacgccg	gctggatcgg	agtcagcatc	gagggcctcg	accaggagac	15960
gttcagctac	aagccgatgg	cgaccgggct	gtacgacggc	atcgcgggaa	tggcgctgac	16020
gtacgcgtac	gccgcccga	cgtcggcga	cgagcgtac	ctcgacctga	cccgcgtac	16080
cgtcaagctg	gtctccggct	atctgcggta	cctcggcag	caccggatcg	tggagacgggt	16140
cggggcgtac	agcgggatgg	ccggcctgct	ctacacgctg	gatcacgtcg	cccatgccac	16200
cggcgacgcg	tcgctgctgg	gcgagatcga	ggccgcgctg	ccctggctgc	gggagtgcgc	16260
taccgcgag	gagtgcccgg	acctgatcgc	cggcctggcc	ggttgcgccc	tcgtcgcgct	16320
gtcgtgtac	cggcggcacg	gcatcggccg	ttaccgcgag	gtcgcggaga	tctgcggccg	16380
gcgactggcc	ggcaccgcgg	tcgacgtcga	ggcgcgcg	ggctgggccc	cgaccgggac	16440
cggcgtgate	ctcggcggtt	tctcgcacgg	ctcggccggg	atcgccctgg	ccctgcacga	16500
gctcgcgccc	gagttcggtg	accgggacct	gcgcgagctg	gccgaccggg	cggtcagatt	16560
cgaccggcgg	ctgtacgttc	cggccgcgg	cgctggcgc	gacctgcggc	ccgagatggc	16620

-continued

---

cggcaccgac	ggttaccg	cgctctggtg	tcacggcgcc	gccggcatcg	gcctgtccc	16680
gctgctgac	caccggatcc	ggccggacga	gcggctcgcc	gaggaggccc	gcgccgcggt	16740
ggcgtggtc	cggcggcacg	gcttcggcca	caatcacagc	ctctgccacg	gcgacttcgg	16800
cgcgctggcc	ctgctcgcc	tggccgaccg	cgcgtggccc	gggtcgggcg	gccacgacga	16860
gcgtgccggc	gcggtcgtgc	gggacatcgg	cgagaccggt	ctgcgctgcg	ggctgggcaa	16920
cggcatccgg	atgccgggtc	tgatgctcgg	cgccgcgggc	gccggactga	gcctgctccg	16980
gctggccgcy	cccgcgacg	tggccgcggt	cacctggctg	gaaccgccc	ggggcacgca	17040
tgtctgagac	ggccgggctg	ctgcggcgga	gcctgctcga	tcaccggggc	aaactcggcc	17100
ccgtggccgg	tctcgccgtc	gccggggctg	gctgccagct	gggccagccc	ttcctcatcc	17160
ggcgcgtgct	cacggcggtg	cagtcgcgac	agccgtaccg	ccaattggct	ctcgccgctc	17220
tggcggcat	ggtcgctggc	gcggcgctgg	gcgcgctcca	gcagttcctg	ctgcagcgca	17280
ccggggaggc	gatggctctc	acggtgcgcc	gcacgctcgt	cgcgcacctg	ctgcccgtgc	17340
cggtcgccc	ctacgacgag	cggcagtcgg	gcgatctggt	gtcccgggtc	ggcgccgaca	17400
ccgcccaggt	gcgctcggtg	atcacgtccg	gggtggtcga	cctggccggg	ggcgtcctgc	17460
tcgtcggcgg	ctcgatcgcc	ggcatgatca	tcattgatcc	ggtcctgctc	ggcgtcagcc	17520
tggcgcgggt	gctgtgcggc	gccgcggggg	tccggctggt	cgcccgctcg	ctgcgcccgc	17580
tcagctcggc	ggtccaggag	tcgatcggcg	cgctcaccgc	ctcgaccacc	cgggccctcg	17640
gcgcgatccg	cacgatccgg	gtcgccggcg	ccaccgagcg	cgagaccgcc	ctgatcgctg	17700
ccgaggccga	ccgcgcccgg	gcggcggggc	tccggctcgc	cctggtcgcg	gcccaggccc	17760
gcccgatcgt	ccggctcgcc	ctgcagggcg	cgctcgtcgc	ggtgatcggc	ttcggcggt	17820
accgggtcgc	gaacggcgcg	gtgtcggctg	gcgacctggt	cgcgctcacg	ctgctgctgt	17880
tcacgctggc	gctgcccctg	gcccagctcg	ccgaggcggc	caccggatc	cagaccgggc	17940
tggcgcggct	gaccggatc	gaggagatcc	tggccctgcc	ggacgaggac	agcgcgctcg	18000
gcgtccgtgc	gaggacgccc	gccacgggtc	ggcacgatcc	ggtgctgctg	gagttcgatc	18060
acgtgtcggt	ccgctatccc	accggcgggg	agatcctcgg	cgacgtcagc	ttccgggtgc	18120
cggccggcag	caccaccgcy	ctcgctcggc	cgccggggc	cggcaagtcg	acgatcctgg	18180
cactgatcgc	ccggctctac	gaggtccacg	gtggccggat	cctgctgcac	ggccgcgaca	18240
tccgcgacta	cccgctcgcc	gagctgcggg	ccgcctcgg	ctacgtcgag	caggaggccc	18300
cggctgctgg	cggcaccgtc	cgggacaacc	tgacactggc	cgcccgggac	gtcgcggaac	18360
acgcgatccg	ccacgtcacc	gcacgggtca	acctcgacga	cctgctcgcc	cgtgaccggg	18420
ccggcctgga	cgcgcccgtc	ggggacggcg	gcgtgctggt	ctccggcggt	gaacggcaac	18480
ggctcgcggt	cgcccggacc	ctgctcgccc	cggcggaact	gctgctcttc	gacgagccga	18540
ccgcccacct	ggacgcccgc	aacgagcagg	cgctgcagca	cggcctgacc	gcgcacgccc	18600
ccggccggac	gctgggtggtg	gtcgcgcacc	gcctggcgac	cgctcgcgac	gccgaccaga	18660
tcctggtgat	cgacgacggt	cgttcggctg	ccgcccggcg	gcacgaggag	ctgctcgctc	18720
gcgaccgac	ctaccgcyag	ttcgccaccc	gtcaactgct	gacctgaatc	ccgaggtgta	18780
cgccatgctc	agtgtcctgg	accaggtgcc	cgtgttcggt	ggcgacgacc	ccgcccaggc	18840
ggtccgcyag	gcccgcggc	tcgcccgggc	cgccgagctg	ctcggtatc	accggttctg	18900
gatcgcgcyag	catcacggca	gcgcccga	cgcgtgcgcy	gcgcccggaga	tcgtggcggc	18960
ggccgctcgc	ggagccaccg	aacggatccg	ggtgggcacc	gggggagtg	tgctgcccga	19020

-continued

---

ctacagcccg	ctcaaggtgg	cggaggcctt	ccgggtgctg	gcggcgctgt	atccggggcg	19080
gatcgacctc	gggttcgggc	ggggcagggg	cgggccggcg	gtgatggccg	agctgctcaa	19140
cccgtacgcg	atcgcgaccg	aggaggcgta	cgccgagcag	gtcggccggc	ttctcgcgtt	19200
cctgggcgac	gcgcggaccg	tcagccgggt	gtcggtcacg	ccggcgggtc	aggaccgcgc	19260
gttgccgtgg	ctgctcggct	ccggcgtcgg	cagcgcgccg	ctcgcggga	tgctcggcgt	19320
gccgttctgc	ttcgcgcagt	tcatcgcgac	cgaggagtgc	ccggaggcga	tcgcggcgta	19380
ccaggagtgc	ttccggagct	cgccgtggct	ggacgagccg	caggcgatgc	tggcgttgcg	19440
ggtgctcgcg	gccggcaccg	ccgaggacgc	cgaggagtgc	gccaccggct	tctggatgtc	19500
gtgcaccacc	ggatggcggg	cccaggctcc	gccggacgac	gactaccggg	gtggcgtgcc	19560
gaacctggcg	gacgcccagc	ggtacacgct	gaccgaggag	gacctggcga	tgcgcgcgag	19620
ccggccgtac	ctgcagatct	ccggcacggc	ggagacggtc	ggcgaggaga	tccggcgact	19680
gcgcaaggtg	tacgacgtgg	ccgaggctcat	gctcaccacg	aactgtcccg	gggcggccgc	19740
cccggcgccg	gtcctacgag	ctgctggccg	ccgagctcgg	gctgaccgcg	ccggcgtgac	19800
ccgggtcagg	ccagctcgtc	ggtggtgagg	ccggcggcgt	acgccagcac	ggcggcctgc	19860
acccggttgg	ccacaccgag	cttgccgagg	atgacgctga	cgtactcctt	gaccgtggag	19920
tcgctgatga	acaggcggcc	ggcgatctcc	gcgttggtca	gcccctgccc	gatcaacccc	19980
agaacggcct	gttcccggtc	ggagagctgt	ttgacctcgt	cgaccgcgtt	ctcggcggcc	20040
ggagtgcccc	ggcaggccgc	gcccagcatg	atcgacgagg	cctccggcgc	cagcacggtc	20100
accccgacg	ccagcgcgcg	gaccgccgcg	accagttgct	ccggctgact	gtccttgagc	20160
aggaagccgc	aggcgccacc	gcgcagcgac	tccagcacgg	tgctggacgc	cgccagcgtg	20220
gccagcaccg	ccagcgcggg	cccggactcc	aggtcgcgca	gccgggtcag	cagcggcacg	20280
ctctccggca	gggtcgcgtg	cgcgtccagc	aggacgaccg	cgggccgggtg	ctcgcgtgacc	20340
gcggcgagcg	cgctgtcgcg	gtcagcggcg	acgacggaga	agccacccat	cgtctccagg	20400
atcatcttga	tgccgatcga	gaccagggcc	tctcggcca	ccaccagtac	gtccgccatg	20460
cctcccccg	gcaatgtagc	cgtacgagat	ttgatagtgc	acaaaaacca	tcgaattact	20520
gctctttcga	atcatacatg	tatttatgca	aatttctggt	caggaaacgg	ggacgatccg	20580
agacgcccgg	gccggcgtct	cggatcgtcc	ttcaccgcgc	acggctatcg	cacgagccct	20640
tccgcggggg	cgatccgcgt	ggctcgcgca	gccggcgcca	ggctggccag	cacaccgggtg	20700
accgcggcgg	ccaccagcac	gagaccacgc	tgcggccacg	ccagcatgat	caccggttcg	20760
gcctgcgggc	ccacggccgc	gatcacgccc	accagcccga	ccggcacccc	gatgacgatg	20820
ccggccaccg	tgccgaccag	cgtgatcgtg	accgcctcga	cggcgacccat	cgcgcgcagc	20880
cggtccggc	gggtgcccag	cgcccgcagc	aggccatct	cccgggttcg	ttcgatcacc	20940
gagaggccga	gcaggttggc	gatgccgagc	agcgcgatca	ccacgggtgac	cgccagcatg	21000
cccagcgaca	gtccgagcag	gatggacagg	acgttcatga	tgtcgcggcc	ctcggtgaca	21060
ccgcgcgcca	cctccacacc	ggcgtcgcgt	gccgccaccg	cgttgacgtc	ggcggccagc	21120
gtctcccgg	cgaagccgcc	cggcgcgggtg	cccagaccg	tggtcggcac	ggtccggacc	21180
ccggcggcgg	tcaggacgtc	accggtgggtg	acgcgagca	gctgcccgg	cgtgtcggcc	21240
agccgcgagc	cccgggcgg	gaaccgcagg	tcccgcggc	cgcccggtgac	cgtgagcgga	21300
gcaccgtccg	tcagcccgcg	cgccgtcagg	taggaggccg	gcaccagcag	caccgggtcc	21360

-continued

---

ccggtggacg	cgctcagctc	cggcgcgagg	cgcccggcca	cgtcggtggg	gagcgcgcg	21420
atccgggccc	gcgtaggttt	gcccgcggcc	gggaacgtcg	ccgcgctcgt	cgccacggtg	21480
gccgtggtca	gcccggatgat	cccggacagc	gcccggaccg	tgcggctcgtc	gatcgccgcg	21540
ccgtcgggtg	gcacgctgac	cgccaccgga	tagcgcgcct	ccaggtcggc	ctccaccgtg	21600
gcccgcggc	tgcgagggc	cacggccagg	ccggtgatca	gcgcgcccc	gacgaccacg	21660
gccatcgtcg	ccgacgccgt	ccggcgcgcg	ttctgccgga	ggttgctgcc	ggccaggctc	21720
gcccgcacc	cgaaccgttc	caggccgcgc	gcccgcggcg	gcaacagcag	ggcgatgccc	21780
agcggcagcg	cggtcagcag	cccggcggcg	agcagcacc	cgccgaccag	cgcgagcggc	21840
agggaggtgc	cgatcgcggc	gagaccacgc	acgcccacgg	ccaggccgat	caggatcagc	21900
ccggcgacca	ggcggcggcc	gcccgcggacc	tgtgcgggaa	gagcgtccgg	cacctcctgc	21960
agcgcgcgca	ccgggggaaac	ccgggtcgca	cggcgggccc	gcgcccaggc	cgcgacgacc	22020
gtggcgccca	ccccggtgag	cacacacagc	gccagcacga	tccgggtgac	cgccaggccc	22080
ccgccgttga	tgtcgagcag	gcccggcccc	agatagccga	gcccgacacc	ggcgaccgcg	22140
ccgatcaccg	cgccgatgct	cccggcgatc	gcccgcctccg	ccagcaccac	ccggctcacc	22200
tggcggcgg	gcccgcggac	cagccgcagc	aacgcgacct	ggcggacccg	ctgggagacg	22260
atcacctgga	aggtgttcgc	gatgaccagg	atcgacgcga	gcagcgccac	cgcgggcgaac	22320
gccagcatca	gcacgaccag	ctgggtgttg	ccaccggcga	accggccggc	ggcgcgctcg	22380
gcggccgccc	acgctcgggt	cgcggtcgcc	cccggcggca	gggcccggcc	gaccgcgctcg	22440
acggtctcgg	ccagccggtc	ccggctccgtg	acggtgagca	gcgcgccggg	cgcgctgtcc	22500
ccggcgaaga	acgacgcggc	ggcgtagaac	cggtagtccg	agccggtcag	cgggcgggaa	22560
ccgagatcgg	ccgagccgac	cacggtcacc	ggcaccgggg	cgcccgctgc	ctgcccgaag	22620
tgcaggtggg	cgccgacccc	gacgcggagg	tccgtgaggg	tccgcccgtc	ggcgacgacc	22680
tgcccgccc	cgctcggcca	ggtgccctcg	tgcacggtga	accagcgcac	cgacgcggtc	22740
gcccggatgc	tctgcacgtt	ggccgagccc	cgccggctcg	cgccgaagac	gctgaccgtc	22800
cgtgcgtact	gcccggctgac	gctccgcacg	ccccgcaccc	cgccggcccgc	ctggtaccac	22860
tgcgggtcgt	gcaccgtgtc	gtcggcgtcg	agcacgatgt	ccgccgtggt	caacggggcc	22920
gcggcggtga	gcccgcagacc	ctcgtccgag	gtgctcgcg	acgtggccgt	ggcggccagg	22980
aagccggtgg	ccagcacgac	cgccggcagc	atcgcgagca	gcccggccggg	gtgcgaccgg	23040
acctcgacc	aggccagcgt	gaagatcatg	acgtcaccgt	caccgacgcc	atgaccgaca	23100
tgatcgactc	cagtgtgggc	gctcggagct	cgcccagag	ccgcccgtcg	gccatgatca	23160
agaccgatc	ggcgtacgtc	gcggcggcag	cgatcagcgt	caccatgatg	atcgtctggc	23220
tggcctgcc	ggcggcgttc	tgcagcccgg	cgagcagcgc	ccggccgggtg	gcgatgtcca	23280
gcgcgccgg	cggctcgtcg	gcgaacacca	ccgacggctc	ggtgagcagc	gcgctgcca	23340
ccgcgacccg	ctgctgctgg	ccaccggaca	gctcggcggg	ccgatggccc	agccggctcg	23400
cgatctgcag	cgacgcggcg	atgcgctgca	gcccggctcg	gtccaccgga	cgccgggcca	23460
gcccagcgg	cagcacgatg	ttctgctcgg	cggtcagcgt	gggcagcagg	ttgaacgcct	23520
ggaagatgaa	gcccgacccg	tcccggcgca	ggtcgggtgag	cgcgcggtcg	tccagcccgg	23580
cgagcgcgg	gcccggcagg	ctgacctcgc	cctcggctcg	tgtgtccagc	ccggcgagca	23640
ggtgcatcag	cgtggtcttg	ccggagcccg	aggggcccac	gatcgcggtg	aactcgcccg	23700
ccgcgaagga	ggtcgacacc	ccgtcgacgg	cgaccaccgc	ggcgtccccg	gttccgtacc	23760

-continued

---

gtttacgcag	ggtgcggcaa	ctgaccatgg	agctgctctt	cgtctgcatc	atcacggttg	23820
cgacgttagg	gaagtggcgg	gccgcccaca	tccgtccggg	gcatcgccgc	gaccgatacc	23880
aaggtatcga	cctggcgtgc	ggatggtgcc	gcgagcgtc	gcggtcccta	ctctgagagc	23940
gtgggaagct	gggacaggag	aacgctgacg	gtcgatacgg	tgatcgccgg	cgccgcggtc	24000
atggtgtgcc	tgctgctcgg	gttggccggg	ctggacgagt	ggtactggtc	ggccgcgctc	24060
tgctgcccc	tggtgatccg	gcgctcggct	ccggtggtct	tccctcgctc	ggtcgcggtg	24120
ctctccggca	tccacatgat	ctactccggc	agcttcgctg	tccccggtga	cctggtcgat	24180
ctggtcgccg	tgacgcccgt	cgccggttac	ggccccggcc	gggtccggca	cctgggcctg	24240
ctgctcggcg	tggccggcag	cctggtggtg	accgcccggg	cgctgcacga	cgggctgccc	24300
tcgtccgcga	cgctgcccgc	cgcgctgatc	gtcgccgcga	ccctggccgc	ctggtcgacc	24360
ggcctgatgc	aacgccggca	gcgggccgac	gtgatcgagg	ccgatcaccg	ccgcccggctc	24420
gccgagcagg	acagcgcgat	gcgtgcccgg	ctcgccgcga	tcgaggagcg	caccgcatc	24480
agtcaggaga	tgacgacat	catcgcccac	tcgctggcct	cggtgatcgc	ccaggccgag	24540
ggcggccggg	tcgcccgcgc	cgccgacgcg	gtcgtcgccg	gcccgtgtt	cgaccgcatc	24600
gcgcagatcg	gccgggaggc	cctcaacgac	gtgaagcggc	tgctgaactc	gatcgacggc	24660
gacacgccgg	acgacttcgc	gcagggcctg	cccgacctgc	cgggcctgct	ggccggggctc	24720
tccgcccgcg	gcctcgacgt	gacgttcgag	gtggccggcc	cggagcagcc	gctcgcgctc	24780
ggcatggacc	tggcgggtga	ccgggtgatc	caggagtca	tgaccaacgt	gctcaaacac	24840
gccacgcagc	ggcaggcccg	gctcagcctg	gtgtggacgc	cggcgtggct	cgaggtcagc	24900
gtgaccagcc	cgctgacctt	cgccggcgcg	ctccgcgagg	gtcgcgggct	gtccggcatc	24960
cggcagcggg	gctcgttgtt	caacggcgac	tgcgagatcg	tggccgggca	gaccttcagc	25020
gtgatcacc	gctggccgct	cgcccgtccg	gaggttgccg	tcccatgacc	gagccgcaga	25080
tcgacgtggt	gatcgccgac	gatcaggacc	tcgtccggac	gggcttcgcc	ctggtcgctc	25140
actcgcccc	ggacatgcgg	gtggtcgcg	ccgcggcgga	cgccgcccag	gtggtgcggc	25200
tggccgcgga	gttccgcccc	gacgtggtgc	tgatggacat	ccggatgccc	cggtcgacg	25260
gcatcaccgc	ggcccggcgc	atcctggagg	gcaacgctca	gccgcccgaag	atcgtcgcg	25320
tgaccaccta	cgacaacgat	gagtacgcca	gccggatcct	ggccgcccgc	gccagtgggt	25380
acctgttgaa	ggacaccacc	gccgagggcc	tgaccgcggc	gatccggacg	gtgcaccgcg	25440
gcggctcggt	gctggccccg	tccaccaccc	accgctggt	gaccgcgcac	cgtcagcatc	25500
cggcacgccc	gtccgcgctg	ctggattcct	tcaccacccg	ggagcgcgag	gtcttcgacc	25560
tgatcgtggc	cgccgcccagc	aacgcggaga	tcgcccagcc	cctgaacctg	gcggaggtca	25620
cgatcaagac	ccacgtcggc	cgggtgctgg	ccaagatcgg	cgtccgcgac	cggtgaacg	25680
tcgtgatctg	ggcctaccgg	aacggcgccg	ggccgagctg	agcaggggcc	aggccgcgct	25740
cgactcggc	cgaatcccga	aaagcggcta	ggggaagcgg	atctcggcgg	ccagcggcag	25800
gtggtcactg	ccggtccggg	ggagggccgt	cagccgcgtg	accgtcatcg	atcgcccgag	25860
cacctggtcg	atccgggcca	ccggcgtccg	cgccggccag	gtgaacgcga	agtccgcggg	25920
cgaatcgatc	atcacttgc	ggatcgcccg	cagcccggcg	tcgtccaccg	acgtgttcag	25980
gtccccgatc	acgaccagcc	gcggaaccgg	gtcgccggcg	agcagcgcgc	cgagcttccg	26040
ggcgtctcg	tcccgcgctg	ccgaggtgag	tcccgcgcg	gtgaccgca	ccgacggcag	26100

-continued

---

atgcgcgacg	tacaccgcgg	tgtccccgcc	cggcgtccgg	gccaccgccc	gcagcccccg	26160
gttccagtcc	tcgcccaggt	catgcggccg	gatgtcgatc	gcctccgcgc	cggtcagcgg	26220
atagcgcgac	cacagcgcca	cggtcccctg	cacgggtgtg	aacggaagct	ccgcgtcgag	26280
cacaccccgg	taggcggcca	ccgcctccgg	cagcacctcc	tccagcccga	ccaggtccgg	26340
atgtgccgcg	agcagcgccc	gggcggtccc	cgccgggtcc	gggttctcgt	cgctcacggt	26400
gtgctgcacg	acgatcagat	ccggcgtgcc	ggtgtcccgg	tcgaccacgt	agccgcccga	26460
atggatcagc	cacgcgccc	gcggcagcag	caccgcggcg	aggccgggtca	gcgatcgccg	26520
catcagcgcc	agcaggagca	ggaccggcac	ggccagcccg	aaccacggca	aaaacgcctc	26580
gatcaggctg	cccgcgttgc	cgaccgcggt	ggggaccaga	cggtgaccga	gaatgaccgc	26640
cccggccaga	acagcgggtc	acaagatcgg	catcgggaga	tgttatctta	tttcgcatgc	26700
gaaataatga	gacggtagcg	atcccggtag	cgaccggcgg	cgccgtcacg	gccacgctgt	26760
tcgcgcccga	gtccgcgcgt	gcccgtgctg	tcgtgcaccc	ggcgaccgcg	actccgcagg	26820
gcttctacgc	gtcgttcgcc	acctacctgg	cgagaacgg	gatcgccacg	gtcacctacg	26880
actaccgtgg	caccggccgt	tccggctccc	cgcgcgacca	ccgtgacctg	ggcatgcgcg	26940
actggatcgg	cgccgacgcc	ccggccgctg	cggcgtgggc	cgccgaccgc	ttcccgggcc	27000
tgcccgggct	cgccgcccgt	cacagcctcg	gcgggcacgt	gategcgctc	ggcgcgggccg	27060
gcccggatct	ggccgcctcg	gtgatcgtcg	cctcgcacat	cgccgcgctg	cgccacctcc	27120
cgagccggct	ggagcgggtc	cgcggtcgaa	tcatgcttca	catcctgggt	ccggccctcg	27180
ggcggtgct	gggctacgtg	ccggccagaa	gtctgggctc	cggcgaggac	ctgccggccg	27240
ccgcgatggt	ggagtggggc	ggctggggcg	gcagggacaa	ctacttcttc	gacgaccctg	27300
cgatgcgcgc	cgccgagcgc	gcccgcaccc	tgaccggccc	ggtcctggcc	gtcggcacca	27360
cggaagaccc	gtggtccacg	ccgcgccaga	tggacgcctc	caccgtgcac	ctgaccagcg	27420
catccgtgga	gcggcgaacc	tactcaccgg	ccgccgcggg	ggtcccgggt	atcgggcacc	27480
acggcctggt	ccggcgcgcc	gtgcgcgaca	ccgtctggcc	ggaactgctg	gcctgggtgc	27540
acgcccactc	ggagaaggcg	tcaagatgac	cgcggtcgcc	tgctcgcctc	gatcttctctg	27600
ctcttcaacg	ccgaccgcgc	ggtccggcgc	tggatcgacg	cccgttccgg	tgacaccggg	27660
atcggcgcggt	ccggcgcccg	cgtgctgttc	tacctcgccg	gtcacgagaa	cgccctcatc	27720
ggcgacgtga	ccgcggccct	gggtgctgca	ccatccggca	tgagcggcct	ggtgaaccgc	27780
ctggagcgtg	gcggttgccct	gaccgcctcg	caggaccggg	ccgacgcccg	cgcggtgctg	27840
ctgcacctga	ccccgcgcgg	acaccaggtg	gtgatccacg	cccgcgggct	ggtcgacgac	27900
ctgaacgagc	agctcacggc	cggtttcgac	gacgccgaga	tagcggctctg	ccaacgctgg	27960
ctggagcagc	tgaccggggt	gtccgtgcaa	cgtgaggagc	gactcgggta	gcgtccgggtg	28020
atcagctaaa	cctccgggac	gggcccgcga	agtgaggtgt	cgcaaggcac	caccgcttcc	28080
gatccgcccct	tgaggagacc	catggctgac	tccgtcgtct	tcgaccagat	ccccgtcgtc	28140
cgcgccatcg	gcccaggcac	cacctcgctg	agcgccttcc	acgacgcgct	ggtgaccatg	28200
gagtgcgggtt	tctacaacct	tgtccggctc	tccagcgtca	tcccgcgggg	caccgcccgtc	28260
gaccccagcg	gcaaggctcc	ggtcccggtc	ggggcgtggg	gcgacaagct	gtactgcgtc	28320
tacgcccagc	agcacgccag	ccagccgggc	gaggaggcgt	gggcccggcat	cggtggggtg	28380
cagcgcgcgc	acggccaggg	cggcctgttc	gtcgagcacg	agggcaccag	cgagtcgttc	28440
gtccgcgagg	cgatcaaggc	cagcctccgc	gacctggtca	agggccacga	ggacgacttc	28500



-continued

---

gacggcccgg	acttcgtcgt	ccacggcgtg	gtctccgacg	gcgagccggt	ctgcgcgatg	28560
gtgctcgccc	cctacgagac	cgccccgtgg	cgcgccgtcc	gtgccaccga	cccggcccggc	28620
atgaactgac	ctgtcaccac	gagagcctcg	cctcgcacgt	cggggcgagg	ctttcggcat	28680
tcgcttttca	cttcgacaac	cccctccgta	ccgaagaaat	cgaagatcaa	attcttcatt	28740
gcctatctcc	gctgtggtcc	agatcgtegc	tcccgcgggg	acccttccgg	tctgagcagg	28800
gccgtaaccg	gcccagaacg	ctcagcccga	aagggcgacc	tccgtggcgg	ggcacggcca	28860
gggcaaaatt	ccgtcgccgg	tcgccaggga	ttcgccgcgg	gttgctgcgg	gtgggggtgcg	28920
gcggtccgcc	ggaggtatgg	gttgccgcta	cgctcggcta	gctttcgacc	accggtaacg	28980
tgtaattccc	cttcggtcca	cctacgcccc	ttgtgatctc	cttatggtgg	gctcgcttat	29040
cctcgtoctg	tgcactctgg	ccgcatcggc	cgcatgttc	ttccggctgt	cctctccggc	29100
ccggacgccc	ggcaccctg	cctggcgttt	cgccccgac	ctgaccgccc	gtttcgcgat	29160
tccgctcgcc	gccgcctacg	gtcggcagga	ctggtccacc	ttcgggtcgc	tgctggctgc	29220
cggcctggcc	gccttcgagg	tccgtctcta	cctgctccgt	cccgtccgcc	tctgatccat	29280
actcggctgt	tgtgacgacc	cggatgcccc	gcctcgagat	cgaatactgc	acacagtgcc	29340
gctggctgct	ccgcgcgcgg	tggtggcgcc	aggagctgct	caccacattc	ccccgcgatc	29400
tcggcgagg	tgccctggtc	cccgggatcg	gcggcgctct	cgaggtccgc	ctcgacggcg	29460
agatcctctg	gaaccgcaag	ccggacggct	tccccgacct	cgcccagctc	aagcgcctgg	29520
tccgcgaccg	ggtcgccccg	ggccgcgacc	tcggcactc	cgaccgcgcc	gccaccgact	29580
cctagcccac	acgtcctcct	ccaccgctcc	ggccgcggga	cgctctctacg	cgtaacaggat	29640
ccggctcgatc	gtctcgcggg	ggagcagcgt	gcgggcccgc	ccaccgcaga	ggcgaccac	29700
cgccggccgc	ccgacataga	catcgccggc	ctggtggtac	gccccggtac	cgacagcgc	29760
caccagatca	ccggccgcca	tgtcaccggc	cagctccgcc	accgccaccg	tcgctcccc	29820
gcagcgaacc	gtgatcgacc	ggcccggcgc	cggcgacgcc	cgcccgatca	gcgctgccgt	29880
gtgcaggccg	gcgagtcctg	ccccgggcag	gcagtcgggg	acgtccccgt	ccagctcgat	29940
cacgcccgtc	ccggcggcca	ccactcgggt	caccgtgatc	ccggcacgac	ccagcagcgc	30000
acgcccgggc	gacacgtgca	cctcgggggg	ctcaatgccg	taccctcgg	aagtgacctg	30060
cgcgaccgcc	cgcaacctgg	cagcgaat	gcccaccggg	agatcggcgg	catggccgcc	30120
gccgaggttg	agcacgggca	ccgtcgtccg	cagtcgcggc	acgaaccgga	tcgctcacg	30180
caggcaactc	tcgtaggtgc	cgaagcgggt	cagccgggtc	ccgagcgagc	agtccagccc	30240
ggccagcacc	agcctccgcg	accgggtcac	ctggcgacg	gcggcgagcg	cgcccgagct	30300
gttcagccgc	accccgtagc	cgcgctgtgc	gctgcccggc	cggaccctca	gcaggacgcg	30360
ctgcccgggc	cgggaccgcg	ccgcgaccac	ttccgcctcg	gaggccgagc	cgatcacgac	30420
ggcggcgccc	caggacagtg	ccgcctccag	atccgccacg	gacttcccgc	tcccgaacag	30480
cgccagcgac	tccgggcgga	tccccgcgtc	gagcgcggc	cgagttcgg	cgcccgagcg	30540
gcagtagcag	cccagcccgt	cccgcgcgat	ccaccgcgcg	gcaccctga	gcaggccgcc	30600
cttggcgctg	cagcacaccg	cgcccggccc	gaacgcgcg	acgtactccg	cgagcgcgact	30660
gtgcacatcg	gtctcgtcga	tcacgtgcac	cggagtgcgg	tgggcccggg	cgatccgggt	30720
caccggcacc	ccgcgacgg	tgaggtcacc	gggtcggtc	cagcgtgcgg	tgagcggcca	30780
gttcgccccg	tcgagcgcg	ggcggagcga	cgcccaggt	gagggcagaa	tctcggacaa	30840

-continued

---

cgatcataccg	cgagcctgct	cgccggccccg	tgcccagaaa	gatccggata	cgccacgttg	30900
acgatcgacg	tgccgttggt	gacgtgtcgc	ctacaggtcg	gggctgtcgg	cgggagccat	30960
gatccgcagc	gcgttcgggt	cgatcgcgat	ccgcatcggc	gtcgtgcccc	gaggctcgcc	31020
gtcgacctcg	acggccaccg	gccgatccgt	ctccagccag	agttcccga	ccgcgatgaa	31080
agggcgttca	tgcagggtac	ggcgatgccc	ggtggcccg	ttccgggccc	tctcgcgag	31140
cagctcccgc	cggctcgccc	cgcccaccgg	ataggcgacc	agcagccggt	cgtcggcgtg	31200
cgcgtcccg	gtgatcggcc	ggccggcgtg	gaaaccgccc	ttcgcgacgt	acacctgatg	31260
ggtgtggaac	cgcagctccc	gcccctcggc	ccgcatcacc	gcgcggaccg	gcccgtgccc	31320
ggcgagcagc	ccgagcggg	tcatcggata	cgccagccgc	cccacggccc	gtttcaaccg	31380
cggcggcgg	ctgatcatca	cctcggcgg	gagcccgatc	ccgacgtggt	tggtgaacgg	31440
cacgtccccg	gagacgccc	ggtccacgtc	gatgactttg	ccgtccacca	gggtcgcgat	31500
ggcggcttcg	aggtccggct	cgatccgcac	ggtccgggg	aagttggtg	tggtgcccag	31560
cggcagcacc	ccgagcggc	cgtcccgggt	tgccagcacc	cgccccggg	tgetgatcgt	31620
cccgtccccg	cccccgggc	tcagcaggtc	gggtctttc	ctgagcgtt	cgagatcag	31680
cccgtccagc	ccgcccggc	gctccagcgc	atacgtccc	agcagctcga	accggcctc	31740
gacaagccgc	cgccgcgct	cttcgtagag	gagccgccc	cgccgggacc	gcgtggtgac	31800
aacaagaacc	gcccggcgg	ctcggcggat	gtcagcactg	tgtcccgtt	tactacgcac	31860
ccgcccagcc	tatccgccc	aaccaccca	acgcccacgc	ctcgttccc	cccggcccgt	31920
cccagaccgt	gatcaccagc	cgcaaggcct	cagctggcgt	tgacggctga	tttcggccc	31980
gttttgccg	gtaggcgcca	gcccgcaggt	gtcggctggc	gttcagggt	ggattcggct	32040
cggttttgag	ccgtgggtgc	cagctggggg	ctcggccgg	aagggggtg	atgtggggat	32100
gccccggggc	cgtaggcctc	ggggcaccga	aaaagcgaac	cagctcagct	gttggcgatg	32160
aacgcccgat	gagacagcag	gaacgtgtcg	atctggtcct	tcttgatcga	cttcagcagg	32220
tccatgctgt	cgtcgtcag	gagctcgacg	ctcgggagc	ccggcacgtt	ctccgagttc	32280
agcttgccgg	cgttggtcct	gatggtgagg	agcttgccg	gcttgaggct	gcgcatcgg	32340
agcggccagt	cggccaggtc	gatgccaccg	tcgtcgaccg	tcacgcctt	gcccgaacgc	32400
ctgagcagct	tggcagcct	ggtcggcgag	tcgaggcgt	ccttcagcgc	ctggttgatg	32460
atcgccttga	agaactgctg	ctggtgccgc	tgccgaccgt	agtcgagcga	gttgtcggcg	32520
agcaggtcac	gctggcggac	gaagtcgagc	gcctggccgg	gggtgaagca	gtggtcggcc	32580
ttggtgtacg	tgttcggcgt	cacgcccag	atcttgcct	tcagcgtgcc	gtccgggtt	32640
atcacgaacg	gcttggcgg	cttgccgttc	tggtccttgc	ccaggtggat	cgacttggtc	32700
gtggtgtcca	cgtacatgca	gaccttgccg	agcacgttca	ccacgtcgcg	gaagccctgg	32760
aagtcgatga	tcgccccggc	gtccggcgtg	atgccggtea	gttccttgac	ggtcattggtg	32820
agcaactcga	agcgtgctg	cagcgcctcg	ttgcccttga	gcccgggggt	gcccgaacgc	32880
aacgcccgt	tgatcttcgt	cttgccggc	gcccacttct	gcttcccgt	gtcgtacgcc	32940
gggatgtaga	cgtagctgtc	ccgggggagc	gagatcatgt	aaccgctgct	gtggtccttg	33000
ttgatgtgca	gcaggatgat	cgagtccgac	cggaggggct	cgccgttgg	ctcgtgggg	33060
cgtggctcga	tgcgacgag	caggagattc	ttcggcccgt	cgaggttcgc	gttcttcttc	33120
tcctcggcgg	gtttcggcga	gcccagcagc	gactcctgcc	cgaccgagga	ggtggcccg	33180
gccaccgtcg	cgttcagccc	gatcgcgcca	ccgcccaccg	cgaccagcag	cagtgcgccc	33240

-continued

---

aagaccacgg	tccagaaagc	ccagcgggggt	gtgcggcgtc	ggcgcttgct	ggtcctacgc	33300
aaggggtctc	ctctaatecg	ggcggtcggt	ccgccccagg	acaatctagg	acggtcgttc	33360
cacccatgaa	gacgggcgcc	gcgagcgaaa	agattgcctg	cggaacattg	aattttcctg	33420
agcgtcaggt	agctacaagc	tgaacgtcgc	gctcgtgccc	cgtggcgctc	cggaacgttg	33480
cttcctggt	actccccaac	gcgacgtctg	gtgtaacca	tcgcaccacc	aaggcgacct	33540
aggttctgca	cggccccggg	ccccgaggt	tccgacaaa	ttgccccaa	cgagtcgcca	33600
tgcctcaga	gccggatgtc	agtgtcgtca	ttccgacgtg	taaccggccg	gagttggccg	33660
tccgcgcgg	gcgacgcgcc	ctcgggcaga	cgcaccgga	cctcgaggtg	atcgtcgtcg	33720
tcgacggtec	cgacgaggcg	accgtgacgg	cgctgggcga	ggtcggtgac	ccgcgactca	33780
gctgatcgt	gctgccggag	cgtggcaagg	ccccgaacgc	gcggaacact	ggcgcccggg	33840
ccgcccggg	ccgctggacg	gcgatgctcg	acgacgacga	cgagtggctg	cccaccaaga	33900
tcgaacggca	gctggagacg	gccgcggcgg	cgaccgtgga	gcgcccggtg	gtggcctgcc	33960
ggatgatcag	ccggacgcgc	cgggcccaca	cgatcatgcc	gcgcccggctg	cccagaccgg	34020
gtgagccgat	cagtgaatac	ctgctggctc	gccgcggctc	gttctacggc	gacggcttcg	34080
tgcagacgtc	ctgcatcatg	gcccgcaccg	agctgtggcg	gaaggtgccg	ttcacctcg	34140
gcctgcgccg	cgcgcaggag	ctggactgga	cgctgcgggc	gatgcgcgag	ccgggcaccg	34200
cgctgatcta	cgccgaggag	ccgctggctc	tctggcacca	ggacgagaac	cgtagaccgga	34260
tcagcctgca	gaaccctggg	cgcgagcaac	tggagtggct	gcgcccgaac	cgggagctgt	34320
tcacgcgcgc	tgcctacgcc	gcgttcacgc	tgagtgtgct	gagctcgatg	gccgcgccga	34380
cccgggacac	cgggctcttc	cgtgagctgc	tcgcccaggc	ccgcacgcac	ggcgaccggg	34440
gcaccgtcga	ctaccttacg	cacatgcaga	tctgggacct	cccgccgagc	gtccggcacc	34500
gcctgcgtga	cgtegtggtg	ggccgcggca	agacgagcag	caatgccggc	tgagcgcggg	34560
gtcgcgatct	ggcgcagttc	gatgctgccc	ggctccgaga	cgttcgtccg	caatcaggcc	34620
gacgcgctga	cccgtggac	cccggcctat	gtcggcgccg	tccggcacga	gtcggtgctg	34680
tcccgcgccg	acgacgtgat	cgccttcccg	ggcggcaagg	ggttcctgcg	actgcggctg	34740
accggggcgt	ctcccagct	gcagaagacg	atttccgcgc	tacggccgaa	tctggttcat	34800
gccatttcg	gtggtgacgg	atggctggtg	agccactccg	cccagcagct	gggggtgccg	34860
ctggccgtca	ccgtgcacgg	gcacgacgtg	accctcagc	cgccagccc	ggcgcggaag	34920
ggcgtgcgct	accgccgcaa	cctgcagacc	gttttcacgc	ggcgctcgct	ggtcacgcgc	34980
gtctcggagg	tgatccgcgc	ccaggcgatc	aggtggggcg	ccgaccggc	gaaggtgaag	35040
gtgcaactaca	ccggcatcgc	ggttcccccg	gagcagcccg	aggaggtgcc	gaagcgggtg	35100
gacgtggtgt	tcatcgcccg	ttcgtcgc	aagaagggcg	tcgacgacct	gctcaccgcg	35160
ctcgcgcgg	tcgagtcgcg	cccgcgcgcg	ctgctcatcg	gcgacggcga	gctgatgacg	35220
gcgatgcgtg	cccgtgccga	gcagctgggc	gtggacgtca	cgttcgcggg	cagccggacc	35280
cccgagcagg	tcgggcgcca	cctgctggag	tcgcgctgc	tggcctgccc	gtcgaagacc	35340
gcgccggacg	gggacaccga	gggctgccc	accacgatcc	tggaggcggc	cgcgctcggc	35400
ctgccgggtg	tcgcaacccg	gcacagcggc	atcccggagg	ccgtgatcga	cggtgagacc	35460
ggcctgctca	gcccggaggc	ggaccggcg	gcgctggcgg	tgtegctgac	ccggtgctc	35520
ggtgacgagg	atctccagcg	ccggctcgg	gcgcccggc	ggcggcacgt	cacggcacac	35580

-continued

---

ttcgatctcg	tggagcagac	cagggcggctg	gaggacctgt	atgacgaggt	cgtggcggggc	35640
gctaggggtct	aggcctgcct	gtccggcttc	ctgggggaaa	tcatgatctg	cacgcactgc	35700
ggctcaccgg	cggcgccgac	cgtcggccccg	tgccccgggt	gcggcctcc	ggtctccgcc	35760
ccggccgggg	tgttcccga	cccgtggcc	gcgcccccg	agcggtcgct	ccccacgtcg	35820
gcgtacagcg	tgccggtcga	tccgtacacc	ggccccacca	ccggtgacct	gttcgcccgc	35880
gactcgttcc	acaccccgcc	gcccggctcc	ccgatgccc	cgccggtgac	cgagccgatc	35940
acgcccagcg	cgcccccgcc	ggcctacgcc	ccgccccgc	agtacagccc	gcccgcgtat	36000
gcgggggcgc	ccggtcagcc	ctatccgggt	cagccttacc	caggtcagcc	ctaccggga	36060
cagccctacc	ccgggcagca	gccgtatccc	ggccagcagc	cctacccgg	atacggccag	36120
tccaacagcc	aggccctgac	catcgtcgcc	tacgtcctcg	gcggcttcgg	tctcctgacc	36180
atgacccccg	tcatcggcgt	cgtcggcctg	gtcctggcga	acttcgcgaa	gcgcccgtac	36240
gagcgcaatg	cctcgatcgc	ggtcaagatc	gtcgcggcc	tggtgatcgc	cgctttggtg	36300
ctgagcatcg	tggaccgat	cgtttaaggc	ctgcccctgc	gatcactcag	ggcggcgact	36360
tctggggcgc	gggggtgctc	ccctcgccgg	aaaggatgtc	cggttcccgg	gatggtcagt	36420
actgtcggct	catgggcgaa	catttcgatc	ttgtcgtgct	gggcgcccgt	ccgggtggat	36480
atgtcggcgc	gatccgccc	gctcaactgg	gcctgaccac	cgcgatcgtc	gaggacaagt	36540
actggggcgc	cgtctgcctc	aacgtcggct	gcatcccgtc	gaaagcgtg	ctgcgcaacg	36600
cggagctggc	gcacatcttc	caccaccagg	cgagacctt	cggcatcgag	gggaaggcca	36660
ccttcgactt	cgccgtcgcc	caccagcgc	gccgcagcgt	cgccgacggc	cgcgccaagg	36720
gcgtgcactt	cctgatgaag	aagaacggga	tcaccgagat	ccaggggctg	ggcgagttca	36780
ccgacgcgca	cacgctgcgg	gtcggcgacc	ggacggtcac	gttcgacaac	tgcacctgg	36840
cgaccggcgc	gagcaccgg	atgattccc	gcacgagcgt	ctcgaagcgg	gtcgtgacgt	36900
acgaggagca	gatcctcgac	cccgcctgc	cggacagcat	cgtgatcgtc	ggcgcggcg	36960
cgatcggcgt	cgagttcgc	tatgtgctgc	gcaactacgg	cgtcgacgtg	accatcgtgg	37020
agttcctcga	ccggatgctg	ccgctggagg	acgaggaggt	ctccaaggag	ctgctccggc	37080
agtaccgcaa	gctcggcgtc	gacgtgcggg	tcggcaccgg	ggtggagggc	atcagggagg	37140
gcgcccactc	ggtccgctc	accgtctcca	agaacgggaa	gaccgaggtc	ctcagggccg	37200
acaaggatgat	gcaggcgatc	ggcttcaagc	ccaacgtgga	gggctacggg	ctggagacca	37260
ccggcgtcac	ggtgtccgac	cggcgccgg	tcgagatcga	cgacttctgc	cgtaacgaacg	37320
tgccccgcat	ctacgccatc	ggcgacgtca	ccgcgaagct	gatgctggcg	cacgcccggc	37380
aggcgatggg	catcgtggcg	gccgagacga	tcgcccggcg	cgagacgatg	gccctcgact	37440
accggatgat	cccgcgcgcg	actttctgcc	agccgcaggt	cgccagcttc	gggtggaccg	37500
aggcgcaggc	ccgcgagcag	ggcttcgacg	tcaaggtggc	caagttccc	ttcaccgca	37560
acggcaaggc	gcacggcctc	ggcgacgcga	ccgggttcgt	gaagatcctc	agtgacgcga	37620
agtacgggga	gctgctcggc	gcgcacctga	tcgggcccga	cgtgaccgag	ctgctacccg	37680
agctgacctt	ggcccagcag	tgggacctga	ccgtccacga	ggtcgggccc	aacgtgcacg	37740
cgatccgac	gctcggcag	gcggcgaag	aggcgatcca	cgccctggcc	ggccacatga	37800
tcaacttctg	agtccgccc	tcggccgacg	ggtccgccc	tcggccgacg	ggtccgccc	37860
tcggccgacg	ggtccgctgt	ccggccgacg	agtccgccc	ccggctgacg	cccgggggag	37920
tagccggagc	cgccccgacc	gcgctcggc	tagcccgaat	acctacgccc	ggatgacgac	37980

-continued

---

tccgccccgc	cggtcgggaa	cgctgagcct	tgtgaccctg	accgtcgagc	ctccgatcgc	38040
cccggcgccg	cccgcgcgcc	cggggcgatc	cggcgggcgc	aggctgggct	atctggcggt	38100
cgtgctggtc	gcggtggtgg	cgggtggtgac	gctgcgcgac	cggctgccgg	atccggggga	38160
gttctctgac	gcgctgcgag	cggccgactg	gcggtgggcg	gcgctcgcg	tgggggcccg	38220
ggtgctgtcc	cagatcgct	acgccgagca	gcagcgccgg	cttctcgccg	cgttcggagt	38280
gcgctgccc	gcccggcggg	cgatcgcgat	gacgtacgtc	cggtcggcgc	tgagcatggc	38340
gctgccggcc	gggtcggcgg	cctccgcggc	gtacgccttc	caggtctatc	gtcgccacgg	38400
cgccaccgcg	gcgatctccg	cgacggcgac	cctgatctcg	acggctctga	ccgtgatgtc	38460
gctgggectg	ctctacgccg	cgacctggtc	gctgaccgcc	accgtcgtgg	ccggcctggc	38520
cgttctcctg	ctgtggatct	accggaccgt	gcggggcccg	gtccccgcgc	gtgcccggcg	38580
gcccgcgcgt	ctgagggtcg	ccccgatcgc	ccgcctgctc	cagcggcccc	ccgtggccca	38640
ggcgtccgg	ggtgcacggt	ccgtcccggc	ccggacgtgg	ctcacggtga	ccctggccgg	38700
cgtgatcaac	tggctgctgg	acatggcctg	cctgctctc	gcggccgacg	cgctgcacgc	38760
cgggctcggc	tggagccggc	tcgcgctgat	ctacctggcc	gtccaggtgg	tccggcagat	38820
cccgtcacc	cccggcggca	tcggcctgat	cgagaccagc	atgctcgccg	gcctgatcgc	38880
cgcggggccc	ccgcaggtca	ccgccgcccg	gatcgtcctg	atctaccggc	tgatctcggt	38940
ctggctgata	ctgccagcg	ggctggcccgc	ccacctgacc	ctgcgccggg	ggaccgtgcc	39000
gccggtgact	ccgggctgac	cgccggggct	caggcgcggg	cgaactgctg	gaggacggcg	39060
ccgaggccga	gcgtcagggc	cgggcccggc	agtctgaggt	ccagccccta	ccgccggccc	39120
gggttctccc	gatcgaccag	gtcctgccag	agcccggctc	ccggatcgcc	cagccccggc	39180
aggctcgtgc	cggccgcccg	gagcagctcg	gccaggctgt	tctgctggcg	cagccgctgc	39240
tcctcgaaga	tctggctcca	ctgcatcagc	gagatcgacg	cctccagtgt	gtccggcacc	39300
gtctcgtcca	gcacggcag	cggctcgcgc	gcggcccacg	ccgcgagctg	cgccccggtc	39360
accgtgccgg	gatcgtcgtc	gcggctgcgc	gccagcgcgt	acgacagcag	cgccgtggtc	39420
tccaccagca	ggtgctgcac	cgggacgcgc	gccggcgggt	ccagccacca	gtggtccgcc	39480
tcgagcaggg	ccgcggcgtg	ccgggtcgc	gcccgccacc	agccgtcgtc	gcgcgcggcc	39540
agggcgtcgg	tgtaggacca	caggaaggtc	acccttcctg	gcctaccagc	ggcacttgac	39600
acgagtcaat	cacgcgaacg	cgtggcgacg	accgcgatcg	cttcgacgga	gatcagcagc	39660
ccgtgcggga	gaaccacgcc	ggcggggcgc	gaccggggcg	gcggcgggtc	gggcatgtgc	39720
cgcgccagca	cctggttgat	caccgggaag	tcctcgacgt	gcgtgtagaa	gacggtcagc	39780
ttcaccagcc	cgtccagccc	gtccagcccc	gagccggccc	ccgccagcac	cgccccgagg	39840
ttgcacagcg	cctgctcggg	ctgcgcctcg	atgccgtcca	ccggcttccc	ggtcgcgggg	39900
tcgatccccg	gcaccccgga	gcagaacacg	aacccgcccg	cgacgatcgc	ctggctgtag	39960
ggccccagcg	ccgtgggggc	ccgctcactc	gtcacgcgga	tgcgatccat	cgggcgagtc	40020
tcccgcaccg	ggcatcgatg	gtctttcggc	tttatgacac	gggtgggagc	ttgacagccg	40080
tacatcgttt	atcgattatc	aatatatcga	aaaacgataa	gggggtacgt	cgtgaagacc	40140
gactggttga	cggagttcca	ccagggtctg	ctggtcgcgc	cgctgggccc	cggggcccgc	40200
gccgtcctcg	ggaccgtcgg	gctcgtgggtg	caggacgagg	tcgtcgtccc	gggcggcacg	40260
tcggctccgg	cgagcgtggg	cagcgacccc	agcgtcacc	agctcctgct	cgccgtggcg	40320

-continued

---

 gccgccgtgc cgacgtacct gctggcgacc gccatgctgg tgctgctgta ccggttggtc 40380

ggcgccgcgc gtcgcgggga tc 40402

&lt;210&gt; SEQ ID NO 201

&lt;211&gt; LENGTH: 334

&lt;212&gt; TYPE: PRT

<213> ORGANISM: *Actinoplanes liguriae*

&lt;400&gt; SEQUENCE: 201

 Val Arg Leu Arg Ile Gln Arg Arg Leu Ala Asp Glu Leu Gly Pro Thr  
 1 5 10 15

 Leu Tyr Thr Thr Gly Gln Ser Glu Asp Leu Asp Ala Arg Val Arg Asp  
 20 25 30

 Ala Leu His Asp Leu Leu Ala Arg Glu Glu Thr Pro Leu Ser Gly Ala  
 35 40 45

 Asp Arg Ala Arg Ile Thr Arg Glu Val Thr Asp Glu Val Leu Gly His  
 50 55 60

 Gly Pro Ile Glu Ser Leu Leu Arg Asp Pro Ser Val Thr Glu Val Met  
 65 70 75 80

 Val Asn Gly Pro Tyr Ser Val Tyr Val Glu Arg Phe Gly Arg Leu Glu  
 85 90 95

 Lys Val Ala Ala Glu Phe Asp Asp Glu Gln His Leu Arg Arg Ile Ile  
 100 105 110

 Asp Arg Ile Cys Ser Arg Val Gly Arg Arg Val Asp Glu Ala Ser Pro  
 115 120 125

 Thr Val Asp Ala Arg Leu Pro Asp Gly Ser Arg Val Asn Ala Val Val  
 130 135 140

 Pro Pro Ile Ala Leu Asp Gly Ser Thr Leu Thr Ile Arg Lys Phe Ala  
 145 150 155 160

 Ala Val Pro Leu Thr Val Gly Asp Leu Leu Gln Tyr Gly Thr Leu Thr  
 165 170 175

 Arg Gln Ala Ala Glu Phe Leu Asp Ala Cys Val Arg Gly Arg Arg Thr  
 180 185 190

 Ile Leu Val Ser Gly Gly Thr Gly Ser Gly Lys Thr Thr Ile Leu Asn  
 195 200 205

 Val Leu Ser Ser Phe Val Pro Ala Asp Glu Arg Ile Val Thr Ile Glu  
 210 215 220

 Asp Ala Ala Glu Leu Gln Leu Val Gln Asp His Val Val Arg Leu Glu  
 225 230 235 240

 Ser Arg Pro Pro Asn Ser Glu Gly Arg Gly Thr Ile Thr Thr Arg Asp  
 245 250 255

 Leu Val Arg Asn Ala Leu Arg Met Arg Pro Asp Arg Ile Val Val Gly  
 260 265 270

 Glu Val Arg Asp Ala Ala Ala Leu Asp Met Leu Gln Ala Met Asn Thr  
 275 280 285

 Gly His Asp Gly Ser Leu Thr Thr Leu His Ala Asn Thr Pro Arg Asp  
 290 295 300

 Ala Leu Ser Arg Leu Glu Thr Met Val Leu Met Ala Gly Met Asp Leu  
 305 310 315 320

 Pro Ile Arg Ala Ile Arg Asp Gln Ile Ser Ser Ala Val Asp  
 325 330

&lt;210&gt; SEQ ID NO 202

&lt;211&gt; LENGTH: 358

&lt;212&gt; TYPE: PRT

-continued

&lt;213&gt; ORGANISM: Actinoplanes liguriae

&lt;400&gt; SEQUENCE: 202

```

Met Ser Glu Leu Glu Ser Tyr Leu Pro Arg Tyr Pro Glu Thr Leu Leu
 1          5          10          15
Val Val Ile Gly Ala Val Val Asp Leu Asp Glu Ala Leu Met Phe Thr
      20          25          30
Ala Tyr Gln Arg Leu Gln Arg Pro Val Ile Gly Val Val Leu Ile Arg
      35          40          45
His Ala Ile Glu Ala Gly Val Val Leu Arg Cys Leu Gln Ser Gly Ile
      50          55          60
Arg Asp Leu Val Ala Glu Glu Asp Glu Glu Gly Ile Arg Ser Ala Thr
65          70          75          80
Val Arg Ser Val Asp Leu Ser Lys Ala Leu Ser Thr Thr Met Arg Gly
      85          90          95
Thr Gly Asp Asn Ala Pro Tyr Ala Ser Val Val Thr Val Phe Ala Gly
      100          105          110
Lys Gly Gly Cys Gly Arg Ser Val Val Ala Val Asn Leu Ala Val Ala
      115          120          125
Leu Ala Gly Ala Gly Arg Arg Val Leu Leu Met Asp Leu Asp Leu Gln
130          135          140
Phe Gly Asp Val Ala Ile Met Met Lys Leu Ser Pro Glu Arg Asn Ile
145          150          155          160
Ala Gly Gly Leu Gln Met Ala Gly Arg Leu Asp Glu Pro Gly Leu Arg
      165          170          175
Ser Ile Val Thr Thr Tyr Arg Gln Ser Leu Asp Ala Leu Leu Ala Pro
      180          185          190
Ala Ser Pro Ala Glu Gly Glu Gln Val Arg Arg Glu Phe Val Val Glu
195          200          205
Leu Leu Asp Val Ala Arg Pro Leu Tyr Asp Phe Ile Val Val Asp Thr
210          215          220
Pro Ser Val Val Thr Asp Gln Val Leu Ala Ala Leu Asp Met Ser Asp
225          230          235          240
Trp Phe Ile Pro Ile Val Thr Pro Asp Leu Pro Ala Leu Lys Ser Val
      245          250          255
Arg Leu Thr Ala Glu Met Phe Asp Leu Leu Asp Tyr Pro Lys Asp Lys
      260          265          270
Arg Leu Leu Val Phe Asn Arg Ala Gly Ala Gln Val Gly Leu Ser Pro
      275          280          285
Ser Glu Val Glu Val Ala Ala Gly Met Pro Phe Ala Val Gln Val Pro
290          295          300
Ala Ser Arg Asp Val Thr Val Ser Val Asn His Gly Glu Pro Ile Ala
305          310          315          320
Val Thr Asp Pro Leu His Pro Val Ser Arg Ala Ile Arg Glu Leu Gly
      325          330          335
Asp Arg Ile Ala Gly Val Gly Thr Thr Pro Gln Arg Arg Arg Gly Phe
      340          345          350
Leu Gly Arg Leu Phe Pro
      355

```

&lt;210&gt; SEQ ID NO 203

&lt;211&gt; LENGTH: 266

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes liguriae

-continued

&lt;400&gt; SEQUENCE: 203

Met Arg Arg Arg Ile Leu Ile Leu Leu Ala Ala Leu Val Leu Ala Gly  
 1 5 10 15  
 Ile Ser Gly Ala Ala Val Leu Ser Tyr Ala Arg Ser Ala Asp Arg Arg  
 20 25 30  
 Ala Leu Ser Gly Arg Glu Gly Thr Trp Ile Leu Val Ala Gly Gln His  
 35 40 45  
 Ile Pro Ser Gly Thr Ser Gly Ala Glu Ile Arg Ala Arg Gly Leu Thr  
 50 55 60  
 Glu Arg Leu Leu Val Pro Thr Val Thr Val Pro Ala Gly Ala Leu Thr  
 65 70 75 80  
 Thr Trp Asp Ser Ala Leu Asp Pro Leu Arg Leu Gly Gly Asp Leu Gln  
 85 90 95  
 Pro Arg Gln Leu Leu Met Arg Thr Leu Phe Val Pro Ala Ser Pro Ala  
 100 105 110  
 Pro Ser His Thr Gly Arg Ile Pro Val Pro Arg Arg Ser Leu Ala Val  
 115 120 125  
 Ser Val Ala Leu Asn Val Ala Pro Gln Val Ala Gly Asn Ile Thr Pro  
 130 135 140  
 Gly Asp Gln Val Ala Val Tyr Tyr Thr Tyr Gln Ala Lys Val Leu Met  
 145 150 155 160  
 Ala Glu Asp His Glu Thr Ile Pro Met Thr Glu Leu Leu Leu Pro Lys  
 165 170 175  
 Ala Arg Val Ile Thr Ile Gly Glu Ala Glu Pro Gly Gln Ala Pro Val  
 180 185 190  
 Thr Pro Ser Pro Ser Pro Thr Pro Gly Pro Ser Ala Ser Ala Gly Asp  
 195 200 205  
 Ser Thr Ala Ala Val Lys Glu Ile Gln Arg Tyr Val Val Thr Leu Ala  
 210 215 220  
 Val Gly Asp Thr Asp Ala Leu Arg Leu Val His Ala Ala Gln Ser Gly  
 225 230 235 240  
 Ser Leu Tyr Leu Ala Leu Leu Gly Pro Asn Ala Thr Ala Ser Thr Gly  
 245 250 255  
 Pro Ala Ile Asp Thr Ser Trp Val Val Arg  
 260 265

&lt;210&gt; SEQ ID NO 204

&lt;211&gt; LENGTH: 432

&lt;212&gt; TYPE: PRT

<213> ORGANISM: *Actinoplanes liguriae*

&lt;400&gt; SEQUENCE: 204

Met Arg Arg Leu Ile His Ala Leu Phe Pro Pro Arg Gly Glu His Gly  
 1 5 10 15  
 Val Ile Thr Ala Leu Val Ala Val Leu Ala Gly Ala Gly Val Leu Leu  
 20 25 30  
 Gly Met Ala Ala Leu Val Ile Asp Ile Gly Ala Leu Tyr Ala Glu Arg  
 35 40 45  
 Glu Gln Leu Gln Ser Gly Ala Asp Ala Ala Ser Trp Lys Val Ala Gln  
 50 55 60  
 Ala Cys Ala Gly Thr Ala Gly Arg Asp Leu Thr Ser Ala Thr Cys Thr  
 65 70 75 80  
 Val Ala Ala Gln Arg Asp Asn Ala Gln Arg Tyr Ala Asp Arg Asn Ala  
 85 90 95



-continued

---

Lys Asp Leu Val Ser Asp Val Gln Phe Cys Ile Thr Thr Val Ser Ala  
 100 105 110  
 Ala Gly Val Thr Thr Ala Asp Ala Gly Cys Pro Ser Ser Trp Asn Thr  
 115 120 125  
 Pro Val Thr Cys Pro Ala Pro Pro Ser Ala Ser Gly Pro Tyr Arg Tyr  
 130 135 140  
 Val Glu Val Arg Thr Ser Thr Arg Asn Ser Asp Asn Thr Ser Val Val  
 145 150 155 160  
 Pro Pro Leu Phe Gly Arg Gly Leu Ala Gly Ser Ala Tyr His Gly Ala  
 165 170 175  
 Lys Met Gly Ala Cys Gly Arg Val Ala Trp Gly Ala Pro Ala Val Thr  
 180 185 190  
 Asp Val Leu Ala Leu Gly Val Ser Arg Cys Asp Phe Leu Arg Leu Thr  
 195 200 205  
 Gly Asp Tyr Thr Arg Phe Phe Ala Pro Pro Pro Pro Thr Gly Pro Asn  
 210 215 220  
 Pro Gln Thr Gly Val His Pro Leu Leu Gly Leu Ser Asp Pro Thr Ala  
 225 230 235 240  
 Gly Tyr Ile Pro Ile Ser Asp Gly Ile Leu Ala Thr Ser Cys Pro Ala  
 245 250 255  
 Asp Ala Gly Glu Thr Val Ala Gly Tyr Thr Trp Leu Gly Gln Pro Asp  
 260 265 270  
 Gly Pro Pro Ala Leu Pro Gly Leu Leu Pro Val Ser Ala Pro Asp Ala  
 275 280 285  
 Ser Cys Glu Leu Thr Gly Ile Pro Ala Thr Asp Gly Pro Ala Asp Ser  
 290 295 300  
 Trp Val Gly Gly Phe Thr Ile Gly Pro Gly Asn Ala Ser Ala Ala Thr  
 305 310 315 320  
 Ala Cys Leu Asp Arg Leu Asn Val Leu Ile Thr Ser Gly Gln Pro Val  
 325 330 335  
 Leu Val Pro Ile Phe Asp Arg Gln Val Ala Val Ile Gly Thr Leu Pro  
 340 345 350  
 Ser Tyr Tyr Arg Ile Ala Gly Phe Ala Pro Leu Val Leu Thr Gly Tyr  
 355 360 365  
 Glu Ser Pro Val Ser Gly Pro Val Ser Pro Gly Ser Ala Val Pro Ser  
 370 375 380  
 Leu Val Pro Gly Ala Gln Arg Ala Leu Cys Ala Ala Gln Ser Cys Leu  
 385 390 395 400  
 Tyr Gly Tyr Phe Thr Arg Ala Leu Val Thr Asp His Val Pro Thr Arg  
 405 410 415  
 Phe Ala Thr Ser Arg Tyr Tyr Gly Ala Met Val Ile Gly Arg Thr Gly  
 420 425 430

&lt;210&gt; SEQ ID NO 205

&lt;211&gt; LENGTH: 136

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes liguriae

&lt;400&gt; SEQUENCE: 205

Met Trp Lys Ala Thr Glu Arg Gln Gly Pro Val Val Leu Leu Val Glu  
 1 5 10 15  
 Asp Asp Glu Asp Leu Arg Glu Leu Ala Ala Gln Met Leu Glu Met Arg  
 20 25 30  
 Gly Phe Val Val Leu Val Ala Lys Asp Pro Val Ser Ala Ile Met Thr  
 35 40 45

-continued

Cys Arg Val His Ser Gly Ala Ile Asp Val Leu Leu Thr Asp Leu Gly  
 50 55 60  
 Leu Pro Gly Val Ser Gly Gly Glu Leu Ala Arg Ser Ala Ser Glu Val  
 65 70 75 80  
 Arg Pro Gly Met Lys Ile Val Tyr Val Ser Gly Val Pro Glu Glu Ile  
 85 90 95  
 Ala Ile Lys Lys Gly Leu Ile Arg Ala Gly Ser Pro Phe Val Ala Lys  
 100 105 110  
 Pro Tyr Thr Ala Asp Arg Leu Ala Gly Met Leu Arg Thr Val Leu Ala  
 115 120 125  
 Gln Gly Ala Glu Ser Ser Ala Arg  
 130 135

<210> SEQ ID NO 206  
 <211> LENGTH: 363  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes liguriae

<400> SEQUENCE: 206

Met Phe Asn Tyr Val Ser Phe Val Arg Pro Lys Thr Phe Ala Ala Thr  
 1 5 10 15  
 Phe Ala Ala Ala Ala Leu Leu Leu Gly Ser Gly Ala Cys Ala Lys Ser  
 20 25 30  
 Glu Asp Ser Gly Asp Thr Val Ala Ala Gly Pro Ala Pro Ser Ala Ala  
 35 40 45  
 Gln Val Val Gln Ser Ala Ser Ala Gly Ser Ala Thr Cys Ala Leu Asp  
 50 55 60  
 Gln Tyr Gly Ala Ser Lys Leu Asp Leu Lys Thr Ala Ser Val Gly Phe  
 65 70 75 80  
 Ser Gln Ser Glu Lys Glu Ala Asn Pro Phe Arg Ile Ala Glu Thr Lys  
 85 90 95  
 Ser Ile Lys Asp Glu Ala Ala Lys Leu Gly Ile Thr Asn Leu Lys Thr  
 100 105 110  
 Ser Asn Ala Asn Ser Gln Phe Asn Lys Gln Ile Ala Asp Val Glu Gln  
 115 120 125  
 Met Ile Asp Ala Gly Val Gln Leu Leu Val Ile Ala Pro Leu Asn Ser  
 130 135 140  
 Asp Gly Trp Asp Ser Val Phe Ala Lys Ala Thr Ala Lys His Ile Pro  
 145 150 155 160  
 Ile Ile Thr Ile Asp Arg Lys Ile Asn Ala Thr Ala Cys Lys Asp Tyr  
 165 170 175  
 Leu Thr Phe Ile Gly Ser Asp Phe Ala Glu Gln Gly Lys Arg Ala Ala  
 180 185 190  
 Asp Ala Leu Ala Lys Ser Leu Gly Asn Lys Gly Glu Val Ala Ile Leu  
 195 200 205  
 Leu Gly Ala Pro Gly Asn Asn Val Thr Thr Leu Arg Thr Ser Gly Phe  
 210 215 220  
 Lys Asp Glu Ile Ala Lys Val Ala Pro Asp Ile Lys Ile Thr Phe Glu  
 225 230 235 240  
 Gln Thr Gly Asn Phe Ser Arg Glu Asp Gly Gln Lys Val Ala Glu Gln  
 245 250 255  
 Leu Leu Gln Ser Lys Pro Asn Ile Asn Gly Ile Tyr Gly Glu Asn Asp  
 260 265 270  
 Glu Met Ala Leu Gly Ala Ile Thr Ala Leu Lys Gly Ala Gly Lys Lys

-continued

---

275	280	285
Ala Gly Asp Val Lys Ile Val Ser Ile Asp Gly Thr Lys Gly Ala Val		
290	295	300
Gln Gly Ile Val Asp Gly Trp Val Ser Ala Val Ile Glu Ser Asn Pro		
305	310	315
Arg Phe Gly Pro Leu Ala Phe Asp Thr Ala Thr Lys Phe Phe Gly Gly		
	325	330
		335
Glu Pro Val Gly Gln Asp Ile Val Ile Gln Asp Arg Ala Tyr Asp Glu		
	340	345
		350
Ser Asn Ala Lys Thr Asp Ile Gly Ser Ala Tyr		
	355	360
<210> SEQ ID NO 207		
<211> LENGTH: 501		
<212> TYPE: PRT		
<213> ORGANISM: Actinoplanes liguriae		
<400> SEQUENCE: 207		
Met Leu Leu Glu Val Ser Gly Val Ser Lys Thr Phe Pro Gly Val Arg		
1	5	10
Ala Leu Asp Gly Val Ser Phe Thr Leu Asn Pro Gly Glu Val His Ala		
	20	25
		30
Leu Val Gly Glu Asn Gly Ala Gly Lys Ser Thr Leu Ile Lys Val Leu		
	35	40
		45
Thr Gly Val Tyr Gln Pro Asp Ser Gly Glu Leu Arg Tyr Arg Gly Glu		
	50	55
		60
Pro Ala Arg Phe Ala Thr Pro Leu Asp Ala Gln Arg Ala Gly Ile Ser		
65	70	75
		80
Thr Ile Tyr Gln Glu Val Asn Leu Val Pro Leu Met Ser Val Ala His		
	85	90
		95
Asn Leu Phe Leu Gly Arg Glu Pro Arg Asn Arg Phe Gly Leu Leu Asp		
	100	105
		110
Glu Ala Arg Met Val Ala Glu Ala Thr Glu Ile Leu Ala Gly Tyr Gly		
	115	120
		125
Val Arg Thr Asp Val Arg Arg Arg Leu Gly Thr Leu Ala Leu Gly Ala		
	130	135
		140
Gln Gln Met Val Ala Leu Ala Arg Ala Val Met Val Asp Ala Arg Val		
145	150	155
		160
Val Val Met Asp Glu Pro Thr Ser Ser Leu Glu Pro Arg Glu Val Glu		
	165	170
		175
Thr Leu Phe Gly Val Ile Arg Glu Leu His Thr Ala Gly Ile Gly Ile		
	180	185
		190
Val Tyr Val Ser His Arg Leu Asp Glu Leu Tyr Arg Val Cys Asp Ala		
	195	200
		205
Val Thr Ile Leu Arg Asp Gly Lys Leu Val His Thr Gly Arg Met Ala		
	210	215
		220
Asp Leu Asp Arg Arg Thr Leu Val Ser Leu Met Leu Gly Arg Glu Phe		
225	230	235
		240
Gly Ala Asp Phe Thr Ser Phe Ser Glu Ser Pro Gln Ser Thr Pro Glu		
	245	250
		255
Gly Glu Pro Val Leu Arg Val Ser Gly Leu Thr Ser Arg Pro Arg Leu		
	260	265
		270
Asp Asp Ile Ser Phe Asp Val Arg Pro Gly Glu Val Val Gly Leu Gly		
	275	280
		285

-continued

---

Gly Leu Leu Gly Ala Gly Arg Ser Glu Thr Ile Lys Ala Ile Gly Gly  
 290 295 300  
 Ala Tyr Pro Ile Asp Ser Gly Val Ile Glu Val Gly Gly Val Arg Leu  
 305 310 315 320  
 Gly Arg Pro Ser Thr Val Arg Ala Val Arg Ala Gly Val Ala Thr Gln  
 325 330 335  
 Pro Glu Asp Arg Lys Ala Glu Gly Ile Val Pro Gly Leu Ser Ile Arg  
 340 345 350  
 Asp Asn Ile Ala Leu Ala Ile Leu Pro Arg Met Ala Arg Phe Gly Leu  
 355 360 365  
 Val Ser Asp Lys Arg Ile Asp Ser Ile Val Ala Thr Tyr Met Ser Arg  
 370 375 380  
 Leu Arg Ile Lys Ala Ser Gly Pro Asp Gln Ala Val Gly Asp Leu Ser  
 385 390 395 400  
 Gly Gly Asn Gln Gln Lys Val Leu Leu Ala Arg Leu Leu Ala Thr Gly  
 405 410 415  
 Pro Lys Val Leu Leu Leu Asp Glu Pro Thr Arg Gly Ile Asp Val Gly  
 420 425 430  
 Ala Lys Ala Glu Val Gln Ala Leu Ile Asp Glu Leu Ala Lys Glu Gly  
 435 440 445  
 Leu Gly Val Val Leu Val Ser Ser Asp Ala Glu Glu Leu Val Glu Gly  
 450 455 460  
 Ala Asp Arg Val Val Val Leu Arg Asp Gly Ala Val Val Gly Thr Leu  
 465 470 475 480  
 Thr Gly Asp Arg Val Thr Thr Glu Ala Leu Met Ala Thr Ile Ala Glu  
 485 490 495  
 Ala Ala Asp Glu His  
 500

<210> SEQ ID NO 208  
 <211> LENGTH: 319  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes liguriae

<400> SEQUENCE: 208

Met Ser Thr Glu Thr Leu Thr Arg Pro Arg Met Thr Phe Asn Pro Ala  
 1 5 10 15  
 Trp Ala Ala Arg Tyr Gly Val Tyr Ala Ala Ile Val Leu Leu Ile Val  
 20 25 30  
 Val Asn Ile Ala Phe Thr Pro Tyr Phe Leu Thr Leu Ser Asn Leu Arg  
 35 40 45  
 Ile Gln Leu Ile Gln Ala Ala Pro Val Val Ile Val Ala Leu Gly Met  
 50 55 60  
 Ala Leu Val Ile Gly Thr Glu Gly Ile Asp Leu Ser Val Gly Ser Val  
 65 70 75 80  
 Met Ala Leu Ala Ala Ala Phe Ile Pro Leu Tyr Leu Gly Tyr Gly Val  
 85 90 95  
 Thr Ala Ala Ile Leu Val Ser Leu Leu Ala Gly Val Ala Val Gly Leu  
 100 105 110  
 Ile Asn Gly Val Leu Val Ala Lys Ala Gly Leu Gln Pro Ile Val Ala  
 115 120 125  
 Thr Leu Ala Leu Phe Val Gly Gly Arg Gly Leu Ala Val Val Ile Ser  
 130 135 140  
 Gly Gly Gln Leu Lys Asp Val Arg Asn Ala Asp Leu Leu Tyr Leu Gly  
 145 150 155 160

-continued

Ser Gly Asp Leu Leu Gly Val Pro Val Leu Val Trp Ile Ala Ala Leu  
 165 170 175

Leu Val Leu Val Val Ala Phe Val Val Arg Arg Thr Val Phe Gly Arg  
 180 185 190

Arg Leu Leu Ala Val Gly Gly Asn Arg Pro Ala Ala Glu Leu Ala Gly  
 195 200 205

Leu Pro Val Lys Arg Val Leu Ile Gly Val Tyr Val Phe Cys Ala Val  
 210 215 220

Leu Ala Ser Ile Ala Gly Leu Leu Ser Val Ala Arg Ile Gln Ser Ser  
 225 230 235 240

Asp Ala Ser Ala Val Gly Leu Leu Ile Glu Leu Ser Ala Ile Thr Ala  
 245 250 255

Val Val Val Gly Gly Thr Pro Leu Thr Gly Gly Arg Val Arg Val Leu  
 260 265 270

Gly Thr Val Ala Gly Ala Leu Leu Met Gln Leu Val Val Ala Thr Met  
 275 280 285

Ile Lys His Asp Leu Pro Pro Ser Thr Thr Glu Met Val Gln Ala Val  
 290 295 300

Ile Ile Leu Val Ala Val Tyr Val Ala Arg Glu Arg Arg Thr Arg  
 305 310 315

&lt;210&gt; SEQ ID NO 209

&lt;211&gt; LENGTH: 320

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes liguriae

&lt;400&gt; SEQUENCE: 209

Met Ser Ile Pro Val Pro Ala Phe Arg Asn Gly Gly Phe Val Gln Arg  
 1 5 10 15

Gln Gly Ala Leu Ala Val Leu Val Thr Val Val Ala Ile Ser Leu Ala  
 20 25 30

Ala Phe Pro Gly Phe Arg Ser Ala Asp Asn Ala Gly Thr Ile Leu Val  
 35 40 45

Ala Ala Ala Pro Pro Met Leu Ile Ala Leu Gly Met Thr Phe Val Ile  
 50 55 60

Ile Thr Gly Gly Ile Asp Leu Ser Val Gly Ser Leu Tyr Val Leu Gly  
 65 70 75 80

Gly Val Val Ala Ala Trp Ala Ser Gln Trp Gly Val Val Ala Ala Leu  
 85 90 95

Ala Ala Pro Leu Leu Leu Cys Gly Ala Ile Gly Val Leu Asn Gly Ile  
 100 105 110

Leu Ile Ser Arg Thr Gly Met Ala Pro Phe Ile Val Thr Leu Ala Ala  
 115 120 125

Leu Leu Gly Ala Arg Gly Leu Met Arg Ser Ile Ser Asp Glu Gly Ser  
 130 135 140

Thr Thr Tyr Leu Val Arg Ser Asp Val Phe His Glu Leu Gly Thr Gly  
 145 150 155 160

Ser Leu Leu Gly Val Gly Leu Pro Val Trp Leu Ala Ala Val Leu Val  
 165 170 175

Gly Ala Gly Ile Leu Val Leu Asn Arg Thr Arg Phe Gly His Ala Val  
 180 185 190

His Ala Ile Gly Gly Ser Glu Asp Ala Ala Ala Leu Met Gly Leu Pro  
 195 200 205

Val Arg Arg Ile Lys Val Trp Val Tyr Leu Leu Ser Gly Leu Leu Ala

-continued

210	215	220
Gly Leu Ala Gly Ala Ile Asn Ala Ala Lys Leu Gly Ser Gly Val Thr 225	230	235
Val Leu Gly Ser Gly Met Glu Leu Asp Ala Ile Ala Ala Val Val Ile 245	250	255
Gly Gly Thr Leu Leu Thr Gly Gly Ser Gly Ser Ile Ala Gly Thr Val 260	265	270
Ala Gly Val Leu Leu Leu Gly Val Ile Gln Asn Leu Ile Asn Gln Val 275	280	285
Gly Asn Val Asn Ser Asn Trp Gln Gln Val Ile Ser Gly Gly Phe Leu 290	295	300
Ala Ala Val Val Val Ala Gln Thr Thr Leu Val Arg Ala Arg Arg Ser 305	310	315
<210> SEQ ID NO 210		
<211> LENGTH: 486		
<212> TYPE: PRT		
<213> ORGANISM: Actinoplanes liguriae		
<400> SEQUENCE: 210		
Met Arg Thr Ser Ala Gly Thr Arg Val Leu Thr Val Gly Ala Thr Val 1	5	10
Val Leu Ala Leu Ala Ala Ala Ala Ala Pro Ala Gln Ala Gly Pro Ser 20	25	30
Pro Ser Pro Gly Ser Ala Gly Leu Gly Asp Arg Leu Tyr Pro Leu Leu 35	40	45
Gly Asn Gly Gly Tyr Asp Val Leu Asp Tyr Asp Leu Arg Leu Arg Tyr 50	55	60
Pro Glu Lys Asp Pro Lys Gln Val Val Ser Gly Asp Val Thr Ile Thr 65	70	75
Ala Val Ala Gly Gln Ser Leu Ser Arg Phe Asp Leu Asp Phe Gly Gly 85	90	95
Ala Ser Ile Gly Arg Val Ser Val Asp Gly Gln Pro Ala Arg Ala Ala 100	105	110
Arg Asp Gly Asp Glu Leu Thr Val Ile Pro Arg Arg Pro Leu Pro Arg 115	120	125
Gly Arg Leu Phe Arg Val Thr Val Ala Asn Phe Thr Ala Ala Pro Ala 130	135	140
Ala Leu Val Ala Thr Pro Asp Gly Thr Val Leu Ala Ala Gln Pro Gly 145	150	155
Ser Ala His Leu Leu Phe Pro Gly Asn Asp His Pro Arg Asp Lys Ala 165	170	175
Thr Phe Thr Ile Thr Leu Thr Val Pro Ala Gly Trp Thr Gly Thr Ala 180	185	190
Asn Gly Thr Leu Val Ser Thr Thr Glu His Asp Gly His Val Ser Ser 195	200	205
Val Tyr Arg Glu Ser Ala Pro Met Ala Thr Glu Leu Val Gln Thr Ala 210	215	220
Val Gly Asp Phe Val Val Glu Arg Arg Pro Ala Ala Gly Gly Thr Pro 225	230	235
Ile Arg Asp Val Val Pro Arg Arg Leu Ala Gly Thr Leu Leu Pro Ala 245	250	255
Ile Ala Gly Glu Arg Glu Gln Leu Ala Trp Met Glu Lys Gln Ala Gly 260	265	270



-continued

Asp Arg Pro Asp Ala Ser Leu Arg Glu Ile Ala Arg His Ala Gly Val  
 165 170 175  
 Ser Pro Ser Thr Ala Arg Asp Val Arg Asp Arg Leu His Arg Gly Glu  
 180 185 190  
 Asp Pro Ile Pro Ala Thr Gln Arg Ala Ala Ala Arg Pro Gly Asn Asp  
 195 200 205  
 Ser Pro Pro Leu Arg Ser Leu Val Gln Gly Leu Ala Ser Asp Pro Ser  
 210 215 220  
 Leu Arg Phe Ser Glu Ser Gly Arg Asp Leu Leu Arg Trp Leu Ile Ala  
 225 230 235 240  
 His Ala Val Gln Asp Gly Glu Trp Lys Gly Leu Val Asp Thr Ile Pro  
 245 250 255  
 Ala His Ser Ala Gln Ala Leu Ala Lys Ile Ala Arg His Cys Ser Arg  
 260 265 270  
 Glu Trp Arg Glu Phe Ala Asp Ile Leu Glu Lys Asp Ala Ala  
 275 280 285

<210> SEQ ID NO 212  
 <211> LENGTH: 64  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes liguriae

<400> SEQUENCE: 212

Met Ser Ala Ile Thr Val Glu Thr Thr Trp Lys Asn Thr Asp Leu Arg  
 1 5 10 15  
 Glu Asp Leu Thr Ala His Pro Ala Gly Leu Gly Phe Gly Glu Leu Ser  
 20 25 30  
 Phe Glu Asp Leu Arg Glu Asp Arg Thr Ile Tyr Ala Ala Ser Ser Gly  
 35 40 45  
 Trp Val Cys Thr Leu Thr Ile Glu Cys Gly Thr Leu Val Cys Ala Cys  
 50 55 60

<210> SEQ ID NO 213  
 <211> LENGTH: 1046  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes liguriae

<400> SEQUENCE: 213

Met Ser Ser Phe Ala Ile Ala Ala Ser Pro Ala Ser Ala Tyr Leu His  
 1 5 10 15  
 Glu Arg Ser Ala Gly Pro Gly Gly Asp Pro Val Ala Glu His Glu Arg  
 20 25 30  
 Val Glu Ser Trp Arg Glu Ser Ala Phe Leu Asp Asp Pro Val Leu Asp  
 35 40 45  
 Ile Arg Leu Arg Glu Leu Gly Leu Ser Arg Ala Glu Phe Gly Arg Leu  
 50 55 60  
 Leu Thr Asp Gly Ala Tyr Asp Ala Gly Ser Thr Ala Leu Asp Trp Ala  
 65 70 75 80  
 Gly Glu Leu Ala Ala Val Leu Ala Thr Gly Thr Gly Ala Val Thr Gly  
 85 90 95  
 Leu Ala Arg Ser Thr Lys Leu Trp Ala Gln Gly Phe Asp Arg Leu Pro  
 100 105 110  
 Phe Ala Gly Leu Ile Glu Arg Phe Leu Ala Tyr Tyr Glu Pro Arg Val  
 115 120 125  
 Pro Arg Thr Ala Gly Thr Val Arg Val Ser Leu Leu Glu Ser Leu Ala  
 130 135 140



-continued

---

Asn	Arg	Leu	Leu	Thr	Val	Ala	Thr	Arg	Thr	Leu	Leu	Leu	Glu	Leu	Asn	145	150	155	160
Val	Ala	Arg	Val	His	Gly	Arg	Leu	Thr	Gly	Ala	Thr	Pro	Gly	Glu	Arg	165	170	175	
Tyr	Asp	His	Tyr	Asp	Arg	Val	Leu	Leu	Thr	Asp	Pro	Asp	Tyr	Leu	Arg	180	185	190	
Ser	Leu	Phe	Gly	Glu	Tyr	Pro	Val	Leu	Gly	Arg	Ala	Met	Val	Glu	Cys	195	200	205	
Gly	Arg	Arg	Trp	Ala	Ser	Ala	Met	Ala	Glu	Leu	Phe	Gln	Arg	Leu	Asp	210	215	220	
Ala	Asp	Arg	Pro	Ala	Leu	His	Ala	Ala	Gly	Leu	Leu	Pro	Ala	Gly	Ala	225	230	235	240
Gly	Glu	Val	Thr	Ala	Leu	Arg	Pro	Asp	Leu	Gly	Asp	Pro	His	Asn	Ser	245	250	255	
Gly	Arg	Ala	Val	Ala	Ile	Leu	Thr	Phe	Arg	Ser	Gly	Ala	Gln	Leu	Val	260	265	270	
Tyr	Lys	Pro	Arg	Pro	Val	Gly	Pro	Glu	Arg	Ala	Tyr	Ala	Glu	Thr	Ala	275	280	285	
Ala	Ala	Leu	Asn	Arg	His	Gly	Leu	Ser	Leu	Pro	Leu	Thr	Ala	Val	Asp	290	295	300	
Val	Leu	Asp	Arg	Gly	Ala	Tyr	Gly	Trp	Cys	Glu	Leu	Val	Arg	His	Glu	305	310	315	320
Pro	Cys	Ala	Asp	Arg	Ala	Asp	Leu	Asp	Arg	Phe	Tyr	Arg	Arg	Thr	Gly	325	330	335	
Ala	Val	Leu	Ala	Thr	Thr	Leu	Leu	Leu	Gly	Ala	Val	Asp	Val	His	Met	340	345	350	
Glu	Asn	Val	Ile	Ala	Ala	Gly	Ser	Ser	Cys	Met	Pro	Ile	Asp	Leu	Glu	355	360	365	
Thr	Leu	Leu	Gln	Pro	Gly	Val	Pro	Ser	Gly	Asp	Ala	Thr	Asp	Ala	Tyr	370	375	380	
Thr	Arg	Ala	Leu	Asp	Leu	Leu	Asn	Gln	Ser	Val	Leu	Ala	Ile	Gly	Ile	385	390	395	400
Leu	Pro	Ala	Arg	Ala	Phe	Gly	Gly	Arg	Glu	Arg	Lys	Ser	Val	Asp	Val	405	410	415	
Ser	Ala	Ile	Gly	Gly	Gly	Glu	Ala	Gln	Thr	Ala	Pro	Arg	Pro	Val	Pro	420	425	430	
Met	Val	Val	Glu	Pro	Phe	Thr	Asp	Val	Ala	Arg	Ile	Glu	Ala	Val	Glu	435	440	445	
Ala	Thr	Met	Leu	Gly	Ala	Gln	Asn	Arg	Pro	Val	Leu	Val	Gly	Ala	Glu	450	455	460	
Val	Arg	Pro	Glu	Glu	His	Thr	Glu	Ala	Val	Val	Ala	Gly	Phe	Thr	Glu	465	470	475	480
Ala	Tyr	Asp	Leu	Ile	Val	Arg	His	Arg	Glu	Asp	Phe	Ala	Asp	Leu	Leu	485	490	495	
Ala	Gly	Phe	Gly	Asp	Val	Glu	Val	Arg	Tyr	Leu	Pro	Arg	Pro	Thr	Arg	500	505	510	
Arg	Tyr	Ser	Met	Phe	Leu	Thr	Glu	Ser	Tyr	His	Pro	Asp	Tyr	Leu	Arg	515	520	525	
Asp	Ala	Arg	Asp	Arg	Asp	Arg	Leu	Leu	Asp	Lys	Leu	Trp	Thr	Ala	Ala	530	535	540	
Gly	Ala	Arg	Pro	Asp	Leu	Ile	Pro	Ile	Ile	Glu	Ser	Glu	Lys	Arg	Gln	545	550	555	560

-continued

---

Leu Leu Ala Gly Asp Ile Pro Cys Phe Arg Ala Leu Ala Gly Asp Arg  
 565 570 575  
 Ala Ile Arg Thr Ala Ser Ala Pro Val Ala Pro Asp Phe Phe Asp Ala  
 580 585 590  
 Pro Gly Ile Glu Val Leu Ala Gly Arg Leu Arg Gln Phe Gly Pro Val  
 595 600 605  
 His Arg Ala Ala Gln Leu Arg Ile Ile Arg Glu Ser Met Gly Thr Met  
 610 615 620  
 Pro Ala Pro Gly Pro Ile Ala Gly Thr Pro Ala Pro Ser Ser Glu Arg  
 625 630 635 640  
 Arg Gly Gly Leu Asp Pro Arg Glu Ala Ala Thr Leu Gly Asp Arg Leu  
 645 650 655  
 Val Arg Glu Leu Ala Asp Glu Ala Ile Leu Gly Ala Asp Asp Ala Gly  
 660 665 670  
 Trp Ile Gly Val Ser Ile Glu Gly Leu Asp Gln Glu Thr Phe Ser Tyr  
 675 680 685  
 Lys Pro Met Ala Thr Gly Leu Tyr Asp Gly Ile Ala Gly Met Ala Leu  
 690 695 700  
 Thr Tyr Ala Tyr Ala Ala Arg Thr Leu Gly Asp Glu Arg Tyr Leu Asp  
 705 710 715 720  
 Leu Thr Arg Arg Thr Val Lys Leu Val Ser Gly Tyr Leu Arg Tyr Leu  
 725 730 735  
 Ala Glu His Arg Ile Val Glu Thr Val Gly Ala Tyr Ser Gly Met Ala  
 740 745 750  
 Gly Leu Leu Tyr Thr Leu Asp His Val Ala His Ala Thr Gly Asp Ala  
 755 760 765  
 Ser Leu Leu Gly Glu Ile Glu Ala Ala Leu Pro Trp Leu Arg Glu Cys  
 770 775 780  
 Ala Thr Arg Glu Glu Cys Pro Asp Leu Ile Ala Gly Leu Ala Gly Cys  
 785 790 795 800  
 Ala Val Val Ala Leu Ser Leu Tyr Arg Arg His Gly Ile Ala Gly Tyr  
 805 810 815  
 Arg Glu Val Ala Glu Ile Cys Gly Arg Arg Leu Ala Gly Thr Ala Val  
 820 825 830  
 Asp Val Glu Gly Ala Ala Gly Trp Ala Ala Thr Arg Thr Gly Val Ile  
 835 840 845  
 Leu Gly Gly Phe Ser His Gly Ser Ala Gly Ile Ala Trp Ala Leu His  
 850 855 860  
 Glu Leu Ala Ala Glu Phe Gly Asp Arg Asp Leu Arg Glu Leu Ala Asp  
 865 870 875 880  
 Arg Ala Val Glu Phe Asp Arg Arg Leu Tyr Val Pro Ala Ala Gly Ala  
 885 890 895  
 Trp Arg Asp Leu Arg Pro Glu Met Ala Gly Thr Asp Gly Tyr Pro Ala  
 900 905 910  
 Leu Trp Cys His Gly Ala Ala Gly Ile Gly Leu Ser Arg Leu Leu Ile  
 915 920 925  
 His Arg Ile Arg Pro Asp Glu Arg Leu Ala Glu Glu Ala Arg Ala Ala  
 930 935 940  
 Val Ala Leu Val Arg Arg His Gly Phe Gly His Asn His Ser Leu Cys  
 945 950 955 960  
 His Gly Asp Phe Gly Ala Leu Ala Leu Leu Gly Leu Ala Asp Arg Ala  
 965 970 975  
 Trp Pro Gly Ser Gly Gly His Asp Glu Arg Ala Gly Ala Val Val Arg

-continued

---

980	985	990
Asp Ile Gly Glu Thr Gly Leu Arg Cys Gly Leu Gly Asn Gly Ile Arg		
995	1000	1005
Met Pro Gly Leu Met Leu Gly Ala Ala Gly Ala Gly Leu Ser Leu		
1010	1015	1020
Leu Arg Leu Ala Ala Pro Ala Asp Val Pro Ala Val Thr Trp Leu		
1025	1030	1035
Glu Pro Pro Arg Gly Thr His Val		
1040	1045	
 <210> SEQ ID NO 214		
<211> LENGTH: 575		
<212> TYPE: PRT		
<213> ORGANISM: Actinoplanes liguriae		
 <400> SEQUENCE: 214		
Met Ser Glu Thr Ala Gly Leu Leu Arg Arg Ser Leu Leu Asp His Arg		
1	5	10
Gly Lys Leu Ala Ala Val Ala Gly Leu Ala Val Ala Gly Val Gly Cys		
20	25	30
Gln Leu Gly Gln Pro Phe Leu Ile Arg Arg Val Leu Thr Ala Val Gln		
35	40	45
Ser Ala Gln Pro Tyr Arg Gln Leu Ala Leu Ala Val Leu Ala Val Met		
50	55	60
Val Val Gly Ala Ala Leu Gly Ala Val Gln Gln Phe Leu Leu Gln Arg		
65	70	75
Thr Gly Glu Ala Met Val Phe Thr Val Arg Arg Thr Leu Val Ala His		
85	90	95
Leu Leu Arg Leu Pro Val Ala Ala Tyr Asp Glu Arg Gln Ser Gly Asp		
100	105	110
Leu Val Ser Arg Val Gly Ala Asp Thr Ala Gln Val Arg Ser Val Ile		
115	120	125
Thr Ser Gly Val Val Asp Leu Ala Gly Gly Val Leu Leu Val Gly Gly		
130	135	140
Ser Ile Ala Gly Met Ile Ile Ile Asp Pro Val Leu Leu Gly Val Ser		
145	150	155
Leu Ala Pro Val Leu Cys Gly Ala Ala Gly Val Arg Leu Val Gly Arg		
165	170	175
Arg Leu Arg Pro Leu Ser Ser Ala Val Gln Glu Ser Ile Gly Ala Leu		
180	185	190
Thr Ala Ser Thr Thr Arg Ala Leu Gly Ala Ile Arg Thr Ile Arg Val		
195	200	205
Ala Gly Ala Thr Glu Arg Glu Thr Ala Leu Ile Val Ala Glu Ala Asp		
210	215	220
Arg Ala Arg Ala Ala Gly Val Arg Leu Ala Leu Val Ala Ala Gln Ala		
225	230	235
Gly Pro Ile Val Arg Leu Ala Leu Gln Gly Ala Phe Val Ala Val Ile		
245	250	255
Gly Phe Gly Gly Tyr Arg Val Ala Asn Gly Ala Val Ser Val Gly Asp		
260	265	270
Leu Val Ala Phe Thr Leu Leu Leu Phe Thr Leu Ala Leu Pro Leu Ala		
275	280	285
Gln Leu Ala Glu Ala Ala Thr Arg Ile Gln Thr Gly Leu Gly Ala Leu		
290	295	300

-continued

Thr Arg Ile Glu Glu Ile Leu Ala Leu Pro Asp Glu Asp Ser Ala Leu  
 305 310 315 320  
 Gly Val Arg Ala Arg Thr Pro Ala Thr Val Arg His Asp Pro Val Leu  
 325 330 335  
 Leu Glu Phe Asp His Val Ser Phe Arg Tyr Pro Thr Gly Gly Glu Ile  
 340 345 350  
 Leu Arg Asp Val Ser Phe Arg Val Pro Ala Gly Ser Thr Thr Ala Leu  
 355 360 365  
 Val Gly Pro Ser Gly Ala Gly Lys Ser Thr Ile Leu Ala Leu Ile Ala  
 370 375 380  
 Arg Leu Tyr Glu Val His Gly Gly Arg Ile Leu Leu His Gly Arg Asp  
 385 390 395 400  
 Ile Arg Asp Tyr Pro Leu Ala Glu Leu Arg Ala Ala Leu Gly Tyr Val  
 405 410 415  
 Glu Gln Glu Ala Pro Val Leu Ala Gly Thr Val Arg Asp Asn Leu Thr  
 420 425 430  
 Leu Ala Ala Pro Asp Val Ala Glu His Ala Ile Arg His Val Thr Ala  
 435 440 445  
 Ser Val Asn Leu Asp Asp Leu Leu Ala Arg Asp Pro Ala Gly Leu Asp  
 450 455 460  
 Ala Pro Val Gly Asp Gly Gly Val Leu Phe Ser Gly Gly Glu Arg Gln  
 465 470 475 480  
 Arg Leu Ala Val Ala Arg Thr Leu Leu Ala Pro Gly Glu Leu Leu Leu  
 485 490 495  
 Phe Asp Glu Pro Thr Ala His Leu Asp Ala Arg Asn Glu Gln Ala Leu  
 500 505 510  
 Gln His Gly Leu Thr Ala His Ala Ala Gly Arg Thr Leu Val Val Val  
 515 520 525  
 Ala His Arg Leu Ala Thr Val Ala His Ala Asp Gln Ile Leu Val Ile  
 530 535 540  
 Asp Asp Gly Arg Ser Val Ala Ala Gly Arg His Glu Glu Leu Leu Val  
 545 550 555 560  
 Arg Asp Pro Thr Tyr Arg Glu Phe Ala Thr Arg Gln Leu Leu Thr  
 565 570 575

&lt;210&gt; SEQ ID NO 215

&lt;211&gt; LENGTH: 347

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes liguriae

&lt;400&gt; SEQUENCE: 215

Met Leu Ser Val Leu Asp Gln Val Pro Val Phe Arg Gly Asp Asp Pro  
 1 5 10 15  
 Ala Glu Ala Val Arg Glu Ala Val Gly Leu Ala Arg Ala Ala Glu Ser  
 20 25 30  
 Leu Gly Tyr His Arg Phe Trp Ile Ala Glu His His Gly Ser Ala Ala  
 35 40 45  
 Asn Ala Cys Ala Ala Pro Glu Ile Val Ala Ala Ala Val Ala Gly Ala  
 50 55 60  
 Thr Glu Arg Ile Arg Val Gly Thr Gly Gly Val Leu Leu Pro Tyr Tyr  
 65 70 75 80  
 Ser Pro Leu Lys Val Ala Glu Ala Phe Arg Val Leu Ala Ala Leu Tyr  
 85 90 95  
 Pro Gly Arg Ile Asp Leu Gly Phe Gly Arg Gly Arg Gly Gly Pro Ala  
 100 105 110

-continued

Val Met Ala Glu Leu Leu Asn Pro Tyr Ala Ile Ala Thr Glu Glu Ala  
 115 120 125  
 Tyr Ala Glu Gln Val Gly Arg Leu Leu Ala Phe Leu Gly Asp Ala Arg  
 130 135 140  
 Thr Val Ser Arg Val Ser Val Thr Pro Ala Val Gln Asp Pro Pro Leu  
 145 150 155 160  
 Pro Trp Leu Leu Gly Ser Gly Val Gly Ser Ala Arg Leu Ala Gly Met  
 165 170 175  
 Leu Gly Val Pro Phe Cys Phe Ala Gln Phe Ile Ala Thr Glu Glu Cys  
 180 185 190  
 Pro Glu Ala Ile Ala Ala Tyr Gln Glu Ser Phe Arg Ser Ser Pro Trp  
 195 200 205  
 Leu Asp Glu Pro Gln Ala Met Leu Ala Leu Arg Val Leu Ala Ala Gly  
 210 215 220  
 Thr Ala Glu Asp Ala Glu Glu Leu Ala Thr Gly Phe Trp Met Ser Cys  
 225 230 235 240  
 Thr Thr Gly Trp Arg Ala Gln Val Arg Pro Asp Asp Asp Tyr Arg Gly  
 245 250 255  
 Gly Val Pro Asn Leu Ala Asp Ala Gln Arg Tyr Thr Leu Thr Glu Glu  
 260 265 270  
 Asp Leu Ala Met Arg Ala Ser Arg Pro Tyr Leu Gln Ile Ser Gly Thr  
 275 280 285  
 Ala Glu Thr Val Gly Glu Glu Ile Arg Arg Leu Arg Lys Val Tyr Asp  
 290 295 300  
 Val Ala Glu Val Met Leu Thr Thr Asn Cys Pro Gly Ala Ala Ala Pro  
 305 310 315 320  
 Ala Pro Val Leu Arg Ala Ala Gly Arg Arg Ala Arg Ala Asp Arg Ala  
 325 330 335  
 Gly Val Thr Arg Val Arg Pro Ala Arg Arg Trp  
 340 345

<210> SEQ ID NO 216  
 <211> LENGTH: 217  
 <212> TYPE: PRT  
 <213> ORGANISM: *Actinoplanes liguriae*

<400> SEQUENCE: 216

Met Ala Asp Val Leu Val Val Ala Glu Glu Ala Leu Val Ser Ile Gly  
 1 5 10 15  
 Ile Lys Met Ile Leu Glu Thr Met Gly Gly Phe Ser Val Val Ala Ala  
 20 25 30  
 Asp Arg Asp Ser Ala Leu Ala Ala Val Ser Glu His Arg Pro Ala Val  
 35 40 45  
 Val Leu Leu Asp Ala His Ala Thr Leu Pro Glu Ser Val Pro Leu Leu  
 50 55 60  
 Thr Arg Leu Arg Asp Leu Glu Ser Gly Pro Ala Leu Ala Val Leu Ala  
 65 70 75 80  
 Thr Leu Ala Ala Ser Ser Thr Val Leu Glu Ser Leu Arg Gly Gly Ala  
 85 90 95  
 Cys Gly Phe Leu Leu Lys Asp Ser Gln Pro Glu Gln Leu Val Ala Ala  
 100 105 110  
 Val Arg Ala Leu Ala Ser Gly Val Thr Val Leu Ala Pro Glu Ala Ser  
 115 120 125  
 Ser Ile Met Leu Gly Ala Ala Cys Arg Gly Thr Pro Ala Ala Glu Asn



-continued

Arg	Gln	Val	Ser	Arg	Val	Val	Leu	Ala	Glu	Ala	Ala	Ile	Ala	Gly	Ser	290	295	300	
Ile	Gly	Ala	Val	Ile	Gly	Ala	Val	Ala	Gly	Val	Gly	Leu	Gly	Tyr	Leu	305	310	315	320
Gly	Ala	Gly	Leu	Leu	Asp	Ile	Asn	Gly	Gly	Gly	Leu	Ala	Val	Asn	Pro	325	330	335	
Ile	Val	Leu	Ala	Leu	Cys	Val	Leu	Thr	Gly	Val	Gly	Ala	Thr	Val	Val	340	345	350	
Ala	Ala	Trp	Ala	Pro	Ala	Arg	Arg	Ala	Thr	Arg	Val	Pro	Pro	Val	Arg	355	360	365	
Ala	Leu	Gln	Glu	Val	Pro	Asp	Ala	Leu	Pro	Ala	Gln	Val	Arg	Gly	Gly	370	375	380	
Arg	Arg	Leu	Val	Ala	Gly	Leu	Ile	Leu	Ile	Gly	Leu	Ala	Val	Gly	Val	385	390	395	400
Leu	Gly	Leu	Ala	Ala	Ile	Gly	Thr	Ser	Leu	Pro	Leu	Ala	Leu	Val	Gly	405	410	415	
Gly	Val	Leu	Leu	Ala	Ala	Gly	Leu	Leu	Thr	Ala	Leu	Pro	Leu	Gly	Ile	420	425	430	
Ala	Leu	Leu	Leu	Pro	Pro	Ala	Ala	Arg	Gly	Leu	Glu	Arg	Phe	Gly	Val	435	440	445	
Ala	Ala	Ser	Leu	Ala	Gly	Ser	Asn	Leu	Arg	Gln	Asn	Ala	Arg	Arg	Thr	450	455	460	
Ala	Ser	Ala	Thr	Met	Ala	Val	Val	Val	Gly	Ala	Ala	Leu	Ile	Thr	Gly	465	470	475	480
Leu	Ala	Val	Ala	Ser	Ala	Ser	Gly	Arg	Ala	Thr	Val	Glu	Ala	Asp	Leu	485	490	495	
Glu	Ala	Arg	Tyr	Pro	Val	Ala	Val	Ser	Val	His	Thr	Asp	Gly	Ala	Ala	500	505	510	
Ile	Asp	Asp	Arg	Thr	Val	Arg	Ala	Leu	Ser	Gly	Ile	Thr	Gly	Leu	Thr	515	520	525	
Thr	Ala	Thr	Val	Ala	Thr	Ser	Ala	Ala	Thr	Phe	Pro	Ala	Ala	Gly	Lys	530	535	540	
Pro	Thr	Pro	Ala	Arg	Ile	Ala	Ala	Leu	Pro	Thr	Asp	Val	Ala	Gly	Arg	545	550	555	560
Leu	Ala	Pro	Glu	Leu	Ser	Ala	Ser	Thr	Gly	Asp	Pro	Val	Leu	Leu	Val	565	570	575	
Pro	Ala	Ser	Tyr	Leu	Thr	Ala	Arg	Gly	Leu	Thr	Asp	Gly	Ala	Pro	Leu	580	585	590	
Thr	Val	Thr	Ala	Gly	Gly	Arg	Asp	Leu	Arg	Phe	Thr	Ala	Arg	Gly	Ser	595	600	605	
Arg	Leu	Ala	Asp	Thr	Thr	Gly	Gln	Leu	Leu	Gly	Val	Thr	Thr	Gly	Asp	610	615	620	
Val	Leu	Thr	Ala	Ala	Gly	Val	Arg	Thr	Val	Pro	Thr	Thr	Val	Trp	Gly	625	630	635	640
Thr	Ala	Pro	Gly	Gly	Phe	Asp	Arg	Glu	Thr	Leu	Ala	Ala	Asp	Val	Asn	645	650	655	
Ala	Val	Ala	Ala	Arg	Asp	Ala	Gly	Val	Glu	Val	Gly	Gly	Gly	Val	Thr	660	665	670	
Glu	Gly	Gly	Asp	Ile	Met	Asn	Val	Leu	Ser	Ile	Leu	Leu	Gly	Leu	Ser	675	680	685	
Leu	Gly	Met	Leu	Ala	Val	Thr	Val	Val	Ile	Ala	Leu	Leu	Gly	Ile	Ala	690	695	700	
Asn	Leu	Leu	Gly	Leu	Ser	Val	Ile	Glu	Arg	Thr	Arg	Glu	Met	Ala	Leu				

-continued

705	710	715	720
Leu Arg Ala Leu Gly Thr Arg Arg Ser Arg Leu Arg Ala Met Val Ala			
	725	730	735
Val Glu Ala Val Thr Ile Thr Leu Val Gly Thr Val Ala Gly Ile Val			
	740	745	750
Ile Gly Val Pro Val Gly Leu Val Gly Val Ile Ala Ala Val Gly Arg			
	755	760	765
Gln Ala Glu Pro Val Ile Met Leu Ala Trp Pro Gln Leu Gly Leu Val			
	770	775	780
Leu Val Ala Ala Ala Val Thr Gly Val Leu Ala Ser Leu Ala Pro Ala			
	785	790	795
Arg Arg Ala Thr Arg Ile Ala Pro Ala Glu Gly Leu Val Arg			
	805	810	

<210> SEQ ID NO 218  
 <211> LENGTH: 240  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes liguriae

<400> SEQUENCE: 218

Met Val Ser Cys Arg Asn Leu Arg Lys Arg Tyr Gly Thr Gly Asp Ala			
1	5	10	15
Ala Val Val Ala Val Asp Gly Val Ser Thr Ser Phe Ala Ala Gly Glu			
	20	25	30
Phe Thr Ala Ile Met Gly Pro Ser Gly Ser Gly Lys Thr Thr Leu Met			
	35	40	45
His Leu Leu Ala Gly Leu Asp Thr Pro Thr Glu Gly Glu Val Ser Leu			
	50	55	60
Ala Gly Thr Ala Leu Ala Gly Leu Asp Asp Arg Ala Leu Thr Asp Leu			
	65	70	75
Arg Arg Asp Arg Val Gly Phe Ile Phe Gln Ala Phe Asn Leu Leu Pro			
	85	90	95
Thr Leu Thr Ala Glu Gln Asn Ile Val Leu Pro Leu Arg Leu Ala Gly			
	100	105	110
Arg Pro Val Asp Arg Asp Arg Leu Gln Arg Ile Ala Ala Ser Leu Gln			
	115	120	125
Ile Gly Asp Arg Leu Gly His Arg Pro Ala Glu Leu Ser Gly Gly Gln			
	130	135	140
Gln Gln Arg Val Ala Val Ala Arg Ala Leu Leu Thr Glu Pro Ser Val			
	145	150	155
Val Phe Ala Asp Glu Pro Thr Gly Ala Leu Asp Ile Ala Thr Gly Arg			
	165	170	175
Ala Leu Leu Ala Gly Leu Gln Asn Ala Ala Arg Gln Ala Ser Gln Thr			
	180	185	190
Ile Ile Met Val Thr His Asp Ala Ala Ala Ala Thr Tyr Ala Asp Arg			
	195	200	205
Val Leu Ile Met Ala Asp Gly Arg Leu Trp Asp Glu Leu Arg Ala Pro			
	210	215	220
Thr Leu Glu Ser Ile Met Ser Val Met Ala Ser Val Thr Val Thr Ser			
	225	230	235
			240

<210> SEQ ID NO 219  
 <211> LENGTH: 362  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes liguriae



-continued

&lt;400&gt; SEQUENCE: 219

Val Ile Ala Gly Ala Ala Val Met Val Cys Leu Leu Leu Gly Leu Ala  
 1 5 10 15  
 Gly Leu Asp Glu Trp Tyr Trp Ser Ala Ala Leu Cys Val Pro Leu Val  
 20 25 30  
 Ile Arg Arg Ser Ala Pro Val Val Phe Leu Ala Leu Val Ala Val Leu  
 35 40 45  
 Ser Gly Ile His Met Ile Tyr Ser Gly Ser Phe Ala Phe Pro Gly Asp  
 50 55 60  
 Leu Val Asp Leu Val Ala Val His Ala Val Ala Gly Tyr Gly Pro Ala  
 65 70 75 80  
 Arg Val Arg His Leu Gly Leu Leu Leu Gly Val Ala Gly Ser Leu Val  
 85 90 95  
 Val Thr Ala Arg Ala Leu His Asp Gly Leu Pro Ser Ser Ala Thr Leu  
 100 105 110  
 Pro Ala Ala Leu Ile Val Ala Ala Thr Leu Ala Ala Trp Ser Thr Gly  
 115 120 125  
 Leu Met Gln Arg Arg Gln Arg Ala Asp Val Ile Glu Ala Asp His Arg  
 130 135 140  
 Arg Arg Leu Ala Glu Gln Asp Ser Ala Met Arg Ala Arg Leu Ala Ala  
 145 150 155 160  
 Ile Glu Glu Arg Thr Arg Ile Ser Gln Glu Met His Asp Ile Ile Ala  
 165 170 175  
 His Ser Leu Ala Ser Val Ile Ala Gln Ala Glu Gly Gly Arg Val Ala  
 180 185 190  
 Ala Arg Ala Asp Ala Val Val Ala Gly Pro Leu Phe Asp Arg Ile Ala  
 195 200 205  
 Gln Ile Gly Arg Glu Ala Leu Asn Asp Val Lys Arg Leu Leu Asn Ser  
 210 215 220  
 Ile Asp Gly Asp Thr Pro Asp Asp Phe Ala Gln Gly Leu Pro Asp Leu  
 225 230 235 240  
 Pro Gly Leu Leu Ala Gly Val Ser Ala Ala Gly Leu Asp Val Thr Phe  
 245 250 255  
 Glu Val Ala Gly Pro Glu Gln Pro Leu Ala Ser Gly Met Asp Leu Ala  
 260 265 270  
 Val Tyr Arg Val Ile Gln Glu Ser Leu Thr Asn Val Leu Lys His Ala  
 275 280 285  
 Thr Gln Arg Gln Ala Arg Leu Ser Leu Val Trp Thr Pro Ala Trp Leu  
 290 295 300  
 Glu Val Ser Val Thr Ser Pro Leu Thr Phe Ala Gly Ala Leu Arg Glu  
 305 310 315 320  
 Gly Arg Gly Leu Ser Gly Ile Arg Gln Arg Cys Ser Leu Phe Asn Gly  
 325 330 335  
 Asp Cys Glu Ile Val Ala Gly Gln Thr Phe Ser Val Ile Thr Arg Trp  
 340 345 350  
 Pro Leu Ala Arg Pro Glu Val Ala Val Pro  
 355 360

&lt;210&gt; SEQ ID NO 220

&lt;211&gt; LENGTH: 218

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes liguriae

&lt;400&gt; SEQUENCE: 220

-continued

---

Met Thr Glu Pro Gln Ile Asp Val Val Ile Ala Asp Asp Gln Asp Leu  
 1 5 10 15  
 Val Arg Thr Gly Phe Ala Leu Val Val Asp Ser Ala Pro Asp Met Arg  
 20 25 30  
 Val Val Ala Thr Ala Ala Asp Gly Ala Glu Val Val Arg Leu Ala Ala  
 35 40 45  
 Glu Phe Arg Pro Asp Val Val Leu Met Asp Ile Arg Met Pro Arg Val  
 50 55 60  
 Asp Gly Ile Thr Ala Ala Arg Ala Ile Leu Glu Gly Asn Ala Gln Pro  
 65 70 75 80  
 Pro Lys Ile Val Ala Leu Thr Thr Tyr Asp Asn Asp Glu Tyr Ala Ser  
 85 90 95  
 Arg Ile Leu Ala Ala Gly Ala Ser Gly Tyr Leu Leu Lys Asp Thr Thr  
 100 105 110  
 Ala Glu Gly Leu Thr Ala Ala Ile Arg Thr Val His Arg Gly Gly Ser  
 115 120 125  
 Val Leu Ala Pro Ser Thr Thr His Arg Leu Val Thr Ala His Arg Gln  
 130 135 140  
 His Pro Ala Arg Pro Ser Ala Leu Leu Asp Ser Phe Thr Thr Arg Glu  
 145 150 155 160  
 Arg Glu Val Phe Asp Leu Ile Val Ala Gly Ala Ser Asn Ala Glu Ile  
 165 170 175  
 Ala Asp Arg Leu Asn Leu Ala Glu Val Thr Ile Lys Thr His Val Gly  
 180 185 190  
 Arg Val Leu Ala Lys Ile Gly Val Arg Asp Arg Val Asn Val Val Ile  
 195 200 205  
 Trp Ala Tyr Arg Asn Gly Ala Gly Pro Ser  
 210 215

<210> SEQ ID NO 221  
 <211> LENGTH: 301  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes liguriae  
 <400> SEQUENCE: 221

Met Pro Ile Leu Trp Thr Ala Val Leu Ala Gly Ala Val Ile Leu Gly  
 1 5 10 15  
 His Arg Leu Val Pro Asn Ala Val Gly Asn Ala Gly Ser Leu Ile Glu  
 20 25 30  
 Ala Phe Leu Pro Trp Phe Gly Leu Ala Val Pro Val Leu Leu Leu Leu  
 35 40 45  
 Ala Leu Met Arg Arg Ser Leu Thr Gly Leu Ala Ala Val Leu Leu Pro  
 50 55 60  
 Leu Gly Ala Trp Leu Ile His Phe Gly Gly Tyr Val Val Asp Arg Asp  
 65 70 75 80  
 Thr Gly Thr Pro Asp Leu Ile Val Val Gln His Asn Val Ser Asp Glu  
 85 90 95  
 Asn Pro Asp Pro Ala Gly Thr Ala Arg Ala Leu Leu Ala Ala His Pro  
 100 105 110  
 Asp Leu Val Gly Leu Glu Glu Val Leu Pro Glu Ala Val Ala Ala Tyr  
 115 120 125  
 Arg Gly Val Leu Asp Ala Glu Leu Pro Phe His Thr Val Gln Gly Thr  
 130 135 140  
 Val Ala Leu Trp Ser Arg Tyr Pro Leu Thr Gly Ala Glu Ala Ile Asp  
 145 150 155 160

-continued

Ile Arg Pro His Asp Leu Gly Glu Asp Trp Asn Arg Gly Leu Arg Ala  
 165 170 175  
 Val Ala Arg Thr Pro Gly Gly Asp Thr Ala Val Tyr Val Ala His Leu  
 180 185 190  
 Pro Ser Val Arg Val Thr Ala Ala Gly Leu Thr Ser Ala Arg Arg Asp  
 195 200 205  
 Glu Ser Ala Arg Lys Leu Gly Ala Leu Leu Ala Ala Asp Pro Val Pro  
 210 215 220  
 Arg Leu Val Val Ile Gly Asp Leu Asn Thr Ser Val Asp Asp Arg Gly  
 225 230 235 240  
 Leu Arg Pro Ile Arg Gln Val Met Ile Asp Ser Pro Ala Asp Phe Ala  
 245 250 255  
 Phe Thr Trp Pro Ala Arg Thr Pro Val Ala Arg Ile Asp Gln Val Leu  
 260 265 270  
 Ala Arg Ser Met Thr Val Thr Arg Leu Thr Ala Leu Pro Arg Thr Gly  
 275 280 285  
 Ser Asp His Leu Pro Leu Ala Ala Glu Ile Arg Phe Pro  
 290 295 300

&lt;210&gt; SEQ ID NO 222

&lt;211&gt; LENGTH: 290

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes liguriae

&lt;400&gt; SEQUENCE: 222

Met Arg Asn Asn Glu Thr Val Arg Ile Pro Val Ala Thr Gly Gly Ala  
 1 5 10 15  
 Val Thr Ala Thr Leu Phe Ala Pro Glu Ser Ala Arg Ala Val Leu Val  
 20 25 30  
 Val His Pro Ala Thr Ala Thr Pro Gln Gly Phe Tyr Ala Ser Phe Ala  
 35 40 45  
 Thr Tyr Leu Ala Glu Asn Gly Ile Ala Thr Val Thr Tyr Asp Tyr Arg  
 50 55 60  
 Gly Thr Gly Arg Ser Gly Ser Pro Arg Asp His Arg Asp Leu Gly Met  
 65 70 75 80  
 Arg Asp Trp Ile Gly Ala Asp Ala Pro Ala Val Ala Ala Trp Ala Ala  
 85 90 95  
 Asp Arg Phe Pro Gly Leu Pro Arg Leu Ala Ala Gly His Ser Leu Gly  
 100 105 110  
 Gly His Val Ile Ala Leu Gly Ala Ala Gly Pro Asp Leu Ala Ala Ser  
 115 120 125  
 Val Ile Val Ala Ser His Ile Ala Ala Leu Arg Thr Ile Pro Ser Arg  
 130 135 140  
 Leu Glu Arg Phe Arg Val Arg Ile Met Leu His Ile Leu Gly Pro Ala  
 145 150 155 160  
 Leu Gly Arg Leu Leu Gly Tyr Val Pro Ala Arg Ser Leu Gly Leu Gly  
 165 170 175  
 Glu Asp Leu Pro Ala Ala Ala Met Leu Glu Trp Gly Gly Trp Ala Arg  
 180 185 190  
 Arg Asp Asn Tyr Phe Phe Asp Asp Pro Ser Met Arg Ala Ala Glu Arg  
 195 200 205  
 Ala Ala Thr Leu Thr Gly Pro Val Leu Ala Val Gly Thr Thr Asp Asp  
 210 215 220  
 Pro Trp Ser Thr Pro Arg Gln Met Asp Ala Leu Thr Val His Leu Thr



-continued

100					105					110					
Phe	Val	Arg	Glu	Ala	Ile	Lys	Ala	Ser	Leu	Arg	Asp	Leu	Val	Lys	Gly
	115						120					125			
His	Glu	Asp	Asp	Phe	Asp	Gly	Pro	Asp	Phe	Val	Val	His	Gly	Val	Val
	130					135					140				
Ser	Asp	Gly	Glu	Pro	Val	Cys	Ala	Met	Val	Leu	Ala	Pro	Tyr	Glu	Thr
	145					150					155				160
Ala	Pro	Trp	Arg	Gly	Val	Arg	Ala	Thr	Asp	Pro	Pro	Gly	Met	Asn	
				165					170					175	
<210> SEQ ID NO 225															
<211> LENGTH: 406															
<212> TYPE: PRT															
<213> ORGANISM: Actinoplanes liguriae															
<400> SEQUENCE: 225															
Met	Thr	Leu	Ser	Glu	Ile	Leu	Pro	Ser	Leu	Gly	Ala	Ser	Leu	Arg	Pro
1				5					10					15	
Arg	Leu	Asp	Pro	Ala	Asn	Trp	Pro	Leu	Thr	Ala	Arg	Trp	Thr	Glu	Pro
			20					25					30		
Gly	Asp	Leu	Thr	Val	Gly	Gly	Val	Pro	Val	Thr	Arg	Ile	Ala	Ala	Ala
	35						40					45			
His	Gly	Thr	Pro	Val	His	Val	Ile	Asp	Glu	Thr	Asp	Val	His	Ser	Arg
	50					55					60				
Cys	Ala	Glu	Tyr	Val	Ala	Ala	Phe	Gly	Pro	Gly	Ala	Val	Cys	Cys	Ser
	65					70					75				80
Ala	Lys	Gly	Gly	Leu	Leu	Arg	Gly	Ala	Ala	Arg	Trp	Ile	Ala	Arg	Asp
				85					90					95	
Gly	Leu	Gly	Cys	Tyr	Cys	Arg	Ser	Ala	Ala	Glu	Leu	Arg	Thr	Ala	Leu
			100					105					110		
Asp	Ala	Gly	Ile	Arg	Pro	Glu	Ser	Leu	Ala	Leu	Phe	Gly	Ser	Gly	Lys
	115						120					125			
Ser	Val	Ala	Asp	Leu	Glu	Ala	Ala	Leu	Ser	Cys	Gly	Ala	Ala	Val	Val
	130						135				140				
Ile	Gly	Ser	Ala	Ser	Glu	Ala	Glu	Val	Val	Ala	Ala	Arg	Ser	Arg	Pro
	145					150					155				160
Gly	Gln	Arg	Val	Leu	Leu	Arg	Val	Arg	Pro	Gly	Ser	Ala	Gln	Arg	Gly
				165					170					175	
Tyr	Gly	Val	Arg	Leu	Asn	Ser	Ser	Ala	Ala	Leu	Ala	Ala	Val	Ala	Thr
			180					185					190		
Val	Thr	Arg	Ser	Arg	Arg	Leu	Val	Leu	Ala	Gly	Leu	Asp	Cys	Ser	Leu
		195					200					205			
Gly	His	Arg	Leu	Asn	Arg	Phe	Gly	Thr	Tyr	Glu	Ser	Cys	Leu	Arg	Glu
	210					215					220				
Ala	Ile	Gly	Phe	Val	Ala	Arg	Leu	Arg	Thr	Thr	Val	Pro	Val	Leu	Asn
	225					230					235				240
Leu	Gly	Gly	Gly	His	Ala	Ala	Asp	Leu	Pro	Val	Gly	Ile	Phe	Ala	Ala
				245					250					255	
Arg	Leu	Arg	Ala	Val	Ala	Gln	Val	Thr	Ser	Glu	Gly	Tyr	Gly	Ile	Glu
			260					265					270		
Pro	Pro	Glu	Val	His	Val	Ser	Pro	Gly	Arg	Ala	Leu	Leu	Gly	Arg	Ala
		275					280						285		
Gly	Ile	Thr	Val	His	Arg	Val	Val	Ala	Ala	Gly	Asp	Gly	Val	Ile	Glu
	290						295				300				

-continued

Leu Asp Gly Asp Val Pro Asp Cys Leu Pro Gly Ala Asp Cys Ala Gly  
 305 310 315 320  
 Leu His Thr Ala Ala Leu Ile Gly Arg Ala Ser Pro Ala Pro Gly Arg  
 325 330 335  
 Ser Ile Thr Val Arg Cys Gly Asp Ala Thr Val Ala Val Ala Glu Leu  
 340 345 350  
 Pro Gly Asp Met Ala Ala Gly Asp Leu Val Ala Leu Ser Gly Thr Gly  
 355 360 365  
 Ala Tyr His Gln Arg Arg Asp Val Tyr Val Gly Arg Pro Ala Val Val  
 370 375 380  
 Ala Val Cys Gly Gly Arg Ala Arg Thr Leu Leu Pro Arg Glu Thr Ile  
 385 390 395 400  
 Asp Arg Ile Leu Tyr Ala  
 405

<210> SEQ ID NO 226  
 <211> LENGTH: 309  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes liguriae

<400> SEQUENCE: 226

Val Arg Ser Lys Arg Glu His Ser Ala Asp Ile Arg Arg Gly Arg Arg  
 1 5 10 15  
 Ala Val Leu Val Val Asn Thr Arg Ser Arg Arg Gly Arg Leu Leu Tyr  
 20 25 30  
 Glu Glu Ala Arg Arg Arg Leu Val Glu Ala Gly Phe Glu Leu Leu Gly  
 35 40 45  
 Thr Tyr Ala Leu Glu Gln Ser Gly Gly Leu Asp Gly Leu Ile Ser Glu  
 50 55 60  
 Ala Leu Arg Lys Glu Pro Asp Leu Leu Ile Ala Gly Gly Gly Asp Gly  
 65 70 75 80  
 Thr Ile Ser Thr Ala Gly Arg Met Leu Ala His Arg Asp Val Ala Leu  
 85 90 95  
 Gly Val Leu Pro Leu Gly Thr Thr Asn Asn Phe Ala Arg Thr Val Arg  
 100 105 110  
 Ile Glu Pro Asp Leu Glu Ala Ala Ile Ala Thr Leu Val Asp Gly Lys  
 115 120 125  
 Val Ile Asp Val Asp Leu Gly Val Ala Gly Asp Val Pro Phe Thr Asn  
 130 135 140  
 His Val Gly Ile Gly Leu Ser Gly Glu Val Met Ile Ser Ala Pro Pro  
 145 150 155 160  
 Arg Leu Lys Arg Ala Val Gly Arg Leu Ala Tyr Pro Met Thr Ala Leu  
 165 170 175  
 Gly Leu Leu Ala Arg His Arg Pro Val Arg Ala Val Ile Arg Ala Glu  
 180 185 190  
 Gly Arg Glu Leu Arg Phe His Thr His Gln Val Tyr Val Ala Asn Gly  
 195 200 205  
 Gly Phe His Ala Gly Arg Pro Ile Thr Ala Asp Ala His Ala Asp Asp  
 210 215 220  
 Arg Leu Leu Val Ala Tyr Pro Val Gly Gly Ala Ser Arg Arg Glu Leu  
 225 230 235 240  
 Leu Arg Glu Thr Ala Arg Asn Ala Ala Thr Gly His Arg Arg Thr Leu  
 245 250 255  
 His Glu Arg Pro Phe Ile Ala Val Arg Glu Leu Trp Leu Glu Thr Asp  
 260 265 270

-continued

---

Arg Pro Val Ala Val Glu Val Asp Gly Glu Pro Arg Gly Thr Thr Pro  
 275 280 285

Met Arg Ile Ala Ile Asp Pro Asn Ala Leu Arg Ile Met Ala Pro Ala  
 290 295 300

Asp Ser Pro Asp Leu  
 305

<210> SEQ ID NO 227  
 <211> LENGTH: 367  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes liguriae

<400> SEQUENCE: 227

Val Val Phe Gly Ser Leu Leu Leu Val Gly Gly Gly Gly Ala Ile  
 1 5 10 15

Gly Leu Asn Ala Thr Val Ala Ala Ala Thr Ser Ser Val Gly Gln Glu  
 20 25 30

Ser Leu Leu Gly Ser Ala Lys Pro Ala Glu Glu Lys Lys Asn Ala Asn  
 35 40 45

Leu Asp Gly Ala Lys Asn Leu Leu Leu Val Gly Ile Asp Gln Arg Pro  
 50 55 60

Thr Gln Thr Asn Gly Glu Pro Leu Arg Ser Asp Ser Ile Ile Leu Leu  
 65 70 75 80

His Ile Asn Lys Asp His Ser Ser Gly Tyr Met Ile Ser Leu Pro Arg  
 85 90 95

Asp Ser Tyr Val Tyr Ile Pro Ala Tyr Asp Asn Gly Lys Gln Lys Trp  
 100 105 110

Ala Gly Gly Lys Thr Lys Ile Asn Ala Ala Phe Ala Phe Gly Thr Arg  
 115 120 125

Gly Leu Lys Gly Asn Glu Ala Leu Gln His Gly Phe Glu Leu Leu Thr  
 130 135 140

Met Thr Val Lys Glu Leu Thr Gly Ile Thr Pro Asp Ala Gly Ala Ile  
 145 150 155 160

Ile Asp Phe Gln Gly Phe Arg Asp Val Val Asn Val Leu Gly Lys Val  
 165 170 175

Cys Met Tyr Val Asp Thr Thr Thr Lys Ser Ile His Leu Gly Lys Asp  
 180 185 190

Gln Asn Gly Lys Thr Ala Lys Pro Phe Val Ile Asn Pro Asp Gly Thr  
 195 200 205

Leu Lys Ser Lys Ile Ser Gly Val Thr Pro Asn Thr Tyr Thr Lys Gly  
 210 215 220

Asp His Cys Phe Thr Pro Gly Gln Ala Leu Asp Phe Val Arg Gln Arg  
 225 230 235 240

Asp Leu Leu Ala Asp Asn Ser Leu Asp Tyr Gly Arg Gln Arg His Gln  
 245 250 255

Gln Gln Phe Phe Lys Ala Ile Ile Asn Gln Ala Leu Lys Asp Gly Leu  
 260 265 270

Asp Ser Pro Thr Lys Leu Pro Lys Leu Leu Ser Ala Phe Gly Lys Ala  
 275 280 285

Met Thr Val Asp Asp Gly Gly Ile Asp Leu Ala Asp Trp Ala Leu Ala  
 290 295 300

Met Arg Ser Leu Lys Pro Asp Lys Leu Leu Thr Ile Lys Thr Asn Ala  
 305 310 315 320

Gly Lys Leu Asn Ser Glu Asn Val Pro Gly Ser Gly Ser Val Glu Leu

-continued

325					330					335					
Leu	Ser	Asp	Asp	Ser	Met	Asp	Leu	Leu	Lys	Ser	Ile	Lys	Lys	Asp	Gln
			340					345					350		
Ile	Asp	Thr	Phe	Leu	Leu	Ser	His	Pro	Ala	Phe	Ile	Ala	Asn	Ser	
		355					360					365			
<210> SEQ ID NO 228															
<211> LENGTH: 317															
<212> TYPE: PRT															
<213> ORGANISM: Actinoplanes liguriae															
<400> SEQUENCE: 228															
Met	Pro	Ser	Glu	Pro	Asp	Val	Ser	Val	Val	Ile	Pro	Thr	Cys	Asn	Arg
1				5					10					15	
Pro	Glu	Leu	Ala	Val	Arg	Ala	Val	Arg	Ser	Ala	Leu	Gly	Gln	Thr	His
			20					25					30		
Arg	Asn	Leu	Glu	Val	Ile	Val	Val	Val	Asp	Gly	Pro	Asp	Glu	Ala	Thr
		35					40					45			
Val	Thr	Ala	Leu	Gly	Glu	Val	Gly	Asp	Pro	Arg	Leu	Ser	Val	Ile	Val
	50					55					60				
Leu	Pro	Glu	Arg	Gly	Lys	Ala	Pro	Asn	Ala	Arg	Asn	Thr	Gly	Ala	Arg
65					70					75					80
Ala	Ala	Arg	Gly	Arg	Trp	Thr	Ala	Met	Leu	Asp	Asp	Asp	Asp	Glu	Trp
				85					90					95	
Leu	Pro	Thr	Lys	Ile	Glu	Arg	Gln	Leu	Glu	Thr	Ala	Ala	Ala	Ala	Thr
			100					105						110	
Val	Glu	Arg	Pro	Val	Val	Ala	Cys	Arg	Met	Ile	Ser	Arg	Thr	Pro	Arg
		115					120					125			
Ala	Asp	Thr	Ile	Met	Pro	Arg	Arg	Leu	Pro	Glu	Pro	Gly	Glu	Pro	Ile
	130					135					140				
Ser	Glu	Tyr	Leu	Leu	Val	Arg	Arg	Gly	Leu	Phe	Tyr	Gly	Asp	Gly	Phe
145					150					155					160
Val	Gln	Thr	Ser	Cys	Ile	Met	Ala	Pro	Thr	Glu	Leu	Trp	Arg	Lys	Val
				165					170					175	
Pro	Phe	Thr	Val	Gly	Leu	Arg	Arg	Ala	Gln	Glu	Leu	Asp	Trp	Thr	Leu
			180					185						190	
Arg	Ala	Met	Arg	Glu	Pro	Gly	Thr	Ala	Leu	Ile	Tyr	Ala	Glu	Glu	Pro
		195					200					205			
Leu	Val	Leu	Trp	His	Gln	Asp	Glu	Asn	Arg	Asp	Arg	Ile	Ser	Leu	Gln
	210					215					220				
Asn	Pro	Trp	Arg	Glu	Gln	Leu	Glu	Trp	Leu	Arg	Gly	Asn	Arg	Glu	Leu
225					230					235					240
Phe	Thr	Pro	Arg	Ala	Tyr	Ala	Ala	Phe	Thr	Leu	Ser	Val	Leu	Ser	Ser
				245					250					255	
Met	Ala	Ala	Pro	Thr	Arg	Asp	Thr	Gly	Leu	Phe	Arg	Glu	Leu	Leu	Ala
			260					265					270		
Glu	Ala	Arg	Thr	His	Gly	Asp	Pro	Gly	Thr	Val	Asp	Tyr	Leu	Thr	His
		275					280					285			
Met	Gln	Ile	Trp	Ala	Leu	Pro	Pro	Ser	Val	Arg	His	Arg	Leu	Arg	Asp
	290					295					300				
Val	Val	Val	Gly	Arg	Gly	Lys	Thr	Ser	Ser	Asn	Ala	Gly			
305					310						315				

&lt;210&gt; SEQ ID NO 229

&lt;211&gt; LENGTH: 369



-continued

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes liguriae

&lt;400&gt; SEQUENCE: 229

Met Pro Ala Glu Arg Arg Val Ala Ile Trp Arg Ser Ser Met Leu Pro  
 1 5 10 15  
 Gly Ser Glu Thr Phe Val Arg Asn Gln Ala Asp Ala Leu Thr Arg Trp  
 20 25 30  
 Thr Pro Ala Tyr Val Gly Ala Val Arg His Glu Ser Val Leu Ser Arg  
 35 40 45  
 Pro Asp Asp Val Ile Ala Phe Pro Gly Gly Lys Gly Phe Leu Arg Leu  
 50 55 60  
 Arg Leu Thr Gly Ala Ser Pro Gln Leu Gln Lys Thr Ile Ser Ala Val  
 65 70 75 80  
 Arg Pro Asn Leu Val His Ala His Phe Gly Gly Asp Gly Trp Leu Val  
 85 90 95  
 Ser His Ser Ala Gln Gln Leu Gly Val Pro Leu Ala Val Thr Val His  
 100 105 110  
 Gly His Asp Val Thr Arg Gln Pro Ser Ser Pro Gly Ala Lys Gly Val  
 115 120 125  
 Arg Tyr Arg Arg Asn Leu Gln Thr Val Phe Thr Arg Ala Ser Leu Val  
 130 135 140  
 Ile Ala Val Ser Glu Val Ile Arg Gly Gln Ala Ile Arg Trp Gly Ala  
 145 150 155 160  
 Asp Pro Ala Lys Val Lys Val His Tyr Thr Gly Ile Ala Val Pro Pro  
 165 170 175  
 Glu Gln Pro Glu Glu Val Pro Lys Arg Trp Asp Val Val Phe Ile Gly  
 180 185 190  
 Arg Phe Val Ala Lys Lys Gly Val Asp Asp Leu Leu Thr Ala Leu Ala  
 195 200 205  
 Ala Val Glu Ser Arg Pro Arg Ala Leu Leu Ile Gly Asp Gly Glu Leu  
 210 215 220  
 Met Thr Ala Met Arg Ala Arg Ala Glu Gln Leu Gly Val Asp Val Thr  
 225 230 235 240  
 Phe Ala Gly Ser Arg Thr Pro Glu Gln Val Arg Arg His Leu Leu Glu  
 245 250 255  
 Ser Arg Leu Leu Ala Cys Pro Ser Lys Thr Ala Pro Asp Gly Asp Thr  
 260 265 270  
 Glu Gly Leu Pro Thr Thr Ile Leu Glu Ala Ala Ala Leu Gly Leu Pro  
 275 280 285  
 Val Val Ala Thr Arg His Ser Gly Ile Pro Glu Ala Val Ile Asp Gly  
 290 295 300  
 Glu Thr Gly Leu Leu Ser Pro Glu Ala Asp Pro Ala Ala Leu Ala Val  
 305 310 315 320  
 Ser Leu Thr Arg Leu Leu Gly Asp Glu Asp Leu Gln Arg Arg Leu Gly  
 325 330 335  
 Ala Arg Ala Arg Arg His Val Thr Ala His Phe Asp Leu Val Glu Gln  
 340 345 350  
 Thr Arg Arg Leu Glu Asp Leu Tyr Asp Glu Val Val Ala Gly Ala Arg  
 355 360 365  
 Val

&lt;210&gt; SEQ ID NO 230

&lt;211&gt; LENGTH: 459

-continued

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Actinoplanes liguriae

&lt;400&gt; SEQUENCE: 230

Met Gly Glu His Phe Asp Leu Val Val Leu Gly Ala Gly Pro Gly Gly  
 1 5 10 15  
 Tyr Val Ala Ala Ile Arg Gly Ala Gln Leu Gly Leu Thr Thr Ala Ile  
 20 25 30  
 Val Glu Asp Lys Tyr Trp Gly Gly Val Cys Leu Asn Val Gly Cys Ile  
 35 40 45  
 Pro Ser Lys Ala Leu Leu Arg Asn Ala Glu Leu Ala His Ile Phe His  
 50 55 60  
 His Gln Ala Gln Thr Phe Gly Ile Glu Gly Lys Val Thr Phe Asp Phe  
 65 70 75 80  
 Ala Val Ala His Gln Arg Ser Arg Ser Val Ala Asp Gly Arg Val Lys  
 85 90 95  
 Gly Val His Phe Leu Met Lys Lys Asn Gly Ile Thr Glu Ile Gln Gly  
 100 105 110  
 Arg Gly Glu Phe Thr Asp Ala His Thr Leu Arg Val Gly Asp Arg Thr  
 115 120 125  
 Val Thr Phe Asp Asn Cys Ile Leu Ala Thr Gly Ala Ser Thr Arg Met  
 130 135 140  
 Ile Pro Gly Thr Ser Val Ser Lys Arg Val Val Thr Tyr Glu Glu Gln  
 145 150 155 160  
 Ile Leu Asp Pro Asp Leu Pro Asp Ser Ile Val Ile Val Gly Ala Gly  
 165 170 175  
 Ala Ile Gly Val Glu Phe Ala Tyr Val Leu Arg Asn Tyr Gly Val Asp  
 180 185 190  
 Val Thr Ile Val Glu Phe Leu Asp Arg Met Leu Pro Leu Glu Asp Glu  
 195 200 205  
 Glu Val Ser Lys Glu Leu Leu Arg Gln Tyr Arg Lys Leu Gly Val Asp  
 210 215 220  
 Val Arg Val Gly Thr Arg Val Glu Gly Ile Glu Glu Gly Ala Asp Ser  
 225 230 235 240  
 Val Arg Val Thr Val Ser Lys Asn Gly Lys Thr Glu Val Leu Glu Ala  
 245 250 255  
 Asp Lys Val Met Gln Ala Ile Gly Phe Lys Pro Asn Val Glu Gly Tyr  
 260 265 270  
 Gly Leu Glu Thr Thr Gly Val Thr Val Ser Asp Arg Gly Ala Val Glu  
 275 280 285  
 Ile Asp Asp Phe Cys Arg Thr Asn Val Pro Gly Ile Tyr Ala Ile Gly  
 290 295 300  
 Asp Val Thr Ala Lys Leu Met Leu Ala His Ala Ala Glu Ala Met Gly  
 305 310 315 320  
 Ile Val Ala Ala Glu Thr Ile Ala Gly Ala Glu Thr Met Ala Leu Asp  
 325 330 335  
 Tyr Arg Met Ile Pro Arg Ala Thr Phe Cys Gln Pro Gln Val Ala Ser  
 340 345 350  
 Phe Gly Trp Thr Glu Ala Gln Ala Arg Glu Gln Gly Phe Asp Val Lys  
 355 360 365  
 Val Ala Lys Phe Pro Phe Thr Ala Asn Gly Lys Ala His Gly Leu Gly  
 370 375 380  
 Asp Ala Thr Gly Phe Val Lys Ile Leu Ser Asp Ala Lys Tyr Gly Glu  
 385 390 395 400

-continued

Leu Leu Gly Ala His Leu Ile Gly Pro Asp Val Thr Glu Leu Leu Pro  
 405 410 415  
 Glu Leu Thr Leu Ala Gln Gln Trp Asp Leu Thr Val His Glu Val Gly  
 420 425 430  
 Arg Asn Val His Ala His Pro Thr Leu Ala Glu Ala Val Lys Glu Ala  
 435 440 445  
 Ile His Gly Leu Ala Gly His Met Ile Asn Phe  
 450 455

<210> SEQ ID NO 231  
 <211> LENGTH: 348  
 <212> TYPE: PRT  
 <213> ORGANISM: Actinoplanes liguriae

<400> SEQUENCE: 231

Met Thr Thr Pro Pro Arg Arg Ser Gly Thr Leu Ser Leu Val Thr Leu  
 1 5 10 15  
 Thr Val Glu Pro Pro Ile Ala Pro Ala Pro Pro Ala Ala Pro Gly Arg  
 20 25 30  
 Ser Arg Arg Arg Arg Leu Gly Tyr Leu Ala Phe Val Leu Val Ala Val  
 35 40 45  
 Val Ala Val Val Thr Leu Arg Asp Arg Leu Pro Asp Pro Gly Glu Phe  
 50 55 60  
 Leu Asp Ala Leu Arg Ala Ala Asp Trp Arg Trp Ala Ala Leu Ala Val  
 65 70 75 80  
 Gly Ala Gly Val Leu Ser Gln Ile Ala Tyr Ala Glu Gln Gln Arg Arg  
 85 90 95  
 Leu Leu Ala Ala Phe Gly Val Arg Val Pro Ala Arg Arg Ala Ile Ala  
 100 105 110  
 Met Thr Tyr Val Arg Ser Ala Leu Ser Met Ala Leu Pro Ala Gly Ser  
 115 120 125  
 Ala Ala Ser Ala Ala Tyr Ala Phe Gln Val Tyr Arg Arg His Gly Ala  
 130 135 140  
 Thr Ala Ala Ile Ser Ala Thr Ala Thr Leu Ile Ser Thr Val Val Thr  
 145 150 155 160  
 Val Met Ser Leu Gly Leu Leu Tyr Ala Ala Thr Trp Ser Leu Thr Ala  
 165 170 175  
 Thr Val Val Ala Gly Leu Ala Val Leu Leu Trp Ile Tyr Arg Thr  
 180 185 190  
 Val Arg Gly Pro Val Pro Ala Arg Ala Gly Val Pro Arg Arg Leu Arg  
 195 200 205  
 Val Ala Pro Ile Ala Arg Leu Leu Gln Arg Pro Ala Val Ala Gln Ala  
 210 215 220  
 Leu Arg Gly Ala Arg Ser Val Pro Ala Arg Thr Trp Leu Thr Val Thr  
 225 230 235 240  
 Leu Ala Gly Val Ile Asn Trp Leu Leu Asp Met Ala Cys Leu Leu Leu  
 245 250 255  
 Ala Ala Asp Ala Leu His Ala Gly Leu Gly Trp Ser Arg Leu Ala Leu  
 260 265 270  
 Ile Tyr Leu Ala Val Gln Val Val Arg Gln Ile Pro Leu Thr Pro Gly  
 275 280 285  
 Gly Ile Gly Leu Ile Glu Thr Ser Met Leu Ala Gly Leu Ile Ala Ala  
 290 295 300  
 Gly Ala Pro Gln Val Thr Ala Ala Gly Ile Val Leu Ile Tyr Arg Leu

-continued

---

305					310					315					320
Ile	Ser	Phe	Trp	Leu	Ile	Leu	Pro	Ser	Gly	Leu	Ala	Ala	His	Leu	Thr
				325					330					335	
Leu	Arg	Arg	Gly	Thr	Val	Pro	Pro	Val	Thr	Pro	Gly				
			340					345							

&lt;210&gt; SEQ ID NO 232

&lt;400&gt; SEQUENCE: 232

000

&lt;210&gt; SEQ ID NO 233

&lt;400&gt; SEQUENCE: 233

000

&lt;210&gt; SEQ ID NO 234

&lt;400&gt; SEQUENCE: 234

000

&lt;210&gt; SEQ ID NO 235

&lt;400&gt; SEQUENCE: 235

000

&lt;210&gt; SEQ ID NO 236

&lt;400&gt; SEQUENCE: 236

000

&lt;210&gt; SEQ ID NO 237

&lt;400&gt; SEQUENCE: 237

000

&lt;210&gt; SEQ ID NO 238

&lt;400&gt; SEQUENCE: 238

000

&lt;210&gt; SEQ ID NO 239

&lt;400&gt; SEQUENCE: 239

000

&lt;210&gt; SEQ ID NO 240

&lt;400&gt; SEQUENCE: 240

000

&lt;210&gt; SEQ ID NO 241

&lt;400&gt; SEQUENCE: 241

000

-continued

---

<210> SEQ ID NO 242

<400> SEQUENCE: 242

000

<210> SEQ ID NO 243

<400> SEQUENCE: 243

000

<210> SEQ ID NO 244

<400> SEQUENCE: 244

000

<210> SEQ ID NO 245

<400> SEQUENCE: 245

000

<210> SEQ ID NO 246

<400> SEQUENCE: 246

000

<210> SEQ ID NO 247

<400> SEQUENCE: 247

000

<210> SEQ ID NO 248

<400> SEQUENCE: 248

000

<210> SEQ ID NO 249

<400> SEQUENCE: 249

000

<210> SEQ ID NO 250

<400> SEQUENCE: 250

000

<210> SEQ ID NO 251

<400> SEQUENCE: 251

000

<210> SEQ ID NO 252

<400> SEQUENCE: 252

000

<210> SEQ ID NO 253

-continued

---

<400> SEQUENCE: 253

000

<210> SEQ ID NO 254

<400> SEQUENCE: 254

000

<210> SEQ ID NO 255

<400> SEQUENCE: 255

000

<210> SEQ ID NO 256

<400> SEQUENCE: 256

000

<210> SEQ ID NO 257

<400> SEQUENCE: 257

000

<210> SEQ ID NO 258

<400> SEQUENCE: 258

000

<210> SEQ ID NO 259

<400> SEQUENCE: 259

000

<210> SEQ ID NO 260

<400> SEQUENCE: 260

000

<210> SEQ ID NO 261

<400> SEQUENCE: 261

000

<210> SEQ ID NO 262

<400> SEQUENCE: 262

000

<210> SEQ ID NO 263

<400> SEQUENCE: 263

000

<210> SEQ ID NO 264

<400> SEQUENCE: 264

-continued

---

000

&lt;210&gt; SEQ ID NO 265

&lt;400&gt; SEQUENCE: 265

000

&lt;210&gt; SEQ ID NO 266

&lt;400&gt; SEQUENCE: 266

000

&lt;210&gt; SEQ ID NO 267

&lt;400&gt; SEQUENCE: 267

000

&lt;210&gt; SEQ ID NO 268

&lt;400&gt; SEQUENCE: 268

000

&lt;210&gt; SEQ ID NO 269

&lt;400&gt; SEQUENCE: 269

000

&lt;210&gt; SEQ ID NO 270

&lt;400&gt; SEQUENCE: 270

000

&lt;210&gt; SEQ ID NO 271

&lt;400&gt; SEQUENCE: 271

000

&lt;210&gt; SEQ ID NO 272

&lt;400&gt; SEQUENCE: 272

000

&lt;210&gt; SEQ ID NO 273

&lt;400&gt; SEQUENCE: 273

000

&lt;210&gt; SEQ ID NO 274

&lt;400&gt; SEQUENCE: 274

000

&lt;210&gt; SEQ ID NO 275

&lt;400&gt; SEQUENCE: 275

000

-continued

---

<210> SEQ ID NO 276

<400> SEQUENCE: 276

000

<210> SEQ ID NO 277

<400> SEQUENCE: 277

000

<210> SEQ ID NO 278

<400> SEQUENCE: 278

000

<210> SEQ ID NO 279

<400> SEQUENCE: 279

000

<210> SEQ ID NO 280

<400> SEQUENCE: 280

000

<210> SEQ ID NO 281

<400> SEQUENCE: 281

000

<210> SEQ ID NO 282

<400> SEQUENCE: 282

000

<210> SEQ ID NO 283

<400> SEQUENCE: 283

000

<210> SEQ ID NO 284

<400> SEQUENCE: 284

000

<210> SEQ ID NO 285

<400> SEQUENCE: 285

000

<210> SEQ ID NO 286

<400> SEQUENCE: 286

000

<210> SEQ ID NO 287



-continued

---

<400> SEQUENCE: 287

000

<210> SEQ ID NO 288

<400> SEQUENCE: 288

000

<210> SEQ ID NO 289

<400> SEQUENCE: 289

000

<210> SEQ ID NO 290

<400> SEQUENCE: 290

000

<210> SEQ ID NO 291

<400> SEQUENCE: 291

000

<210> SEQ ID NO 292

<400> SEQUENCE: 292

000

<210> SEQ ID NO 293

<400> SEQUENCE: 293

000

<210> SEQ ID NO 294

<400> SEQUENCE: 294

000

<210> SEQ ID NO 295

<400> SEQUENCE: 295

000

<210> SEQ ID NO 296

<400> SEQUENCE: 296

000

<210> SEQ ID NO 297

<400> SEQUENCE: 297

000

<210> SEQ ID NO 298

<400> SEQUENCE: 298

-continued

000

&lt;210&gt; SEQ ID NO 299

&lt;400&gt; SEQUENCE: 299

000

&lt;210&gt; SEQ ID NO 300

&lt;211&gt; LENGTH: 48

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic sequence: Primer O/SBDIG-1

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

&lt;222&gt; LOCATION: (30)..(30)

&lt;223&gt; OTHER INFORMATION: n is a, c, g, or t

&lt;400&gt; SEQUENCE: 300

tgggtstgca csctcsacsat cgartgcggn acsgtsatct gcgcstgc 48

&lt;210&gt; SEQ ID NO 301

&lt;211&gt; LENGTH: 16

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic sequence: Primer O/ACT08F

&lt;400&gt; SEQUENCE: 301

tccagcacgc gcgggg 16

&lt;210&gt; SEQ ID NO 302

&lt;211&gt; LENGTH: 16

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic sequence: Primer O/ACT09R

&lt;400&gt; SEQUENCE: 302

gttcgaccag ccgccc 16

&lt;210&gt; SEQ ID NO 303

&lt;211&gt; LENGTH: 27

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic sequence: Primer O/AGvar01bF

&lt;400&gt; SEQUENCE: 303

ttctagacgt tgttctccca ttttcac 27

&lt;210&gt; SEQ ID NO 304

&lt;211&gt; LENGTH: 27

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic sequence: Primer O/AGvar02bR

&lt;400&gt; SEQUENCE: 304

aagatcttcg aaggtgagct cgccgaa 27

&lt;210&gt; SEQ ID NO 305

&lt;211&gt; LENGTH: 94

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial sequence

-continued

---

<220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Primer O/AGvar03F  
  
 <400> SEQUENCE: 305  
  
 gatcttcgcg aggaccgcac catctacgcc gccagcagcg gctgggtgtg tacactgacg 60  
  
 atcgagtgcg gcaccgtgat ctgcgcctgc tgac 94  
  
 <210> SEQ ID NO 306  
 <211> LENGTH: 94  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Primer O/AGvar04R  
  
 <400> SEQUENCE: 306  
  
 ctaggtcagc aggcgcagat cacggtgccg cactcgatcg tcagtgtaca caccagccg 60  
  
 ctgctggcgg cgtagatggt gcggtcctcg cgaa 94  
  
 <210> SEQ ID NO 307  
 <211> LENGTH: 26  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Primer O/AGvar05F  
  
 <400> SEQUENCE: 307  
  
 gcctgctgac ctaggtcgac gatcgt 26  
  
 <210> SEQ ID NO 308  
 <211> LENGTH: 27  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Primer O/AGvar06r  
  
 <400> SEQUENCE: 308  
  
 tgaattcggc tgctccccgc gcgaaat 27  
  
 <210> SEQ ID NO 309  
 <211> LENGTH: 59  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Primer O/SB50F  
  
 <400> SEQUENCE: 309  
  
 attcgccggg gaagtccacc gaaaggaaga cacaccatga ttccggggat ccgtcgacc 59  
  
 <210> SEQ ID NO 310  
 <211> LENGTH: 58  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Primer O/SB51R  
  
 <400> SEQUENCE: 310  
  
 gggcgatgcc cgccccggc cggaacgat cgtcgatcat gtaggctgga gctgcttc 58  
  
 <210> SEQ ID NO 311  
 <211> LENGTH: 59  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Primer O/SB52F

-continued

&lt;400&gt; SEQUENCE: 311

aagtatatat gagtaaactt ggtctgacag ttaccaatga ttccggggat ccgctcacc 59

&lt;210&gt; SEQ ID NO 312

&lt;211&gt; LENGTH: 58

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic sequence: Primer O/SB53R

&lt;400&gt; SEQUENCE: 312

gcttcaataa tattgaaaaa ggaagagtat gagtattcat gtaggctgga gctgcttc 58

&lt;210&gt; SEQ ID NO 313

&lt;211&gt; LENGTH: 19

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic sequence: Compound of Formula I

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: MOD\_RES

&lt;222&gt; LOCATION: (7, 9, 14)

&lt;223&gt; OTHER INFORMATION: Abu

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: THIOETH

&lt;222&gt; LOCATION: (1)..(6)

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: THIOETH

&lt;222&gt; LOCATION: (7)..(12)

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: THIOETH

&lt;222&gt; LOCATION: (9)..(17)

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: MISC\_FEATURE

&lt;222&gt; LOCATION: (14)..(19)

&lt;223&gt; OTHER INFORMATION: Linked by Y, where Y is -S- or -S(O)-

&lt;400&gt; SEQUENCE: 313

Ala Ser Gly Trp Val Ala Xaa Leu Xaa Ile Glu Ala Gly Xaa Leu Val  
1 5 10 15

Ala Ala Ala

&lt;210&gt; SEQ ID NO 314

&lt;211&gt; LENGTH: 19

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Artificial sequence

&lt;220&gt; FEATURE:

&lt;223&gt; OTHER INFORMATION: Synthetic sequence: Compound of Formula I

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: MOD\_RES

&lt;222&gt; LOCATION: (7, 9, 14)

&lt;223&gt; OTHER INFORMATION: Abu

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: THIOETH

&lt;222&gt; LOCATION: (1)..(6)

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: THIOETH

&lt;222&gt; LOCATION: (7)..(12)

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: THIOETH

&lt;222&gt; LOCATION: (9)..(17)

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: MISC\_FEATURE

&lt;222&gt; LOCATION: (14)..(19)

&lt;223&gt; OTHER INFORMATION: Linked by Y, where Y is -S- or -S(O)-

&lt;400&gt; SEQUENCE: 314

Ala Ser Gly Trp Val Ala Xaa Leu Xaa Ile Glu Ala Gly Xaa Val Val  
1 5 10 15

Ala Ala Ala

-continued

<210> SEQ ID NO 315  
 <211> LENGTH: 19  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Compound of Formula I  
 <220> FEATURE:  
 <221> NAME/KEY: MOD\_RES  
 <222> LOCATION: (7, 9, 14)  
 <223> OTHER INFORMATION: Abu  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (1)..(6)  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (7)..(12)  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (9)..(17)  
 <220> FEATURE:  
 <221> NAME/KEY: MISC\_FEATURE  
 <222> LOCATION: (14)..(19)  
 <223> OTHER INFORMATION: Linked by Y, where Y is -S- or -S(O)-  
  
 <400> SEQUENCE: 315

Ala Ser Gly Trp Val Ala Xaa Leu Xaa Ile Glu Ala Gly Xaa Leu Ile  
 1 5 10 15

Ala Ala Ala

<210> SEQ ID NO 316  
 <211> LENGTH: 20  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Compound of Formula I  
 <220> FEATURE:  
 <221> NAME/KEY: MOD\_RES  
 <222> LOCATION: (8, 10, 15)  
 <223> OTHER INFORMATION: Abu  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (2)..(7)  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (8)..(13)  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (10)..(18)  
 <220> FEATURE:  
 <221> NAME/KEY: MISC\_FEATURE  
 <222> LOCATION: (15)..(20)  
 <223> OTHER INFORMATION: Linked by Y, where Y is -S- or -S(O)-  
  
 <400> SEQUENCE: 316

Ala Ala Ser Gly Trp Val Ala Xaa Leu Xaa Ile Glu Ala Gly Xaa Leu  
 1 5 10 15

Val Ala Ala Ala  
 20

<210> SEQ ID NO 317  
 <211> LENGTH: 20  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Compound of Formula I  
 <220> FEATURE:  
 <221> NAME/KEY: MOD\_RES  
 <222> LOCATION: (8, 10, 15)  
 <223> OTHER INFORMATION: Abu  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH

-continued

<222> LOCATION: (2) .. (7)  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (8) .. (13)  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (10) .. (18)  
 <220> FEATURE:  
 <221> NAME/KEY: MISC\_FEATURE  
 <222> LOCATION: (15) .. (20)  
 <223> OTHER INFORMATION: Linked by Y, where Y is -S- or -S(O)-

<400> SEQUENCE: 317

Ala Ala Ser Gly Trp Val Ala Xaa Leu Xaa Ile Glu Ala Gly Xaa Val  
 1 5 10 15

Val Ala Ala Ala  
 20

<210> SEQ ID NO 318  
 <211> LENGTH: 20  
 <212> TYPE: PRT  
 <213> ORGANISM: Artificial sequence  
 <220> FEATURE:  
 <223> OTHER INFORMATION: Synthetic sequence: Compound of Formula I  
 <220> FEATURE:  
 <221> NAME/KEY: MOD\_RES  
 <222> LOCATION: (8, 10, 15)  
 <223> OTHER INFORMATION: Abu  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (2) .. (7)  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (8) .. (13)  
 <220> FEATURE:  
 <221> NAME/KEY: THIOETH  
 <222> LOCATION: (10) .. (18)  
 <220> FEATURE:  
 <221> NAME/KEY: MISC\_FEATURE  
 <222> LOCATION: (15) .. (20)  
 <223> OTHER INFORMATION: Linked by Y, where Y is -S- or -S(O)-


<400> SEQUENCE: 318

Ala Ala Ser Gly Trp Val Ala Xaa Leu Xaa Ile Glu Ala Gly Xaa Leu  
 1 5 10 15

Ile Ala Ala Ala  
 20

The invention claimed is:

1. A compound of the formula:



wherein:

-X1-X2- represent -Leu-Val-[ -Val-Val- ] or -Leu-Ile-;

Y is —S— or —S(O)—;

Z is either —NH<sub>2</sub> or an amino acid; and

R represents the group —OH or —NR<sup>1</sup>R<sup>2</sup>, wherein R<sup>1</sup> and R<sup>2</sup> independently represent:

(i) hydrogen;

(ii) a group of formula —(CH<sub>2</sub>)<sub>n</sub>—NR<sup>3</sup>R<sup>4</sup>, in which n represents an integer from 2 to 8 and R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen or (C<sub>1</sub>-C<sub>4</sub>) alkyl, or R<sup>3</sup> and R<sup>4</sup> taken together represent —(CH<sub>2</sub>)<sub>3</sub>—, —(CH<sub>2</sub>)<sub>4</sub>—, (CH<sub>2</sub>)<sub>2</sub>—O—(CH<sub>2</sub>)<sub>2</sub>—, —(CH<sub>2</sub>)<sub>2</sub>—S—(CH<sub>2</sub>)<sub>2</sub>— or —(CH<sub>2</sub>)<sub>5</sub>—;

or R<sup>1</sup> and R<sup>2</sup> taken together with the adjacent nitrogen atom represent a piperazine which may be substituted in position 4 with a substituent selected from:

(a) (C<sub>1</sub>-C<sub>4</sub>)alkyl;

(b) (C<sub>5</sub>-C<sub>7</sub>)-cycloalkyl,

(c) pyridyl,

(d) —(CH<sub>2</sub>)<sub>p</sub>—NR<sup>5</sup>R<sup>6</sup> in which p represents an integer from 1 to 8 and R<sup>5</sup> and R<sup>6</sup> independently represent hydrogen or (C<sub>1</sub>-C<sub>4</sub>) alkyl,

(e) piperidinyl,

(f) substituted piperidinyl, wherein the substituted piperidinyl bears a N-substituent which is (C<sub>1-4</sub>)alkyl,

(g) benzyl, and  
 (h) substituted benzyl, wherein a phenyl therein bears 1 or 2 substituents selected from chloro, bromo, nitro, (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>)alkoxy;  
 or a biologically active variant thereof wherein 1, 2, 3 or 4 amino acids at positions 2, 3, 4, 5, 8, 10, 11, 13 or 18 are substituted by another amino acid, and the another amino acid is a naturally occurring amino acid or its D-isoform, or a pharmaceutically acceptable salt of said compound or variant.

2. The compound according to claim 1 wherein Z is an amino acid.

3. The compound according to claim 2 wherein Z is an amino acid selected from the group Ala, Ile-, Lys-, Phe-, Val-, Glu-, Asp-, His-, Leu-, Arg-, Ser- and Trp, and said amino acids are in the D- or L-configuration.

4. The compound according to claim 2 wherein Z is an amino acid selected from the group Ile-, Lys-, Phe-, Val-, Glu-, Asp-, His-, Leu-, Arg- and Ser-.

5. The compound according to claim 2 wherein the amino acid is Ala.

6. The compound according to claim 1 wherein R represents the group —NR<sup>1</sup>R<sup>2</sup>.

7. The compound according to claim 1 wherein R represents the group —NR<sup>1</sup>R<sup>2</sup>, wherein R<sup>1</sup> and R<sup>2</sup> independently represent hydrogen, a group of formula —(CH<sub>2</sub>)<sub>n</sub>—NR<sup>3</sup>R<sup>4</sup>, in which n represents an integer from 2 to 8 and R<sup>3</sup> and R<sup>4</sup> independently represent hydrogen or (C<sub>1</sub>-C<sub>4</sub>) alkyl, or R<sup>3</sup> and R<sup>4</sup> taken together represent —(CH<sub>2</sub>)<sub>3</sub>—, —(CH<sub>2</sub>)<sub>4</sub>—, (CH<sub>2</sub>)<sub>2</sub>—O—(CH<sub>2</sub>)<sub>2</sub>—, —(CH<sub>2</sub>)<sub>2</sub>—S—(CH<sub>2</sub>)<sub>2</sub>— or —(CH<sub>2</sub>)<sub>5</sub>—, or R<sup>1</sup> and R<sup>2</sup> taken together with the adjacent nitrogen atom represent a piperazine which may be substituted in position 4 with a substituent selected from (C<sub>1</sub>-C<sub>4</sub>) alkyl, (C<sub>5</sub>-C<sub>7</sub>)-cycloalkyl, pyridyl, benzyl, and substituted benzyl wherein a phenyl therein bears 1 or 2 substituents selected from chloro, bromo, nitro, (C<sub>1</sub>-C<sub>4</sub>)alkyl and (C<sub>1</sub>-C<sub>4</sub>) alkoxy.

8. The compound according to claim 1 in which the compound comprises a modification to a carboxy function of a side chain of an internal residue such that said function is modified from —COOH to a group —COOR<sup>5</sup> in which R<sup>5</sup> represents hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl or (C<sub>1</sub>-C<sub>4</sub>)alkoxy(C<sub>2</sub>-C<sub>4</sub>)alkyl.

9. The compound according to claim 1 in which the compound comprises a modification to the N-terminal amino group such that this group —NH<sub>2</sub> is instead a group —NHR<sup>6</sup> wherein R<sup>6</sup> represents C<sub>1-4</sub>alkyl.

10. A variant of a compound as described in claim 1, wherein 1, 2, 3 or 4 amino acids are substituted by another amino acid, provided that when both positions 15 and 16 are substituted and none of the other positions are changed, 15 and 16 are not Val and Ile respectively.

11. A pharmaceutical composition comprising a compound according to claim 1 together with a pharmaceutically acceptable carrier or diluent.

12. A method of treatment of a bacterial infection selected from the group consisting of Staphylococcus, Streptococcus, Enterococcus, Clostridium, and Propionibacterium, comprising administering to a subject an effective amount of the compound according to claim 1.

13. The method of treatment of a bacterial infection according to claim 12 wherein said infection is a gut superinfection caused by Clostridium difficile.

14. A method of treatment of a bacterial infection selected from the group consisting of Staphylococcus, Streptococcus, Enterococcus, Clostridium, and Propionibacterium, comprising administering to a subject an effective amount of the compound according to claim 10.

15. The method of treatment of a bacterial infection according to claim 12 wherein said infection is a gut superinfection caused by Clostridium difficile.

\* \* \* \* \*